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xx Abstract 
The  identification  and  characterisation  of  new  virulence  determinants  of  B. 
pertussis  is  providing  important  information  for  understanding  the  colonisation  and 
survival  strategies  of  the  microorganism.  B.  pertussis  deploys  a  range  of  surface-associated 
components  to  enable  its  successful  colonisation  of  the  host.  Bap-5  has  been  identified  as  a 
new  member  of  the  B.  pertussis  autotransporter  family  of  proteins  that  includes  PRN, 
BrkA,  TCF  and  Vag-8,  largely  due  to  its  homology  at  the  C-terminus  and  some  other 
similar  regions  such  as  the  RGD  (integrin-binding)  and  SGXG  (glycosaminoglycan- 
binding)  motifs.  The  bap-5  gene  also  exists  in  B.  bronchiseptica  and  B.  parapertussis. 
Characteristic  upstream  regulatory  sequences  such  as  a  ribosome-binding  site  were  not  seen 
in  bap-5,  but  a  potential  heptameric  BvgA-binding  motif  was  identified.  The  expression  of 
Bap-5  was  confirmed  by  RT-PCR  and  Western  blotting  and  was  shown  to  be  bvg 
dependent.  Although  Bap-5  does  not  possess  a  typical  signal  sequence  like  pertactin 
(PRN),  its  surface  localisation  was  confirmed  by  agglutination  and  immunofluorescence 
assaYs. 
A  potential  role  for  Bap-5  in  infection  was  studied  by  generating  Bap-5  deficient 
mutants  in  two  strains  of  B.  pertussis.  An  allelic  exchange  procedure  with  the  suicide 
vector  pSS1129  carrying  the  bap-5  gene  disrupted  with  a  kanamycin-resistance  cassette 
was  used.  PCR  and  Southern  blotting  confirmed  the  replacement  of  the  wild-type  bap-5 
gene  with  the  mutated  version.  Moreover,  SDS-PAGE  and  Western  blotting  of  outer- 
membrane  preparations  of  B.  pertussis  Taberman  wild-type  and  its  Bap-5-deficient  mutant 
showed  a  clear  difference  in  their  outer-membrane  profile  at  -79.9kDa  presumably 
xxi representing  the  unprocessed  form  and  bands  at  -65  kDa  and  -16  kDa  may  represent  the 
processed  forms  of  the  protein. 
The  Bap-5  characterisation  studies  showed  that  the  Taberman  Bap-5-deficient  strain 
was  less  able  than  the  parent  strain  to  colonise  the  lower  respiratory  tract  of  mice  and 
adhesion  studies  (in  vitro)  showed  that  the  Taberman  parent  was  better  in  adhering  to 
certain  cell  types  than  the  Bap-5-deficient  mutant.  The  study  also  showed  that  a  Bap-5- 
deficient  mutant  was  less  able  to  resist  complement-mediated  killing  by  normal  human 
serum.  A  rabbit  antibody  to  Bap-5  had  the  ability  to  potentiate  bacterial  killing  by 
complement.  Thus,  Bap-5  appears  to  have  properties  in  common  with  other  members  of 
the  B.  pertussis  autotransporter  protein  family  such  as  PRN  and  BrkA. 
The  second  part  of  the  project  dealt  with  the  processing  and  secretion  of  PRN  in  a 
range  of  protease-deficient  strains  of  E.  coli  to  determine  the  involvement  of  particular 
protease(s)  in  the  processing  and  secretion  of  PRN  and  other  autotransporter  proteins.  The 
results  showed  that  the  processing  and  release  of  PRN  does  not  appear  to  rely  on  a  specific 
protease.  However,  secretion  was  defective  in  the  most  protease-deficient  E.  coli  strain 
lacking  several  periplasmic  and  OM-located  proteases. 
The  ability  of  the  recombinant  detergent-extracted  and  re-natured  C-terminal 
domain  (P.  30)  of  PRN  and  of  the  native  mature  domain  (P.  69)  to  function  as  protective 
immunogens  was  compared.  The  study  showed  that  the  P.  30  protein  did  not  have  any 
protective  effect,  under  the  conditions  tested,  against  B.  pertussis  colonisation  of  the 
respiratory  tract  of  mice  whereas  the  P.  69  protein  proved  to  be  an  excellent  protective 
antigen,  in  agreement  with  previously  reported  data. 
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1.1  The  genus  Bordetella 
Introduction 
The  genus  Bordetella  is  comprised  of  small,  aerobic  (with  the  exception  of  the  most 
recently  identified  species  B.  petrii),  non  spore  forming,  Gram-negative  minute  cocco- 
bacilli  (0.3-0.5  jim  x  0.5-2.0  jim).  Members  of  the  genus  Bordetella  are  pathogenic 
bacteria  that  can  cause  respiratory  infections  in  mammalian  as  well  as  avian  species.  The 
genus  was  named  in  honour  of  Jules  Bordet,  who  identified  the  organism  initially  from  a 
patient  with  whooping  cough  in  1906.  The  GC  content  of  these  bacteria  is  in  the  range  of 
61  and  68  mol%  (Gerlach  et  al.,  2001)  and  their  optimal  growth  temperature  is  35'ý-37*C 
(Parton,  1998). 
1.2  Bordetellae  and  their  close  relatives 
Bordetella  species  are  closely  related  to  bacteria  classified  in  the  genera  Alcaligenes 
and  Achromobacter.  Phenotypic  differentiation  between  these  genera  is  virtually 
impossible  and  has  caused  several  misclassifications  in  the  past  (Busse  and  Auling,  1992; 
Vandarnme  et  al.,  1996).  However,  genotypically  all  three  genera  are  clearly  distinct  by 
comparative  16S  RNA  sequence  analysis,  amplified  ribosomal  DNA  restriction  analysis 
and  DNA-RNA  hybridisation  studies  (De  Ley  et  al.,  1986;  Vandarnme  et  al.,  1996).  These 
studies  also  indicated  that  Bordetella  species  are  more  closely  related  to  Achromobacter 
species,  due  to  the  high  GC  content  in  their  DNA,  than  to  members  of  the  genus 
Alcaligenes.  Achromobacter  species  are  environmental  organisms  and  some  of  them  are 
facultative  pathogens,  which  may  cause  uncommon  but  serious  nosocomial  epidemics 
(Granowitz  and  Keenholtz,  1998).  Due  to  the  close  relationship  of  Bordetella  spp  to  some 
environmental  bacteria,  it  is  likely  that  the  pathogenic  species  have  evolved  from 
environmental  relatives  and  have  acquired  relevant  virulence  traits  to  become  successful 
and  obligate  colonisers  and  pathogens  of  mammals  and  birds. 
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1.3  Species  of  Bordetella 
Introduction 
The  following  species  have  been  identified  and  characterised  in  the  genus  Bordetella. 
1.3.1  Classical  species 
These  are  B.  pertussis,  B.  parapertussis  and  B.  bronchiseptica.  They  agglutinate 
erythrocytes  from  a  variety  of  mammals  and  appear  to  be  obligate  mammalian  pathogens. 
Humans  are  the  only  hosts  for  B.  pertussis,  whereas  humans  and  sheep  are  hosts  of  B. 
parapertussis  and  wild  and  domesticated  animals  are  the  hosts  of  B.  bronchiseptica. 
B.  pertussis 
Due  to  the  requirement  for  blood  in  laboratory  media,  B.  pertussis  was  first  classified 
as  Haemophilus  perfussis  (Hornibrook,  1940).  In  1952,  after  several  changes  of  its  name, 
it  was  classified  in  its  own  genus.  It  causes  the  highly  infectious  and  acute  childhood 
disease  known  as  whooping  cough  (pertussis)  with  severe  clinical  manifestations  (section 
1.5)  (Hewlett,  1995). 
B.  parapertussis 
B.  parapertussis  is  responsible  for  a  mild  form  of  whooping  cough  in  hum4ns 
(Khelef  et  al.,  1993).  It  has  been  also  isolated  from  healthy  and  pneumonic  sheep.  Several 
surveys  indicated  that  between  5-25%  of  pertussis-like  cases  in  some  countries  in  Europe 
may  be  caused  by  this  pathogen  (Mertsola,  1985). 
B.  bronchiseptica 
This  organism  was  first  isolated  by  Ferry  (1910)  from  the  respiratory  tract  of  dogs 
and  is  a  cause  of  infection  in  a  wide  range  of  domestic  as  well  as  wild  animals  and  birds 
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(Charles  et  al.,  1994).  It  is  the  cause  of  kennel  cough  in  dogs,  atrophic  rhinifis  in  swine 
and  snuffles  in  rabbits.  It  appears  to  be  more  of  a  respiratory  tract  commensal  and 
opportunist  pathogen,  sometimes  associated  with  cases  of  septicaemia  in  immnuo- 
compromised  patients  (Woolfrey  and  Moody,  1991;  Parton,  1999). 
The  genetic  diversity  between  these  three  Bordetella  species  is  quite  limited  and  all 
three  cause  upper  respiratory  tract  disease  which  involves  the  interaction  of  the  bacteria 
with  ciliated  tracheal  epithelial.  cells,  resulting  in  ciliostasis  and  killing  of  the  ciliated  cells 
(Gerlach  et  al.,  2001). 
1.3.2  Recently  described  species 
B.  avium 
B.  avium  associates  with  ciliated  tracheal  epithelium  and  is  a  causative  agent  of 
infections  of  upper  respiratory  tract.  However,  the  pathogenic  potential  of  B.  avium 
appears  to  be  confined  to  birds,  causing  avian  bordetellosis  and  turkey  coryza  (Skeeles  et 
al.,  1988). 
B.  hinzii 
B.  hinzii  is  the  name  given  to  a  B.  avium-like  group  of  organisms  isolated  from  the 
respiratory  tracts  of  turkeys  and  chickens  (Vandarnme  et  al.,  1995).  It  was  reported  as  the 
causative  agent  of  a  fatal  septicaen-da  in  man  and  other  cases  indicate  that  B.  hinzii  may 
cause  disease  in  humans  under  certain  conditions  e.  g.  in  HIV  and  cystic  fibrosis  patients 
(Cookson  et  al.,  1994;  Funke  et  al.,  1996;  Kattar  et  al.,  2000). 
B.  holmesii 
B.  holmesii  belongs  to  a  group  of  isolates  originally  identified  from  human  blood 
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cultures  (Weyant  et  al.,  1995).  It  is  also  isolated  from  sputum  and,  with  increasing 
incidence,  from  nasopharyngeal  specimens  of  otherwise  healthy  young  people  with  a 
cough  (Mazengia  et  al.,  2000).  As  for  B.  hindi,  the  pathogenic  potential  of  B.  holmesii  is 
not  clear.  Both  B.  holmesii  and  B.  hinzii  appear  to  be  opportunists  in  man  and  have  been 
isolated  mainly  from  compromised  patients.  No  alternative  host  other  than  man  has  been 
reported  for  B.  holmesii  (Parton,  1999). 
B.  trematum 
The  seventh  member  of  this  family  is  B.  treinatum  which  was  isolated  from  wounds 
and  infected  ears  in  humans  but  not  from  the  respiratory  tract  (Vandamme  et  al.,  1996).  It 
was  originally  described  as  atypical  Bordetella  or  unidentified  organism.  At  present  the 
pathogenic  potential  of  this  species  is  not  clear. 
B.  petrii 
Recently,  a  bacterium  designated  as  strain  SEI  II  IR,  was  proposed  to  represent  a 
novel  Bordetella  species,  Bordetella  petrii  spp.  nov.  It  was  isolated  from  an  anaerobic 
dechlorinating  bioreactor  consortium  enriched  from  river  sediment  (Wintzingerode  et  al., 
2001).  Although  it  represents  the  first  type  of  Bordetella  having  an  environmental  origin 
and  being  an  anaerobic  organism,  detailed  analysis  of  chemotaxonomic,  biochemical  and 
genetic  characters  e.  g.  by  comparative  16S-rDNA  analysis  have  classified  it  as  a  new 
member  of  the  genus  Bordetella  (Wintzingerode  et  al.,  2001). 
Studies  on  the  relatedness  of  B.  pertussis,  B.  parapertussis  and  B.  bronchiseptica  by 
multilocus  enzyme  electrophoresis,  nucleic  acid  hybridisation  analyses  and  other 
comparisons  have  suggested  that  they  are  in  fact  subtypes  of  a  single  genomic  species, 
whereas  B.  avium,  B.  holmesii,  B.  hinzii,  B.  trematum  and  perhaps  B.  petrii  each  form  true 
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genomic  species  (Vandamme  et  al.,  1995,1996;  Weyant  et  al.,  1995;  Wintzingerode  et  al., 
2001). 
1.4  Pertussis  and  its  causative  agent 
1.4.1  Epidemiology  of  pertussis 
Bordetella  pertussis  is  the  causative  agent  of  whooping  cough  and  is  responsible  for 
one  of  the  ten  most  common  causes  of  death  from  infectious  diseases.  The  World  Health 
Organisation  (WHO:  http:  //www.  who.  int/vaccines-diseases/diseases/Pertussisvaccine.  html) 
has  reported  50  million  cases  and  350,000  deaths  world-wide  per  year,  mainly  among 
unvaccinated  children  in  third  world  countries.  In  the  USA,  where  there  is  a  high  vaccine 
uptake,  9500  cases  were  reported  in  1994-95.  In  the  UK,  2390  cases  were  reported  in 
1996,  despite  a  vaccine  uptake  of  95  %  (Miller  et  al.,  1992).  However,  it  is  widely 
believed  that  the  actual  number  of  cases  is  much  higher.  The  organism  is  highly 
communicable  with  attack  rates  of  50-100  %  depending  upon  the  intensity  of  exposure.  It 
is  believed  that  transmission  of  B.  pertussis  occurs  via  aerosol  droplets,  expelled  by  severe 
coughing  from  the  respiratory  tract  of  infected  individuals  to  the  susceptible  hosts.  It  has 
been  shown  that  whether  immunisation  is  practised  or  not,  the  disease  is  endemic.  In  most 
countries  an  epidemic  occurs  approximately  every  3-4  years,  possibly  due  to  an  increasing 
number  of  susceptible  individuals  in  the  population  reaching  a  threshold  level.  The 
organism  is  not  thought  to  survive  in  the  environment  for  a  prolonged  period,  and  so 
transmission  must  occur  from  one  individual  to  another.  Recent  evidence  suggested  that 
adults  and  adolescents  even  when  they  have  mild  or  unrecognised  disease  constitute  an 
important  reservoir  of  infection  (Black,  1997;  Cherry,  1999).  Physicians  and  researchers 
have  known  for  decades  that  the  pathogen  destroys  the  ciliated  cells  in  the  epithelial  lining 
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of  the  respiratory  tract.  The  hair-like  cilia  sweep  away  mucus  but,  when  they  die, 
coughing  provides  the  only  way  to  clear  the  airway.  The  result  likely  contributes  to  the 
intense  gasping  cough  that  not  only  gives  the  disease  its  name  but  also  spreads  the 
bacterium  to  other  victims  (Strauss,  1999). 
1.4.2  Clinical  disease 
Early  in  this  century,  Mallory  and  Homor  characterised  pertussis  infection  as  a  non- 
invasive  bacterial  colonisation  of  the  ciliated  cells  in  the  respiratory  epithelium.  The 
bacterium  damages  the  epithelium  and,  more  recently,  this  has  been  confirmed  by  nasal 
biopsies  taken  from  children  with  whooping  cough.  The  consequent  impairment  of 
mucociliary  transport  is  thought  to  be  responsible  for  the  paroxysmal  coughing  and 
choking  which  characterises  the  illness  (Soane  et  al.,  2000). 
Pertussis  is  characterised  by  three  phases.  Following  exposure  in  a  susceptible 
individual,  there  is  an  incubation  period  of  5  to  7  days  prior  to  the  development  of 
symptoms.  Non-sPecific  symptoms,  similar  to  those  of  the  common  cold,  lasting 
approximately  7  days,  constitute  the  catarrhal  phase,  during  which  the  isolation  rate  of  the 
organism  may  be  as  high  as  90  %.  This  gradually  becomes  the  paroxysmal  phase  as  the 
dry  non-productive  cough  becomes  a  paroxysmal  cough  with  mucus  secretion  and 
vomiting  (Wardlaw  and  Parton,  1988).  Coughing  is  an  attempt  to  clear  the  respiratory 
secretions,  and  is  followed  by  inspiration  against  the  still-narrowed  glottis  to  produce  the 
characteristic  whoop,  from  which  the  alternative  name  "whooping  cough"  is  derived. 
Other  characteristic  signs  during  this  phase  include  leukocytosis,  lymphocytosis,  weight 
loss  and  occasional  hypoglycaemia.  The  recovery  rate  of  the  organism  is  much  reduced  by 
the  time  of  the  paroxysmal  phase.  Since  the  organism  is  only  rarely  isolated  from  the 
blood  of  a  patient,  it  has  been  suggested  that  most  of  the  clinical  findings  may  be  due  to 
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toxin  release  and  dissemination.  The  paroxysmal  phase  lasts  at  least  2  weeks.  The  third 
stage  of  the  disease  is  the  convalescent  stage  which  can  last  for  weeks  or  even  months  and 
eventually  leads  to  a  gradual  disappearance  of  the  severe  symptoms  (Gerlach  et  al.,  2001). 
A  high  percentage  of  all  reported  cases  of  pertussis  require  hospitalisation,  especially  in 
those  infants  around  6  months  of  age.  The  case  fatality  rate  due  to  pertussis  has  been 
estimated  as  up  to  0.2  % in  USA  and  the  majority  (84  %)  of  these  deaths  were  in  infants 
aged  about  6  months  (Chen-y  et  al.,  1988,1996;  Hewlett,  2000).  The  impairment  of  the 
respiratory  tract  defences  also  makes  the  individual  more  susceptible  to  secondary 
infections  with  other  bacteria.  Secondary  infections  such  as  otitis  media  and  pneumonia 
are  relatively  frequent,  especially  in  infants  and  may  result  from  impairment  of  clearance 
mechanisms  by  the  bacterium.  Central  nervous  disturbances,  in  the  form  of  seizures  and 
encephalopathy  may  also  occur  and  are  thought  to  be  due  to  hypoxia  or  possibly  to 
bacterial  toxins.  There  is  evidence  that  B.  pertussis  inhibits  the  immune  responses  within 
the  respiratory  tract.  Recent  studies  have  suggested  that  B.  pertussis  has  the  capability  of 
inducing  mucin  gene  expression  in  infected  bronchial  tissues,  to  which  B.  pertussis  can 
bind  and  colonise  the  host  effectively  and  thereby  subvert  the  host  innate  defences 
(Bechler  et  al.,  2000). 
1.4.3  Diagnosis 
Clinical  diagnosis  of  pertussis  is  often  possible  due  to  the  characteristic  and 
prolonged  paroxysmal  coughing  in  the  disease.  However  clinical  features  tend  to  vary 
with  age  and  immune  status.  A  pronounced  leukocytosis  is  also  suggestive  of  pertussis. 
The  WHO  definition  of  pertussis  requires  a  mJnimum.  of  21  days  of  paroxysmal  coughing 
with  laboratory  confirmation  or  epidemiological  linkage  (WHO,  1991).  Laboratory 
methods  include  direct  detection  of  B.  pertussis  by  culture,  direct  fluorescent  antibody  test 
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(DFA  test)  and  PCR  methods,  or  indirect  diagnosis  by  serology  (Muller  et  al.,  1997; 
Hallander,  1999;  Kerr  and  Mathews,  2000). 
1.4.4  Antimicrobial  therapy 
Several  antibiotics  including  erythromycin,  tetracycline,  chloramphenicol, 
trimethoprim-sulpamethoxazole  are  effective  but  erythromycin  is  usually  considered  a 
better  choice  for  treating  pertussis  patients  (Hoppe,  1992).  Antibiotic  treatment  in  the 
early  (catarrhal  or  early  paroxysmal)  stages  proves  to  be  more  effective  in  ameliorating  the 
symptoms  of  pertussis  (Cheny  et  al.,  1988). 
1.4.5  Virulence  factors 
Bordetella  species  produce  a  variety  of  surface-associated  and  secreted  molecules 
(Table  1.1).  These  products  are  presumed  to  be  involved  in  adhesion  to  eukaryotic  tissues, 
evasion  of  host  defences  and  toxicity  towards  the  host.  Some  of  these  secreted  products, 
including  pertussis  toxin,  adenylate  cyclase  toxin,  pertactin  and  filamentous 
haemagglutinin  have  been  most  extensively  studied  in  B.  pertussis.  However  the  fastidious 
nature  of  this  species  in'the  laboratory  in  some  cases  has  led  to  use  of  E.  coli  recombinant 
strains  and  Salmonella  spp.  for  their  expression  and  investigating  their  role  in  virulence 
(Shareck  and  Cameron,  1984;  Fairweather  et  al.,  1990;  Makoff  et  al.,  1990;  Strugnell  et 
al.,  1992;  Charles  et  al.,  1994;  Anderson  et  al.,  1996). 
1.4.5.1  Adhesins 
Pertussis  is  a  multifactorial  disease  process  that  is  dependent  on  the  well-orchestrated 
action  of  numerous  virulence  factors  of  B.  pertussis.  The  ability  of  bacteria  to-gain  access 
to  ihe  respiratory  tract  by  developing  its  association  to  the  ciliated  cells  is  provided  by  an 
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array  of  adhesins.  Adhesins  may  be  considered  the  first  instrument  of  developing  B. 
pertussis  infection  as  they  are  required  to  bring  B.  pertussis  into  close  contact  with  the 
target  cells  for  their  toxic  effect  to  be  induced  (Cundell  et  al.,  1994). 
1.4.5.1.1  Fimbfide 
Fimbriae  are  long,  thread-like  surface  structures  found  on  the  bacterial  surface  at  up 
to  500  copies  per  cell.  B.  pertussis  fimbriae  (Willems  et  al.,  1993)  are  proteinaceous 
appendages  that  protrude  from  the  cell  surface.  They  are  usually  -200  nm  in  length  and  -5 
nm  in  diameter  (Zhang  et  al.,  1985).  The  main  body  of  fimbriae  is  composed  of  a  major 
subunit  protein,  Fim2  or  Fim3,  of  22.5  kDa  and  22  kDa,  respectively.  The  tips  of  both 
types  (Fim2  and  Fim3)  of  fimbriae  are  occupied  by  a  minor  40-kDa  fimbrial  protein  called 
FimD  (Geuijin  et  al.,  1997). 
The  structural  genes  for  Fim2  and  Fim3  are  scattered  on  the  chromosome,  likewise 
the  gene  for  another  fimbrial  subunit,  FimX  (Stibitz  and  Garletts,  1992).  ThefimX  gene  is 
not  expressed  in  B.  pertussis  because  of  a  deletion  in  its  promoter  region  (Willems  et  al., 
1993).  GenesfimB-D  are  required  for  export  and  assembly  of  fimbrial  subunits  (Fim2  and 
Fim3)  and  are  located  between  the  structural  gene  for  FHA  (fhaB)  and  a  gene  for  FHA 
secretion  JhaC  (Section  1.8.1.2)  (Willems  et  al.,  1993).  The  arrangement  of  the  genes  is 
finzABCD,  which  is  like  other  fimbrial  operons  in  other  organisms,  with  the  first  gene 
encoding  the  major  fimbrial  subunit.  However  thefimA  (Fiml)  gene  is  not  expressed  in  B. 
pertussis  because  of  deletion  at  its  5'  end,  whereas  it  is  intact  in  B.  parapertussis  and  B. 
bronchiseptica  and  it  is  expressed  in  B.  bronchiseptica  (Willems  et  al.,  1993;  Boschwitz  et 
al.,  1997). 
It  has  been  shown  that  B.  pertussisfim  mutants  are  more  adherent  to  Vero  cells  than 
wild  type  B.  pertussis  but  less  adherent  to  tracheal  rings  prepared  from  the  primate  Papio 
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anubis  (Funnel  and  Robinson,  1993).  The  purified  fimbriae  bind  to  sulphated  sugars, 
which  are  commonly  found  in  the  respiratory  tract  (Geuijen  et  al.,  1996).  A  B.  pertussis 
strain  unable  to  produce  fimbriae  due  to  a  mutation  infimB  was  less  able  to  colonise  the 
nasopharynx,  trachea  and  lungs  of  intranasally-infected  mice  when  compared  with  its  wild- 
type  parent  and  the  effect  was  more  pronounced  in  the  trachea  (Geuijen  et  al.,  1997). 
However,  the  mutation  also  reduces  the  production  of  FHA  by  75  %.  A  strain  with  a 
mutation  injhaC,  which  inhibited  the  production  of  FHA  specifically,  was  less  affected  for 
respiratory  tract  colonisation,  as  was  a  strain  unable  to  produce  Fim2  and  Fim3  (Geuijen  et 
al.,  1997).  A  firnbrial  mutant  AfImBCD  of  B.  bronchiseptica  appeared  to  be  altered  in  its 
ability  to  cause  respiratory  tract  infection  in  the  rat  trachea,  although  adhesion  to  cell  lines 
e.  g.  human  epithelial  laryngeal  (Hep-2)  cells  was  not  affected  (Mattoo  et  al.,  2000).  It 
appears  that  the  binding  of  fimbriae  to  non-ciliated  cells  including  monocytes  may  promote 
phagocytosis.  Fimbriae  on  B.  pertussis  interact  with  very  late  antigen-5  (VLA-5)  on 
monocytes  which  activates  complement  receptor  3  (CR3),  which  is  a  receptor  for  FHA 
(section  1.4.5.1.2),  reflecting  their  synergistic  action  during  infection. 
The  initial  translocation  of  fimbrial  components  across  the  cytoplasmic  membrane 
is  dependent  on  the  normal  type  II  export  system  (1.7.3.2).  However,  further  export  from 
the  periplasm  to  the  cell  exterior  is  mediated  by  a  specific  two-component  system 
consisting  of  a  periplasmic  chaperone  and  an  usher  (1.7.3.6),  which  is  an  outer  membrane 
located  pore  which  serves  as  the  assembly  platform  (Jones  et  aL,  1996). 
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Purified  fimbriae  are  protective  immunogens  in  mice  and  induce  agglutinating 
antibodies  (Ashworth  et  al.,  1982;  Robinson  et  al.,  1986,1989;  Gustafsson  et  al.,  1996; 
Willems  et  al.,  1998).  This  is  consistent  with  the  finding  that,  to  some  extent,  sero-specific 
protection  occurs  when  children  are  immunised  with  whole-cell  vaccine  preparations 
(Mooi  et  al.,  1998).  The  five-component  acellular  pertussis  vaccine  (APVs)  containing 
Fim2  and  Fim3  is  very  efficacious  in  humans  infants  (Ashworth  et  al.,  1982;  Robinson  et 
al.,  1986,1989;  Gustafsson  et  al.,  1996) 
1.4.5.1.2  Filamentous  haemagglutinin 
The  closely-related  Bordetellae  species,  namely  B.  pertussis,  B.  parapertussis  and  B. 
bronchiseptica,  produce  a  similar  array  of  virulence  factors.  Among  these,  FHA  is 
regarded  as  the  dominant  attachment  factor  (Arico  et  al.,  1993;  Locht  et  al.,  1993),  and  has 
been  shown  to  promote  attachment  to  a  variety  of  eukaryotic  cell  types  and  tissues  and 
appears  to  interact  with  complementary  receptors  through  a  number  of  different 
mechanisms  (Hannah  et  al.,  1994). 
In  B.  pertussis,  the  mature  220  kDa,  form  of  FHA  derives  from  a  370  kDa  FbaB 
precursor  by  an  as  yet  uncharacterised  proteolytic  removal  of  a  large  150  kDa  C-terminal 
portion  (Domenighini  et  al.,  1990;  Renauld-Mongenie  et  al.,  1996).  FHA  is  a  large 
filamentous  protein  with  dimensions  of  2  nm  x  40-100  nm,  quite  distinct  from  B.  pertussis 
fimbriae  (Relman  et  al.,  1989)  and  is  both  surface-associated  and  secreted  from  virulent 
bacteria  (Hannah  et  al.,  1994).  Most  B.  bronchiseptica  isolates  produce  and  secrete  FHA 
at  significantly  lower  levels  than  B.  pertusssis.  This  may  reflect  differences  in  strength  of 
their  respective  FHA  promoters,  in  the  primary  structures  or  function  of  the  FhaC 
accessory  proteins,  or  in  the  overall  cell  envelope  structure  (Locht  et  al.,  1993). 
The  fate  of  the  carboxy  terminal  domain  is  unlike  that  of  PRN,  BrkA  and  TCF 
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(section  1.8)  and,  following  cleavage  it  may  be  probably  degraded  in  the  periplasm. 
However,  It  has  also  been  suggested  that  the  C-terminal  domain  of  precursor  FhaB  anchors 
FHA  in  the  cell  envelope,  perhaps  by  spanning  the  periplasmic  space  and  in  this  way 
linking  the  inner  and  outer  membranes  (Domenighini  et  al.,  1990).  Proline  rich  repeats 
have  been  identified  in  the  carboxy  terminal  domain  of  FhaB  (Domenighini  et  al.,  1990). 
Such  a  proline  rich  region  exists  in  the  mature  PRN  protein,  close  to  the  putative  C- 
terminal  processing  site  (Charles  et  al.,  1989).  These  regions  are  thought  to  be 
characteristic  of  proteins  that  act  as  anchors  and  span  the  periplasm  (Domenighini  et  al., 
1990). 
A  noteworthy  feature  of  FHA  is  its  high  level  of  secretion  by  B.  pertussis  (Locht  et 
al.,  1993).  FHA  represents  the  most  abundant  polypeptide  in  the  culture  supernatant  of  B. 
pertussis  grown  in  vitro.  It  is  also  associated  with  the  bacterial  outer  membrane.  Coating 
of  the  bacterial  outer  surface  with  FHA  is  thought  to  be  responsible  for  self-agglutination 
of  the  bacteria  by  FHA-FHA  (intramolecular)  homotypic  interactions  (Menozzi  et  al., 
1994).  It  has  also  been  suggested  that  FHA  (and  perhaps,  pertussis  toxin  as  well)  released 
from  B.  pertussis  in  the  respiratory  tract  could  bind  to  other  bacteria  by  a  process  which  is 
known  as  'piracy  of  adhesins'  allowing  these  other  bacteria  to  efficiently  adhere  to  cilia 
and  promoting  secondary  bacterial  infections  (Tuomanen,  1993). 
The  multiple  binding  activities  of  the  mature  220  kDa  protein  have  been  the  focus  of 
many  studies.  FHA  is  recognized  by  lactose-containing  glycolipids  on  ciliated  respiratory 
epithelial  cells  (Tuomanen  et  al.,  1988).  It  also  binds  to  sulphated  carbohydrates  of 
sulPhatides  and  proteoglycans  on  the  surface  of  epithelial  cells  or  in  the  extracellular 
matrix  (Brennan  et  al.,  1991).  In  addition,  it  possesses  an  Arg-Gly-Asp  tri-peptide  (RGD 
motif),  which  is  a  recognition  sequence  for  the  members  of  the  integrin  family.  This  RGD 
site  within  the  mature  protein  is  recognized  by  the  P-3  leukocyte  response  integrin,  in 
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concert  with  an  integrin-associated  protein  (Ishibashi  et  al.,  1994).  A  recent  study  has 
suggested  that  B.  pertussis  FHA  may  promote  invasion  of  human  respiratory  cells  through 
the  interaction  of  its  RGD  sequence  with  host  cell  a5PI  integrin  (Ishibashi  et  al.,  2001).  As 
the  dominant  adhesin,  differences  in  FHA-mediated  function  might  contribute  to 
differences  in  Bordetella  host  species  tropism. 
A  number  of  in  vitro  adhesion  assays  using  primary  cell  lines  and  tissues  of  various 
types  and  from  a  variety  of  species  have  indicated  that  FHA  is  the  major  B.  pertussis 
adhesin  (Funnell  and  Robinson,  1993;  Bassinet  et  al.,  2000).  However  studies  with  a  B. 
pertussis  FHA  mutant  using  the  mouse  model  of  infection  have  suggested  that  FHA  is  far 
less  important  in  vivo  (  Roberts  et  al.,  1991;  Khelef  et  al.,  1994;  Geuijen  et  al.,  1997).  In 
some  cases  this  might  have  been  due  to  the  mutants  being  created  by  an  internal  in-frame 
deletion  in  JhaB  which  might  have  allowed  the  production  of  truncated  FHA  that  possibly 
would  have  retained  some  activity.  On  the  other  hand  anJhaC  mutant  (deficient  in  surface 
exposed  FHA)  exhibited  a  slight,  transient  defect  in  colonisation  of  the  nasal  cavity  and 
trachea  of  mice  (Geuijen  et  al.,  1997).  B.  bronchiseptica  FHA  is  required  for  tracheal 
colonisation  of  rats,  but  it  is  insufficient  for  colonisation  when  expressed  ectopically  in  the 
Bvg"  phase  (Cotter  el  al.,  1998).  FHA  is  absolutely  required  for  the  colonisation  of  the 
tracheas  of  conscious  but  not  anaesthetised  rats  by  B.  bronchiseptica.  The  use  of 
anaesthesia  in  mice  may  be  the  factor  responsible  for  the  relative  lack  of  effect  of  FHA 
mutations  observed  in  some,  but  not  all,  of  the  experiments  with  B.  pertussis  (Cotter  et  al., 
1998). 
B.  pertussis  FHA  is  also  highly  immunogenic  in  humans  and  a  protective  antigen  in 
animal  models  (Amsbaugh  et  al.,  1993).  Most  monoclonal  antibodies  generated  against 
FHA  from  B.  pertussis  cross-react  with  FHA  from  B.  bronchiseptica,  indicating  shared 
epitopes  (Menozzi  et  al.,  1994).  FHA  is  one  of  the  main  components  of  most  APVs 
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currently  in  use  in  humans  (Mills  et  al.,  1998;  Mahon  et  al.,  1996;  Guiso  et  al.,  1999). 
The  other  adhesins,  along  with  some  other  functionally  different  virulence  factors 
of  B.  perlussis,  are  described  in  section  1.8  under  the  heading  of  members  of  B.  pertussis 
autotransporter  family. 
1.4.5.2  Toxins 
After  successful  colonisation,  different  toxins  play  their  role  in  completing  the 
pathogenic  cycle  of  B.  pertussis  and  establishing  the  full  spectrum  of  whooping  cough 
(pertussis).  For  example,  tracheal  cytotoxin  is  thought  to  be  the  cause  of  ciliostasis  and 
eventually  death  of  columnar  epithelial  cells,  producing  local  lesions  on  the  mucosa, 
accumulation  of  mucus  and  debris,  and  hence  eliciting  the  paroxysmal  cough.  Adenylate 
cyclase  toxin  and  probably  pertussis  toxin  help  to  protect  the  organisms  from  clearance  by 
phagocytic  cells  and  may  stimulate  secretion  of  fluid  and  mucus. 
1.4.5.2.1  Pertussis  toxin 
Pertussis  toxin  (PTX)  is  an  exotoxin  and  a  major  virulence  factor  of  B.  pertussis 
(Locht  and  Keith,  1986)  and  in  its  toxoided  form  is  the  main  component  of  all  acellular 
pertussis  vaccines  (Castro  et  al.,  2001).  It  has  a  remarkable  range  of  biological  activities  in 
vivo  and  in  vitro,  resulting  from  its  action  on  many  different  cell  types  and  tissues  and 
hence  is  implicated  as  having  a  fundamental  role  in  the  pathogenesis  of  pertussis. 
PTX  is  a  complex  protein  of  105  kDa  comprised  of  5  subunits  that  are  the  products 
of  five  genes  (sl-s5),  present  in  the  ratio  of  1:  1:  1:  2:  1  and  together  constitute  a  complex 
with  ADP-ribosylating  activity.  The  crystal  structure  of  PTX  reveals  one  or  more 
intrachain  disulphide  bonds  that  stabilise  each  of  the  subunits  in  the  mature  toxin  (Stein  et 
al.,  1994). 
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al.,  1994).  PTX  is  an  AB5  toxin;  with  S1  being  the  enzymatic  subunit  of  the  toxin  and  the 
B  oligomer  being  the  pentamer  that  binds  to  the  surface  receptors  on  eukaryotic  cells  and 
translocates  the  toxic  subunit  across  the  cell  membrane.  Some  of  the  properties  of  PTX  are 
completely  dependent  upon  the  binding  of  the  B-oligomer  to  cell  surfaces.  These  include 
haemagglutination  and  T-cell  mitogenicity  (Ui,  1988;  Kaslow  and  Bums,  1992)  and  at 
least  some  of  its  adjuvant  activities  (Roberts  et  al.,  1995;  Ryan  et  al.,  1997).  The  other, 
harmful,  effects  depend  on  the  activities  of  the  holotoxin.  Upon  receptor-binding,  PTX  is 
taken  into  the  eukaryotic  cell  by  receptor-mediated  endocytosis.  PTX  interferes  with 
cellular  signalling  processes  across  the  membrane  by  ADP-ribosylating  the  (x-subunit  of 
various  regulatory  G  proteins  (Krueger  and  Barbieri,  1995).  This  results  in  a  variety  of 
consequences  including  inhibition  of  chernotactic  detection  by  leukocytes,  lymphocytosis 
and  increased  vascular  permeability  (Craig,  1988). 
PTX  is  secreted  as  an  assembled  protein  complex  and  novel  machinery  is  needed 
(Weiss,  1994).  This  export  pathway  has  been  termed  type  IV  secretion  (section  1.7.3.4). 
Most  proteins  are  presented  to  the  translocation  apparatus  in  the  form  of  a  long  slender  like 
structure,  which  is  secreted  in  an  unfolded  state  and  folds  following  secretion.  However, 
pertussis  toxin  is  an  exception.  The  export  of  a  functional  toxin  complex  prevents  energy 
from  being  wasted  on  producing  subunits  that  do  not  become  part  of  a  functional  toxin 
ffeigý,  1,904). 
Most  of  the  PTX  is  secreted  but  some  remains  surface-associated,  as  depicted  by 
electron-microscopy  (Ashworth  et  al.,  1985).  The  surface  located  PTX  may  take  part  in 
adhesion  of  B.  pertussis  to  eukaryotic  cells  (Tuomanen,  1988)  as  evident  by  50  %  decrease 
in  binding  of  a  B.  pertussis  PUC  mutant  to  human  respiratory  ciliated  cells  (Relman  et  al., 
1989).  PTX  has  also  been  shown  to  play  role  in  adherence  of  B.  pertussis  to  non-ciliated 
epithelial  cells  (Relman  et  al.,  1989).  The  S2  or  S3  subunit  binding  to  the  macrophages 
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enhances  the  binding  of  B.  pertussis  to  the  CR3  integrin  mediated  by  FHA.  The  activation 
of  CR3  and  augmentation  of  FHA-binding  is  a  property  that  PTX  shares  with  B.  pertussis 
firnbriae  (section  1.4.5.1.1).  PTX  (B  oligomer)  enables  B.  pertussis  to  bind  to  eukaryotic 
cells  including  human  respiratory  ciliated  cells  and  macrophages  (Sandros  and  Tuomanen, 
1993).  The  nature  of  the  lectin-like  interaction  between  the  B-subunits  and  the  eukaryotic 
cell  mimics  the  relationship  between  the  leukocyte  surface  and  the  capillary  wall  that 
occurs  during  early  diapedesis  (Sandros  and  Tuomanen,  1993).  The  B  subunit  targets  PTX 
to  eukaryotic  cells  by  binding  to  glycoconjugates,  preferentially  glycoproteins  (Brennan  et 
al.,  1988;  Tyrrell  et  al.,  1989;  Saukkonen  et  al.,  1992;  Armstrong  et  al.,  1994). 
In  a  coughing  rat  model  of  pertussis,  a  wild  type  B.  pertussis  strain  produced  a 
significant  number  of  coughing  paroxysms  where  as  PTX-  mutant,  a  phase  IV  strain  and  a 
B.  parapertussis  strain,  none  of  which  produced  PTX,  did  not  (Parton  et  al.,  1994).  PTX 
has  been  shown  to  be  involved  in  lethal  B.  pertussis  infection  of  infant  mice  although 
mutations  affecting  the  production  of  PTX  did  not  affect  the  growth  of  B.  pertussis  in 
murine  lungs  (Weiss  et  al.,  1984;  Weiss  and  Goodwin,  1989).  However,  in  the  adult  non- 
lethal  mouse  model,  a  B.  Pertussis  PT)C  mutant  strain  inflicted  a  less  severe  pulmonary 
inflammation  as  compared  to  its  wild-type  strain  (Khelef  et  al.,  1994). 
The  exact  role  of  PTX  in  the  pathogenesis  of  whooping  cough  and  its  main  site  of 
action  in  the  host,  whether  locally  in  the  respiratory  tract  or  systemically,  perhaps  in  the 
central  nervous  system  remains  obscure  (Hewlett,  1997),  although  its  absence  in  B. 
parapertussis  implies  that  it  may  have  only  a  minor  role  in  causing  the  typical  whooping 
cough  symptoms  (Parton,  1996).  Despite  the  uncertainty  of  the  role  of  PTX  in 
pathogenesis,  toxoided  PTX  (PTD),  is  included  in  all  acellular  vaccines  due  to  successful 
provision  of  protection  in  mouse  models  involving  either  intracerebral  or  aerosol  challenge 
with  B.  pertussis  (Sato  et  al.,  1984;  Sato  and  Sato,  1988,1990).  Chemical  detoxification 
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of  PTX  however  is  known  to  reduce  its  immunogenicity  and  more  immunogenic, 
genetically  detoxified,  recombinant  PTD  (rPTD)  is  now  available  (Rappuoli  et  al.,  1992a, 
1992b). 
1.4.5.2.2  Adenylate  cyclase  toxin 
A  second  important  protein  toxin  of  B.  pertussis  called  adenylate  cyclase  toxin 
(ACT)  or  CyaA,  is  a  bifunctional  protein  of  molecular  weight  200  kDa  comprising  of 
1,706  amino  acids  (Hewlett  et  al.,  1976).  B.  parapertussis  and  B.  bronchiseptica  have 
ACT  activity  similar  to  that  of  B.  pertussis  but  the  toxins  are  antigenically  distinct 
(Gueirard  and  Guiso,  1993).  CyaA  exhibits  a  number  of  striking  features:  (Loqht  et  al., 
2001).  It  is  secreted  by  virulent  bacteria,  (section  1.7.3.1),  it  is  activated  by  the  eukaryotic 
calcium-binding  protein  calmodulin  (CAM),  and  it  can  enter  eukaryotic  cells,  where  upon 
after  activation  by  endogenous  CAM,  it  catalyses  high  level  synthesis  of  cyclic  3'-5'AMP 
(cAMP),  an  important  signalling  molecule,  which  in  turn  alters  cellular  physiology  due  to 
the  depletion  of  ATP 
CyaA  is  constructed  in  a  modular  fashion:  the  ATP-cyclizing  and  CAM-activated 
catalytic  adenylate  cyclase  domain  (AC)  is  located  in  the  400  an-ýino-proximal  residues, 
whereas  the  carboxy-terminal  1306  residues  of  CyaA  are  responsible  for  the  pore-forming 
and  haemolytic  phenotype  of  B.  pertussis.  The  haemolysin  domain  (residues  400-1706) 
displays  structural  characteristics  that  link  CyaA  to  a  family  of  bacterial  toxins  known  as 
the  RTX  (repeat  in  toxin)  family,  the  prototype  of  which  is  the  E.  coli  a-  haemolysin.  The 
haemolysin  domain  mediates  the  binding  and  internalisation  of  the  toxin  into  eukaryotic 
cells  (Ladant  and  Ullman,  1999).  The  toxin  is  synthesized  as  an  inactive  precursor  and 
then  converted  to  its  active  form  by  CyaC-mediated.  palmitoylation  of  Lys983.  This 
palmitoylation  is  required  for  binding  to  eukaryotic  cells  and  for  the  formation  of  a  pore 
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through  which  the  catalytic  subunit  can  penetrate  into  the  cell  (Betsou  et  al.,  1993). 
Immune  effectors  cells  such  as  neutrophils,  monocytes,  macrophages  and  natural 
killer  cells  are  thought  to  be  the  primary  targets.  ACT  has  also  been  suggested  to  play  a 
role  in  mucus  secretion  to  produce  the  excessive  fluid  as  seen  in  clinical  pertussis  cases. 
The  mouse  model  of  infection  using  ACT-deficient  mutants  has  suggested  its  importance 
as  a  virulence  factor  in  the  infectious  process.  ACT-deficient  mutants  have  reduced  ability 
to  cause  lethal  infection  in  infant  mice  and  to  colonise  the  lungs  of  older  mice  (Weiss  and 
Goodwin,  1989;  Khelef  et  al.,  1994).  Recent  studies  have  confinned  that  phagocytic  cells 
are  the  primary  target  of  ACT.  It  can  induce  apoptosis  in  mouse  alveolar  macrophages  in 
vitro  and  in  vivo  (Gueirard  et  al.,  1998).  Comparison  of  the  effects  of  wild-type  and  ACT- 
mutant  B.  bronchiseptica  strains  during  infection  of  normal  and  immunodeficient  mice  has 
suggested  that  neutrophils  are  critical  in  providing  the  early  defence  against  infection  and 
that  ACT  was  responsible  for  overcoming  this  arm  of  the  innate  immune  system  (Harvill  et 
al.,  2000).  Other  studies  have  suggested  that  the  expression  of  ACT  inhibits  uptake  and 
possible  destruction  of  B.  pertussis  by  human  respiratory  epithelial  cells  (Bassinet  et  al., 
2000)  and  by  human  neutrophils  after  opsonisation  (Weingart  and  Weiss,  2000). 
ACT  is  not  included  in  the  current  acellular  pertussis  vaccines  but  it  has  been  shown 
to  be  a  protective  antigen  in  number  of  studies.  The  purified  AC  enzymic  moiety  of  ACT 
was  shown  to  protect  mice  against  B.  pertussis  colonisation  of  the  respiratory  tract  and 
brain  after  sublethal  intranasal  and  lethal  intracerebral  challenge,  respectively  (Guiso  et  al., 
1991).  Anti  ACT-antibodies  have  been  shown  to  protect  mice  against  lethal  intranasal 
infection  with  B.  pertussis  (Brezin  et  al.,  1987).  Other  studies  suggested  that  immunisation 
with  either  native  ACT  or  recombinant  active  (acylated)  ACT  will  promote  more  rapid 
clearance  of  B.  pertussis  from  the  respiratory  tract  than  in  controls  or  in  mice  immunised 
with  inactive  (non-acylated)  recombinant  ACT  (Betsou  et  al.,  1993;  Hormozi  et  al.,  1999). 
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1.4.5.2.3  Tracheal  cytotoxin 
The  paraoxysmal  cough,  a  distinctive  characteristic  of  pertussis  has  been  attributed  to 
the  elaboration  of  the  tracheal  cytotoxin  (Cookson  et  al.,  1989).  Goldman  and  colleagues 
purified  tracheal  cytotoxin  (TCT),  a  peptidoglycan  fragment,  from  culture  supernates  of  B. 
pertussis  and  the  material  caused  progressive  cytotoxic  changes  in  ciliated  cells  of  hamster 
tracheal  organ  cultures  (Flak  and  Goldman,  1999). 
TCT  is  an  unusual,  low  molecular  weight  (921  Da)  toxin  consisting  of  muramyl 
peptide  containing  N-acetylglucosamine,  N-acetylmurarnic  acid,  alanine,  glutarnic  acid  and 
diaminopimelic  acid  in  the  molar  ratio  1:  1:  2:  1:  1  (Goldman,  1988;  Cookson  et  al.,  1989). 
TCT  and  related  muramyl  peptides  have  been  associated  with  diverse  biological  activities 
such  as  ciliostasis,  pyrogenicity,  adjuvanticity,  and  arthritogenicity,  induction  of  slow- 
wave  sleep  and  stimulation  of  IL-I  production  which  causes  increase  in  body  temperature. 
The  abnormal  release  of  large  amounts  of  TCT  by  Bordetella  spp.  causes  an  exaggerated 
response  that  results  in  respiratory  tract  pathology  (Flak  et  al.,  2000).  The  cytopathic 
effects  of  TCT  have  been  related  to  its  triggering  effect  on  the  production  of  IL-I  which 
stimulates  nitric  oxide  (NO)  production  leading  to  epithelial  cell  damage.  The  cytopathic 
effects  were  initially  thought  to  be  specific  for  ciliated  cells;  however  in  another  study  both 
ciliated  and  non-ciliated  human  nasal  epithelial  cells  were  damaged  by  the  toxin  (Soane  et 
al.,  2000).  TCT,  even  at  very  low  concentrations,  also  impairs  neutrophil  functions  and 
may  thereby  contribute  to  survival  of  bordetellae  in  vivo  (Cundell  et  al.,  1994).  There  is  no 
information  so  for  available  which  can  categorise  the  TCT  molecule  as  an  immunogen. 
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1.4.5.2.4  Dermottecrotic  toxin 
Introduction 
B.  pertussis  produces  a  highly  lethal  toxin  called  dermonecrotic  toxin  (DNT),  also 
known  as  heat-labile  toxin  (HLT)  (Pullinger  et  al.,  1996),  which  is  thought  to  induce 
inflammation,  vasoconstriction  and  necrotic  lesions  around  the  areas  where  B.  pertussis 
colonise  in  the  respiratory  tract.  The  lethal  toxin  is  a  102  kDa  protein  composed  of  four 
subunits,  two  of  24  kDa  and  two  of  30  kDa.  DNT  belongs  to  the  same  toxin  family  as  the 
cytotoxic  necrotising  factor  (CNFI  and  2)  of  E.  coli  which  affects  mammalian  cell  division 
or  cell  differentiation  (Pullinger  et  al.,  1996).  Purified  DNT  has  also  been  found  to 
stimulate  DNA  and  protein  synthesis  in  mammalian  cells  without  cell  division,  leading  to 
polymicleation.  It  also  induces  the  assembly  of  actin  stress  fibres  and  tyrosine 
phosphorylation  of  focal  adhesion  kinase  (Horiguchi  et  al.,  1994).  DNT  is  believed  to 
cause  these  effects  by  glutamine  63-deamidation  of  the  small  GTP-binding  protein,  RhoA, 
involving  residues  1136  to  1451  of  DNT  (Schmidt  et  al.,  1999).  Glutamine  63  is  essential 
for  GTP  hydrolysis  by  Rho.  Deamidation  of  glutamine  by  DNT  inhibits  the  GTPase 
activity  of  Rho  and  renders  the  Rho  protein  constitutively  active.  Rho  GTPases  are 
regulators  of  actin  cytoskeleton  and  act  as  molecular  switches  to  trigger  several 
intracellular  signalling  pathways. 
DNT  is  a  cytoplasmic  component  of  the  bacterium  and  does  not  seem  to  be  released 
by  actively-growing  cells  (Nikai  et  al.,  1985;  Walker  et  al.,  1994).  A  B.  pertussis 
transposon  insertion  mutant  deficient  in  DNT  production  was  found  to  be  unaltered  in  its 
ability  to  cause  a  lethal  intranasal  infection  in  infant  mice  (Weiss  and  Goodwin,  1989). 
However,  studies  on  other  Bordetella  species  in  their  natural  hosts  have  suggested  that 
DNT  does  appear  to  play  a  role  both  in  disease  process  and  colonisation.  In  B. 
bronchiseptica,  DNT  seems  to  be  involved  in  producing  the  turbinate  atrophy  associated 
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with  atrophic  rhinitis  in  pigs  as  a  DNT-deficient  mutant  was  associated  with  significantly 
less  atrophy  and  pneumonia  compared  with  wild-type  parent.  A  B.  bronchiseptica  DNT- 
mutant  was  also  unable  to  colonise  the  nasal  cavity  as  efficiently  as  the  wild-type  parent 
(Brockmeier  et  al.,  2000).  Another  study  with  a  B.  avium  DNT-  mutant  has  suggested  that 
the  mutant  was  less  virulent  and  persisted  for  a  shorter  period  of  time  in  young  turkeys, 
and  was  also  less  adherent  to  turkey  ciliated  tracheal  cells  in  vitro  (Temple  et  al.,  1998). 
The  protective  nature  of  DNT  in  toxoided  form  in  humans  and  animals  remains  to  be 
addressed.  On  the  other  hand,  it  has  been  suggested  that  it  is  not  an  essential  component 
for  protection  as  it  is  destroyed  or  removed  during  whole  cell  and  acellular  vaccine 
preparation,  respectively.  Moreover,  convalescent  sera  lack  anti-DNT  antibodies 
(Wardlaw  and  Parton,  1988).  Thus,  DNT  is  a  complicated  toxin  which  may  have  a 
significant,  but  as  yet  unclear  role  in  the  alteration  of  the  host  physiological  reactions  in 
response  to  B.  pertussis  infection  (Babu  et  al.,  2001). 
1.4.5.2.5  Lipopolysaccharide 
The  lipopolysaccharide  (LPS)  constitutes  an  integral  part  of  the  outer-membrane  of 
B.  pertussis,  in  common  with  other  Gram-negative  bacteria.  The  LPS  of  B.  pertussis,  but 
not  that  of  B.  bronchiseptica  and  B.  parapertussis,  lacks  an  0-polysaccharide  side-chain 
characteristic  of  the  LPS  of  the  enteric  bacteria  and  because  of  this  it  is  sometimes  referred 
to  as  lipooligosaccharide  (Chabby  and  Caroff,  1988;  Martin  et  al.,  1992;  Le  Blay  et  al., 
1994  ;  Preston  et  al.,  1996). 
LPS  has  the  usual  properties  of  endotoxins  such  as  general  toxicity,  pyrogenicity 
and  adjuvanticity  as  well  as  some  unusual  properties  such  as  ability  to  induce  resistance  to 
mouse  adenovirus  infection  and  the  ability  of  the  polysaccharide  component  to  induce  B- 
cell  mitogenicity  and  polyclonal  B  cell  activation  in  mice  (Chabby  and  Caroff,  1988). 
22 Habib  Bokhari  Introduction 
Endotoxins  mediate  most  of  their  diverse  biological  effects  by  triggering  cytokine 
production  by  monocytes.  More  recently,  LPS  has  been  shown  to  act  synergistically  with 
tracheal  cytotoxin  to  induce  inflammation  in  the  respiratory  mucosa  by  inducing  nitric- 
oxide  (NO)  production  and  release  by  tracheal  cells  and  thereby  poisoning  the  activity  of 
adjacent  ciliated  epithelial  cells  (Flak  and  Goldman,  1999;  Caroff  et  al.,  2000;  Flak  et  al., 
2000). 
LPS  probably  causes  much  of  the  reactogenicity  of  the  whole-cell  pertussis  vaccine 
and  one  of  the  main  aims  in  pertussis  vaccine  development  has  been  to  eliminate  its 
adverse  effects  from  the  new  generation  of  acellular  pertussis  vaccines.  Nevertheless,  LPS 
may  have  a  role  in  inducing  immunity  to  pertussis  infection.  It  was  reported  that  anti-LPS 
antibodies  may  be  bactericidal  in  the  presence  of  complement  (Ackers  and  Dolby,  1972). 
The  presence  of  smooth  LPS  in  B.  bronchiseptica  correlated  with  the  resistance  to  killing 
in  vitro  by  antibody  and  complement  and  antimicrobial  peptides  whereas  B.  pertussis, 
lacking  the  0-polysaccharide  side-chains,  was  more  sensitive  to  these  agents  (Banemann  et 
al.,  1998;  Byrd  et  al.,  1998).  The  role  of  LPS  in  B.  pertussis,  B.  bronchiseptica  and  B. 
parapertussis  has  been  investigated  by  deleting  the  wbl  locus  required  for  the  synthesis  of 
polysaccharide  domains  consisting  of  lipid  A  and  the  core  oligosaccharide  (Harvill  et  al., 
2000).  Mutants  of  all  three  species  were  found  to  be  defective  in  colonising  the  trachea 
but,  in  addition,  the  B.  pertussis  mutant  was  also  less  able  to  colonise  the  nasal  cavity  than 
the  wild-type  strain.  The  other  interesting  observation  was  that  the  wbl  mutation  rendered 
the  normal  resistant  strains  of  B.  bronchiseptica  and  B.  parapertussis,  sensitive  to  killing 
by  normal  rabbit  serum,  whereas  B.  pertussis  wild-type  and  mutant  were  equally  killed 
(Harvill  et  al.,  2000).  Thus  the  role  of  LPS  seems  to  be  different  in  different  Bordetella 
species  in  determining  host-pathogen  interaction. 
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1.5  Regulation  of  Virulence 
Introduction 
Like  many  other  bacterial  pathogens,  the  expression  of  virulence  factors  in  B 
pertussis  is  controlled  by  growth  conditions.  These  virulence  factors  include  cell  surface 
proteins  e.  g.  adhesions,  and  several  extracellular  toxins  that  inhibit  host  defences  and 
induce  damage  to  host  tissues.  The  virulence  genes  of  B.  pertussis  are  scattered  around  the 
chromosome  and  not  grouped  together  in  distinct  mobile  elements.  However,  some  of  the 
virulence  genes  are  clustered  together,  such  as  bvgAS,  j%a  and  fim  genes.  In  many 
instances  the  structural  genes  are  linked  to  the  accessory  genes.  This  is  the  case  for  PTX,  a 
toxin  composed  of  five  subunits,  the  structural  genes  of  which  are  organised  in  an  operon 
and  this  is  followed  by  an  additional  seven  accessory  genes,  named  ptl  genes,  that  are 
involved  in  the  secretion  of  toxin  (section  1.8.2.1)  (Weiss  et  al.,  1993).  Two  important 
phenomena  in  the  regulation  of  virulence  genes  are  phase  variation  and  phenotypic 
modulation.  Phase  variation  indicates  a  reversible  alteration  in  the  genotype  caused  by 
frame  shift  mutations  in  which  the  virulent  bacteria  simultaneously  lose  the  ability  to 
synthesize  toxins  and  other  factors  associated  with  pathogenicity  (Weiss  and  Falkow, 
1984).  Differential  erythromycin  tolerance  has  been  shown  to  be  a  phase  marker  caused 
by  extensive  alterations  in  the  surface  properties  between  the  virulent  and  a  non-virulent 
strain,  and  this  confers  susceptibility  to  the  virulent  (phase  I)  strain  (Weiss  and  Falkow, 
1984).  The  natural  emergence  of  phase  variants  in  the  later  stages  of  infection  implies  that 
phase  changes  could  be  a  defence  mechanism  to  escape  immune  detection,  like  Salmonella 
flagellar  phase  variation  where  the  change  of  antigenic  type  helps  the  bacteria  to  evade  the 
immune  system.  Non-virulent  phase  variants  arise  in  a  population  at  a  frequency  of  10-3  to 
10-6  . 
The  other  phenomenon  is  termed  phenotypic  modulation  and  was  first  observed  by 
Lacey  in  1960.  It  is  characterised  by  lack  of  expression  of  virulence  factors,  except  the 
tracheal  cytotoxin,  at  low  temperature  (25'C)  or  in  the  presence  of  in  vitro  modulators  such 
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as  nicotinic  acid,  sulphate  ions  (SO-4)  and  chlorate  ions  (CIO-4)  (Lacey,  1960;  Scarlato  et 
al.,  1990). 
Genetic  analysis  has  shown  that  both  phenotypic  modulation  and  phase  variation  are 
under  the  control  of  a  single  genetic  locus,  the  bvg  locus  (Weiss  et  al.,  1983;  Arico  et  al., 
1989;  Stibitz  and  Yang,  1991).  The  bvg  locus  occupies  -5  kb  of  the  total  genome  and 
codes  for  the  BvgA  and  BvgS  proteins  and  another  gene  downstream  bvgR  codes  for  the 
protein,  BvgR  (Arico  et  al.,  1989;  Stibitz  and  Yang,  1991;  Sindt  et  al.,  1994).  The  bvg 
locus  has  been  shown  to  regulate  production  of  the  virulence  determinants  of  both  B. 
pertussis  and  B.  bronchiseptica  organism,  by  controlling  the  expression  of  virulence- 
activated  genes  (vags)  and  virulence-repressed  genes  (vrgs)  (Stibitz  et  al.,  1988; 
McGillivray  et  al.,  1989;  Scarlato  et  al.,  1993;  Fernandez  and  Weiss,  1994;  Finn  and 
Amsbaugh.,  1998).  BvgS  is  a  135  kDa  periplasmic  sensor  histidine  kinase.  It  consists  of  a 
periplasmic  input  domain  and  several  cytoplasmic  domains,  the  linker,  transmitter,  receiver 
and  the  C-terminus.  The  BvgS  periplasn-&  domain  senses  external  stimuli  (perhaps  via 
dimerization)  and  triggers  a  series  of  phosphorylation  steps  starting  with 
autophosphorylation  in  the  transmitter  domain  at  a  conserved  histidine  residue.  This  is 
followed  by  the  transfer  of  the  phosphate  group  to  a  conserved  aspartic  acid  in  the  receiver 
domain,  which  transfers  it  to  a  histidine  at  the  C-terminal  domain  (Roy  et  al.,  1990;  Uhl 
and  Miller,  1995;  Beier  et  al.,  1996).  BvgA,  a  response  regulator,  is  a  23  kDa  cytoplasmic 
protein  comprising  an  N-terminal  receiver  and  a  C-terminal  output  domain,  which  contains 
a  helix-tum-helix  (HTH)  DNA  binding  motif.  BvgA  is  activated  by  the  transfer  of  the 
phosphate  group  from  the  C-terminus  of  BvgS  to  a  conserved  aspartic  acid  in  the  BvgA  N- 
terminal  receiver  domain.  Upon  phosphorylation,  BvgA  positively  regulates  the  bvgAS 
and  other  virulence  factor  promoters,  including  bvgR,  by  binding  to  the  heptameric  target 
sequence  MCCTA  (Karimova  and  Ullmann,  1997).  It  has  also  been  shown  that  BvgA  is 
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able  to  dimerize  in  solution  and  this  may  represent  a  possible  means  to  enhance  its  DNA- 
binding  property  (Scarlato  et  al.,  1990).  Transcription  of  the  bvgR  gene  produces  a 
repressor  of  vrg gene  transcription  (Karimova  and  Ullmann,  1997). 
Studies  on  the  bvg  locus  have  revealed  that  its  transcription  is  controlled  by  a  350  bp 
DNA  fragment  having  four  promoters.  Three  of  them,  PI,  P2  and  P3,  are  involved  in  the 
transcription  of  the  bvg  locus,  while  the  fourth,  P4,  is involved  in  the  synthesis  of  an  anti- 
sense  RNA.  Under  non-inducing  conditions,  the  promoter  P2  is  active  and  maintains  a  low 
level  of  the  regulatory  protein  BvgA  and  BvgS  which  is  not  enough  to  activate  the 
virulence  genes.  Under  inducing  conditions,  BvgA  is  activated  by  phosphorylation, 
following  which  it  activates  the  promoters  PI,  P3,  P4  and  the  other  promoters  of  the 
virulence-activated  genes  (vag).  Expression  of  these  genes  represents  the  Bvg+  phenotype. 
The  antisense  RNA  coded  from  P4  positively  regulates  PI,  P2  and  P3  by  hybridization  to 
their  5'  untranslated  regions.  Hybridization  inhibits  the  fonnation  of  secondary  structure 
in  the  mRNAs,  thereby  favouring  their  interaction  with  the  ribosome.  This  causes  a  50- 
fold  increase  in  their  rate  of  translation  (Scarlato  et  al.,  1990).  The  Bvg-  phase  is  defined 
by  the  absence  of  vag-encoded  factors  and  occurs  when  the  bvg  locus  is  deleted  or  when 
BvgAS  activity  is  suppressed  by  modulating  conditions.  It  is  also  involved  in  the 
regulation  of  the  virulence-repressed  genes  (vrg)  (Beattie  et  al.,  1993),  namely  vrg6,  vrg18, 
vrg24,  vrg53  and  vrg73.  The  first  four  of  these  vrg  genes  mentioned  are  regulated  by 
BvgR  through  a  conserved  repressor  binding  site. 
The  Bvg'  phase  is  thought  to  be  necessary  and  sufficient  for  the  colonisation  of 
animal  respiratory  tracts  (Cotter  and  Miller,  1994;  Martinez  et  al.,  1998),  while  the  Bvg- 
phase  appears  not  to  play  a  role  in  virulence  (Akerley  et  al.,  1995).  However  there  is  some 
indication  of  the  presence  of  a  Bvg'  (intermediate  phase)  and  its  expression  in  vivo  but  the 
significance  of  this  phase  is  not  completely  understood. 
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The  product  of  one  such  bvgi  gene,  biIA  (Bordetella  intimin-like),  has  been  recently 
identifiea  in  B.  bronchiseptica  whose  closest  homologue  is  intimin  expressed  by 
enteropathogenic  E.  coli.  The  product  of  MA  has  been  shown  to  be  involved  in 
colonisation  in  a  mbbit  model  (Stockbauer  et  al.,  2001).  The  bvg-repressed  genes  of  B. 
bronchiseptica  appear  to  be  involved  in  survival  outside  the  host  (Mcmillan  et  al.,  1996), 
whereas  their  function  in  B.  pertussis  is  unknown.  However,  it  has  been  shown  that  BvgR- 
mediated  regulation  of  gene  expression  contributes  to  respiratory  infection  in  mice  because 
a  mutant  of  B.  pertussis  with  a  mutation  in  the  bvgR  gene  failed  to  colonise  mice  as  well  as 
the  wild-type  (Merkel  et  al.,  1998).  The  virulence  factors  of  B.  pertussis  have  been  shown 
to  be  expressed  differentially,  when  their  time  course  of  expression  was  analysed  in 
laboratory  conditions.  The  results  indicated  that  the  adhesins  are  the  first  to  be  expressed 
in  order  to  colonise  the  respiratory  tract  of  the  host  and  toxins  are  expressed  late  when  they 
are  needed  (Scarlato  et  al.,  1993;  Kinnear  et  al.,  2001). 
Several  lines  of  evidence  suggest  that  the  mechanism  of  regulation  by  the  bvg  locus 
is  different  for  different  virulence  loci.  Other  work  has  also  implicated  the  requirement  of 
additional  factors  or  the  differential  effects  of  DNA  topology  (Graeff  et  al.,  1995),  for 
selective  activation  of  some  promoters.  Given  the  varied  aspects  of  BvgA-mediated 
transcriptional  activation,  the  bvg  regulon  has  proved  to  be  an  excellent  system  for  the 
study  of  differential  and  timely  regulation  of  target  promoters  to  optimise  the  infection 
process. 
1.6  Vaccines 
Whooping  cough  is  an  important  example  of  a  highly  contagious  and  dangerous 
disease  which  can  be  controlled  by  the  availability  of  effective  vaccination.  In  fact,  there 
are  still  several  pockets  of  disease  around  the  world,  significantly  in  developing  nations, 
27 Habib  Bokhari  Introduction 
where  the  death  toll  remains  high  due  to  non-availability  of  proper  vaccination.  Effective 
killed  whole-cell  vaccines  against  B.  pertussis-mediated  disease  have  been  used  in 
developed  countries  for  more  than  50  years  and  have  led  to  dramatic  reductions  in 
morbidity  and  mortality.  Despite  extensive  research  on  virulence  factors  and  potential 
vaccine  candidates,  there  has  been  no  consensus  as  to  the  molecular  nature  of  the  antigens 
which  confer  protective  immunity. 
The  protection  afforded  by  the  whole-cell  vaccine  comes  at  the  cost  of  its  associated 
reactogenicity  ranging  from  local  and  systemic  reactions  to  permanent  brain  damage  and 
death  (Cherry  et  al.,  1988;  Griffith,  1989;  Hodder  and  Mortimer,  1992).  These  problems 
of  reactogenicity  have  acted  as  a  stimulus  for  the  development  of  non-toxic  efficacious 
vaccines  in  the  form  of  acellular  vaccines.  The  research  is  focused  on  the  identification  of 
defined  protective  antigens  that  would  be  efficacious  and  non-toxic  (Cherry  and  Hewlett, 
1990).  Various  pertussis  virulence  factors  have  been  shown  to  be  more  or  less  protective 
when  used  in  an  acellular  vaccine  e.  g.  pertussis  toxoid,  filamentous  haemagglutinin, 
pertactin,  and  flimbriae  (Trollfors  et  al.,  1995).  The  safety  and  the  extent  of 
immunogenicity  afforded  by  these  vaccines  paved  the  way  for  their  consideration  as 
candidates  for  booster  immunization  of  older  children  and  adults  to  control  pertussis  more 
effectively  in  populations  (Keital  and  Edwards,  1995:  Cherry,  1998). 
The  major  hindrance  in  the  area  of  better  vaccine  development  has  been  the 
shortcomings  associated  with  various  animal  models  available  for  assessing  mechanisms  of 
virulence  and  immunity,  although  the  mouse  models,  using  intracerebral,  intranasal.  and 
aerosol  challenge  have  provided  much  useful  information  (Sato  and  Sato,  1988).  The 
intracerebral  mouse  protection  test  has  provided  a  reliable  estimate  of  the  potencies  of 
WCPVs  for  children  but  is  unreliable  for  assessing  the  potency  of  APVs  (Robinson  and 
Funnell,  1992).  Thus  the  identification  and  characterisation  of  the  protective  antigens  of  B. 
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pertussis  has  been  slow  and  is  still  underway.  The  other  emerging  problem  regarding  the 
use  of  vaccines  is  that  there  is  evidence  to  suggest  that  they  have  acted  as  a  driving  force  in 
microevolution  of  B.  pertussis,  leading  to  resurgence  in  the  incidence  of  pertussis  in  the 
last  ten  years  in  several  countries  with  an  historical  low  incidence,  attributable  to  high 
vaccine  uptake.  Several  sequence  polymorphisms  in  the  S1  subunit  gene  of  PTX  and 
within  the  pnz  gene  were  found  which  led  to  slightly  altered  protein  sequences  compared 
with  the  corresponding  factors  present  in  the  vaccine  preparations.  Protective  immunity 
against  strains  expressing  such  sequence  variants  might  be  reduced.  It  has  been  suggested 
that  vaccination  programmes  have  caused  a  selective  force  leading  to  an  antigenic  shift  in 
important  antigens  which  gradually  may  have  decreased  vaccine  efficacy,  allowing  the  re- 
occurrence  of  pertussis  epidemics  (Mills,  2001). 
1.7  General  mechanism  for  secretion  in  Gram-negative  bacteria 
1.7.1  Outer  membrane  assembly 
The  outer  membrane  of  Gram-negative  bacteria  protects  it  from  the  surrounding 
harsh  environment.  At  the  same  time,  the  embedded  proteins  fulfil  a  number  of  tasks  that 
are  crucial  to  the  bacterial  cell,  such  as  solute  and  protein  translocation,  as  well  as  signal 
transduction  (Koebnik  et  al.,  2000).  The  outer  membrane  functions  as  an  exclusion  barrier 
with  selective  permeability  which  allows  the  control  of  substances  moving  in  and  out  of 
the  cell.  In  Gram-negative  bacteria,  the  major  porin  is  involved  in  such  control.  This  porin 
consists  of  complexes  of  a  monomer  of  approximately  40  kDa  that  assembles  in  the  outer 
membrane  and  allows  the  passage  of  ionic  molecules  (Armstrong  and  Parker,  1986;  Li, 
1991).  The  B.  pertussis  major  porin  has  been  characterised  (Hannah,  1994).  The  porin 
prevents  passage  of  hydrophobic  and  large  hydrophilic  molecules  into  the  cell,  and 
numerous  proteins,  peptides,  carbohydrates  and  hydrophobic  drugs  are  actively  exported 
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by  other  means  (secretory  pathways)  from  the  cytoplasm  into  the  extra-cellular  medium 
I 
(Dinh  et  al,  1994). 
1.7.2  Surface-located  outer  membrane  proteins 
Nearly  all  bacterial  virulence  factors  are  either  located  on  the  bacterial  surface  or 
secreted.  In  the  past  few  years,  there  has  been  an  explosion  of  information  identifying 
bacterial  factors  that  are  needed  as  accessories  to  transport  virulence  factors  to  the  cell 
surface  and  into  the  surrounding  environment  (Finlay  and  Falkow,  1997).  Pathogenic 
bacteria  produce  virulence  factors  that  cross  the  bacterial  cell  envelope  from  cytoplasm  to 
extracellular  milieu  where  they  promote  disease.  In  some  cases  export  is  a  single  energy- 
coupled  translocation  due  to  a  secretion  (Sec)  apparatus  associated  with  both  inner  and 
outer  membranes  of  Gram-negative  bacteria.  In  other  cases,  secretory  intermediates 
accumulate  in  the  periplasm  and  two  distinct,  independently  functioning  processes  are 
responsible  for  transport  across  the  two  membranes  of  the  cell  (Hancock,  1991). 
1.7.3  Protein  translocation  to  the  cell  exterior  /  pathways  of  secretion 
The  mechanisms  by  which  proteins  traverse  bacterial  membranes  vary  considerably 
(Sandkvist,  2001).  In  Gram-negative  bacteria,  six  non-homologous  protein  export  systems 
have  been  identified  (Figure  1.1)  allowing  them  not  only  to  construct  their  membrane  and 
cell  envelope  but  also  to  secrete  an  array  of  toxins,  adhesins  and  hydrolytic  enzymes.  The 
secretion  systems  vary  in  a  number  of  important  properties,  including  complexity, 
dependence  on  a  protein  signal  sequence  (Sec),  and  whether  the  secretion  across  the  inner 
and  outer  membrane  is  achieved  in  a  single  step.  Of  these  systems,  only  one,  the  type  11 
secretion  system  is  essential  for  cell  viability  (Finlay  and  Falkow,  1997). 
At  the  moment  it  is  not  understood  why  certain  proteins  are  secreted  via  one  pathway 
30 Fig.  I.  I:  Shows  the  different  secretion  pathways  used  by  Gram-negative 
bacteria  for  exporting  their  protein  products 
Among  the  six  major  protein-secretion  pathways  of  Gram-negative  bacteria,  four 
depend  on  the  Sec  system  for  protein  transport  across  the  inner  membrane  (IM). 
Autotransporters  (also  known  as  type  V  secretion  systems)  mediate  the  transport  of  a 
passenger  domain  across  the  outer  membrane  (OM).  Type  VI  (chaperone/usher)  pathway 
requires  a  chaperone  termed  an  usher  and  an  outer  membrane  protein,  for  the  secretion  of 
the  proteins.  The  type  II  secretion  systems  mediate  the  transport  of  extracellular  enzymes 
and  toxins,  involving  12-16  proteins,  most  of  which  are  associated  with  the  inner 
membrane  (IM).  Four  inner  membrane  proteins  are  proposed  to  form  a  pilus-like  structure 
that  could  function  as  a  piston  to  push  protein  through  the  OM  pore  (indicated  by  an 
arrow).  Type  IV  secretion  systems  transport  a  variety  of  substrates,  some  of  which  e.  g. 
pertussis  toxin,  require  a  Sec  system  for  secretion  (a),  whereas  others  like  the  T-DNA- 
protein  complexes  of  Agrobacterium  tuniefaciens  are  transported  directly  from  the  cytosol 
(b).  The  type  I  and  type  III  secretion  pathways  are  Sec-independent.  Type  I  systems 
secrete  toxins,  proteases,  lipases  and  S-layer  proteins  directly  into  the  extracellular  milieu, 
whereas  type  III  secretion  systems  mediate  delivery  of  virulence  proteins  into  the  host  cell. 
Extracellular  appendages  are  associated  with  several  type  III  and  type  IV  systems. 
The  figure  and  legend  is  taken  from  Buttner  and  Bonas,  (2002). Ilabib  Rokhati 
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and  not  another.  It  is  possible  that  the  choice  of  the  secretion  pathway  for  individual 
proteins  is  determined  in  part  by  the  function  they  perform  at  the  extracellular  site  where 
they  are  delivered,  as  suggested  by  Lorry  (1998). 
1.7.3.1  Signal  sequence  independent  pathway  (Type  I) 
The  type  I  secretion  pathway  (Fig  1.1)  is  wholly  independent  of  the  general  secretory 
pathway  (GSP)  formed  by  the  products  of  the  sec  genes  and  hence  is  known  as  a  Sec- 
independent  pathway.  This  system  is  relatively  simple,  involving  protein  secretion  directly 
from  the  cytoplasm  to  the  exterior  of  the*bacterial  cell  without  a  periplasmic  intermediate 
stage  (Kerr,  1999).  Sec-independent  proteins  mediate  their  own  transport  via  several 
accessory  proteins  that  form  a  transmembrane  channel  through  which  the  secreted 
molecule  moves  (Femlee  et  al.,  1985). 
The  prototype  member  of  the  Sec-independent  pathway  is  the  E.  coli  a-hemolysin. 
Proteins  like  adenylate  cyclase  toxin  from  B.  pertussis,  alkaline  protease  from 
Pseudomonas  aeruginosa,  leukotoxin  from  Pasteurella  haemolytica,  and  proteases  of  the 
plant  pathogen  Erwinia  chrysanthemi,  are  also  exported  via  this  pathway  (Finlay  and 
Falkow,  1997). 
The  proteins  targeted  through  the  type  I  pathway  have  no  classical  amino-tenninal 
signal  sequences  and  are  translocated  with  the  assistance  of  accessory  proteins  (membrane 
traffic  wardens)  encoded  by  the  structural  genes,  which  recognise  a  signal  at  the  C- 
terminus  of  the  proteins.  The  clustering  of  structural  gene(s)  and  secretory  apparatus  genes 
has  allowed  cloning  of  several  complete  enzyme  secretion  systems  into  E.  coli,  aiding  their 
molecular  analysis  (Salmond  and  Reeves,  1993).  B.  pertussis  CyaA  toxin  is  secreted  via  a 
type  I  secretion  system,  which  does  not  involve  a  cleavable  signal  peptide  and  a 
periplasmic  inten-nediate,  but  requires  the  accessory  proteins  CyaB,  Cyal)  and  CyaE. 
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1.7.3.2  General  secretory  pathway  (Type  II) 
Introduction 
The  type  II  secretion  system  is  thought  to  be  the  major  export  pathway  in  most 
Gram-negative  organisms  (Salmond  and  Reeves,  1993).  Several  virulence  factors  use  a 
type  II  secretion  system  for  their  translocation  in  Gram-negative  organisms  (Pugsley, 
1993).  The  type  11  secretion  system  is  a  two-step  process  that  has  best  been  studied  for  the 
pullulanase  enzyme,  PuIA,  from  Klebsiella  oxytoca  (Henderson  et  al.,  1998;  Hueck,  1998). 
Type  II  secreted  proteins  first  pass  across  the  inner  membrane  via  the  Sec  system  of  the 
general  secretory  pathway  'GSP'  (Fig  1.1)  and  is  dependent  on  several  Sec  proteins  (Sec 
A,  B,  D,  E,  F).  These  proteins  are  all  probably  involved  both  in  recognition  of  the  signal 
sequence  and  in  a  subsequent  interaction  with  the  inner  membrane  protein  SecY,  which 
may  form  the  part  of  a  specific  translocation  channel  (Henderson  et  al.,  1998). 
Transport  across  the  outer  membrane  is  subsequently  mediated  by  a  dedicated 
secretion  apparatus  composed  of  13  or  14  different  gene  products  (Pugsley,  1993;  Filloux 
and  Hardie,  1998;  Henderson  et  al.,.  1998).  Like  the  type  I  secretion  system,  one 
component  of  this  system  has  a  consensus  ATP-binding  site  (Walker  box),  which  indicates 
that  energy  for  export  comes  from  this  high  energy  nucleotide.  These  systems  also  encode 
a  peptidase  that  cleaves  off  a  small  N-terminal  sequence  which  plays  a  role  in  delivery  of 
these  proteins  to  the  Sec  machinery  (Perlman  and  Halvorson,  1983;  Finlay  and  Falkow, 
1997).  At  least  II  proteins  and  one  RNA  species  are  known  to  be  directly  involved  in  this 
secretion  pathway  in  E.  coli  (Economou,  1998). 
This  pathway  is  the  carrier  for  many  of  the  B.  pertussis  proteins  like  the 
autotransporter  proteins  pertactin,  tracheal  colonisation  factor,  etc  (section  1.8)  as  well  as 
the  major  B.  pertussis  adhesin  FHA  and  fimbriae  across  the  inner  membrane  and  into  the 
periplasmic  space  (section  1.4.5.1).  Type  Il  secretion  pathway  is  also  presumed  to  be 
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involved  in  transporting  the  pertussis  toxin  sub-units  into  the  periplasmic  space  (section 
1.4.5.2.1). 
1.7.3.3  Contact-dependent  pathway  (Type  III) 
More  recently,  a  third  major  highly-conserved  export  system,  which  plays  an  active 
role  in  the  specific  secretion  of  virulence  factors  in  both  human  and  animal  pathogens,  has 
been  identified  (  Salmond  and  Reeves,  1993).  The  recent  interest  in  type  III  (Fig  1.1) 
secretion  system  (TTSS)  emerges  largely  from  the  evidence  that  host-pathogen  interaction 
influences  the  regulation  of  the  secretion  products,  with  the  result  that  secreted  proteins  are 
often  delivered  directly  into  the  target  cells.  This  triggering  of  secretion  in  response  to  the 
presence  of  host  cells,  termed  contact-dependent  secretion,  helps  to  ensure  that  effectors 
are  secreted  only  when  required  (Lewthwaite  et  al.,  1998;  Beuzon  et  al.,  1999;  Comeils 
and  Gigsegem,  2000).  This  can  make  the  systems  difficult  to  study.  Because  of  the  nature 
of  the  TTSS,  secreted  proteins  are  often  not  produced  in  sufficient  quantities  to  be  readily 
detectable  in  culture  supernatants,  and  are  secreted  only  when  the  right  environmental 
conditions  are  in  place.  The  type  III  secretion  apparatus  is  composed  of  approximately  20 
proteins  (d'Enfert,  1993;  Bergmann  et  al.,  1994;  Allaoui  et  al.,  1994,1995),  most  of  which 
are  located  in  the  inner  membrane,  and  assembly  of  these  structures  requires  a  cytoplasmic, 
probably  membrane-associated  ATPase  (Hueck,  1998). 
This  type  of  export  system  is  responsible  for  secretion  of  Yops  (Yersinia  outer 
membrane  proteins;  prototype)  in  Yersinia  species  (Michiels  et  al.,  1990;  Wattiau  et  al., 
1996),  Salmonella  and  Shigella  invasion  and  virulence  factors,  (Galan  et  al.,  1992;  Allaloui 
et  al.,  1995;  Shea  et  al.,  1996),  EPEC  signal  transduction  molecules,  and  virulence  factors 
in  several  plant  pathogens  including  Pseudomonas  solanacearum  and  Erwinia  species 
(Finlay  and  Falkow,  1997).  Secretion  of  bacterial  pathogenic  proteins  by  type  III  pathway 
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and  their  injection  into  the  cytosol  of  animal  or  plant  cell  initiates  a  sophisticated 
biochemical  cross  talk  between  pathogen  and  host.  The  injected  proteins  often  resemble 
eukaryotic  factors  with  signal  transaction  functions  and  are  capable  of  interfering  with 
eukaryotic  signalling  pathways  (Hueck,  1998;  Kerr,  1999). 
More  recently,  homologues  to  the  proteins  secreted  by  TTSS  in  Gram-negative 
bacteria  have  been  identified  in  B.  bronchiseptica  (BscN),  (Yuk  et  al.,  1999)  and  in  B. 
pertussis  (BpeI)  (Kerr,  1999),  and  are  under  the  control  of  the  bvgAS-locus.  The  TTSS  of 
B.  bronchiseptica  interferes  with  the  action  of  the  components  of  the  innate  and  acquired 
immune  systems,  enabling  the  long  term  persistence  of  B.  bronchiseptica  in  the  trachea  of 
rodents  (Yuk  et  al.,  2000).  TTSS  may modulate  immune  responses  during  infection  by 
inhibiting  NF-KB  activation  by  TNF(x.  The  role  of  TTSS  in  B.  pertussis  is  yet  to  be 
determined.  In  most  cases  reported  to  date,  the  G+C  mol  %  contents  of  TTSS  genes  in 
various  Gram-negative  bacteria  are  lower  than  the  surrounding  genome,  an  indication  of 
acquisition  by  horizontal  transmission  from  a  host  with  a  lower  G+C  mol  %  content. 
Even  when  the  difference  in  G+C  mol  %  content  does  not  appear  to  be  significant,  closer 
analysis  provides  support  for  the  notion  of  gene  transfer.  In  B.  bronchiseptica,  G+C  mol 
%  levels  in  the  TTSS  genes  are  only  2-3%  lower  than  overall  G+C  mol  %  contents  for 
these  organisms  (Winstanley  et  al.,  2000). 
1.7.3.4  Type  IV  secretion 
This  pathway  is  primarily  involved  in  mobilisation  of  DNA  either  between  bacteria 
or  from  bacteria  to  plant  cells;  however,  recently  the  type  IV  system  has  also  been  found  to 
transport  proteins,  such  as  B.  pertussis  PTX  and  Helicobacter  pylori  CagA  antigen  (Bums 
et  al.,  1999;  Segal  eý  al.,  1999;  Stein  et  al.,  2000).  While  the  DNA  is  thought  to  be 
transferred  as  a  DNA-protein  complex  in  one  single  step  across  the  cell  envelope,  PTX 
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appears  to  be  transported  to  the  periplasmic  compartment  in  a  Sec-dependent  (type  11) 
manner  and  then  translocated  across  the  outer  membrane  in  a  separate  step  (Fig  1.1). 
Interaction  between  components  of  the  pertussis  toxin  liberation  (Ptl)  system  and  a  region 
of  the  SI  subunit  appears  to  be  essential  for  secretion  of  the  assembled  toxin  (Craig-Mylius 
et  al.,  2000).  Only  the  holotoxin  and  not  the  SI  subunit  in  the  absence  of  B  oligomer  is 
exported  (Farizo  et  al.,  2000).  Recent  findings  have  suggested  that  disulphide  bond 
forming  enzymes  or  Dsb  proteins  are  required  for  assembling  the  toxin's  subunits  in  the 
periplasm  (DsbA)  whereas  another  enzyme  DsbC  is  necessary  for  extracellular  secretion  of 
the  toxin  (Stenson  and  Weiss,  2002).  Translocation  of  the  holotoxin  across  the  outer 
membrane  is  mediated  by  an  operon  of  seven  genes  (ptlB  to  ptIH)  that  are  located 
downstream  from  the  ptx  operon  and  are  co-transcribed  with  the  ptx  structural  genes  from 
the  ptx  promoter  (Weiss  et  al.,  1993;  Ricci  et  al.,  1996;  Craig-Mylius  and  Weiss,  1999; 
Bums,  1999;  Farizo  et  al.,  2000).  They  have  extensive  homology  with  the  outer  membrane 
complex  responsible  for  the  transfer  of  DNA  from  the  plant  pathogen  Agrobacterium 
tumefaciens.  In  the  latter  system,  the  turnour  inducing  T-DNA  is  secreted  in  the  form  of  a 
complex  of  protein  that  coats  the  DNA  (Weiss,  1994;  Ricci  et  al.,  1996). 
1.7.3.5  A  utotransporters  /Type  V  secretion 
The  autotransporters  are  a  growing  family  of  extracellular  proteins,  found  in  many 
Gram-negative  bacteria  that  have  many  different  functions  but  appear  to  have  the  same 
mechanism  of  export  (Jose  et  al.,  1995;  Loveless  and  Saier,  1997;  Henderson  et  al.,  1998). 
As  the  name  implies,  secretion  through  the  autotransporter  pathway  does  not  require  any 
accessory  factors.  The  proteins  containing  the  N-terminal  signal  sequence  are  first 
translocated  across  the  cytoplasmic  membrane  via  the  Sec  machinery.  The  signal 
recognition  particles  (SRP),  the  soluble  nucleoprotein  complex,  binds  to  hydrophobic 
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targeting  signals  that  are  found  both  in  presecretory  and  integral  membrane  proteins 
(Kurzchalia  et  al.,  1986)  The  signal  sequence  of  type  V  proteins,  essential  for  moving  the 
pre-protein  to  the  periplasm,  is  often  highly  unusual,  being  characterized  by  10-15 
additional  residues  present  after  the  amino  terminal  methionine  and  often  preceding  an 
unusually  high  number  of  positive  charges  compared  with  conventional  amino-terminal 
export  signals.  Nevertheless,  it  has  been  suggested  that  the  majority  of  these  proteins  are 
initially  transported  by  the  inner  membrane  Sec  system  (Blobel  and  Doberstein,  1975; 
Henderson  et  al.,  1998).  In  the  cases  of  many  proteins  which  do  not  have  typical  signal 
peptides,  the  first  transmembrane  segment  can  be  the  alternative  choice  for  crossing  the 
inner  membrane  (Friedlander  and  Blobel,  1985).  Once  the  signal  sequence  is  cleaved,  the 
respective  C-terminal  domains  of  these  secreted  proteins  are  thought  to  insert  into  the  outer 
membrane  forming  a  pore  that  allows  transport  of  the  N-terminal  portion  (passenger 
domain)  to  the  cell  surface.  The  mature  portion  of  the  protein  can  then  be  released  from 
this  pore  structure  by  proteolytic  cleavage. 
Table  1.2  shows  the  diversity  of  functions  associated  with  the  autotransporter 
passenger  domains  of  bacteria  in  Gram-negative  bacteria.  Some  of  the  members  of  this 
diverse  family  are  immunoglobulin  A  (IgA)  proteases  from  Neisseria  gonorrhoeae 
(YJauser  et  al.,  1993),  and  Haemophilus  influenzae  (Poulsen  et  al.,  1989),  the  AIDA-I 
adhesin  from  E.  coli  (Maurer  et  al.,  1997;  Suhr  et  al.,  1996),  IcsA  from  Shigellaflexneri  ( 
Suzuki  et  al.,  1995)  which  is  involved  in  intracellular  spread,  Tsh  a  temperature-sensitive 
hemagglutinin  from  an  avian  Exoli  strain  (Provence  et  aL,  1995)  and  tracheal  colonization 
factor  (Finn  and  Stevens,  1995),  the  adhesin,  pertactin  (Charles  et  al.,  1994)  and  serum 
resistance  protein  BrkA  (Fernandez  and  Weiss,  1994)  from  Bordetella  pertussis  (section 
1.8).  All  of  these  proteins  are  grouped  together  by  the  following  characteristics  in  their 
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respective  organism: 
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They  usually  contain  an  N-terminal  signal  sequence.  Most  of  the  mature  proteins 
are  proteolytically  processed  into  an  approximately  30-kDa  C-terminal  domain  and  a  much 
larger  N-terminal  domain.  The  C-terminal  domains  are  predicted  to  form  amphipathic  P- 
barrels  in  the  outer  membrane  through  which  the  N-terminal  passenger  domain  is 
translocated. 
In  the  proposed  model  of  autotransporter  secretion  (Fig  1.2)  (Klauser  et  al.,  1993), 
an  N-terminal  signal  sequence  enables  translocation  across  the  cytoplasmic  membrane. 
Once  the  protein  is  in  the  periplasm,  the  signal  sequence  is  cleaved  and  the  C-terminal 
domain  then  inserts  itself  into  the  outer  membrane.  It  presumably  forms  a  pore  through 
which  the  N-terminal  domain  is  exported  by  the  formation  of  hairpin  loop.  Cleavage  of  the 
N-terminal  domain  is  thought  to  occur  after  translocation  through  the  outer  membrane, 
either  autoproteolytically  or  by  another  protease  (Egile  et  al.,  1997).  There  is  no  evidence 
of  autoproteolytic  processing  in  the  case  of  any  of  the  autotransporter  proteins  known,  with 
the  exception  of  IgAl  protease  (Jose  et  al.,  1995).  C-terminal  domains  of  autotransporter 
proteins  exhibit  sequence  similarity  whereas  the  N-terminal  virulence  factors  are  generally 
non-homologous  except  in  cases  of  functionally  similar  proteins  from  related  bacteria  (Jose 
et  al.,  1995).  The  antiparallel  P-strands  are  considered  to  be  amphipathic  and  interspersed 
with  hairpin  turns  and  loops  (Suzuki  et  al.,  1995). 
The  hydrophobic  sides  of  the  P-strands  presumably  face  the  lipid  bilayer  while  the 
hydrophilic  faces  comprise  an  aqueous  pore.  Secretion  of  the  N-terminal  domain  takes 
place  by  an  energy-independent  unspecified  mechanism  as  it  passes  through  the  P-barrel 
channel  in  a  denatured  or  partially  denatured  state  (Yanagida  et  al.,  1986).  In  some  cases 
38 Fig.  1.2:  Shows  the  model  for  the  secretion  of  autotransporter  proteins  in  Gram- 
negative  bacteria 
The  model  presented  shows  the  steps  involved  in  the  processing  of  an 
autotransporter  precursor  protein  into  its  processed  constituents  i.  e.  passenger  domain  and 
C-terminal  domain.  The  N-terminal  signal  peptide  is  cleaved  after  targeting  of  the 
precursor  protein  to  the  Sec  apparatus,  located  in  the  inner  membrane  of  Gram-negative 
bacteria.  The  periplasmic  intermediate  then  travels  to  the  outer  membrane  where  its  C- 
terminal  domain  forms  a  P-barrel  pore  through  which  its  passenger  domain  traverses  to 
reach  the  outer-membrane  (surface)  of  the  bacteria.  Once  exposed  on  the  outer-membrane, 
the  passenger  domain  can  be  cleaved  off  or  remain  attached  to  its  C-terminal  domain. 
Model  is  taken  from  Klauser  et  al.,  (1993). Habib  BoAhari 
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the  secreted  proteins  remain  attached  to  the  bacterial  surface  whereas  some  proteins  are 
released  into  the  external  medium.  The  junctional/linker  region  between  the  passenger 
domain  and  its  autotransporter  domain  may  then  guide  the  folding  of  the  exported 
virulence  factor  to  its  active  conformation  (Ohnishi  et  al.,  1994;  Loveless  and  Saier,  1997). 
It  is  assumed  that  in  an  autotransporter  there  is  a  conserved,  potential  nucleotide  binding 
motif,  however,  dogma  demands  that  the  periplasm  is  devoid  of  ATP,  and  the  significance 
of  such  a  motif  would  therefore  have  to  be  questioned  (Holland,  1998). 
1.7.3.6  Type  VI  secretion  Pathway  (hvo-partner  secretion:  TPS) 
This  pathway  (Fig  1.1)  involves  two  steps  in  which  proteins  containing  N-terminal 
signal  peptides  are  first  translocated  across  the  cytoplasmic  membrane  via  the  Sec 
machinery.  Following  the  removal  of  the  signal  peptide  and  release  into  periplasm,  the 
mature  protein  requires  an  accessory  protein  for  translocation  of  the  proteins  through  the 
outer  membrane  and  is  also  known  as  chaperon  usher  pathway. 
B.  pertussis  FHA  (1.4.5.1.2)  is  exported  by  this  pathway,  initially  a  signal  peptide 
(22  residues)-dependent  process  allows  passage  across  the  cytoplasmic  membrane  and 
thereafter  it  requires  a  single  specific  accessory  protein,  FhaC,  for  its  translocation  across 
the  outer  membrane  (Jacob-Dubuisson  et  al.,  1996;  1999;  2000).  An  N-proximal  115 
residue  region  of  FhaA,  called  the  secretion  domain  is  essential  for  its  secretion.  This 
region  probably  interacts  with  FhaC  in  a  specific  manner  to  drive  the  translocation  of  FhaA 
through  the  outer  membrane.  During  the  maturation  of  FhaA,  the  C-terminal  domain  of 
the  precursor  FhaB  is  cleaved.  The  function  of  this  cleaved  carboxy-terminus  (150  KDa) 
in  this  instance  is  probably  to  prevent  the  formation  of  a  hairpin  structure  within  the 
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Table  1.2:  Autotransporter  pro 
negative  bacteria 
Organism  Protein 
Bordetella  spp.  Pertactin 
BrkA 
Tcf 
Vag8 
Introduction 
teins  and  their  predicted  functions  in  Gram. 
Function 
Adhesin 
Serum  resistance 
Adhesin 
Adhesin? 
Dichelobacter  nodusus  BprV  Elastase? 
BprB  Elastase? 
AprV2  Elastase? 
BprX  Elastase? 
Escherichia  coli  Esp  Proteolytic  toxin 
Pet  Proteolytic  toxin 
Sat  Proteolytic  toxin 
Tsh  Hernagglutinin/hemoglobin  binding 
Pic  Mucinase 
AIDA-I  Adhesin 
TibA  Adhesin 
Ag43  Biofilrn  formation/Adhesin 
Haemophilus  influenzae  IgA  I  protease  Cleavage  of  IgAl 
Hap  Adhesin/protease 
Hia  Adhesin 
Hsf  Adhesin 
Helicobacter  mustelae  Hsr  S  layer? 
Helicobacterpylori  VacA  Toxin 
BabA  Adhesin 
Moraxella  catarrhalis  UsPAI  Adhesin 
UspA2  Serum  resistance 
UspA2h  Adhesin 
Neisseria  spp.  IgAl  protease  Cleavage  of  IgAl 
Pasteurella  haemolytica  Ssal  Protease 
Pseudomonas  aeruginosa  EstA  Esterase 
Pseudomonasfluorescens  PspA  Protease 
PspB  Protease 
Rickettsiales  rOmpA  Adhesin 
rOmpB  S  layer/adhesin 
Salmonella  enterica  sero-  ApeE  Esterase 
var  Typhimutium 
Serralia  marcescens  PAS  Protease 
PrtT  Protease 
Ssp-HI  Protease 
Ssp-H2  Protease 
Shigellaflexneri  SepA  Protease/inflarnmation/invasion 
Pic  Mucinase 
SigA  Proteolytic  toxin 
IcsA  Mediator  of  intracellular  motility 
Xeno-rhabdus  luminescens  PlaA  Lipase 
?=  Not  definite 
The  table  is  adapted  from  Henderson  et  al.,  (2001) 
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periplasmic  space  and  possibly  to  aid  presentation  of  the  N-terminal  domain  to  FhaC 
(Renauld-Mongenie,  1996).  The  C-terminal  domain  may  also  prevent  premature 
interaction  between  the  N-terminal  region  and  FhaC  during  export  of  these  proteins 
towards  the  outer  membrane  (Renauld-Mongenie,  1996).  The  C-terminal  domain  of 
precursor  FhaB  is  probably  therefore  an  intramolecular  chaperone  of  FHA  (Jacob- 
Dubuisson  et  al.,  1996). 
1.8  Members  of  the  Bordetella  pertussis  autotransporter  family 
Recent  work  has  shown  that  the  vag-encoded  virulence  proteins  PRN, TCF,  BrkA, 
Vag-8  and  most  recently  Bap-5  are  a  family  of  proteins  that  have  structural  homology  at 
their  C-termini  and  also  share  common  properties  such  as  RGD  and  SGXG  motifs, 
although  they  may  be  functionally  different.  Figure  1.3  shows  the  major  structural 
similarities  among  the  autotransporter  proteins  of  B.  pertussis. 
1.8.1  Pertactin 
Pertactin  (PRN)  is  one  of  a  family  of  closely  related  proteins  expressed  by  the 
bordetellae.  Pertactins  are  detected  as  polypeptide  bands  of  molecular  weight  of  69  kDa 
(P.  69)  in  B.  pertussis,  P.  70  in  B.  parapertussis  and  P.  68  in  B.  bronchiseptica  in  SDS- 
PAGE  profiles  of  their  outer  membrane-enriched  fractions.  Sequencing  of  these  relevant 
genes  has  shown  that  they  all  contain  an  open  reading  frame  encoding  larger  precursor 
polypeptides  of  similar  size.  Thus  it  appears  that  the  structure  of  these  genes  is  highly 
conserved  in  the  bordetellae.  In  fact,  the  carboxy-terminal  region  is  the  most  highly 
conserved  region  between  the  pertactins  from  the  three  Bordetella  species  suggesting  the 
functional  importance  of  this  region  (Charles  et  al.,  1994). 
42 Fig.  1.3:  Shows  some  of  the  important  structural  features  of  autotransporter  proteins 
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The  full-length  priz  gene  of  B.  pertussis  comprises  an  open  reading  frame  of  2730  bp 
capable  of  expressing  a  mature  protein  of  93.4  kDa.  The  expression  of  the  pertactin  gene 
family  is  under  the  control  of  the  bvg  global  regulatory  system  in  the  bordetellae.  The  bvg- 
regulated  promoters  express  poorly  in  the  absence  of  the  bvg  locus,  hence  expression  of  the 
full  length  genes  in  a  heterologous  host  requires  the  use  of  a  functional  promoter  (Charles 
et  al.,  1994).  The  precursor  protein  contains  a  34  amino  acid,  amino-terminal  signal 
sequence  and  a  30  kDa  carboxy-tenninal  (P-barrel)  sequence  thought  to  be  involved  in 
translocation  of  the  mature  pertactin/P.  69  onto  the  surface  of  B.  pertussis. 
The  PRN  cleavage  event  is  thought  to  occur  at  a  protease  recognition  site  Lys-Arg  at 
position  597  in  the  sequence  (Capiau  et  al.,  1990).  The  P-helix  of  PRN  is  thought  to  be  the 
longest  helix  reported  to  date.  Several  loops  protrude  from  the  helix  that  are  associated 
with  the  biological  function  of  pertactin  including  the  major  immunodominant  region  and 
the  cell-binding  motif  (Fig:  1.4)  (Ernsley  et  al.,  1996). 
An  interesting  feature  of  the  PRN  molecule  is  the  presence  of  two  regions  of  direct 
repeats  and  in  each  case  the  motif  is  repeated  five  times  (Charles  et  al.,  1989).  The  first 
repeat  is  located  towards  the  N-terminus  of  the  mature  protein,  adjacent  to  the  RGD  motif 
and  has  the  sequence  Gly-Gly-X-X-Pro  (GGXXP).  The  second  repeat  is  located  near  the 
C-terminus  and  has  the  sequence  of  Pro-Gln-Pro  (PQP).  Epitope  mapping  using  a  number 
of  pertactin-specific  monoclonal  antibodies  has  shown  that  both  of  the  repeat  regions  are 
immunodominant  B-  cell  epitopes  with  PQP  as  a  major  partner  (Charles  et  al.,  1991). 
PRN/P.  69  is  a  surface-associated  protein  of  B.  pertussis  that  is  involved  in  the 
adherence  process  of  the  bacterium  to  eukaryotic  cells  (Leininger  et  al.,  1991;  Roberts  et 
al.,  1991).  The  mature  PRN  as  well  as  its  autotransporter  domain  contain  one  RGD  motif. 
This  provided  the  preliminary  information  that  PRN  may  act  as  an  adhesin.  Chinese 
hamster  ovary  cells  (CHO)  were  shown  to  interact  with  PRN  in  microtitre  plate  wells  that 
44 Fig.  1A  shows  the  crystal  structure  of  pertactin  (P.  69) 
The  three  dimensional  structure  of  B.  pertussis  pertactin  (P.  69)  determined  by  X- 
ray  crystallography  showing  the  functionally  important  regions  of  the  molecule  and  B 
helix.  The  figure  shows  the  positions  of  the  immunodominant  repeat  regions  i.  e.  GGXXP 
and  PQP,  of  the  pertactin  molecule.  It  also  shows  the  RGD  peptide  (integrin-binding  site) 
Figure  is  taken  from  Ems1ey  et  al.,  (1998). Ilabib  RoAhari 
GGXXP  loop 
PQP  repeat  reg 
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were  previously  coated  with  mature  purified  PRN.  Moreover  a  B.  pertussis  PRY  mutant 
exhibited  reduced  adherence  to  epithelial  cells  e.  g.  CHO,  Hep-2;  HeLa  cells  (Leininger  et 
al.,  199  1).  It  has  also  been  noted  that  a  B.  bronchiseptica  PRN'  mutant  were  less  adherent 
to  macrophages  and  porcine-ciliated  respiratory  cells  (Forde  et  al.,  1999).  B.  pertussis 
PRN-  mutants  were  also  found  to  be  less  invasive  for  cultured  epithelial  cells  and  synthetic 
peptides  containing  the  PRN-derived  RGD  sequence  were  found  to  be  inhibitory  to 
invasion  of  these  cells  but  not  peptides  containing  the  FHA-based  RGD  sequence  (Roberts 
et  al.,  199  1;  Leininger  et  al.,  1992). 
However,  recent  studies  have  suggested  that  expression  of  PRN  by  B.  pertussis 
may  actually  reduce  its  invasion  of  human  tracheal  epithelial  cells  (Bassinet  et  al.,  2000). 
XL  In  addition,  the  B.  pertussis  pm  or  prn-j,,  aB  mutants  were  found  to  colonise  mice  as 
efficiently  as  the  wild-type  strain  (Roberts  et  al.,  1991),  although  in  a  separate  study  using 
the  same  strains,  the  pnz-flzaB  mutant  but  not  the  prn  mutant  was  cleared  more  rapidly 
from  the  lungs  of  intranasIly  infected  mice  compared  to  the  wild-type  strain  (Khelef  et  al., 
1994).  Insertional  inactivation  of  the  pm  gene  in  B.  bronchiseptica  reduced  its  ability  to 
colonise  the  lower  respiratory  tract  but  not  the  nasal  cavity  of  mice  (Prof.  M.  Roberts, 
unpublished).  There  is  some  evidence  that  PRN  and  FHA  functionally  interact  (section 
1.4.5.1.2)  (Arico  et  al.,  1993).  Natural  and  recombinant  preparations  of  purified 
pertactin/P.  69  have  been  shown  to  induce  protective  immune  responses  against  B.  pertussis 
in  experimental  models  (Shahin  et  al.,  1990;  Roberts  et  al.,  1992).  In  addition,  PRN  has 
been  identified  as  a  critical  antigen  for  improving  the  efficacy  of  acellular  whooping  cough 
vaccines  in  humans. 
P.  69  is  exposed  on  the  surface  of  B.  pertussis  (Roberts  et  al.,  1991).  Mature  P.  69 
was  detected  at  the  cell  surface  of  E.  coli  TG1  only  when  the  full  length  pm  gene  was 
used.  The  presence  of  PRN  signal  sequence  alone,  without  the  intact  C-terminal  domain, 
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did  not  appear  to  be  sufficient  to  direct  the  mature  PRN  protein  to  the  E.  coli  cell  surface. 
It  is  not  clear  whether  the  P.  30  carboxy  terminal  domain  plays  an  active  role  in  targeting 
P.  69  to  the  cell  surface  like  the  C-terminal  domains  of  secreted  virulence  factors  produced 
by  other  Gram-negative  bacteria  such  as  the  IgA-proteases  of  Neisseria  gonorrhoeae  and 
Haemophilus  influenzae  and  elastase  of  Pseltdomonas  aerilginosa  have  been  shown  to  play 
an  active  role  in  targeting  these  proteins.  Comparison  of  the  P.  93,  P.  69  and  P.  30  amino 
acid  sequences  with  those  of  IgA  proteases,  elastase  and  haernolysin  did  not  reveal  any 
significant  homology  (Charles  et  al.,  1994). 
1.8.2  Tracheal  colonisation  factor 
A  virulence-associated  factor,  known  as  tracheal  colonisation  factor  (TCF)  is 
produced  by  strains  of  B.  pertussis,  but  not  B.  parapertussis  and  B.  bronchiseptica  (Finn 
and  Stevens,  1995).  This  protein  is  encoded  by  the  tcfA  gene.  The  derived  amino  acid 
sequence  contains  a  RGD  and  three  SGXG  motifs  and  is  a  proline-rich  protein  (Finn  and 
Stevens,  1995).  Tracheal  colonisation  factor  is  a  member  of  the  autotransporter  family 
defined  upon  the  basis  of  the  C-terminal  domain  that  is highly  conserved  among  members 
of  this  family.  Western  blot  analysis  and  protein  staining  (immunofluorescence)  data 
indicate  that  most  of  the  apparent  90  kDa  form  of  TCF  is  cell  associated,  whereas  the 
apparent  60  kDa  form  can  be  found  as  a  major  band  in  the  supernatant  fraction  of  cultures. 
The  C-terminal  30  kDa  tail  of  TCF  has  50  %  identity  over  300  amino  acids  to  the  full 
length  precursors  of  the  PRN  proteins.  The  similarity  in  the  region  extends  to  the  proposed 
proteolytic  cleavage  site  identified  in  PRN.  The  ability  of  purified  TCF  to  protect  against 
B.  pertussis  infection  has  not  been  reported  so  far.  However  its  immunogenicity  has  been 
indicated  by  intranasal  immunisation  of  mice  with  an  attenuated  Vibrio  cholerae  strain 
expressing  TCF,  which  reduced  the  ability  of  B.  pertussis  to  colonise  the  trachea  (Chen  et 
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al.,  1998). 
1.8.3  Bordetella  resistance  to  killing  (BrkA) 
Fernandez  and  Weiss  (1994)  identified  an  insertional  mutant  of  B.  pertussis  which 
was  at  least  10-fold  more  susceptible  to  serum  killing  than  the  wild-type  and  was  less 
virulent  in  mice.  The  brk  locus  encoding  this  serum  resistance  function  encodes  two 
divergently  transcribed  open  reading  frames  (ORFs),  termed  brkA  and  brkB  (Fernandez 
and  Weiss,  1994).  Within  the  300  bases  which  separate  the  two  ORFs  are  putative  sites  for 
BvgA  binding.  The  BrkA  precursor  lacks  a  typical  N-terminal  signal  sequence  and  it  is 
presumed  to  cross  the  inner  membrane  with  the  assistance  of  the  inner  membrane  protein 
BrkB.  It  has  been  reported  that  brkB  has  homology  with  ORFs  of  unknown  function 
identified  in  E.  coli  and  Mycobacterium  leprae  and  is  predicted  to  be  a  cytoplasmic 
membrane  protein  (Fernandez  and  Weiss,  1994).  The  103  kDa  BrkA  precursor  is 
processed  to  yield  a  73  kDa  mature  protein  and  a  -30  kDa  C-terminal  autotransporter 
domain  (Fernandez  and  Weiss,  1994).  The  recombinant  BrkA  C-terminal  domain  can 
form  pores  in  lipid  bilayers  (Shanon  and  Fernandez,  1999).  The  gene  products  brkA  and 
brkB,  regulated  by  the  bvgAS  locus,  appear  to  be  essential  for  resistance  to  killing  by  the 
classical  (antibody-dependent)  complement  pathway  contributing  to  a  substantial  amount 
of  resistance  (section  1.9).  BrkA  and  BrkB  also  separately  reduce  the  susceptibility  of  B. 
pertussis  to  antimicrobial  peptides  such  as  the  defensins  that  are  an  important  feature  of  the 
mucosal  immune  system  (Fernandez  and  Weiss,  1994,1996).  Recent  evidence  suggested 
that  a  B.  pertussis  BrkB  mutant  was  less  able  to  survive  in  human  serum,  but  this  was  not 
found  to  be  statistically  significant  difference  compared  to  the  BrkB  wild-type  strain 
(Fernandez  and  Weiss,  1998). 
BrkA  shows  29  %  identity  to  PRN  and  has  two  RGD  motifs  in  addition  to  conserved 
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proteolytic  processing  site  and  an  outer  membrane-targeting  signal  (Fig  1.3)  and  like  PRN, 
a  role  in  adhesion  to  epithelial  cells  and  invasion  of  eukaryotic  cells  has  also  been 
suggested  for  BrkA  (Fernandez  and  Weiss,  1994,1996).  Despite  the  similarities,  a 
pertactin  mutant  was  not  as  sensitive  to  serum  killing  as  the  BrkA  or  BrkB  mutants.  BrkA 
protein  has  most  homology  with  PRN  at  its  C-tenaiinus  but  there  is  no  amino  terminal 
signal  sequence  (Fernandez  and  Weiss,  1994). 
In  addition  to  two  RGD  motifs,  there  are  also  two  SGXG  glycosaminoglycan 
(heparin)  binding  motifs  which  may  also  mimic  the  FHA-heparin  interaction  but  could 
allow  efficient  binding  of  the  highly  glycosylated  Cl  inhibitor  (Barnes  and  Weiss,  2001), 
or  have  a  role  in  inhibiting  the  polymerisation  of  C9  and  hence  preventing  bacterial  lysis. 
By  preventing  activation  of  the  complement  cascade  (Fig  1.6)  beyond  C4,  BrkA  protects 
the  bacterium  against  all  the  effects  of  complement  activation  products  such  as 
upregulation  of  the  immune  response  by  C4a,  C3a  and  C5a  ;  opsonisation  of  pathogens  by 
Ob  and  i0b;  and  direct  killing  of  Gram-negative  bacteria  by  the  membrane  attack 
complex  (Barnes  and  Weiss,  2001).  In  Southern  blot  analysis,  brkAB  sequences  were 
found  in  B.  bronchiseptica  and  B.  parapertussis  but  not  in  B.  avium.  Clinical  isolates  of  B. 
pertussis  and  B.  parapertussis  were  serum  resistant,  and  wild-type  strains  possessing  an 
additional  copy  of  the  brkA  locus  were  2  to  5-fold  more  resistant  to  serum  killing 
(Fernandez  and  Weiss,  1998).  Although  BrkA  confers  on  B.  pertussis  a  resistance  to 
killing  by  human  serum,  interestingly,  loss  of  BrkA  in  B.  bronchiseptica  did  not  confer 
sensitivity  to  complement  mediated  killing  (Rambow  et  al.,  1998).  This  may  be  explained 
by  the  fact  that  B.  bronchiseptica  is  inherently  more  resistant  to  complement  than  B. 
pertussis  (sections  1.4.5.2.5,1.9)  (Henderson  and  Nattaro,  2001).  A  BrkA  mutant  of  B. 
pertussis  was  found  to  be  10-fold  less  virulent  in  intranasally-infected  infant  mice  (Weiss 
and  Goodwin,  1989;  Fernandez  and  Weiss,  1994).  There  is  no  information  regarding  the 
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ability  of  BrkA  to  function  as  a  protective  immunogen  and  it  is  not  part  of  any  current 
acellular  vaccines. 
1.8.4  Virulence-  activated  gene-8  (Vag-8) 
B.  pertussis  expresses  a  byg-regulated  95-KDa  protein  called  Vag-8.  This  bvg- 
regulated  protein  is  the  fourth  member  of  the  Bordetella  autotransporter  family  to  be 
identified  (Finn  and  Amsbaugh,  1998).  The  other  members  of  this  family,  PRN,  TCF  and 
BrkA,  are  expressed  as  large  precursor  proteins,  and  cleavage  of  a  C-terminal  30-kDa 
fragment  results  in  the  mature  protein.  The  N-terminus  of  Vag-8  possesses  a  predicted  37 
amino  acid  signal  sequence,  the  cleavage  of  which  yields  a  predicted  polypeptide  of  91 
kDa.  It  is  not  clear  whether  this  -91  kDa  detected  on  the  surface  of  B.  pertussis  represents 
either  a  Vag-8  precursor  that  is  not  processed  to  remove  the  30  kDa  C-terminal 
autotransporter  domain  or  the  mature  protein  with  the  predicted  molecular  weight  of 
61kDa  which  migrates  anomalously  at  -91  kDa  on  SDS-PAGE  like  PRN  and  TCF.  The 
highest  degree  of  sequence  similarity  in  Vag-8  with  other  autotransporters  of  B.  pertussis 
was  found  in  the  carboxy-terminal  portion  of  this  protein.  Vag-8  like  other  well  known  B. 
pertussis  autotransporters  i.  e.  PRN, TCF  and  BrkA,  also  contains  an  RGD  site  and  two 
SGXG  motifs  (Fig  1.3).  The  original  transposon  Tnpho-vag8  mutant  was  found  to  be 
reduced  in  its  ability  to  colonise  the  respiratory  tract  of  mice  but  a  later  derived  non-polar 
vag8  mutant  colonised  the  respiratory  tract  normally  (Finn  and  Amsbaugh,  1998).  The 
Vag-8  deficient  mutant  colonised  the  trachea  and  lungs  of  mice  as  efficiently  as  the 
isogenic  parent.  Southern  blot  analysis  indicates  that  strains  of  B.  bronchiseptica  and  B. 
parapertussis  carry  sequences  similar  to  vag-8,  yet  expression  of  the  protein  has  not  been 
detected  in  B.  parapertussis  (Finn  and  Amsbaugh,  1998).  Antibodies  to  Vag-8  recognised 
a  protein  of  95  kDa  in  a  whole-cell  lysates  of  B.  pertussis  and  B.  bronchiseptica  but  not  in 
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B.  parape  ussis.  In  addition,  supernatant  fractions  of  strains  of  B.  pertussis  do  not  contain 
a  protein  which  reacts  with  antibodies  raised  to  Vag-8  (Finn  and  Amsbaugh,  1998). 
1.8.5  B.  perfussis  autotransporter  protein-5  (Bap-5) 
A  PCR  amplicon  MR30  produced  by  Prof.  M.  Roberts  (Department  of  Veterinary 
Pathology,  University  of  Glasgow)  using  primers  directed  to  the  region  encoding  the  C- 
terminal  domain  of  pertactin  on  B.  pertussis  genomic  DNA,  was  later  identified  as  a  gene 
for  fifth  member  of  B.  pertussis  autotransporter  family  (Blackburn,  2000).  The  gene 
sequence  was  deposited  in  Genbank  under  accession  no.  AF081494.  Because  of  its 
sequence  similarity  to  pm  and  genes  encoding  three  other  autotransporters,  namely  TCF, 
BrkA  and  Vag-8,  the  product  of  bap-5  was  designated  as  Bap-5  (Bordetella  autotransporter 
protein-5). 
The  predicted  open  reading  frame  (ORF)  of  the  pertactin-like  sequence  was 
determined  by  amino  acid  homology  with  PRN  and  BrkA  which  begins  at  a  serine  residue 
encoded  at  nucleotide  position  300  (Appendix  11).  This  information  leads  to  an  assumption 
that  a  methionine  upstream  from  this  sequence  (nucleotide  position  261)  mayý  be  the 
possible  translational  start.  The  presence  of  an  upstream  stop  codon  in  this  particular 
reading  frame  also  infers  that  the  open  reading  frame  begins  at  this  point.  There  are, 
however,  alternative  potential  translational  start  sites  downstream  and  it  would  require 
further  investigation  to  ascertain  the  true  ATG/GTG  translational  start  codon.  There  is  no 
translational  stop  codon  until  position  2538  within  the  expected  reading  frame,  which  is 
consistent  with  previously  described  B.  pertussis  autotransporters  as  it  is  immediately 
preceded  by  a  consensus  outer-membrane  localization  motif.  There  is  a  potential 
transcriptional  terminator  in  the  form  of  mRNA  secondary  hairpin  structure  located 
downstream  of  the  predicted  ORF  (Blackburn,  2000). 
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Sequence  analysis  has  shown  the  presence  of  two  integrin-binding  motifs  (RGD),  a 
glycosaminoglycan-binding  site  (SGSG),  a  proteolytic  processing  site  (ALSKRLGEL)  and 
an  outer-membrane  localization  signal  (FHLGYRYRW,  position  2510-2537)  (Appendix 
II).  No  typical  signal  sequence  or  upstream  regulatory  elements  (e.  g.  ribosome  binding  site 
or  promoter  sequences)  have  been  identified  in  bap-5  gene.  The  predicted  molecular 
weight  of  Bap-5  is  79.9  kDa  using  the  first  ATG  translational  start  codon.  The  processing 
at  the  predicted  proteolytic  cleavage  site  yields  a  predicted  mature  N-terminus  of  49  kDa 
leaving  a  30-  kDa  P-barrel  fonning  C-tenninus.  Protein  sequence  analysis  has  shown  that 
Bap-5  shares  the  highest  similarity  at  its  C-terminus  with  that  of  PRN.  It  was  indicated  by 
Southern  blotting,  using  a  bap-5  specific  probe,  that  a  bap-5-like  sequence  also  existed  in 
B.  parape  ussis  and  B.  bronchiseptica  and  preliminary  evidence  indicated  its  expression 
as  measured  by  RT-PCR  in  B.  pertussis  (Blackburn,  2000).  The  final  work  of  P.  Blackburn 
was  the  cloning  of  a  disrupted  bap-5  gene  (with  a  kanamycin  resistance  cassette  insertion) 
in  the  pGEMT  Easy  vector  and  I  took  over  the  project  from  this  stage  onwards. 
Genes  encoding  several  other  putative  autotransporters,  in  addition  to  the  above 
mentioned  autotransporters,  were  identified  in  the  genome  of  B.  pertussis  (Dubuisson  et 
al.,  2000).  Several  of  them  have  significant  sequence  similarities  to  proteases,  whereas 
others  are  more  related  to  adhesins.  Whether  any  of  them  plays  a  role  in  B.  pertussis 
virulence  remains  to  be  investigated  e.  g.  the  gene  products  of  five  of  them  (Phg,  AidB, 
SphBl,  SphB2  and  SphB3)  are  serine  protease  homologues.  It  has  been  reported  that 
expression  levels  of  the  sphB2  and  sphB3  genes  were  very  low  or  undetectable,  while  the 
phg,  aidB  and  sphB1  genes  were  better  expressed.  In  addition,  sphB1  was  strongly 
activated  by  bvg,  making  it  a  new  vag  gene  (Locht  et  al.,  2001).  Figure  1.5  shows  an 
overall  view  of  the  various  adhesins  and  toxins  produced  by  B.  pertussis. 
1) 
52 Fig.  1.5:  B.  pertussis  virulence  factors 
Diagram  showing  the  export  of  the  various  virulence  factors  of  B.  pertussis  and 
their  corresponding  secretion  mechanisms.  Adhesins  such  as  Fim,  FHA,  autotransporter 
proteins  e.  g.  PRN,  TCF,  BrkA,  Vag8,  other  Bordetella  autotransporters  (Bats)  and  toxins 
namely  PTX  and  CyaA  (ACT)  are  transported  across  the  outer  membra,  ne  via  different 
secretory  pathways.  It  also  indicates  the  import  of  the  siderophore  (alcaligin)  and  the 
regulatory  systems  BvgA,  BvgS  and  BvgR  controlling  the  release  of  virulence  factors  and 
uptake  of  siderophores. 
Figure  is  taken  from  Locht  et  al.,  (2001). Ilabib  BoAhari 
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1.9  General  defence  strategies  deployed  by  B.  pertussis 
Gram-negative  bacteria  can  employ  its  range  of  surface-associated  or  released 
proteins  to  escape,  delay  or  overcome  the  immune  effector  mechanisms  deployed  by  the 
host  against  it.  A  summary  of  this  strategy  employed  by  B.  pertussis  is  given  in  the 
Discussion  section,  Table  8.1.  One  of  the  main  immune  effector  mechanisms  to  effectively 
kill  the  microorganism  and  relevant  to  the  present  study  will  be  discussed  here  i.  e. 
complement-mediated  killing. 
The  complement  system  is  a  series  of  proteins  that  act  in  a  defined  sequence  (Fig 
1.6)  to  promote  immune  clearance  by  opsonising  or  killing  micro-organisms.  Antigen- 
antibody  complexes  on  the  surface  of  a  micro-organism  can  activate  the  classical  pathway 
of  complement,  a  part  of  the  acquired  immune  system,  by  providing  a  binding  site  for  CI 
deposition.  This  will  lead  to  a  cascade  of  proteolytic  activation  steps  that  lead  to 
deposition  of  CO,  C2a,  Ob  and  C5b  on  the  bacterium.  Finally,  after  a  series  of  binding 
steps  the  formation  of  the  membrane  attack  complex  (C5b-9)  occurs  which  promotes  the 
lysis  of  the  bacterium. 
The  complement  cascade  can  be  activated  by  carbohydrates  on  bacterial  surfaces 
(such  as  lipopolysaccharide,  LPS),  that  can  activate  the  alternate  pathway  (Taylor,  1992; 
Moffit  and  Frank,  1994).  Serum  mannose-binding  lectin  (MBL),  is  able  to  trigger 
complement  activation  through  both  the  classical  (Ikeda  et  al.,  1987;  Kawasaki  et  al., 
1989)  and  alternative  pathways  (Schweinle  et  al.,  1989),  upon  binding  to  pathogens 
possessing  mannose,  leading  to  direct  killing. 
There  are  various  mechanism  operative  in  Gram-negative  bacteria  to  interfere  or 
disrupt  the  activity  of  the  complement  system  at  many  steps  in  the  cascade  (Joiner,  1988; 
Cooper,  1991;  Frank,  1992).  For  example,  Pseudomonas  aeruginosa  produces  proteases 
54 Fig.  1.6:  Activation  of  complement  leading  to  formation  of  the  lytic  membrane  attack 
complex. 
In  the  immune  individual,  the  classical  pathway  of  complement  activation  occurs 
following  binding  of  specific  antibody  to  outer  membrane  proteins  (OMPs)  and 
polysaccharide  antigens  on  the  surface  of  B.  pertussis  whereas,  in  the  non-immune 
individual,  the  alternative  complement  pathway  is  activated  following  binding  of  Ob  to 
the  bacterial  cell  surface.  For  both  pathways  of  complement  activation,  the  final  common 
pathway  is  formation  of  a  lytic  membrane  attack  complex,  which  punches  a  hole  in  the 
outer  membrane  of  the  organism.  Deposition  of  complement  on  the  cell  surface  also 
induces  phagocytosis  but  the  relative  contribution  of  antibody,  complement  and 
phagocytes  to  immunity  in  vivo  is  unknown.  +  indicates  a  factor  that  enhances  formation 
of  complement  complex  and  -  indicates  a  factor  that  inhibits  components  of  the 
complement  cascade. 
Figure  has  been  taken  and  modified  from  Pollard  and  Frasch  (2001). Habib  Bokhari 
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specific  for  Clq  and  C3  (Hong  and  Ghebrehiwet,  1992),  enteric  E.  coli  produces  a  highly 
polymerised  LPS  to  prevent  the  deposition  of  the  complement  in  the  close  proximity  of  its 
outer  membrane  (Bum  and  Hull,  1998).  Another  strategy  adopted  by  some  Gram-negative 
bacteria  is  to  recruit  host  regulatory  proteins  as  a  self-defence  measure.  For  example  Y 
enterocolitica  (Pilz  et  al.,  1992)  and  S.  pyogenes  (Hong  et  al.,  1990)  bind  the  host 
regulatory  factor  H  (Fig  1.6),  which  in  turn  regulates  the  enzymes,  convertases,  required 
for  the  activation  of  C3  and  C5.  An  interesting  way  of  avoiding  the  host  defence  cells  is 
operative  in  N.  gonorrhoeae,  which  neutralises  the  complement  resistance  strategy  of  the 
host  cell  by  cellular  mimicry  by  producing  high  density  sialic  acid  on  the  surface, 
incorporating  sialic  acid  into  its  LPS  which  has  similarities  to  host  cell  structures  (Jarvis 
and  Verdos,  1987). 
The  capacity  of  the  B.  pertussis  to  survive  killing  by  the  classical  pathway  is 
regulated  by  bvgAS  locus  with  the  products  of  the  brk  locus  (BrkA  and  BrkB  contributing 
to  a  substantial  amount  of  the  resistance  against  human  serum  (section  1.8.3).  BrkB  has 
been  proposed  to  aid  BrkA  in  its  translocation  across  the  inner  membrane.  However,  A 
BrkB-deficient  mutant  of  B.  pertussis  has  not  been  shown  to  be  significantly  sensitive  to 
complement-mediated  serum  killing  compared  to  wild-type  B.  pertussis.  BrkA  protein 
protects  B.  pertussis  Tohama  from  lysis  by  the  classical  (antibody-dependent)  pathway  of 
complement  (Fernandez  and  Weiss,  1994,1998)  and,  to  a  lesser  extent,  lysis  by  certain 
classes  of  antimicrobial  peptides  (Fernandez  and  Weiss,  1996).  The  exact  molecular 
mechanism  of  the  defence  strategy  adopted  by  B.  pertussis  by  deploying  BrkA  on  its 
surface  against  complement  proteins  and  cross-reacting  antibodies  circulating  in  the  serum 
is  not  known.  BrkA  appears  to  inhibit  the  formation  of  the  membrane  attack  complex 
(Barnes  and  Weiss,  2001).  The  membrane  attack  complex  is  composed  of  activated  C5 
(C5b)  bound  to  of  other  complement  proteins  i.  e.  C6,  C7,  C8  and  C9.  Upon  the  sequential 
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binding  of  C5b  to  C6  and  C7,  the  complex  becomes  (C5b-7)  lipophilic  and  can  insert  itself 
into  the  membrane.  Once  the  complex  is  membrane  inserted,  C8  and  C9  bind  to  it 
followed  by  the  addition  of  more  C9  molecules  to  form  poly-C9  tailing.  The  poly-C9 
forms  the  pore  in  the  membrane  of  Gram-negative  bacteria  (B.  pertussis)  and  leads  to 
bacterial  lysis  and  death  (Fig 1.6).  Alternative  to  this,  C5b-7  complex  can  bind  to  a  soluble 
complement  regulatory  protein,  protein  S,  prior  to  membrane  insertion  and  form  a 
complex,  SC5b-7.  This  complex  is  defective  in  associating  with  the  membrane  but  can 
bind  C8  and  C9,  leading  to  the  formation  of  the  soluble,  inactive  SC5b-9  complex  (Kolb 
and  Muller,  1975).  The  formation  of  SC5-9  is  often  measured  to  determine  activation  of 
the  terminal  complement  cascade  (Rinder  et  al.,  1999).  However,  previous  results 
suggested  that  BrkA  inhibits  the  deposition  of  C3  and  also  C4  or  promotes  the  degradation 
of  C4  after  its  deposition  on  the  bacterial  surface  (Barnes  and  Weiss,  2001).  The 
interaction  of  two  proteoglycan  SGXG  motifs  of  BrkA  with  the  Cl  inhibitor  is  another 
potential  mechanism  of  action,  as  it  can  allow  the  efficient  binding  of  the  highly 
glycosylated  Cl  inhibitor  on  bacterial  surface  (Barnes  and  Weiss,  2001).  Recruitment  of 
the  C4  binding  protein  is  another  possible  mechanism  by  which  BrkA  would  result  in  a 
decrease  in  the  C4  deposition  on  the  bacterial  surface. 
LPS  can  mediate  either  protection  or  susceptibility  to  complement  killing  e.  g.  in 
enteric  bacteria  (E.  coli)  the  long  highly  polymerised  polysaccharide  (0-chain)  of  the  LPS 
on  smooth  strains  protects  the  bacteria  from  complement  while  rough  strains  or  mutants 
lacking  the  sugar  repeats  are  killed  (Frank,  1992;  Taylor,  1992;  Moffit  and  Frank,  1994). 
The  LPS  of  B.  perfussis  was  reported  to  have  a  simple  structure  consisting  of  lipid  A,  core 
polysaccharide  and  a  single  O-chain  trisaccharide  (Lebbar  et  al.,  1994;  Allen  et  al.,  1998). 
However  many  new  genes  and  some  unexpected  genes  (e.  g.  the  capsule  biosynthesis  locus) 
have  been  identified  with  the  completion  of  genome  sequence  of  B.  pertussis,  which  may 
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lead  to  a  new  outlook  on  the  organism  and  the  manner  in  which  it  interacts  with  the  innate 
immune  system  (Preston  and  Maskell,  2002). 
1.10  Protective  capacity  of  B.  pertussis  autotransporters 
One  of  the  main  objectives  of  any  research  on  a  pathogenic  organism  is  to  explore 
its  surface  architecture  and  attempt  to  exploit  that  information  against  it.  That  could  be  a 
achieved  by  the  better  understanding  of  the  virulence  factors  of  the  infectious  organism. 
Most  of  the  members,  if  not  all,  of  the  B.  pertussis  autotransporter  family  characterised  to 
date  have  some  role  in  B.  pertitssis-associated  virulence  mechanisms  as  evident  from  the 
animal  studies.  Purified  pertactin  (P.  69),  one  of  the  well-characterised  autotransporter 
proteins,  has  an  ability  to  provide  protection  against  B.  pertussis  in  the  mouse  respiratory 
tract  (Roberts  et  al.,  1991).  The  protective  properties  of  mature  PRN  (P.  69)  have  been 
well  documented  across  the  Bordetella  spp.  Immunisation  with  vaccines  containing  PRN, 
including  recombinant  PRN,  and  attenuated  S.  typhiniuriunz  expressing  PRN,  provides 
protection  against  B.  pertussis  infection  in  mice  and  B.  bronchiseptica  in  mice  and  pigs 
(Charles  et  al.,  1991;  Roberts  et  al.,  1992;  Mills  et  al.,  1993,1998;  Boursaux-Eude  et  al., 
1999;  Guiso  et  al.,  1999).  However  the  ability  of  the  B.  pertussis  purified  TCF,  BrkA  and 
Vag-8  autotransporter  proteins  in  providing  protection  against  the  colonisation  of  B. 
pertussis  in  the  respiratory  tract  of  mice  is  less  clear  (Fernandez  and  Weiss,  1994;  Finn  and 
Stevens,  1995;  Finn  and  Amsbaugh,  1998).  Also  there  is  a  lack  of  knowledge  regarding 
the  use  of  the  autotransporter  C-terminal  domains  in  vaccine  preparations.  The  protective 
capacity  of  the  C-tennini  of  B.  pertussis  autotransporter  proteins  is  difficult  to  assess  as 
they  have  not  yet  been  shown  to  be  surface  exposed  (Charles  et  al.,  1994).  P.  69  is  an 
important  component  of  the  new  range  of  multicomponent  acellular  vaccines  but  there  is 
no  evidence  to  indicate  whether  its  C-terminus  has  a  role  in  protection.  A  study  has 
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indicated  that  mice  immunised  intranasally  with  an  attenuated  Vibrio  cholerae  strain 
expressing  TCF,  reduced  the  ability  of  B.  pertussis  to  colonise  the  trachea  (Chen  et  al., 
1998). 
The  importance  of  presenting  B.  pertussis  antigens  in  the  correct  form  has  been 
studied  and  it  appears  that  the  best  response  occurs  in  the  mouse  models  when  outer 
membrane  complexes  or  microspheres  are  used  (Hamstra  et  al.,  1995;  Shahin  et  al.,  1995). 
Hamstra  et  al  (1995)  reported  that  an  outer  membrane  complex  (protein-detergent 
micelles)  containing  a  32  kDa  protein  (now  confirmed  as  the  TCF  C-terminus)  was 
protective  in  an  intracerebral  mouse  protection  tests.  The  92  kDa  (presumably  Vag-8) 
protein  described  by  Hamstra  et  al  (1995)  was  protective  only  when  non-protective  levels 
of  pertussis  toxin  were  present.  Monji  et  al.,  (1986),  suggested  a  role  for  a  30  kDa  protein 
(possibly  the  BrkA  C-terminus)  in  B.  pertussis  outer  membrane  preparations  which 
potentiated  an  immune  response  to  Haemophilus  type  B  capsular  polysaccharide, 
indicating  a  role  of  the  C-terminal  domains  as  adjuvants.  The  purified  C-terminal  domains 
of  TCF  and  BrkA  from  B.  pertussis  outer  membranes  were  not  found  to  be  protective  in 
the  intracerebral  mouse  protection  test  (Blackburn,  2000). 
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1.11  Aims  and  objectives 
Introduction 
The  main  objective  of  the  project  was  to  characterise  the  funcfion,  expression,  and 
bvg-regulation  of  the  newly  identified  gene  bap-5,  which  encodes  Bap-5,  an 
autotransporter  protein  of  B.  pertussis,  by  generating  a  Bap-5  deficient  mutant.  It  was  of 
interest  to  determine  the  role  of  this  outer  membrane  protein,  which  shares  many  common 
features  with  other  B.  pertussis  virulence  associated  proteins,  to  provide  a  better 
understanding  of  the  pathogenesis  of  the  disease,  pertussis.  Once  constructed,  a  Bap-5- 
deficient  mutant  could  be  tested  for  virulence  in  a  mouse  model  of  pertussis  and  studies 
could  be  performed  to  determine  its  possible  role  in  adhesion  and  invasion  of  mammalian 
cells  and  in  serum  resistance. 
Part  of  the  project  involved  investigating  the  processing  of  the  autotransporters  into  a 
mature  form.  The  B.  perlussis  autotransporter  PRN  is  processed  into  a  mature  form  P.  69 
from  the  precursor  P.  93.  However,  it  is  not  clear  how  the  mature  PRN  (P.  69)  is  detached 
from  its  -30  kDa  autotransporter  C-terminal  domain.  The  proteolytic  activity  of  PRN  is 
not  known  and  the  primary  and  tertiary  structure  of  PRN  does  not  reveal  any  proteolytic 
domain.  The  possibility  of  involvement  of  unknown  outer  membrane  proteases  for  the 
release  of  PRN  from  its  autotransporter  domains,  as  occur  with  other  Gram-negative 
bacterial  autotransporters,  was  investigated.  The  study  was  designed  to  provide 
information  regarding  the  processing  and  secretion  of  the  PRN  to  the  outer-membranes  and 
into  the  culture  supemate  of  various  protease-deficient  strains  of  E.  coli.  This  would  have 
implications  towards  an  understanding  of  the  processing  of  the  autotransporter  protein  in 
B.  pertussis  and,  possibly,  the  pathogenicity  of  the  organism. 
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2.1  General  bacteriological  procedures 
2.1.1.  Source,  storage  and  media  for  bacteria 
The  details  of  E.  coli  strains  used  in  this  study  are  given  in  Tables  2.1  and  2.2. 
Bordetella  strains  used  in  the  study  are  given  in  the  table  2.4.  The  different  media  used  in 
the  study  were  Luria  Bertani  (LB)  broth  (Sigma)  Luria  Bertani  agar  (Sigma);  Bordet- 
Gengou  agar  (Sigma).  The  compositions  of  the  following  media  and  buffers  used  during 
the  study  are  given  in  Appendix  1:  Casamino  acids  (CAA),  Cyclodextrin  liquid  (CL), 
Stainer-Scholte  and  SOC.  All  media  were  sterilised  by  autoclaving  at  15  p.  s.  i.  (121'C)  for 
15  min  unless  stated.  Heat-labile  ingredients  such  as  antibiotics  (Table  2.3)  and  vitamin 
supplements  were  sterilised  by  filtration  through  a  sterile  0.22  gm  filter  (Gelman  Sciences, 
USA)  and  were  added  to  the  growth  medium  at  appropriate  concentrations.  Glassware  was 
sterilised  by  heating  to  160'C  for  2  h. 
For  routine  long  term  storage,  the  E.  coli  strains  were  kept  at  -70'C  in  LB  broth 
supplemented  with  50%  glycerol  (final  concentration,  v/v)  whereas  Bordetella  strains  were 
resuspended  in  1%  CAA  containing  20%  (v/v,  final  concentration)  glycerol  and  stored  at  - 
701C.  Occasionally,  long  term  storage  was  performed  by  freeze  drying  to  increase  the 
shelf  life  of  bacterial  strains  (E.  coli  and  B.  pertussis). 
2.1.2  Growth  of  E.  coli 
E  coli  strains  were  grown  routinely  overnight  at  37'C  on  LB  agar.  Where 
necessary,  500  ml  of  LB  broth  in  a  2L-dimpled  flask  was  inoculated  from  such  plates  or 
with  5  ml  of  liquid  culture  grown  overnight  in  a  universal  bottle  in  LB  medium.  The  flasks 
were  incubated  overnight  or  for  the  stated  period  of  time  at  37'C  with  shaking  at  150-200 
rpm. 
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Table  2.1:  The  E.  coU  strains  used  in  this  study 
Matetials  &  Methods 
Strain  Genotype/Phenotypes  Source/Remarks 
E.  coli  M  15p(REP4)  Nal',  Stt',  Rif,  'nii-,  Are,  Gal*,  Qiagen;  Recombinant  protein  expression 
Mtl',  RecA',  Uvr,  Lon'  strain 
E.  coli  TOPIOF  F(lacIq,  TnIO(TetR))  MCrA  A(Mrr_  Invitrogen;  General  transformation  strain 
hsdRMS-mcrBQ,  ý801acZAM15, 
AlacX74,  deoR,  recAl,  araD139 
A(ara-leu)7639,  galU,  galK, 
rspL(StrR),  endAI  nupG 
E.  coli  DH5(x  supE44,  AlacU169  (ý801acZW15)  Infection  and  Immunity,  University  of 
hsdR  17,  recA  1,  endA  1,  gyrA96,  thi-  Glasgow;  General  transfon-nation  strain 
1,  re1A  I 
E.  coli  JM109  recAlsuPE44,  endA  1,  hsdR17,  Promega;  General  transformation  strain 
gyrA96,  re1A  1,  thi  A(lac-proAB) 
E.  COH  SM  I  OAPIR  recA::  RP4-2-Tc::  Mu,  KmR,  Apir,  Infection  and  Immunity,  University  of 
IN,  thr,  leu,  lonA,  lacY,  supE  Glasgow;  DNA  mobilising  strain 
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Table  2.2:  The  protease-deficient  strains  of  E.  coli  used  in  the  study 
Strain  Relevant  genotypes  Relevant  protease-deficiency  associated  with  each 
designation  individual  strain  and  their  described  roles 
KS272(parent)  F  AlacX  74,  gaIE,  gaIK,  thi,  Parent  strain 
rpsL(strA),  4pho(pvuII) 
SFI  10  ompT,  degP  OmpT:  A  trypsin  like  outer  membrane  protease  which 
cuts  between  lysine-arginine,  arginine-arginine, 
arginine-valine,  arginine-alanine 
SFI-20  ompT,  degP,  ptr  DegP:  possesses  a  proteolytic  and  general  chaperonic 
activity;  located  in  periplasm  and  may  be  associated 
with  envelopes. 
HMIOI  tsp,  eda  Eda:  An  a1dolase  enzyme  which  was  disrupted  with  a 
tetracycline  resistance  marker  for  selection  purposes. 
HMIII  ompT,  tsp,  eda  Tsp:  a  C-terminal  specific  periplasmic  protease; 
cleaves  by  endoproteolytic  cleavage  and  cuts  between 
alanine-Icucine,  alanine-lysine,  alanine-arginine  and 
valine  -serine 
HM112  pir,  tsp,  eda  Ptr  (Protease  IH):  a  metalloprotease  mainly  found  in 
periplasin  and  perhaps  associated  with  envelopes; 
cleaves  between  phenylalanine-tyrosine,  tyrosine- 
leucine,  tyrosine-isoleucine 
HM120  degP,  ompT,  Isp,  eda 
HM130  degP,  ptr,  ompT,  Isp,  eda 
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Table  2.3:  The  antibiotics  used  in  the  study 
Matetials  &  Methods 
Antibiotic  Concentration  gg/ml 
Ampicillin  (Ap)  100 
Chloramphenicol  (Cm)  20 
1 
Kanamycin  (Km)  40 
Nalidixic  acid  (mono-sodium  salt)  (Nal)  40 
Streptomycin  (Sm)  100 
TetracYclin  (Tet)  40 
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2.1.3  GrowthoMpetlussis 
Materials  &  Methods 
Growth  of  B.  pertussis  requires  special  media  and  a  long  incubation  time  (bacterial 
duplication  time  is  approximately  4-6  h  at  35-37*C).  B.  pertussis  was  grown  on  BG  agar 
containing  15%  (v/v)  deribrinated  horse  blood  (E  and  0  Laboratories,  Scotland)  and  1% 
(v/v)  glycerol.  Plates  were  placed  in  a  humidified  box  and  incubated  for  2  -3  days  at  370C. 
The  B.  perlussis  colonies  can  be  maintained  for  a  period  of  7-10  days  on  BG  agar  plate 
stored  inverted  at  room  temperature  or  at  4'C  in  a  hurnified  condition.  Where  necessary,  a 
large  inoculum,  such  as  loopful  of  bacteria  from  a  plate  grown  to  confluence,  was  added 
into  10  ml  of  CL  medium  in  a  25  ml  dimpled  flask.  After  24-36  h,  this  culture  was  used  to 
inoculate  500  ml  of  fresh  CL  medium  in  2L  dimpled  flask  which  was  incubated  for  2-3 
days  at  37*C  with  shaking  at  150-200  rpm. 
2.1.4  Growth  of  other  Bordelella  strains 
Routinely  B.  bronchiseptica,  B.  parapmussis  and  B.  avium  were  grown  for  24-48  h 
at  37'C  on  BO  agar  plates.  Where  necessary,  500  ml  of  CL  broth  in  2L  dimpled  flasks 
were  inoculated  from  such  BG  plates  and  incubated  for  24-48  h  at  37'C  with  shaking  at 
150-200  rpm. 
2.1.5  Spontaneous  antibiotic  resistant  strains  of  B.  perfussis 
During  the  genetic  manipulations  of  bacteria,  it  is  often  desirable  to  use  strains  that 
can  be  easily  selected,  for  example  on  antibiotic-containing  plates.  The  most  commonly 
used  antibiotics  for  generating  spontaneous  antibiotic  resistant  strains  of  B.  pertussis,  are 
streptomycin  and  nalidixic  acid.  In  order  to  raise  spontaneous  antibiotic  resistant  strains 
for  the  above  mentioned  antibiotics,  a  10  ml  volume  of  a  mid-log  phase  culture  was 
centrifuged  and  resuspended  in  0.1-0.2  ml  of  fresh  Stainer-Scholte  medium.  Aliquots 
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Table  2.4:  The  Bor(lelella  strains  used  during  the  study 
Materials  &  Afelhods 
Strain  Genotype/  Phenotype  SourceARemarks 
B.  pertussis  Parent  Isolated  from  a  child  post-mortem. 
Tabcrinan  Ruchill  Hospital,  Glasgow  (1979) 
B.  Perlussis  Sin"  and  Nal"  derivative  of  BP  Taberman  This  study 
Tabcrinan  I  Parent 
B.  pertussis  Bap-5-insertional  mutant  of  Taberman  I  This  study 
Tabernian  11 
B.  pertussis  Parent  Division  of  Infection  and 
Toharna  Immunity,  University  of  Glasgow 
B.  pertussis  Sm"  and  NaIR  derivative  of  BP  Tolima  parent.  This  study 
Tohaina  I 
B.  pertussis  Bap-5  insertional  mutant  of  Toliama  I  parent  This  study 
Tohama  11 
B.  periussis  Wild-type  Challenge  strain  for  intracercbral 
18-323  mouse  protection  tests.  Manclark, 
C.  Centre  for  Biologics  Evaluation 
and  Research,  Bethesda,  MD 
20892  U.  S.  A. 
B.  pertussis  Toliania  Derivative  of  BP  Tobarna  (Nalt).  Parent  of  Weiss,  A.  Dept  of  Molecular 
(BP338)  Brk-A  mutant  2041  and  BP  347.  Genetics,  University  of  Cincinnati 
B.  Pertussis  Tohama  Deletion  mutant  of  BrkA  Weiss,  A.  Dept  of  Molecular 
(B  P204  1)  Genetics,  University  of  Cincinnati 
B.  periussis  Toharna  SinK  and  Nalk  derivative  of  BP2041,  created  This  study 
(BP204  1)  for  making  a  BrkA  and  Bap-5  double  mutant 
B.  perlussis  Avirulent  mutant.  Tn  insertion  of  Tohama.  Weiss,  A.  Dept  of  Molecular 
Tohama  (BP347)  Bvg*  (Vir)  Genetics,  University  of  Cincinnati 
_  B.  pertussis  BBC29  Wild-type  Prof.  M.  Roberts,  Dept  of 
Veterinary  Pathology,  University 
of  Glasgow 
B.  pertussis  BBC30  Deletion  mutant  of  PRN  Prof.  M.  Roberts,  Dept  of 
Veterinary  Pathology,  University 
of  Glasgow 
Aparapertussis  Wild-type  Division  of  Infection  and 
NCTC5952  Immunity,  University  of  Glasgow 
B.  bronchiseptica  Wild-type  Division  of  Infection  and 
214  Immunity,  University  of  Glasgow 
B.  avitan  Wild-type  R.  Rimler,  Ames,  Iowa 
4480 
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(100  pl,  50  pl)  of  the  bacterial  suspension  were  then  spread  on  BG  agar  plates  containing 
100  pg/ml  of  streptomycin  or  40  pg/ml  of  nalidixic  acid  and  incubated  at  370C  for  4-5 
days  under  humidified  conditions  to  allow  the  growth  of  the  spontaneous  resistant  strains. 
2.1.6  Bacterial  conjugation  and  gene  replacement 
Conjugation  bctween  E.  coli  and  B.  pertussis  is  a  common  way  to  introducc 
DNA  into  the  B.  pertussis  chromosome.  The  structure  of  the  most  widely  used 
conjugative  plasmid  pRTPI  (return  to  pertussis)  in  Bordetella  has  been  described 
previously  (Stibitz  et  al.,  1986).  A  derivative  of  this  plasmid,  pSS1129  (Stibitz  and 
Yang,  1991)  was  used  to  create  B.  pernissis  mutants.  Bacterial  conjugation  was  carried 
out  by  plate  inating  on  BG  agar  plates  between  E.  COU  SMIOAPIR  (donor  strain)  carrying 
the  mutated  bap-5  gene  on  pSS  11229  and  B.  perfussis  recipient  strains  (Taberman  I  and 
Toliama  1).  One  freshly  transformed  colony  of  donor  E.  coli  strain  SMIOAPIR  was 
grown  in  LB  broth  at  37'C  for  4-5  h  to  reach  an  OD6w-O.  4.  B.  pertussis  was  grown  in 
Cyclodextrin  liquid  (CL)  medium  (10  ml)  until  the  OD600-0.5  (-early  logarthmic 
phase).  The  concentration  was  adjusted  by  comparison  with  5'h  International  Reference 
of  Opacity  (Perkins  et  al.,  1973)  to  10  opacity  units  i.  e.  -109  CFU/ml.  Dilutions  of  E. 
COU  SMIOAPIR  cultures  were  then  prepared  containing  -W  or  105  CFU/mi  and 
centrifuged  at  14000  rpm  for  I  min  and,  in  parallel  I  m.  1  culture  of  B.  pertussis 
containing  -109  CFU/ml  was  centrifuged  at  14000  rpm  for  I  min.  The  pellets  were 
resuspended  gently  and  washed  twice  in  their  respective  media  and  pelleted  again  at  the 
same  speed  as  above  for  5  minutes.  Pellets  of  both  donor  and  recipient  strains  were 
resuspended  in  100  pl  of  CL  medium  and  mixed  together  in  a  1.5  ml  eppendorf  tube  at 
different  donor:  recipient  ratios  i.  e.  1:  1,1:  2,1:  3.  The  mixture  was  plated  on  BG  agar 
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plates  supplemented  with  I  OMM  MgC12,  which  is  known  to  facilitate  conjugation,  in  the 
fonn  of  10  pl  drops  at  various  spots  and  incubated  at  37"C  for  14  h  (Stibitz  and  Yang, 
1991). 
T'he  bacterial  cells  were  then  collected  with  the  help  of  loop,  in  Stainer-Scholte 
medium,  washed  and  resuspended  in  fresh  Stainer-Scholte  medium.  Bacterial 
suspensions  obtained  were  then  plated  (100  lil)  onto  BG  agar  plates  supplemented  with 
nalidixic  acid  and  kanamycin  and  incubated  at  37'C  for  4-5  days.  This  step  selected  for 
the  incorporation  of  the  suicide  plasmid  into  the  recipient  chromosome  via  a  single 
cross  over  event.  To  select  for  loss  of  the  plasmid  and  a  second  recombination  event, 
the  exconjugants  were  plated  on  BG  agar  plates  supplemented  with  streptomycin  and 
incubated  at  37'C  for  4-5  days.  This  selected  for  the  loss  of  plasmid  which  codes  for 
sensitivity  to  streptomycin  due  to  the  presence  of  the  nafive  ribosomal  proteins  (rspL). 
'17he  survivors  of  the  streptomycin  selection  were  further  analysed  for  the  loss  of  the 
plasmid  and  retention  of  kanamycin  resistance  by  streaking  on  to  a  BG  plate  containing 
kanamycin  and  streptomycin  together  and  incubating  for  3-4  days  at  37'C.  Further 
confirmation  for  the  loss  of  integrated  plasmid  was  achieved  by  their  inability  to  grow 
on  BG  agar  plates  containing  ampicillin  (a  marker  on  the  suicide  plasmid)  (Stibitz, 
1994). 
2.2  DNA  extraction 
2.2.1  Genomic  DNA 
For  routine  isolation  of  genomic  DNA  from  B.  pertussis,  Promega's  Wizard 
0 
genomic  DNA  purification  kat  was  used.  Bacteria  from  Iml  volumes  of  an  overnight 
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culture  grown  to  OD60N.  -  0.6-0.7  were  harvested  by  centrifugation  at  13,000  rpm  for  2 
min  in  a  1.5  ml  eppendorf  and  the  supemate  was  discarded.  To  the  pellet  was  added  600 
pi  of  nuclei  lysis  solution  (Promega)  and  the  mixture  was  pipetted  gently  to  completely 
mix  and  tile  sample  was  then  incubated  at  80T  for  5  min  and  then  cooled  at  room 
temperature.  3  jil  of  RNase  solution  was  then  added  and,  after  thorough  mixing,  the 
sample  was  incubated  at  37'C  for  30  min  and  then  cooled  to  room  temperature.  After 
cooling,  200  pl  of  protein  precipitation  solution  (Promega)  was  added,  the  mixture 
vortexed  and  incubated  on  ice  for  5  min.  The  sample  was  centrifuged  at  13,000  rpm  for  3 
min  and  the  supernate  was  carefully  transferred  to  an  eppendorf  tube  containing  600  ill  of 
isopropanol  and  mixed  thoroughly.  The  sample  was  centrifuged  at  13,000  rpm  for  2  n-dn 
and  to  the  pellet  was  added  600  ýLl  of  70%  ethanol.  The  sample  was  then  mixed,  and 
centrifuged  for  2  min  at  13,000  rpm.  The  supernate  was  removed  and  the  pellet  was  air- 
dried  to  completely  remove  traces  of  ethanol.  The  DNA  pellet  was  rehydrated  by  adding 
100  lil  of  rehydration  solution  (Promega)  for  Ih  at  65'C  or  occasionally  overnight  at  40C. 
The  DNA  was  aliquoted  and  stored  at  -20"C. 
2.2.2  Plasmid  DNA 
The  QlAprep  0  Miniprep  purification  system  (Qiagen)  was  used  for  plasmid  DNA 
isolation  according  to  the  manufacturer's  protocol.  In  brief,  a  5ml  volume  of  an  overnight 
E.  coli  culture  was  centrifuged  at  10,000  xg  for  10  min  (Biofuge,  Rotor:  HFA  14.2).  The 
resultant  bacterial  pellet  was  resuspended  in  250  pl  of  Buffer  PI  and  lysed  using  250  [d  of 
Buffer  P2  (alkali-detergent  solution)  for  5  min  at  room  temperature.  The  macromolecules 
were  then  precipitated  using  350  pl  of  Buffer  N3  (chaotropic  solution)  and  centrifuged  at 
15,000  xg  for  10  min  (Biofuge,  Rotor:  HFA  14.2).  The  supemate  was  added  to  a 
QlAprep  0 
mini  column  and  centrifuged  at  10,000  xg  for  Imin.  The  flow-through  was 
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discarded  and  the  column  was  then  washed  with  500  pLl  of  Buffer  PB  (trace  nuclease 
removal)  and  centrifuged  at  10,000  xg  for  ln-ýn.  The  flow-through  was  discarded  and  the 
final  wash  was  performed  with  750  pl  of  Buffer  PE  (containing  ethanol)  with  a  further 
centrifugation  at  10,000  xg  for  I  min.  An  additional  centrifugation  was  performed 
following  flow-through  removal  to  ensure  thorough  removal  of  ethanol.  Finally,  the  DNA 
was  eluted  by  centrifugation  after  addition  of  40-80  gl  of  sterile  distilled  preheated  (65'C) 
water.  The  detail  of  plasmids  used  during  the  study  is  given  in  Table  2.5. 
2.3  Agarose  gel  clectrophoresis 
23.1  Sample  preparation 
The  sample  DNA  (5-30  [d)  was  mixed  with  6x  DNA  loading  buffer  (Appendix  1) 
in  a  5:  1  (vol/vol)  ratio  prior  to  loading  into  the  wells.  Molecular  weight  markers  (I  Kb 
ladder,  Gibco  BRL,  UK)  were  utilised  according  to  manufacturer's  instructions. 
2.3.2  Gel  preparation 
Pre-weighed  agarose  (type  11-A  medium  EEO,  Sigma),  was  suspended  in  0.5  x 
Tris-borate-EDTA  (TBE)  buffer  (Appendix  1)  and  heated  until  the  agarose  solution  became 
clear  (completely  dissolved).  The  solution  was  allowed  to  cool  to  the  extent  that  it  was  still 
warm  and  ethidium  bromide  (Bio-Rad,  UK)  was  added  to  a  final  concentration  of  0.5 
jig/ml.  A  gel  tray  was  prepared  by  taping  the  edges  with  adhesive  tape  and  the  gel  was  cast 
to  the  desired  thickness.  Upon  setting,  the  gel  was  immersed  in  0.5  x  TBE  buffers 
containing  ethidium  bromide  (0.5  pg/ml)  in  a  horizontal  submarine  electrophoresis  tank 
(E-C  Apparatus  Corporation,  USA).  A  power  pack  (model  SL3655,  Scotlab,  UK)  was 
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used  to  provide  a  constant  voltage  corresponding  to  1-5  volts/cm.  Electrophoresis  was 
carried  out  until  the  marker  dye  in  the  loading  buffer  migrated  an  appropriate  distance. 
2.3.3  Visualisation  of  DNA 
Ile  ethidium  bromide-stained  DNA  was  visualised  using  a  UV  transilluminator 
(model  TM-40,  UVP  Inc.,  California,  USA).  Images  were  stored  electronically  as 
appropriate  using  the  Gel  Documentation  System-Image  Store  5000,  version  7.2  (Ultra 
Violet  Products,  Cambridge,  UK)  as  well  as  printed  using  a  video  graphic  printer  (model 
UP-860,  Sony).  Electronic  images  were  edited  using  Adobe  Photoshop  3.0  and  images 
labelled  with  Microsoft  PowerPoint  4.0 
2.3.4  Gel  extraction  procedure 
For  DNA  purification  purposes,  a  Qiaex  0  11  purification  kit  (Qiagen)  was  used 
according  to  the  manufacturer's  instructions.  The  band  of  interest  was  excised  from  the 
agarose  gel  and  solubilised  in  Buffer  QXI  (usually  3  volumes  of  buffer  to  one  volume  of 
gel).  Qiaex  resin  (10-15  pl)  was  introduced  and  the  mixture  incubated  at  50'C  for  10  min. 
Following  centrifugation  for  I  n-dn  at  10,000  xg  the  supernate  was  removed.  The  pellet 
was  then  washed  once  with  500  gl  of  Buffer  QXI  and  twice  with  500  [d  of  Buffer  PE,  with 
centrifugation  for  I  minute  at  10,000  x  g.  The  resin/DNA  pellet  was  air-dried,  5-25  pl  of 
sterile  distilled  water  was  added  and,  after  incubation  for  5  min  at  50'C,  the  resin  was 
removed  by  centrifugation  as  before  and  the  eluted  DNA  was  retained. 
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Table  2.5:  Plasmids  used  or  created  during  this  study 
Materials  &  Methods 
Plasmid  Name  Comments  Source/Remarks 
pE-TI  I  a(BCTI)  brkA  C-tcrminal  region  cloned  into  pET11a:  P.  Blackburn,  Div.  of  Infection  and  Immunity 
expression  construct  for  BrkA  C-tcrminus  University  of  Glasgow 
pET33b(PCTI)  pm  C-tcrminal  region  cloned  into  pET33b:  P.  Blackburn,  Div.  of  Infection  and  Immunity 
expression  construct  for  Pm  C-tcrminus  University  of  Glasgow 
pE-T33b(TCTI)  tcf  C-tcrminal  region  cloned  into  pET33b:  P.  Blackburn,  Div.  of  Infection  and  Immunity 
expression  construct  for  Tcf  C-tcrminus  University  of  Glasgow 
pM3b(Bp5CTI)  bal;  -5  C-terminal  region  cloned  into  pET33b:  P.  Blackburn,  Div.  of  Infection  and  Immunity 
expression  construct  for  Bap-5  C-terminus  University  of  Glasgow 
pQE-60(Bp5ATG  1)  bal)-5  cloned  into  pQE-60:  full  length  expression  P.  Blackburn,  Div.  of  Infection  and  Immunity 
construct  for  Bap-5  (from  the  Ist  predicted  University  of  Glasgow 
translational  start  site,  ATGI)  (Appendix  11) 
pGEMT(Bap-5  Km)  bap-5  gene  disrupted  with  kanamycin  resistance  P.  Blackburn,  Div.  of  Infection  and  Immunity 
cassette  in  pGEMT  Easy  vector  University  of  Glasgow 
pBAD/gIIIA  pertactin  C-terminal  and  linker  region  (PCT+Iink)  P.  Blackburn,  Div.  of  Infection  and  Immunity 
(PCTlink)  cloned  into  pBAD/gIIIA:  expression  construct  of  Prn  University  of  Glasgow 
C-tcrminus  and  linker  fused  to  a  signal  sequence 
41869p  Full  length  pertactin  gene  (p.  93)  cloned  into  a  broad-  M.  Roberts,  Dept  of  Veterinary  Pathology, 
host  range  expression  vector  pMMB66EH  University  of  Glasgow 
pSS  1129  Suicide  vector  used  for  gene  replacement  in  B.  Stibitz,  S.  (1994) 
pertussis 
(pBap5-Kana)  Suicide  vector  containing  mutated  bap-5  gene  This  study 
disrupted  by  insertion  of  kanamycin  resistance 
I  cassette 
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2.4  Quantification  of  DNA 
Materials  &  Methods 
The  concentration  of  DNA  was  estimated  by  measuring  the  absorbance  at  260  nm 
in  a  I-cm  quartz  cuvette  and  by  applying  the  equation: 
Concentration  of  DNA  (ng/pl)  =  A260nm  x  50  x  dilution  factor 
2.5  Restriction  enzyme  reactions 
All  reactions  were  performed  according  to  the  manufacturers'  instructions  (Gibco 
BRL,  New  England  Biolabs  or  Promega).  Total  reaction  volumes  of  20  pI  and  30  jil.  were 
commonly  used.  Where  appropriate,  the  enzymes  were  heat-inactivated  (65"C  for  15  min) 
and  the  DNA  was  purified  using  the  Qiaex  0  11  kit,  often  in  conjunction  with  agarose  gel 
electrophoresis  if  isolation  of  a  single  linear  restriction  product  was  required. 
2.6  Polymerase  chain  reaction 
The  PCR  conditions  were  optimised,  where  necessary,  according  to  the  orthogonal 
array  method  described  by  Cobb  et  al.  (1994).  The  annealing  and  elongation  thermal 
parameters  were  then  adjusted  to  obtain  optimal  conditions.  A  Hybaid  thermal  cycler 
(model:  Touchdown,  Hybaid  Ltd,  Middlesex,  UK)  was  used  for  all  reactions.  The 
products  of  the  PCR  were  stored  at  -20'C  or  used  immediately. 
2.6.1  Primers 
During  primer  design,  care  was  taken  to  avoid  potential  internal  secondary  structure 
and,  where  possible,  a  GC  clamp  was  engineered  at  the  3'  end  of  the  primer.  Additionally, 
primers  were  checked  to  avoid  overlap  and  possible  dimerisation,  potential  for  secondary 
structure  formation  and  for  compatible  Trn  values.  Trn  values  were  calculated  according  to 
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the  equation:  Tin  (OC)  =  4(G  +Q+  2(A  +  T)  -  50C 
Materials  &  Methods 
Primers  (50  nniol,  clesalted  and  deprotected)  were  obtained  from  Gibco  BRL  (Paisley,  UK) 
and  resuspended  in  sterile  distilled  water  to  give  final  concentrations  of  50  pmol  /pt]  or  0.5 
pmol  /pl  for  PCR.  The  nucleotide,  sequences  are  taken  from  the  bap-5  gene  sequence 
(Appendix  11). 
Table  2.6:  Primers  used  during  the  study 
Primer  designation  Primer  sequence 
bap-5  Forward  ATGGCACCTCGCCTTCGATTCGCGTCCAAG 
Y-3'  From  nucleotide  286 
bap-5  Reverse  AGGTGGAACGTCCAAGGCAAGGTCAGCTTG 
5'-3'  From  nucleotide  2518 
bap-5  NTS  Forward  ATGGGTGCAAATAACGTCGCTGTG 
5'-3'  From  nucleotide  336 
bap-5  NTS  Reverse  GTCGTAGTAATACTCGACTGCATCG 
Y-T  From  nucleotide  791 
2.6.2  IlotStarlaq  Thl  method 
Hot-start  PCR  was  performed  according  to  the  HotStarTaqTl"  PCR  kit  (Qiagen) 
manufacturer's  instructions.  The  following  master  mix  was  prepared  in  a  thin-walled  0.5 
ml  tube  immediately  before  use  (per  reaction): 
Master  mix  per  reaction  III 
10  x  PCR  buffer  (containing  1.5  mM  MgCl,  )  2.5 
5xQ  solution  5.0 
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dNTP  mix  (10  mM  of  each)  0.5 
HotstarTaq  DNA  polymerase  0.2 
Distilled  water  15.3 
Added  individually  in  tubes  ILI 
5'  primer  (50  pmol/ptl)  0.5 
3'  primer  (50  pmol/ptl)  0.5 
Template  DNA  (100ng-  I  gg)  0.5 
Total  volume  in  each  PCR  tube  25 
Q-solution  changes  the  melting  behaviour  of  the  DNA  and  is  particularly  useful  when 
amplifying  GC  rich  templates.  The  following  thermo-cycling  parameters  were  used: 
Initial  activation  step:  15  min  95"C 
and  30  cycles  of 
Denaturation:  60  see  94'C 
Annealing:  60  sec  60'C 
Extension:  I  min  72'C 
For  PCR  products  longer  than  I  Kb  the  extension  time  was  increased  by  I  min  per  Kb 
DNA.  For  amplification  of  the  full  length  bap-5  gene  (2.2  Kb)  the  extension  time  was 
optimised  at  3  min. 
Final  extension  step  10  min  72'C 
2.7  Cloning  protocol 
2.7.1  DNA  preparation 
Vector  and  insert  DNA  were  subjected  to  restriction  endonuclease  digestion  to 
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obtain  complimentary  cohesive  overhangs.  The  resultant  fragments  were  purified  from  the 
agarose  gel  using  the  Qiagen  purification  kit.  After  gel  purification,  the  resultant  vector 
was  treated  with  alkaline  dephosphorylase  (calf  intestine,  Promega)  at  37'C  for  45  min, 
then  heated  to  65'C  for  10  min  to  inactivate  dephosphorylase  and  then  re-purified  by 
passing  through  a  Qiagen  mini-centrifuge  column  at  10,000g.  DNA  concentrations  were 
estimated  according  to  section  2.5  and  occasionally  DNA  samples  (insert  and  vector)  were 
compared  with  the  I  Kb  ladder  (Gibco,  BRL)  the  concentration  of  whose  individual  bands 
are  given  by  the  manufaturer.  Insert:  vector  ratios  of  1:  1  and  3:  1  were  commonly  used  for 
ligation. 
2.7.2  Ligation  strategies 
Ligation  reactions  were  performed  in  a  total  volume  of  10  gI  using  3  units  of  T4 
DNA  ligase  (Promega,  USA)  and  Promega,  ligase  buffer  or  occasionally  Boehringer  ligase, 
using  their  specified  buffers  according  to  the  manufacturer's  instructions.  After  incubation 
at  16'C  for  l8h  (Promega  ligase)  or  4'C  for  18h  (Boehringer  ligase),  the  ligation  was 
terminated  by  heating  the  reaction  mix  to  70"C  for  10  min  and  the  products  were  stored  at  - 
20'C  until  use. 
2.8  Transformation 
2.8.1  Preparation  of  electroporation-competent  cells 
To  a  2L  dimpled  flask  containing  500  ml  of  LB  medium,  5  ml  of  an  overnight 
culture  of  E.  coli  was  added.  The  flask  was  incubated  at  37'C  on  the  shaker  until  an 
OD600nm  of  0.6-0.8  was  obtained  and  thereafter  it  was  chilled  on  ice.  Bacterial  cells  were 
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harvested  at  7000  g  for  15  min  in  a  Sorvall  superspeed  (rotor  GS-3).  The  resultant 
bacterial  pellet  was  washed  and  resuspended  in  500  ml  of  cold  sterile  distilled  water  and 
centrifuged  as  mentioned  above.  The  cell  pellet  was  again  resuspended  in  250  ml  of  cold 
sterile  water,  centrifuged  as  above  and  resuspended  in  10  ml  of  cold  sterile  water 
containing  10%  (v/v)  glycerol.  Following  a  final  centrifugation,  the  cells  were 
resuspended  in  2.0  ml  of  cold  sterile  glycerol  10%  (v/v)  and  100  gI  aliquots  were  snap 
frozen  in  liquid  nitrogen.  Cells  were  kept  cold  (on  ice)  at  all  times  during  the  procedure 
and  were  stored  at  -70'C. 
2.8.2  Electroporation  procedure 
Electroporation  cuvettes  (0.2  cm)  (Flowgen,  UK))  and  the  safety  chamber  were 
chilled  at  -20'C.  To  the  chilled  cuvette,  48  gI  of  competent  cells  and  2  gl  of  DNA 
(plasmid  preparation)  were  added.  The  mixture  was  mixed  using  a  sterile  yellow  tip, 
shaken  to  the  bottom  of  the  cuvette  and  the  cuvette  placed  in  a  Bio-Rad  Gene  Pulser  set  at 
2.5  KV,  25  gFD  and  was  connected  to  a  Bio-Rad  pulse  controller  set  to  20092.  The  cells 
were  pulsed  once  for  4-5  msec.  Immediately  following  electroporation,  I  ml.  of  pre- 
warmed  (37*C)  SOC  medium  (Appendix  I)  was  added  to  the  cells  and  thoroughly  mixed 
and  then  incubated  in  a  water  bath  at  37'C  without  shaking  for  I  h. 
2.9  Southern  blotting 
The  detailed  composition  of  all  solutions  is  given  in  Appendix  1.  Unless  otherwise 
stated,  all  reagents  were  supplied  by  Boehringer  Mannheim.  The  DNA  samples  to  be 
analysed  were  electrophoresed  on  an  ethidium  bromide-stained  agarose  gel.  The  gel  was 
then  depurinated  by  soaking  it  in  0.25M  hydrochloric  acid  for  15  min  and  then  rinsed 
thoroughly  in  dH20  twice.  The  gel  was  allowed  to  float  in  denaturing  solution  for  45  min 
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with  gentle  shaking  followed  by  rinsing  it  twice  with  dH20.  Then  it  was  soaked  for  30  min 
in  neutralising  solution  (Appendix  I).  The  gel  was  placed  on  the  top  of  a  wick  made  up  of 
3MM  Whatmann  filter  paper  saturated  with  20  x  SSC  (Appendix  1)  and  then  blotted 
overnight  by  capillary  action  onto  positively-charged  nylon  membrane  (Boehringer).  After 
dismantling  the  blotting  set  up,  the  positions  of  wells  were  marked  to  determine  the 
orientation  of  the  gel  later  on.  The  nylon  membrane  was  removed  and  washed  in  2x  SSC 
to  remove  any  agarose  particles  and  wrapped  in  cling  film.  DNA  was  then  crosslinked  to 
the  membrane  with  the  exposure  of  each  side  of  the  membrane  for  1  min  using  a  UV  cross 
linker  (Spectrolinker  XL-1000,  Spectroline,  New  York,  USA).  The  membrane  was  then 
I 
prehybridised  for  4-6  h  in  a  rolling  hybridisation  oven  (model  HB-ID,  Techne,  Cambridge, 
UK)  with  at  least  20ml  of  prehybridising  solution  (Appendix  1).  The  temperature  of  the 
oven  was  set  at  65'C  for  prehbridisation.  This  temperature  was  maintained  for  the 
subsequent  hybridisation  and  washing  steps  (see  below). 
2.9.1  Preparation  of  digoxigenin-labelled  probes 
The  digoxigenin  (Dig)  labelled  probes  were  synthesised  using  a  Dig-labelling  PCR 
kit  (Boehringer  Mannheim).  The  PCR  kit  is  provided  with  the  Dig-labelled  mix,  which  is 
a  mixture  of  lithium  salts  of  dNTPs  and  digoxigenin-11-dUTP.  This  nucleoticle  mixture 
can  be  added  (200  [tM  each  in  final  concentration)  directly  to  the  PCR  reaction  and  the 
Dig-labelled  nucleotides  will  be  incorporated  into  the  PCR  product.  Hotstar  Taq 
polymerase  was  used  under  similar  conditions  to  those  in  section  2.6.2,  using  the  primer 
sequences  bap-5  Forward  and  bap-5  Reverse  (Table  2.6)  which  cover  the  full  length  bap-  5 
gene  (Appendix  II).  The  PCR  product  can  be  cleaned  after  agarose  gel  extraction  as 
described  in  section  2.3.2.  The  contents  of  the  labelling  tube  were  then  added  to  8  ml  of 
78 Habib  Bokhari  Matefials  &  Methods 
prehybridisation  solution  (Appendix  I)  and  stored  at  -201C.  Denaturation  of  the  probe  was 
performed  for  10  min  in  a  boiling  water  bath  followed  by  immediate  chilling  on  ice  just 
before  use. 
2.9.2  Probe  hybridisation 
The  prebridisation  was  perfonned  at  60'C  for  3-4  h  in  prehybridisation  mix 
(Appendix  1).  The  prehybridising  solution  was  then  discarded  and  the  denatured  probe 
immediately  added  to  the  roller  tube  carrying  the  DNA  samples  cross-linked  to  the  nylon 
membrane.  Hybridisation  was  performed  overnight  (12-14  h)  at  60'C.  The  probe  was 
poured  into  a  universal  tube  and  stored  at  -20'C.  The  membrane  was  washed  at  the 
hybridisation  temperature  for  2x  15  min  in  50  ml  of  2x  SSC  /  0.1%  SDS  (w/v)  at  room 
temperature  (low  stringency  washing),  followed  by  2x  15  min  washes  in  50  ml  0.5  x  SSC  / 
0.1%  SDS  (w/v)  at  65*C  (high  stringency  washing). 
2.9.3  Chemiluminescence  detection 
Detection  was  performed  according  to  the  protocol  described  in  the  DIG  system 
User's  Guide  for  Filter  Hybridisation  (Boehringer  Mannheim).  The  washed  membrane 
was  equilibrated  for  1-2  min  in  wash  buffer  (Appendix  1).  Antibody  blocking  solution 
(Appendix  1)  was  then  incubated  with  the  membrane  for  30-60  min.  The  antibody  (anti- 
Dig-conjugated  to  alkaline  phosphatase)  was  centrifuged  for  5  min  to  remove  any 
aggregates  and  then  diluted  to  1  in  5,000  (2  gl  per  10  ml)  in  the  antibody  blocking  buffer 
and  the  membrane  was  then  incubated  for  30  min  in  at  least  20  ml  of  antibody  solution  at 
room  temperature.  The  membrane  was  then  washed  for  2x  15  min  in  washing  buffer  and 
then  equilibrated  in  detection  buffer  (Appendix  1)  for  5  min.  The  alkaline  phosphatase 
substrate  used  (NBT))  was  diluted  to  1  tablet  in  10  ml  of  detection  buffer  and  this  was 
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dripped  onto  the  membrane,  avoiding  air  bubbles,  prior  to  sealing  within  a  plastic  sheet,  for 
5  min.  The  excess  substrate  was  removed  using  a  damp  paper  towel  on  the  top  plastic 
surface.  The  plastic  was  heat-sealed  and  then  left  at  room  temperature  for  15-45  min  in  the 
dark. 
2.10  Protein  analysis 
2.10.1  Fractionation  of  bacterial  cells  and  collection  of  concentrated  supernate 
The  composition  of  all  reagents  and  buffers  can  be  found  in  Appendix  I  or 
otherwise  stated  in  the  text.  Bacteria  cells  were  harvested  from  500  ml  of  broth  culture  at 
5000  g  for  15  min  in  a  Sorvall  superspeed  centrifuge  (rotor  GS-3).  The  pellet  of  bacteria 
was  resuspended  in  50-ml  of  envelope  buffer  (10  mM  sodium  phosphate,  pH  7.2).  The 
cells  were  disrupted  using  a  mechanical  cell  disrupter  (One  Shot,  Constant  Systems, 
Warwick,  UK)  to  15  K  p.  s.  i  or  occasionally,  using  a  cell  sonicator  (Sonics  and  Materials; 
probe  SM  05)  for  3X  45  sec  while  keeping  the  cell  container  on  ice.  The  resultant  lysate 
was  centrifuged  at  2500  xg  for  5  min  in  a  Sorvall  superspeed  centrifuge  (rotor  SS34)  to 
pellet  large  debris  and  unbroken  cells.  The  supernate  was  centrifuged  in  a  Sorvall 
ultracentrifuge  (OTD-COMBI)  at  100,000  rpm  for  60  min  at  4'C.  The  resulting  supernate 
contained  the  soluble  content  of  the  cytoplasm  and  periplasm.  The  pellet  obtained, 
containing  cell  envelopes,  was  rinsed  in  envelope  buffer  and  the  tubes  dried  upside  down 
on  tissue  paper  for  10  min.  It  was  then  resuspended  in  0.5  ml.  of  envelope  buffer 
containing  sodium  N-laurylsarcosinate  (sarcosyl)  0.5%  (w/v)  and  then  mixed  thoroughly 
by  frequent  pipetting  and  brief  vortexing  after  every  5  min  for  30  min  to  differentially 
solubilise  the  cytoplasmic  membrane  proteins.  In  some  experiments,  protease  inhibitor 
cocktail  (Sigma)  was  also  included  at  this  stage.  A  further  centrifugation  was  performed  at 
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100,000  rpm  for  lh  at  4'C  as  described  previously.  The  final  supernate  contained  the 
sarcosyl-soluble  inner  membrane  proteins  and  the  final  pellet  contained  the  sarcosyl 
insoluble  outer  membrane.  The  outer  membrane-enriched  fractions  were  resuspended  in 
0.5-1  ml  of  envelope  buffer  (Appendix  1).  The  10-20  ml  volume  of  the  bacterial  culture 
was  spun  down  at  7000  x9  for  10  min  in  a  Sorval  superspeed  centrifuge  (SS34)  at  4'C. 
The  supemate  fraction  was  transferred  carefully  into  another  tube  without  disturbing  the 
pellet.  The  clear  supemate  fraction  collected  was  passed  through  a  0.2  gin  filter  to  remove 
any  particulate  matter  or  cells.  4.5  ml  of  supemate  was  then  poured  into  a  spin  column 
(Greiner,  30,000  M.  W.  cut-off)  and  centrifuged  at  7500  xg  for  15  min  at  4'C  in  centrifuge 
((Jouan:  MR1822,80mM).  The  concentrated  material  was  collected  and  the  column 
reused  for  further  centrifugation  steps.  The  centrifugation  process  was  repeated  with 
further  volumes  4-6  times  until  the  desired  concentration  (-40  times)  from  an  initial 
volume  of  about  10-20  n-d  was  achieved. 
2.10.2  Expression  of  recombinant  proteins 
The  expression  of  the  different  recombinant  proteins  in  various  E.  coli  strains  was 
regulated  either  by  isopropyl  P-D-  thiogalactopyranoside  (IPTG  from  Sigma)  inducible 
promoters  or  L-arabinose  inducible  promoters. 
Overnight  cultures  (5  ml)  of  E.  coli  strains  (Table  2.1  and  2.2)  containing 
expression  constructs  (Table  2.5)  were  used  to  inoculate  2L  dimpled  flasks  containing  500 
ml  volumes  of  LB  with  appropriate  antibiotics.  The  cultures  were  then  incubated  at  37'C 
with  shaking  until  an  OD600nm  of  0.7-0.9  was  obtained.  Either  IPTG  (ImM  final 
concentration)  or  0.2%  (w/v)  of  L-arabinose  was  added  to  the  culture  and  incubated  at 
37c'C  continued  on  the  shaker  for  further  3  h.  Cells  were  harvested  at  5,000  xg  for  15  min 
in  a  Sorvall  superspeed  centrifuge  (rotor  GS-3). 
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2.10.3  Urea  extraction  of  inclusion  bodies 
After  the  expression  of  recombinant  protein,  bacterial  cells  were  harvested  as 
described  above.  The  cell  pellets  were  resuspended  in  20  ml  of  Buffer  A  (Appendix  II) 
and  incubated  with  lysozyme  (Sigma)  Igg/ml  and  DNasel  (protease  free,  Sigma;  0.5 
ttg/ml)  and  protease  inhibitor  cocktail  2gg/ml  (Sigma)  for  1h  on  ice.  The  cell  suspension 
was  disrupted  using  a  cell  sonicator  and  the  resultant  lysate  was  centrifuged  at  17,000  x 
in  a  Sorvall  Superspeed  centrifuge  (rotor  SS34)  for  30  min  to  allow  inclusion  bodies  to  be 
pelleted.  The  pellets  were  resuspended  in  10  ml  of  Buffer  B  (Appendix  I)  and  inclusion 
bodies  were  solubilised,  with  tube  rotation,  for  4h  at  room  temperature  or  overnight  at 
40C,  until  the  suspension  became  clear.  A  final  ultracentrifugation  step  of  100,000  xg  for 
3h  was  performed  and  the  supernate,  containing  urea-soluble  protein,  was  retained  and 
stored  at  -20'C. 
2.10.4  Small-scale  affinity  purification  (His-tagged  proteins) 
Purification  of  histidine-tagged  proteins  (Blackburn,  2000)  was  performed  with  the 
Ni-NTA  spin  kit  (Qiagen)  according  to  the  manufacturer's  instructions.  Briefly,  a  Ni-NTA 
column  was  set  up  by  pouring  the  column  with  Ni-NTA  agarose  1-2  ml.  equilibrated  with  5 
ml  of  Buffer  A  for  20-30  minutes  by  allowing  the  buffer  to  pass  drop  by  drop.  The  flow- 
through  was  discarded.  To  the  equilibrated  column,  2  mi  of  urea-soluble  protein  in  Buffer 
A  (Appendix  I)  was  added  and  allowed  to  stand  for  2  min  to  interact  with  the  Ni-NTA 
agarose.  It  was  then  allowed  to  flow  through  drop  by  drop.  The  column  was  then  washed 
two  times  with  5  ml  of  Buffer  B  (Appendix  1).  The  protein  bound  to  the  resin  was  again 
washed  with  5  ml  of  Buffer  C (Appendix  1)  twice.  Finally  it  was  eluted  twice  with  500  gl 
of  Buffer  D  (Appendix  I)  and  the  eluates  were  pooled. 
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2.10.5  Protein  estimation 
Materials  &  Methods 
2.10.5.1  Lowry  (modified)  procedurefor  membrane  proteins  (Folin-Ciocalteu) 
The  composition  of  all  the  stock  solutions  relevant  to  this  procedure  is  given  in 
Appendix  I.  To  make  the  working  solution,  100  parts  of  solution  A  were  mixed  with  I  part 
of  reagent  B  to  form  reagent  C,  the  alkaline  copper  reagent.  Sample  volumes  of  Iml 
containing  approximately  10-100  gg/ml  of  protein,  along  with  known  protein  standard 
BSA  ranging  from  20-200  gg/ml,  were  mixed  with  3  ml  of  reagent  C  and  the  tubes  were 
incubated  at  room  temperature  for  10-60  min.  The  samples  were  then  mixed  vigorously 
with  0.3  ml  of  Folin-Ciocalteu  reagent  diluted  in  distilled  water  (lvol/lvol)  and  incubated 
for  45  min  at  room  temperature.  The  absorbance  at  660  nra  was  determined  with  the  help 
of  a  microtiter  plate  reader  and  protein  concentrations  estimated  from  the  standard  curve. 
2.10.5.2  Standard  procedure  for  soluble  proteins  (Bio-Rad) 
Dye  reagent  was  prepared  by  diluting  1  part  of  dye  reagent  concentrate  with  4  parts 
of  double  distilled  water  according  to  the  manufacturer's  instructions.  This  was  filtered 
through  a  Whatmann  No  I  filter  paper  to  remove  particulates.  This  reagent  is  stable  for 
about  2  weeks  when  kept  at  room  temperature.  Dilutions  of  protein  standard  (BSA)  and 
the  protein  solution  to  be  tested  were  prepared.  The  linear  range  of  this  assay  is  50-500 
[tg/ml.  Protein  solutions  were  normally  assayed  in  duplicate  or  triplicate.  20  gl  of  each 
standard  or  sample  solution,  containing  different  protein  concentrations,  was  pipetted 
into  separate  microtitre  plate  wells.  The  diluted  dye  reagent  (200  gl)  was  then  added  to 
each  well.  The  sample  and  reagent  were  thoroughly  mixed  using  a  multichannel  pipete 
to  dispense  the  reagent.  The  samples  were  incubated  at  room  temperature  for  a 
83 Habib  Bokhati  Materials  &  Methods 
maximum  of  Ih  and  absorbance  was  measured  at  595  nm.  The  protein  concentration  in 
the  test  samPle  was  estimated  from  the  standard  curve. 
2.10.6  Sample  preparation  for  electrophoresis 
50  gl  of  sample  was  mixed  with  10  ptl  of  6x  protein  loading  dye  (Appendix  1). 
Samples  were  stored  at  -20T  until  loading.  Just  before  loading  on  to  the  polyacrylamide 
gel,  samples  were  heated  in  a  boiling  water  bath  for  10  min.  A  10  kDa  protein  ladder 
(Gibco  BRQ  or  Bio-Rad  precision  protein  (stained  and  unstained)  standards  were  used 
according  to  the  manufacturer's  instructions. 
2.10.7  Sodium  dodecyl  sulphate-polyacrylamide  gel  electrophoresis  (SDS-PAGE) 
The  method  for  SDS-PAGE  was  adopted  from  Laemmli  (1970)  and  gels  were  set 
up  in  a  vertical  electrophoresis  gel  tank  (model  SE600,  Hoefer  Scientific  Instruments, 
California,  USA).  The  composition  of  all  solutions  can  be  found  in  Appendix  1.  Glass 
plates  were  assembled  according  to  the  manufacturer's  instructions.  Resolving  gels, 
containing  10-14%  acrylamide,  were  poured  in  between  the  assembled  plates  until  the  gel 
was  4  cm  below  the  top  of  the  plates  and  100%  ethanol  was  used  as  an  overlay.  The  gel 
remained  undisturbed  for  approximately  1h  at  room  temperature  until  completely  set.  The 
ethanol  was  poured  off  and  the  gel  surface  washed  with  distilled  water.  A  stacking  gel 
containing  6%  acrylamide  was  poured  onto  the  polymerised  separating  gel  and  a  comb  was 
placed  onto  the  gel  solution.  Again  the  gel  was  left  for  approximately  Ih  at  room 
temperature  until  set.  The  comb  was  removed  and  wells  were  immediately  washed  once 
with  lx  electrode  buffer  and  filled  with  Ix  electrode  buffer  and  assembled  into  the 
electrophoresis  gel  tank.  The  lower  buffer  reservoir  was  stiffed  with  a  magnetic  stirrer 
during  vertical  gel  electrophoresis.  After  addition  of  samples  to  the  wells  the  gel  was  run 
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at  20  mA  until  the  tracer  dye  entered  the  separating  (lower)  gel  and  thereafter  the  current 
was  increased  to  50  mA.  The  gel  was  removed  when  the  tracker  dye  reached  the  bottom  of 
the  separating  gel  (approximately  4  h).  Occasionally  the  gel  was  allowed  to  run  at  constant 
current  20  mA  overnight  (14  h).  The  gel  was  removed  from  the  plates  and  stained  or 
blotted  as  appropriate.  For  staining,  coomassie  blue  stain  (Appendix  1)  was  utilised,  for  a 
minimum  of  3h  or overnight,  on  a  rotating  platform.  The  stain  was  then  replaced  with  de- 
stain  solution  (Appendix  I)  until  the  background  became  transparent. 
2.10.8  Western  blotting 
2.10-8.1  Blotting  protocol 
To  transfer  proteins  resolved  by  SDS-PAGE  onto  the  immobilising  nitrocellulose 
membrane  (Hybond-C,  Amersham  Pharmacia  Biotech)  the  method  of  Towbin  et  al  (1979) 
was  followed.  In  short,  the  stacking  gel  was  cropped  and  the  separating  gel  was  rinsed 
gently  in  electrode  buffer  (Appendix  I)  for  5  min.  The  blot  was  then  assembled  and  placed 
in  the  electroblotting  apparatus  (Trans-Blot  Cell,  Bio-Rad,  USA)  containing  electroblotting 
buffer  (Appendix  1)  with  magnetic  stirring.  The  transference  of  the  proteins  from  the  gel  to 
the  membrane  was  carried  out  at  constant  50  volts  for  1-2  h  and  occasionally  at  30  volts 
ovemight. 
2.10.8.2  Development  of  blots 
Once  proteins  were  transferred  onto  the  membrane,  it  was  equilibrated  for  1-2 
minutes  in  electroblotting  buffer  at  room  temperature.  To  see  if  the  proteins  were 
transferred  effectively,  the  membrane  was  immersed  into  Ponceau  S  solution  (Sigma,  0.1% 
w/v  Ponceau  S  and  5%  v/v  Acetic  acid)  for  1-2  min.  The  stained  background  was  removed 
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by  destaining  in  water  for  2  min  and  the  position  of  the  molecular  weight  markers  marked 
with  indelible  ink  if  unstained  protein  standards  were  used.  The  membrane  was  then 
destained  in  phosphate-buffered  saline  (PBS)  for  10  min  and  incubated  with  blocking 
buffer  (Appendix  I)  for  1h  at  room  temperature  with  gentle  agitation.  The  primary 
antibody  was  diluted  appropriately  in  blocking  buffer  and  incubated  with  the  membrane  for 
1h  at  room  temperature  on  a  rotating  platform.  The  membrane  was  then  washed  for  15 
min  in  2  changes  of  PBS  at  room  temperature.  Horseradish  peroxidase-conjugated 
secondary  antibody  (anti-mouse  or  anti-rabbit  as  appropriate,  Scottish  Antibody  Production 
Unit,  UK)  diluted  1:  1000  (v/v)  in  blocking  buffer  was  added  to  the  membrane  and 
incubated  for  Ih  at  room  temperature.  Again  the  membrane  was  washed  for  2x  15 
minutes  in  PBS  at  room  temperature.  The  membrane  was  then  immersed  in  freshly 
prepared  3,3'diaminobenzidine  (DAB)  (Sigma)  0.05%  w/v  in  PBS  for  approximately  1-2 
min  and  the  staining  reaction  was  stopped  by  washing  the  membrane  with  distilled  water. 
2.11  RNA  analysis 
2.11.1  Extraction  of  total  RNA  from  B.  pertussis 
The  RNeasy  mini  kit  (Qiagen)  was  used  for  the  extraction  of  total  RNA  from  B. 
pertussis  cells  according  to  the  manufacturer's  instructions.  The  bacterial  cells  were 
harvested  from  1  ml  volume  of  mid-log  phase  cultures  in  CL  medium.  Occasionally 
bacteria  were  collected  from  heavily  inoculated  BG-plates  (24-48h  growth)  and 
resuspended  in  I  ml  volume  of  sterile  PBS  in  1.5  ml  eppendorf.  The  number  of  cells  was 
adjusted  to  -IxIO9/ml  using  an  opacity  rod.  The  pellets  were  collected  after  centrifugation 
at  10,000  xg  for  5  min  at  4"C  and  the  supernates  were  discarded.  Cells  were  then 
resuspended  thoroughly  in  100  jil  of  TE  buffer  (lOmM  Tris  +  lmM  EDTA,  pH  8.0) 
containing  400  gg/ml  of  lysozyme,  vortexed  for  5s  and  incubated  at  room  temperature  for 
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5  min.  Then,  350  [d  RLT  buffer  (chaotropic  reagent,  protects  RNA)  was  added  to  the 
sample  and  vortexed  vigorously.  After  centrifugation  for  2  min  at  10,000  x  g,  the 
supernate  was  collected  carefully  without  disturbing  the  pellet.  To  the  lysate  was  added 
250  gI  of  absolute  ethanol  and  then  mixed  well  by  pipetting.  The  sample  was  then  added 
to  the  RNeasy  minispin  column  in  a2  ml  collection  tube.  The  minispin  column  was  then 
centrifuged  for  15  s  at  10,000  xg  and  the  flow  through  was  discarded.  Then  700  gl  RWI 
buffer  (washing  buffer)  was  pipetted  onto  the  RNeasy  mini  column  and  centrifuged  for  15- 
s  at  10,000  x  g.  The  RNeasY  column  was  transferred  into  a  new  2  ml.  collection  tube,  and 
500  [tl  buffer  RPE  was  pipetted  onto  it  and  the  tube  was  centrifuged  for  15  s  at  10,000  xg 
to  wash  off  the  column-bound  RNA.  An  additional  500  gl  of  RPE  buffer  was  added  and 
centrifuged  at  10,000  xg  for  2  min  to  dry  the  RNeasy  spin-column  membrane  completely. 
The  RNeasy  spin  column  was  placed  in  a  new  2  ml  collection  tube  and  centrifuged  at 
10,000  xg  for  I  min.  The  RNeasy  column  was  then  transferred  to  a  new  1.5  ml 
diethylpyrocarbonate  (DEPC:  RNase  inhibitor)  treated  collection  tube  and  30-40  gl  of 
RNase-free  water  was  added  directly  onto  the  RNeasy  membrane.  The  column  was 
centrifuged  for  I  min  at  10,000  x  g.  The  eluted  RNA  was  then  stored  at  -70"C  in  10  ttl 
aliquots  until  used.  For  running  agarose  gels  with  RNA  samples,  the  procedure  was  the 
same  as  in  section  2.3  with  the  exception  that  all  the  buffers  were  made  in  DEPC-treated 
water  and  morpholinopropane-sulphonic  acid  (MOPS)  buffer  (Appendix  I)  was  used 
instead  of  TE  buffer.  The  gel  tank  was  also  treated  with  DEPC-treated  water. 
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2.11.2  Removing  the  co-purified  contaminating  DNA 
This  step  was  adopted  to  remove  any  trace  of  genomic  DNA  co-purified  along  with 
total  RNA.  The  procedure  was  used  for  removal  of  DNA  prior  to  RT-PCR.  All  solutions 
were  made  up  in  DEPC-treated  water  and  RNase  free  tips  and  tubes  were  used 
PROCEDURE 
In  brief  the  following  reagents  were  added  to  the  DEPC-treated  eppendorfs 
Total  RNA  (with  contaminating  DNA)  :! ý  I  gg 
10  x  DNase  buffer  (Appendix  1)  =2  gl 
RNase  inhibitor  (Promega;  RNasin)  =  10  units 
RNase  free  DNase  (Qiagen)  =  0.5  kunitz  units 
Total  volume  of  reaction  set  with  RNase  free  water  =  20  [d 
The  samples  were  incubated  at  37'C  in  a  water  bath  for  30  min  and  the  reaction  was 
stopped  by  adding  5  mM  EDTA,  mixed  thoroughly  and  left  at  room  temperature  for  5  min. 
Finally,  the  samples  were  incubated  at  65C  for  5  min  to  inactivate  DNase  completely. 
Occasionally,  samples  were  spun  down  through  the  mini  columns  provided  with  the 
RNeasy  mini  kit  and  the  RNA  was  collected  by  eluting  it  with  RNase-free  water  (section 
2.11.1).  The  samples  were  stored  at  -70'C  in  aliquots. 
2.11.3  Reverse  transcription-PCR 
The  reverse  transcription-PCR  (RT-PCR)  was  perfonned  using  the  Omniscript  Kit 
(Qiagen,  UK)  according  to  the  manufacturers'  instructions  using  a  two  step  reaction  i.  e. 
cDNA  synthesis  and  PCR.  The  following  components  were  assembled  in  a  thin-walled  0.5 
ml  tube,  on  ice  for  cDNA  synthesis 
RNA  template  (section  2.11.2) 
I  Ox  reverse  transcriptase  buffer 
4-6  gl 
gl 
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5mM  dNTP's  2  gi 
RNasin  1  Al 
Y-5'  primer  (50p/mole  stock;  Reverse  primer)  1  ýd 
Total  volume  adjusted  with  RNase  free  water  20  gI 
The  above  reaction  was  thermocycled  as  follows: 
First  strand  cDNA  synthesis 
1  cycle  39'C  60  min 
I  cycle  93'C  2  min 
cDNA  kept  in  aliquots  of  4  gI  in  0.5  ml  PCR  tubes  at  -200C. 
Second  strand  cDNA  synthesis  (PCR  amplification) 
The  second  strand  synthesis  was  carried  out  using  the  standard  PCR  procedure  with 
the  exception  of  a  slight  modification  (section  2.6.2).  3  gl  of  cDNA  template  obtained 
from  the  previous  step  was  added  to  the  PCR  tube  after  the  initial  step  of  activation  of 
HotStar  Taq  i.  e.  95*C  for  15  min. 
Master  mix  ILI 
IOX  PCR  Buffer  (containing  15  mM  MgCl,  )  2.5 
5x  Q  solution  5.0 
dNTP  mix  (10  mM  of  each)  0.5 
Hotstar  Taq  DNA  polymerase  0.5 
Distilled  water  13.5 
Added  individually  in  tubes 
5'  primer  (50  pmol/gl)  0.5 
3'  primer  (50  pmol/gl)  0.5 
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Template  cDNA  (100  ng-I  gg)  3.0 
Total  volurne  in  each  PCR  tube  25  gI 
The  following  thermo-cycling  parameters  were  used: 
Initial  activation  step:  15  min  95'C 
Denaturation:  30  sec  94'C 
Annealing:  60  sec  60'C  40  Cycles 
Extension:  I  min  72'C 
Final  extension  step  10  min  72'C 
The  products  were  analysed  by  agarose  gel  electrophoresis  according  to  section  2.3 
2.12  Antibody  production 
Rabbit  anti-Bap-5  antibody  was  raised  by  Dr.  D.  Xing,  Department  of 
Bacteriology,  NIBSC,  London,  against  the  purified  full  length  Bap-5  protein  prepared 
during  the  study.  His-tagged  Bap-5  cloned  in  pQE-60  (Bp5ATGI)  expression  construct 
(Table  2.5)  was  expressed  in  E.  coli  M.  15  (Table  2.1)  and  purified  (section  2.10.4).  The 
purified  samples  of  Bap-5  (8  mg/ml)  were  run  on  10%  SDS-PAGE  and  the  protein  was 
transferred  to  nitrocellulose  membrane.  After  the  transfer  it  was  then  briefly  stained  in 
ponceau  S  (Sigma)  to  locate  the  band.  The  protein  bands  were  removed  with  a  sterile  knife 
and  the  membrane  strip  washed  twice  with  sterile  PBS.  After  running  several  gels  to 
obtain  a  sufficient  amount  of  protein,  the  nitrocellulose  membrane  was  chopped  into  very 
fine  pieces  in  a  sterile  petri  dish  and  then  sonicated  in  3-4  ml  of  PBS  to  obtain  an  injectible 
solution  (Diano  et  al.,  1987).  The  material  obtained  was  then  sent  to  Dr  D.  Xing  for  the 
production  of  antiserum. 
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For  the  production  of  antibody,  three  female  New  Zealand  Albino  rabbits,  each 
weighing  approximately  2.5  Kg,  were  used.  Before  injection,  blood  samples  were  taken 
from  each  rabbit.  The  antigen  solution  was  mixed  in  equal  proportion  with  Freund's 
incomplete  adjuvant  such  that  each  0.5  ml  contained  approximately  I  mg  of  antigen.  0.5 
ml  volumes  were  injected  subcutaneously  using  a  21  gauge  needle  at  3  different  sites. 
Four  weeks  later,  the  first  booster  was  given  exactly  in  the  same  way  as  above.  Also  a 
blood  sample  was  taken  at  that  occasion.  The  second  dose  was  given  after  a  further  4 
weeks  and  the  rabbits  were  test  bled  at  this  occasion.  Two  weeks  after  the  second 
boosting,  the  rabbits  were  terminally  bled  and  serum  was  collected  from  each  rabbit  and 
pooled.  The  detail  of  other  antibodies  used  during  the  study  is  given  in  Table  2.7. 
2.13  In  vivo  tests 
2.13.1  Mouse  protection  test  using  P.  30  and  P.  69  antigens 
The  construct  expressing  pertactin  C-terminal  domain  (pET  33b  PCTI;  Table  2.5)  was 
expressed  in  E.  coli  M.  15  (Table  2.1)  and  the  protein  extracted  from  inclusion  bodies  by 
solubilisation  in  8M  urea  (Blackburn,  2000;  Prof.  M.  Roberts,  Department  of  Veterinary 
Pathology,  University  of  Glasgow).  The  crude  urea  extracts  of  P.  30  were  dialysed  against 
IM  urea  and  then  re-folded  by  making  gradual  dilution  using  a  re-foldase  buffer  (Prof.  N. 
Isaacs,  Department  of  Chemistry,  University  of  Glasgow).  To  prepare  the  vaccine  doses 
re-natured  P.  30  or  purified  P.  69  (recombinant  P.  69  purified  from  Pichia  pastoris)  kindly 
provided  by  Prof.  M.  Roberts,  Department  of  Veterinary  Pathology,  University  of 
Glasgow,  100  ýtg/ml  of  protein  was  mixed  with  an  equal  volume  of  a1hydrogel  AI(OH)3- 
Thus  each  0.2-ml  volume  contained  10  Rg  of  protein  and  10  gg  of  a1hydrogel.  A  control 
for  the  experiment  was  to  replace  the  antigen  solution  with  an  equivalent  volume  of  PBS 
added  to  an  equal  volume  of  a1hydrogel. 
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Table  2.7:  Antibodies  used  during  the  study 
Materials  &  Methods 
Antibody  designation  Used  for  Source 
Rabbit  polyclonal  anti-whole  Western  blots  and  immunofluorescence,  This  study 
Bap-5  agglutination  and  bactericidal  assays 
Mouse  polyclonal  anti-whole  Western  blots  P.  Blackburn,  Div.  of  infection  &  immunity, 
Bap5  University  of  Glasgow 
Mouse  polyclonal  anti-Bap-5  Western  blots  P.  Blackburn,  Div.  of  infection  &  immunity, 
N-terminus  (NTS)  University  of  Glasgow 
Mouse  polyclonal  anti-Bap-5  Western  blots  P.  Blackburn,  Div.  of  infection  &  immunity, 
C-terminus  University  of  Glasgow 
Mouse  monoclona  anti-BrkA  Western  blots  J.  B.  Hertz,  Copenhagen,  Hvidovre  Hospital 
C-terminus  (P28) 
Rabbit  polyclonal  anti-whole  Agglutination  test  and  ELISA-based  J.  B.  Hertz,  Copenhagen,  Hvidovre  Hospital 
B.  perlussis  adhesion  studies 
Rabbit  polyclonal  anti-PRN  Western  blots,  agglutination  tests  and  M.  Roberts,  Dept  of  Vet.  Pathology, 
(mature,  p.  69)  bactericidal  assays  University  of  Glasgow 
Mouse  monoclonal  anti-PRN  Western  blots  M.  Roberts,  Dept  of  Vet.  Pathology, 
linkcr-region  (BB05)  University  of  Glasgow 
Mouse  monoclonal  anti-TCF  Western  blots 
C-terminal  (49.3)  J.  B.  Hertz,  Copenhagen,  Hvidovre  Hospital 
FITC  conjugated  goat  anti-  Immunofluorescence  SIGMA 
rabbit  antibody 
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Immunisation 
Materials  &  Methods 
Randomised  groups  of  female  CDI  mice  (Harlan  Olac,  Bicester,  Oxfordshire,  UK)  aged  3- 
4  weeks  (4  mice  per  group),  were  injected  subcutaneously,  under  light  halothane 
anaesthesia,  with  10  gg  of  test  antigen  per  mouse.  One  group  of  mice  was  vaccinated  with 
renatured  P.  30  antigen  whereas  another  group  received  the  same  amount  of  purified 
pertactin  (P.  69),  a  well-known  component  of  acellular  vAccines.  A  third  group  of  mice 
received  only  a1hydrogel  in  PBS.  For  each  test  group,  a  second  dose,  as  above,  was- 
administered  three  weeks  later.  The  weight  of  each  group  of  mice  was  recorded  prior  to 
the  vaccination  and  thereafter  at  regular  intervals  to  check  for  any  toxicity  because  of  the 
antigen  preparation. 
2.13.1.2  Intranasal  challenge 
B.  pertussis  18-323  was  grown  as  a  lawn  on  BG  plates  in  a  humidified  box  at  37*C 
for  24h.  The  resultant  growth  was  suspended  in  1%  (w/v)  casamino  acids  solution  (CAA) 
(Appendix  I)  and  adjusted  to  10  opacity  units  using  the  5  th  International  Reference  of 
Opacity  (Perkins  et  al.,  1973)  i.  e.  approx.  2xlO9  CFU/ml.  Two  weeks  after  the  second 
vaccination  the  challenge  suspension  of  B.  pertussis  18323  containing  -2xI  06  CFU/ml  was 
prepared  and  a  sublethal  dose  of  IXI05  CFU in  50  lil  volume  was  instilled  intranasallY  to 
each  mouse  under  light  halothane  anaesthesia.  The  weight  of  each  group  of  mice  was 
recorded  prior  to  challenge  as  well  as  at  regular  intervals  afterwards.  Four  mice/group 
were  sacrificed  at  each  sampling  time  on  days  0,3,9  and  14  and  the  lungs  and  trachea 
were  separately  removed  aseptically  into  sterile  universal  bottles.  The  nasal  cavities  of 
each  mouse  were  located  carefully  by  detaching  the  head  of  the  animal  first  and  then 
flushing  sterile  casan-ýino  acid  through  the  nasal  cavity  (1ml  each);  the  nasal  washes  were 
collected  in  sterile  tubes. 
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2.13.1.3  Bacterial  counts 
Materials  &  Methods 
The  nasal  washes  were  collected  in  volume  of  I  ml  CAA  and  100  ýfl  volumes  of 
undiluted  samples  were  cultured  on  BG  agar.  Organs  (lungs  and  trachea)  were 
homogenised  in  10  ml  of  CAA  with  a  sterile  homogeniser  (Silverson  machines,  UK).  100 
gl  volumes  from  undiluted  samples  and  1:  10  and  1:  100  dilutions  in  1%  (w/v)  CAA  were 
cultured  on  BG  agar  plates  and  incubated  at  37'C  in  a  tightly  covered  humidified  box. 
Colonies  were  counted  after  3-4  days. 
2.13.2  Virulence  tests 
Randomised  groups  of  female  CDI  mice  (Harlan  Olac,  Bicester,  Oxfordshire,  UK) 
aged  3  weeks  were  allowed  to  acclimatise  for  3-4  days.  They  were  divided  into  different 
challenge  groups,  which  were  categorised  according  to  experiment  number.  In  experiment 
I  mice  were  challenged  intranasally  with  B.  pertussis  strains  18323  (standard  mouse 
virulent  strain),  Taberman  I  strain  (clinical  isolate  of  B.  pertussis)  and  the  Bap-5  deficient 
mutant  of  Taberman.  In  experiment  11  mice  were  challenged  with  B.  pertussis  strain 
BBC29  and  its  PRN-deficient  mutant  strain  BBC30  as  well  as  Taberman  and  its  derivative 
Bap-5-deficient  mutant  strain  as  in  experiment  1.  Each  group  comprised  five  mice  and 
each  mouse  was  challenged  intranasally  with  B.  pertussis  containing  -1x1O5  CFU  in  50  gI 
of  (PBS),  under  halothane  anaesthesia.  The  body  weights  of  the  mice  were  monitored 
regularly  for  7  days.  Mice  were  killed  on  day  7  with  an  overdose  Of  C02  and  viable  counts 
of  B.  pertussis  in  lungs,  tracheas  and  nasal  washings  assayed  as  described  above. 
2.14  Statistical  analysis 
The  number  of  colony  forming  units  per  lung,  trachea  and  nasal  washes  was 
extrapolated  from  the  colony  counts  obtained  on  BG  agar  plates.  Nominal  values  of  10 
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and 
107  were  given  to  counts  outside  the  detection  limits  <100  and  >3x 
106  per  organ 
respectively.  The  logio  counts  were  calculated  and  the  means,  standard  deviation  and 
standard  error  values  of  each  group  were  calculated  in  Excel.  The  data  was  analysed  by 
applying  the  Student's  Mest  and  one  way  of  analysis  of  variance  (ANOVA). 
2.15  In  vitro  tests 
2.15.1  Agglutination  test 
This  test  was  initially  carried  out  to  identify  surface-exposed  Bap-5  in  B.  pertussis 
using  antibodies  to  Bap-5  (anti-whole  Bap-5).  The  Bap-5  deficient  mutant  was  used  as  a 
negative  control.  The  antibodies  to  other  antigens  like  PRN  and  whole  B.  pertussis  were 
also  used  in  the  studies  (Table  2.6).  The  procedure  involved  the  collection  of  bacteria  from 
BG  plates  that  had  been  incubated  for  48-72  h  at  370C.  One  ml  of  a  thick  suspension  was 
obtained  by  spinning  down  -7  ml  volume  of  culture  containing  -2xlO9  CFU/ml  of  the 
various  B.  pertussis  parent  and  mutant  strains  and  re-suspending  the  pellets  in  1  n-d  of  PBS. 
A  100  gl  volume  from  the  thick  suspension  was  added  to  individual  wells  in  a  96  well  u- 
shaped  plate  (Greiner,  UK)  in  quadruplicate.  Thereafter,  50  ýfl  volumes  of  antisera  were 
added  to  each  well.  The  samples  in  each  well  were  mixed  thoroughly  with  a  multichannel 
pipette  and  plate  was  placed  on  a  rotating  shaker  for  1h  at  room  temperature.  The  plate 
was  then  incubated  at  37'C  for  3-4  h  and  thereafter  left  at  4'C  for  24-48  h.  At  the  end  of 
the  experiment,  agglutination  or  button  formation  at  the  bottom  of  each  well  as  well  as  the 
type  of  agglutination  was  observed. 
2.15.2  Fluorescence  microscopy 
Immunofluorescence  was  carried  out  to  identify  Bap-5  on  the  surface  of  B. 
pertussis.  Again,  a  Bap-5  deficient  mutant  was  used  as  a  negative  control.  Rabbit  anti 
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whole  Bap-5  serum  and  flourescein  isothiocyanate  conjugated-alkaline  phosphate  (FITC- 
AP)  anti-rabbit  IgG  whole  molecule  (Sigma)  were  used  in  the  assay. 
2.15.2.1  Staining  of  bactefiafor  immunofluorescence 
One  ml  volume  from  a  B.  pertussis  culture  grown  for  48  h  in  cyclodextrin  liquid 
medium  (013600ý1-0)  or  in  some  experiments  B.  pertussis  grown  on  BG  agar  plates,  was 
re-suspended  to  the  desired  volume  in  PBS  to  make  a  thick  suspension.  The  B.  pertussis 
suspension  was  standardised  to  -2x  108  CFU/mI  using  the  Opacity  rod.  The  cells  were 
centrifuged  at  8,000  xg  for  5  min  in  1.5  ml  eppendorf.  The  pellet  obtained  was  rinsed 
carefully  with  PBS  (pH=7.4)  and  fixed  with  acetic  acid:  ethanol  (3:  1,  v/v)  for  5  min  at 
room  temperature.  The  tubes  were  centrifuged  for  2  min  at  8,000  xg  and  the  pellet 
obtained  was  rinsed  with  PBS  twice  and  then  left  inverted  on  a  clean  paper  towel  for  -5-10 
min  at  room  temperature  to  let  the  pellet  dry  or  occasionally  left  at  4'C,  overnight.  The 
cells  were  then  incubated  with  Hoechst  33258  stain  (I  in  200  v/v  ratio  from  the  stock  of 
5mg/ml  in  70%  ethanol,  in  sterile  PBS)  which  stains  the  nuclear  material  of  bacteria,  for 
30-60  min  at  room  temperature.  The  cells  were  then  washed  with  PBS  3-4  times  for  I  min 
and  finally  once  for  10  min. 
2.15.2.2  Immunofluorescence 
12  well  multitest  slides  (ICN,  Biomedicals)  were  coated  with  0.1  %  poly-lysine 
(Sigma)  in  PBS  overnight  at  40C.  5-10  gl  volume  of  the  suspension  containing  the  stained 
bacterial  cells  was  seeded  into  each  well  and  the  slide  was  covered  and  left  for  10-15  at 
room  temperature.  It  was  then  rinsed  gently  2-3  times  with  0.1%  Tween  20  in  PBS  in  a 
series  of  coplin  jars  for  1-2  min  to  detach  the  loosely-bound  bacteria.  Blocking  was  carried 
out  in  BSA  (2%  w/v)  in  PBS  for  45  min  in  coplin  jar  at  37'C  or  overnight  at  4*C.  The 
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slides  were  then  shifted  into  a  coplin  jar  containing  rabbit  anti-Bap-5  serum  1:  1000  (v/v)  in 
2%  BSA  in  PBS  for  2h  at  37"C.  The  slide  was  then  washed  3-times  for  5  min  in  a  series 
of  coplin  jars  containing  sterile  0.1%  Tween  20  in  PBS.  The  slide  was  then  immersed  in 
coplin  jar-containing  anti  rabbit  FITC-AP  conjugate  diluted  in  2%  BSA  in  PBS  (1:  80)  for  I 
h  at  370C.  Then  the  slide  was  washed  3  times  for  5  min  in  0.1%  Tween  20  in  PBS.  The 
slide  was  kept  in  a  clean  petri  plate  and  to  each  well  was  added  a  tiny  drop  of  glycerine  and 
then  the  slide  was  carefully  covered  with  the  coverslip  without  introducing  air  bubbles  into 
the  wells.  The  slide  was  exposed  for  a  fixed  time  (-18  msec)  and  viewed  under  the  Zeiss 
Axioskop  immunofluoresence  microscope  using  the  magnification  of  63  X  20  (1260). 
2.15.3  Serum  killing  assay 
2.15.3.1  Serum  collection  of  normal  human  serum 
Serum  was  obtained  from  the  blood  samples  of  volunteers  from  the  Division  of 
Infection  and  Immunity  who  were  not  actively  engaged  in  working  with  B.  pertussis.  The 
blood  samples  were  initially  collected  and  allowed  to  clot  for  Ih  at  37'C.  They  were  then 
placed  on  ice  for  1-2  h  to  retract  and  the  clear  serum  was  collected  after  centrifugation  at 
10,000  xg  for  5  min  without  disturbing  the  clot.  The  serum  was  centrifuged  again  to 
remove  any  remaining  particles  and  the  supernate  was  collected.  The  serum  was  pooled 
and  distributed  in  small  aliquots  and  stored  at  -70'C. 
2.15.3.2  Bactericidal  assays  with  normal  human  serum 
B.  pertussis  cells  were  harvested  from  BGA  plates  incubated  at  37'C  for  24-48  h 
and  suspended  at  -2xlO9  CFU/ml  by  comparison  with  Opacity  rod,  in  pre-warmed  (37'C) 
Stainer  and  Scholte  (SS)  medium.  A  volume  of  100  gl  of  bacterial  suspension  was 
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transferred  to  an  eppendorf  containing  350  gl  of  PBS  (pH=7.4)  and  50  gl  of  normal  or  heat 
inactivated  (30  min  at  56'C)  control  serum.  The  tubes  were  incubated  at  37*C  in  a  water 
bath  for  45  min.  The  tube  was  then  shifted  to  ice  for  5  min  to  stop  the  complement 
reaction.  A  20  [d  aliquot  of  the  mixture  was  added  to  180  gI  PBS  with  10  mM  EDTA 
(inactivates  complement  activity).  Ten-fold  serial  dilutions  were  made  in  SS  medium.  The 
dilutions  were  then  plated  on  BG  agar,  and  incubated  at  370C.  Bacterial  colony  forming 
units  were  counted  after  3-4  days.  Survival  was  calculated  as  a  percentage,  when  the 
number  of  survivors  from  the  normal  serum-treated  samples  was  compared  to  the  number 
of  survivors  obtained  from  the  heat-inactivated  serum  control  (non-killing  control) 
(Fernandez  and  Weiss,  1994;  Barnes  and  Weiss,  2001).  Statistical  analysis  was  perfonned 
using  Student's  t-test.  In  some  experiments,  serum  killing  assays  were  carried  out  by 
adding  an  external  source  of  complement  to  the  heat-inactivated  human  serum.  Guinea  pig 
serum  (5  %  v/v)  (Sigma)  in  PBS  (pH=7.4)  was  used  as  a  source  of  complement. 
2.15.3.3  Bactericidal  assays  with  rabbit  anti-,.  Bap-5  serum 
The  anti-,  Bap-5  serum  was  used  at  a  final  concentration  of  2%  v/v,  as  this 
concentration  caused  negligible  reduction  in  CFU/mI  of  B.  pertussis  due  to  agglutination. 
The  bacterial  suspension  was  adjusted  to  contain  approximately  2x  108  CFU  in  100  ptl  in  SS 
medium.  50  gl  of  anti-,  Bap-5  serum  was  added  to  the  bacteria  and  the  mixture  incubated 
for  10  min  at  37"C.  This  allowed  the  bacteria  to  be  pre-sensitized  for  the  next  reaction.  25 
gl  of  normal  or  heat  inactivated  (56'C  at  30  min)  guinea  pig  serum  (5%  v/v)  was  added  to 
the  samples  and  the  total  volume  was  brought  to  500  gl  by  adding  sterile  PBS  (pH=7.4). 
The  samples  were  incubated  at  37'C  for  60  min.  The  reaction  was  halted  by  placing  the 
sample  on  ice  for  5  min  and  then  by  adding  10  mM  EDTA  (final  concentration).  Ten-fold 
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serial  dilutions  in  SS  medium  were  plated  in  100  ptl  volumes  on  BG  agar  plates  and 
bacterial  colonies  were  counted  after  4-5  days.  In  some  antibody-mediated  killing 
experiments  anti-PRN  (P.  69)  antibody  (Table  2.7)  was  used  as  a  control.  In  some  other 
experiments,  EGTA  and  MgC12  (10mM  final  concentration  of  each)  was  incubated  with 
the  sample  to  prevent  the  killing  of  bacteria  by  the  classical  pathway  (Fernandez  and 
Weiss,  1994). 
2.15.4  Adhesion  studies 
2.15.4.1  ELISA-basedprotocolfor  adhesion  studies 
Tissue  culture  cell  lines  (Table  2.8)  were  seeded  (3xlO5)  in  a  100  gI  volume  in  flat 
bottomed  96-well  (Costar)  tissue  culture  plate  and  incubated  at  37'C  under  5%  C02  for  48 
h.  The  cells  formed  confluent  monolayers  during  this  period.  The  medium  was  decanted 
from  the  micro-plates  and  cells  were  washed  three  times  with  pre-warmed  (37C)  I.  OmM 
PBS  (pH=7.4)  using  a  multichannel  pipette  to  get  rid  of  unattached  cells.  100  gl  of  B. 
pertussis  suspension  containing  -ICý  bacteria  was  then  added  to  each  well  and  plates  were 
incubated  at  37'C  under  5%  C02  for  90  min.  In  some  experiments,  plates  were  incubated 
at  40C  to  determine  the  effect  of  low  temperature  on  adhesion.  The  plates  were  washed 
three  times  with  pre-warmed  (37'C)  PBS  to  remove  non-adherent  B.  pertussis.  100  [d  of 
4%  paraformaldehyde  in  PBS  was  added  to  each  well  and  fixation  was  canied  out  at  4'C 
for  60  min.  After  washing  with  PBS  2-3  times,  100  91  of  1%  (v/v)  hydrogen  peroxide 
(Sigma)  in  methanol  was  added  to  each  well  and  plates  were  incubated  at  room 
temperature  for  10  min  to  inactivate  (exhaust)  any  residual  endogenous  peroxidase  activity. 
Blocking  was  carried  out  at  4'C  overnight  or  one  hour  at  370C  in  2%  BSA.  After  washing 
as  above,  100  [d  of  rabbit  polyclonal  anti  whole-B.  pertussis  serum  (Hertz  serum) 
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(1:  10,000)  was  added  to  each  well  and  plates  were  incubated  for  2h  at  37'C.  The  primary 
antibody  was  removed  by  vigorous  tapping  of  the  plate  on  the  thick  layer  of  paper  towels 
and  then  3-4  washes  with  PBS  and  0.1%  Tween  20.  Thereafter,  100  gl  of  anti  rabbit- 
conjugate  (SAPU)  diluted  1  in  1000  in  2%  BSA  in  PBS  was  added  to  each  well  and  plates 
were  incubated  for  2h  at  37'C.  Wells  were  washed  with  PBS  3-4  times  as  above  and  then 
100  gl  of  o-phenylenediamine  (0.4  mg/ml)  in  10  mM  citrate  phosphate  buffer  (pH=  5.0) 
containing  0.02%  hydrogen  peroxide  was  added  to  each  well  and  the  plates  were  incubated 
at  room  temperature  for  15  min.  The  reaction  was  terminated  by  adding  50  gl  of  3M 
sulphuric  acid.  The  absorbance  of  reaction  was  measured  at  492  nm  with  a  microtitre  plate 
reader.  The  increase  in  absorbance  is  directly  proportional  to  the  number  of  B.  pertussis 
adherent  to  the  target  cells  (Roberts  et  al.,  1996).  In  some  experiments,  B.  pertussis 
Taberman  and  its  derivative  Bap-5  mutant  strains  were  first  incubated  with  rabbit  anti- 
whole  anti-,  Bap-5  serum  for  Ih  at  370C  prior  to  start  the  adhesion  assay,  to  see  if  anti- 
,  Bap-5  serum  could  reduce  B.  pertussis  adhesion  to  different  target  cell  lines.  The  bacterial 
cells  treated  with  anti-,  Bap-5  were  then  centrifuged  and  standardised  to  same  number  of 
cells  as  above  _107  bacteria/lOOgI  and  used  along  with  untreated  bacterial  cells  in  adhesion 
assays  as  above. 
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Table  2.8:  Tissue  culture  cell  lines  and  their  growth  media  used  during  the  adhesion 
studies 
Type  of  cells  Description  Media  +Supplements  Reference 
HeLa  229  Human  non  respiratory  DMEM  +  10%  FCS  +  2mM  Bassinet  et  al.,  2000 
epithelial  cells  glutamine 
A549  Human  (Caucasian)  lung-  F12K  +  10%  FBS  +  2mM  Ishibashi  et  al.,  2001 
carcinoma  epithelial  cells  glutamine 
Hep-2  Human  laryngeal  epithelial  DMEM  +  10%  FCS  +  2mM-  Ewanowich  et  al.,  1989 
cells  glutamine 
Caco-2  Human  colon  carcinoma  cell  DMEM  +  10%  FCS  +  2mM-  Schipper  et  al.,  1994 
line  glutamine 
P338D-1  Murine  macrophage  cell  line  L15  +  10%  FCS  +  2mM  J.  Immunol,  1975; 
glutamine 
1 
114:  894 
RAW  264.7  Murine  macrophage  cell  line  L15  +  10%  FCS  +  2m.  M  Forde  et  al.,  1999 
1  glutamine 
FCS=  Foetal  calf  serum 
FBS=  Foetal  bovine  serum 
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3.1:  Expression  of  bap-5  and  construction  of  bap-5-defective  mutants 
The  role  of  bap-5  (2280  bp)  identified  by  Blackburn  (2000),  in  virulence  of  B. 
pertussis,  was  studied  by  RT-PCR  to  show  if  the  gene  was,  in  fact,  expressed  and  by 
generating  knockout  mutants  in  the  gene.  This  would  lead  to  inactivation  of  the  gene  in 
question  and  possibly  a  decrease  in  virulence  of  the  pathogen  if  Bap-5  was  an  important 
virulence  factor. 
3.1.1  Expression  of  bap-5 
A  preliminary  RT-PCR  result  during  this  study  indicated  that  bap-5  appeared  to  be 
expressed  in  B.  pertussis  (Taberman  I  strain)  by  using  a  set  of  primers  (bap-5  forward  + 
NTS  REV;  Appendix  II)  which  amplify  a  product  of  505  bp  from  the  3'  region  of  the  gene 
spanning  the  N-terminal  region  of  the  protein.  RT-PCR  was  done  initially  using  the 
protocol  outlined  by  Blackburn  (2000)  i.  e.  by  isolating  total  RNA  using  an  acid-phenol 
extraction  method  and  subjecting  it  to  a  single  tube  reaction  for  cDNA  synthesis 
(Promega).  But  using  the  same  conditions  and  procedural  steps,  the  RT-PCR  was  not 
reproducible.  Further  study  used  total  RNA  whose  quality  was  confirmed  by  the 
undegraded  nature  of  the  ribosomal  RNA  bands  seen  in  Fig.  3.1.  Total  RNA  was  isolated 
using  the  RNeasy  mini  kit  (section  2.11.1,  Qiagen).  Expression  of  bap-5  was  confirmed  by 
performing  RT-PCR  (section  2.11.3)  with  bap-5-specific  primers  which  were  designed  to 
amplify  the  3region  of  about  505  bp  (Appendix  11,  shown  by  arrows).  The  primers  bap-5 
forward  and  NTS-REV  were  designed  (Table  2.6).  The  reverse  transcription  (Fig.  3.2)  was 
carried  out  in  two  steps,  using  NTS-REV  primer  for  making  cDNA  in  the  first  step  and 
then  subjecting  the  cDNA  to  PCR  as  described  in  section  2.11.3.  Appropriate  controls  for 
the  experiment  were  included  to  eliminate  any  possibilities  of  DNA  being  carried  over  in 
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the  RNA  preparation  and  eventually  an  amplified  PCR  product  was  obtained.  (section 
2.11.2).  Fig.  3.2,  lane  A  shows  the  first  control  reaction  without  added  reverse 
transcriptase.  Another  control  was  included  in  which  no  sample  RNA  was  added,  to 
eliminate  the  possibility  of  any  genomic  DNA  cross  contamination  from  any  of  the 
procedural  steps  or  ingredients  of  the  reaction  involved  (Fig.  3.2,  lane  Q.  The  results 
reproducibly  showed  that  a  transcript  of  the  expected  size  i.  e.  505  bp  was  obtained  with  B. 
pertussis  (Taberman  1)  as  shown  in  Fig.  3.2,  lane  B  indicating  that  bap-5  was  expressed. 
There  is  one  anomaly  i.  e.  lane  B  shows  an  additional,  smaller  band  of  -100  bp.  This  could 
have  been  due  to  contamination  in  the  experimental  tube  but  the  result  was  reproducible 
and  moreover  there  was  no  hint  of  this  band  in  the  control  reactions.  One  possible 
explanation  is  the  presence  of  another,  smaller  transcript  further  inside  the  targeted  region 
towards  the  3'  end  that  may  have  co-amplified  with  the  desired  product. 
3.1.2  Generation  of  bap-5-defective  mutants  of  B.  pertussis 
The  suicide  vector  pSS  1129,  used  for  create  allelic  replacement  of  the  wild-type  bap-5 
gene  with  its  mutated  version,  had  been  used  previously  in  B.  pertussis  (Stibitz,  1994). 
The  salient  features  of  this  construct  are  that  it  has  an  origin  of  transfer  from  plasmid  RP4, 
and,  provided  that  tra  functions  are  supplied  in  trans,  the  vector  will  be  transferred  into  the 
recipient  bacterium  via  conjugation.  The  vector,  having  a  ColEl  origin  of  replication,  is 
unable  to  replicate  in  B.  pertussis.  It  has  the  E.  coli  rspL  gene  which  codes  for  RspL 
protein  and  which  is  responsible  for  the  streptomycin-sensitive  (Sms)  phenotype  in  strains 
normally  resistant  to  streptomycin  (SMR  )  due  to  mutation  in  the  chromosomal  rspL 
homologue.  This  phenotype  conferred  by  the  plasmid  was  checked  by  transforming  the 
vector  into  the  E.  Coli  SMR  strain  JC3272  to  show  that  it  became  Sm'.  Therefore, 
transformation  of  B.  pertussis  with  the  plasmid  carrying  a  gene  disrupted  by  an  antibiotic- 
103 Fig.  3-1:  Agarose  gel  (0.7%)  showing  RNA  samples  extracted  front  B.  pertussis 
pertussis  grown  to  log  phase  (OD6m,,  m=0.7)  in  CL  medium  and  RNA  %vas 
extracted  from  the  2x  109  bacterial  cells  using  the  RNeasy  mini-kit  as  described  in  section 
2.11.1. 
A=  RNA  preparation  from  B.  pertussis  Taberman  I 
B=  RNA  preparation  from  bap-5  mutant  Taberman  11 
Fig.  3.2:  RT-PCR  results  depicting  the  expression  of  bap-5  in  B.  perfussis. 
RT-PCR  was  performed  using  the  RNA  isolated  from  B.  pertussis  Taberman  I  as 
above  according  to  the  procedure  given  in  section  2.11.3 
I=  lKb  marker 
A=  No  added  reverse  transcriptase  (control) 
B=  RT-PCR.  reaction  with  B.  pertussis  Taberman  I  RNA 
C=  No  added  RNA  sample  (control) Habib  Bokhari 
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resistance  marker  can  take  place  via  an  insertion  of  the  plasmid  into  the  chromosome  by  a 
single  homologous  recombination  event  involving  the  cloned  gene.  Further  selection  in 
the  presence  of  streptomycin  promotes  the  loss  of  plasmid  via  a  second  recombination 
event.  The  bap-5  gene  (2.28  Kb)  was  disrupted  by  insertion  of  a  kanamycin  resistance 
cassette  (kni  R)  carrying  its  own  promoter  and  transcription  termination  sequences.  The  kill  R 
cassette  was  initially  amplified  from  pUC4K  using  primers  each  of  which  contained  an 
NcoI  site  and  the  final  product  was  cloned  into  pGEMT  (3  Kb)  to  generate  4.3  Kb 
pGEMT(KANA)  (Blackburn,  2000).  The  bap-5  gene  was  amplified  using  primer  sets 
carrying  Bg1II  sites  to  allow  cohesive  ligation  in  the  later  stages  of  the  experiment.  The 
k-171  R  was  purified  from  pGEMT(KANA)  after  cutting  the  plasmid  with  Ncol  and  inserted  at 
the  Ncol  restriction  site  of  bap-5  (Appendix  11)  already  cloned  into  the  pGEMT  vector 
(Fig.  3.3,  lane  A,  band  at  6.5  Kb),  leaving  bap-5  flanking  regions  of  542  bp  and  1738  bp, 
enough  for  homologous  recombination  to  take  place  for  the  construction  of  the  B.  pertussis 
bap-5  mutant  (Blackburn,  2000).  The  orientation  of  the  cloned  sequence  in  pGEMT  was 
confirmed  by  sequencing,  using  universal  SP6  and  T7  promoter  sequence  primers  by  the 
Molecular  Biology  Sequencing  Unit  of  the  University  of  Glasgow.  BLAST  search  showed 
100%  identity  of  the  insert  with  bap-5  and  to  the  inserted  kanamycin  resistance  cassette, 
which  was  also  sequenced.  A  summary  of  the  steps  involved  while  making  the  bap-5 
construct  is  shown  in  Fig.  3.3.  The  BgIII  fragment  carrying  the  mutated  bap-5  gene  (33 
Kb  fragment)  was  purified  from  the  gel  after  digestion  from  the  pGEMT  plasmid  (Fig.  3.3, 
lane  B  and  Q.  The  next  step  was  to  ligate  it  into  the  Bg1II  site  of  the  suicide  vector 
pSS1129,  linearised  (section  2.7.1)  with  BgIll  (Fig.  3.4,  lane  D,  9.8  Kb).  The  ligation 
(section  2.7.2)  of  the  mutated  bap-5  gene  into  the  suicide  vector  was  achieved  after  many 
attempts  (Fig.  3.3,  lane  E,  13.3  Kb).  The  plasmid  construct  obtained  (Fig.  3.3,  lane  E)  was 
then  transformed  by  electroporation  into  an  E.  coli  mobilising  strain  SM  I  O.  kpR. 
105 Fig.  3.3:  Agarose  (0.7  %)  gel  showing  the  summary  of  the  scheme  for  bap-5  mutant 
construction 
I=  Super-coiled  DNA  ladder 
A=  Whole  plasmid  pGEMT  (bqp-5::  knz  R)  (6.5  Kb)  (Table  2.5) 
B=  BgIII  digestion  releasing  the  mutated  bap-5::  bn  R  (3.5  Kb)  fragment  from 
pGEMT  plasmid  (3  Kb) 
C=  Purified  bap-5::  kMR  fragment 
D=  Suicide  vector  pSS  1129  (9.8  Kb) 
E=  Whole  plasmid  pSS  1129  (pBap5-Kana)  (13.3  Kb)  (Fig  3.3,  Table  2.5) 
F=  Plasmid  pSSI  129  (pBap5-Kana)  digested  with  BgIII  to  release  the  3.5  Kb  bap- 
5::  kMR  fragment 
2  =1  Kb  DNA  ladder 
Arrows  indicate  sizes  of  the  DNA  fragments  (Kb) Habib  Bokhari 
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The  plasmid  (Fig  3.4,  plasmid  construct  pBap5-Kana)  was  isolated  and  digested  with  BgIII 
releasing  mutated  bap-5  (3.5  Kb)  and  suicide  vector  (9.8  Kb),  which  showed  the  successful 
ligation  of  the  mutated  bap-5  in  the  suicide  vector  (Fig.  3.4,  lane  F).  Spontaneous  NaIR  and 
SMR  mutants  of  B.  pertussis  were  isolated  for  subsequent  selection  purposes  in  both 
Taberman  I  and  Tohama  I  strains  by  the  procedure  described  in  section  2.1.5.  Conjugation 
between  the  E.  coli  mobilising  strain  SM  I  OAPIR  and  B.  pertussis  (Taberman  I  or  Tohama  1) 
was  carried  out  according  to  the  procedure  given  in  section  2.1.6.  The  exconjugants  were 
plated  onto  the  first  selection  BG  agar  containing  Km  (20  gg/ml),  Nal  (40  gg/ml)  and 
cephalexin  (40  pg/ml).  Cephalexin  was  included  to  further  minimise  the  carry  over  of  E. 
coli  as  B.  pertussis  can  survive  due  to  an  inherent  resistance  to  this  antibiotic.  The 
survivors  of  this  selection  (single  cross-over)  were  assumed  to  be  B.  pertussis  which 
contained  the  plasmid  integrated  into  the  chromosome.  Thereafter  the  survivors  of  the 
single  cross-over  were  restreaked  onto  BG  agar  containing  Sm  (100gg/ml)  to  select  against 
the  plasmid.  The  survivors  obtained  after  this  selection  were  assumed  to  be  bacteria  that 
had  lost  the  integrated  plasmid  due  to  a  double  cross-over  event.  This  loss  occurred  due  to 
the  homologous  recombination  between  the  regions  of  bap-5  present  on  the  plasmid  and  on 
the  host  chromosome.  A  summary  of  the  molecular  mechanism  of  gene  replacement  by 
this  strategy  is  given  in  Fig.  3.5. 
PCR  was  performed  on  the  selected  colonies  from  the  final  selection  to  show  that 
the  mutated  bap-5  gene  had  successfully  replaced  its  wild-type  counterpart  in  the  B. 
pertussis  chromosome.  PCR  was  carried  out  using  the  bap-5  specific  primers  bap-5 
forward  and  bap-5  reverse  (Table  2.6;  Appendix  11,  shown  by  arrows)  which  cover  the  full 
length  bap-5  gene  starting  from  the  first  methionine  (presumed  start  site).  The  PCR  results 
(Fig.  3.6)  using  genomic  DNA  extracted  (section  2.2.  )  from  B.  pertussis  Taberman  I  strain 
and  its  bap-5  defective  mutant,  as  well  as  B.  pertussis  Tohama  I  and  its  bap-5  defective 
107 Fig.  3.4:  Map  of  suicide  construct  pBap5-Kana 
The  suicide  vector  pSS1  129  was  used  to  create  pBap5-Kana.  7nic  bap-5  gene  was 
disrupted  by  insertion  of  a  kanamycin  resistance  gene  at  a  Ncol  site  501bp  from  the 
predicted  translational  start  site.  The  vector  has  a  ColEl  origin  of  replication  which  is  not 
functional  in  A  perlussis.  It  has  an  origin  of  transfer  (oriY)  from  die  RN  plasmid.  It  also 
contains  the  E.  coli  rspL  gene  which  encodes  streptomycin  sensitivity  and  an  ampicillirl 
resistance  gene.  The  mutated  bap-5  gene  was  cloned  into  pSS  1129  at  a  Bg1lI  site  to  make 
the  pBap5-Kana  construct. Habib  Bokhari 
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Fig.  3.5:  Strategy  adopted  for  replacement  of  bap-5  gene  with  bap-5 
mutated  with  kMR  (bap-5::  kMR) 
Single  cross-over  selection  was  made  by  selecting  for  the  plasmid  (pBap5-Kana)  using 
antibiotics  nalidixic  acid  and  kanamycin. 
pSS1129  +  bap-5::  kMR 
pBap5-Kana 
kMR 
-rspL  540bp  1300bp  1648bp 
amp' 
bap-5 
bap-5  /  2280bp 
I 
sm 
R 
naIR 
B.  pertussis  chromosome 
Double  cross-over  selection  was  made  by  selecting  against  the  plasmid  using  the 
antibiotic  streptomycin. 
+ 
I  bap-5::  kMR  j 
B.  pertussis  chromosome  with  mutated  bap-5  gene 
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109 Fig.  3-6:  Agarose  (0.8%)  gel  showing  the  PCR  products  of  the  wild  type  and  mutated 
versions  of  bap-5 
PCR  was  performed  on  chromosomal  DNA  extracted  as  described  in  section  2.2.1; 
using  primers  bap-5-forward  and  bap-5  reverse  which  amplify  the  whole  gene  (Table 
2.6.1,  Appendix  II) 
I=I  Kb  ladder 
A=  bap-5  gene  amplified  using  DNA  from  B.  pertussis  Taberman  I 
B=  bap-5  gene  amplified  using  DNA  from  B.  pertussis  Tohama  I 
C=  bap-5::  km  R  (mutated  bap-5)  amplified  from  plasmid  construct  pBap5-Kana. 
D=  bap-5::  kMR  amplified  using  DNA  from  B.  pertussis  Taberman  11  mutant 
E=  bap-5::  kMR  gene  amplified  using  DNA  from  B.  pertussis  Tohama  Il  mutant Habib  Bokhari 
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mutant,  clearly  indicated  that  bap-5.,:  kMR  was  present  in  the  chromosome  of  the  B. 
pertussis  mutant  strain. 
Lanes  A  and  B  in  Fig.  3.6  show  the  PCR  product  (2.28  Kb)  from  the  parent  B. 
pertussis  strains  (Taberman  I  and  Tohania  I)  and  lanes  D  and  E  show  the  PCR  products 
(3.58  Kb)  from  the  B.  pertussis  strains  with  mutated  bap-5  (Taberman  11  and  Tohama  II). 
Lane  C  shows  the  PCR  product  from  the  cloned  mutated  bap-5  gene  in  the  suicide  vector 
pBap5-Kana.  There  was  no  evidence  of  a  2.28  Kb  band  in  lanes  D  and  E,  representing  the 
native  bap-5  gene,  from  the  PCR  reactions  with  the  mutant  chromosomal  DNA.  This  was 
clear  evidence  that  cross-overs  had  occurred  on  each  side  of  the  site  of  kMR  cassette 
insertion  and  the  net  result  was  the  complete  replacement  of  the  wild-type  bap-5  allele  in 
the  B.  pertussis  chromosome.  If  such  a  double  cross-over  had  not  occurred,  there  would 
have  been  two  PCR  products  obtained  from  the  B.  pertussis  strain  due  to  the  presence  of 
both  the  wild-type  allele  (bap-5)  and  the  mutated  allele  (bqp-5::  kmR),  because  of  the 
integrated  plasmid. 
Further  confirmation  of  the  successful  construction  of  the  bap-5  mutants  came  from 
the  Southern  blotting  procedure.  Genomic  DNA  from  the  parents  and  bap-5  mutant  strains 
was  digested  with  restriction  enzyme  Sacl  (Fig.  3.7).  This  enzyme  has  no  restriction  sites 
in  bap-5  or  in  the  knIR  locus.  The  rationale  for  doing  this  was  that,  on  probing  the  digested 
DNA  with  a  Dig-labelled  whole  bap-5  specific  probe,  a  size  difference  would  be  seen 
between  the  parent  and  mutant  strains.  Southern  blot  analysis  showed  that  the  Dig-labelled 
bap-5  probe  hybridised  to  an  approximately  5.2  Kb  fragment  in  both  parent  DNA 
preparations,  but  to  an  approx.  6.5  Kb  fragment  in  both  mutant  strains  (Fig.  3.8).  Lanes  A 
and  B  represent  the  SacI  digested  genomic  DNA  from  the  B.  pertussis  Taberman  I  and 
Tohama  I  strains  respectively  probed  with  Dig-labelled  bap-5  gene  (section  2.9.1).  Lanes 
C  and  D  represent  the  bap-5  mutant  strains,  Taberman  11  and  Tohama  II,  respectively, 
III Fig.  3.7:  Agarose  (1  %)  gel  showing  the  genomic  DNA  of  B.  pertussis  strains  digested 
with  SacI  and  used  for  Southern  blotting. 
Chromosomal  DNA  extracted  by  the  procedure  described  in  section  2.2.1,  was 
subjected  to  restriction  digestion  with  SacI  which  does  not  cut  either  the  bap-5  gene  or  the 
kanamycin  resistance  cassette  and  the  fragments  were  separated  on  aI%  agarose  gel. 
A=B.  pertussis  Taberman  I 
B=B.  pertussis  Tohama  I 
C=B.  pertussis  Taberman  II,  bap-5  mutant 
D=B.  pertussis  Toharna  II,  bap-5  mutant 
1=  Dig-labelled  DNA  molecular  weight  marker 
Fig.  3.8:  Southern  blot  showing  bap-5  parent  and  mutant  genomic  DNA  digested 
with  Sacl  and  probed  with  a  ba  -5  specific  probe.  P 
Chromosomal  DNA  was  digested  and  separated  as  in  Fig.  3.7  and  it  was  then 
transferred  to  nylon  membrane  and  probed  with  a  Dig-labelled  bcjl)-5  gene  fragment 
prepared  as  described  in  section  2.9.1. 
A=B.  pertussis  Taberman  1,  wild  type 
B=B.  pertussis  Tohama  I,  wild  type 
C=B.  pertussis  Taberman  11,  bap-5  mutant 
B.  pertussis  Tohama  11,  bap-5  mutant 
I=  Dig-labelled  DNA  molecular  weight  marker Habib  Bokhari 
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containing  the  kanamycin  resistance  cassette  insertion  in  bap-5.  The  difference  of  1.3  Kb 
between  the  parent  strains  and  the  bap-5  mutant  strains  was  expected  from  the  insertion  of 
the  -1.3  Kb  km  R  cassette. 
3.1.3  Characterisation  of  the  bap-5-defective  mutants 
The  growth  kinetics  of  B.  pertussis  Taberman  I  and  its  bap-5-defective  mutant 
Taberman  11  were  measured  over  72  h  by  noting  the  optical  density  at  600  nm  (OD600nm)  at 
intervals.  The  bacteria  were  grown  in  100  ml  volumes  of  cyclodextrin  liquid  (CL)  medium 
inoculated  with  2  ml  of  a  culture  grown  in  CL  medium  for  48  h.  The  growth  curves 
showed  that  the  bap-5  mutagenesis  had  not  affected  the  growth  of  the  B.  pertussis  bap-5 
mutant  (Taberman  II)  in  any  significant  way  (Fig.  3.9).  The  bap-5  mutant  of  B.  pertussis 
Tohama  1,  however,  appeared  to  be  abnormal.  It  produced  non-haemolytic  colonies  on  BG 
agar  and  grew  more  rapidly  than  the  parent  strain  in  the  CL  medium  (not  shown)  hence 
was  not  included  in  the  subsequent  study. 
3.2:  Characterisation  of  the  bap-5  gene  by  deflning  its  role  in  B.  pertussis 
3.2.1  Identification  of  the  C-terminal  domain  of  Bap-5  and  cross  reactivity  with  the 
C-terminal  domains  of  the  other  autotransporter  proteins  of  B.  pertussis 
This  section  was  designed  to  generate  infon-nation  regarding  the  C-terminal, 
autotransporter  domain  of  Bap-5  that,  by  analogy  with  the  other  transporters,  would  be 
involved  in  the  transport  of  the  passenger  domain  of  the  Bap-5  protein  across  the  outer 
membrane.  Immunoblotting  with  a  polyclonal  mouse  antiserum  (Table  2.7)  raised  against 
recombinant  whole  Bap-5  protein  (Blackburn,  2000)  cross-reacted  strongly  with  the 
recombinant  whole  Bap-5  and  a  slight  cross  reaction  was  noted  with  the  whole  cells  of  B. 
113 Fig.  3.9:  Growth  curve  of  B.  pertussis  Taberman  I  and  its  bap-5-defective  mutant. 
Bacteria  were  grown  in  CL  medium  and  the  OD  at  600,,.  was  measured  at  regular 
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pertussis  Taberman  I  (not  shown).  This  same  antiserurn  did  not  show  any  cross-reaction 
either  with  the  outer  membrane-enriched  fractions  from  B.  pertussis  Taberman  1,  or  with 
recombinant,  urea-extracted  C-tenninus  of  Bap-5  (result  not  shown).  Moreover,  a  mouse 
polyclonal  serum  against  the  recombinant  C-terminus  of  Bap-5  (Table  2.7),  raised  by 
Blackburn,  (2000)  did  not  prove  to  be  a  useful  tool  for  specifically  identifying  the  C- 
terminus  of  Bap-5  because  it  cross-reacted  with  other  autotransporter  C-terminal  domains. 
Fig.  3.10  shows  an  immunoblot  of  crude  urea  extracts  containing  recombinant  C-termini  Of 
Bap-5  (lane  A),  PRN  (lane  B),  TCF  (lane  Q  and  BrkA  (lane  D)  when  reacted  with  the 
mouse  anti-C-terminal  Bap-5  serum.  However,  it  appeared  that  the  mouse  anti-Bap-5 
serum  did  cross-react  with  two  components  in  the  preparations  of  the  recombinant  C- 
termini  of  Bap-5  (lane  A)  and  PRN  (lane  B)  and  one  component  in  the  preparation  of  TCF 
(lane  Q  although  not  with  the  recombinant  C-terminal  domain  of  BrkA  (lane  D). 
Another  line  of  investigation  was  to  search  for  cross-reactivity  between  the  Bap-5 
C-terminal  region  and  the  C-termini  of  the  other  autotransporters  i.  e.  TCF,  BrkA  and  PRN, 
using  their  C-terminus-specific  antibodies.  This  would  also  be  useful  in  determining  the 
closest  significantly  homologous  autotransporter  to  Bap-5  from  the  above  mentioned  three. 
Fig.  3.11  shows  the  SDS-PAGE  profiles  of  urea-solubilised  crude  extracts  of  the 
recombinant  C-termini  of  the  different  B.  pertussis  autotransporter  proteins  expressed  in  E. 
coli  (M15)  and  extracted  and  purified  as  the  His-tagged  (2.10.4)  constructs  (Blackburn, 
2000)  (section  2.1.2,  Table  2.5).  Blots  of  these  purified  recombinant  C-termini  were 
incubated  with  mouse  monoclonal  antibodies  to  the  C-termini  of  BrkA  (antibody  P28)  and 
TCF  (antibody  49.3)  as  well  as  with  a  mouse  polyclonal  antibody  to  the  C-terminal  region 
of  pRN  (Table  2.7)  raised  by  Blackburn,  (2000).  Fig.  3.12  shows  all  the  recombinant  C- 
termini  screened  with  the  monoclonal  antibodies  to  BrkA  (C-terminal).  The  antibody 
115 Fig.  3.10:  Immunoblot  indicating  the  cross-reaction  between  the  mouse  polyclonal 
anti-Bap-5  (C-terminus)  antibody  and  various  purified  recombinant  C-terminal 
domains  of  B.  pertussis 
Antiserurn  raised  against  recombinant  C-terminal  domain  of  Bap-5  (section  2.12, 
Table  2.7)  was  used  in  a  western  blot  against  recombinant  preparations  of  the  various 
autotransporter  C-terminal  domains  purified  as  outlined  in  section  2.10.4. 
A=  Purified  recombinant  C-terminus  of  Bap-5 
B=  Purified  recombinant  C-terminus  of  PRN 
C=  Purified  recombinant  C-terminus  of  TCF 
D=  Purified  recombinant  C-terminus  of  Brk-A Habib  Bokhari  Results 
kDa 
116 Fig.  3.11:  SDS-PAGE  of  the  purified  recombinant  C-terminal  domains  of  the  different  B. 
pertussis  autotransporters. 
Purified  recombinant  C-terminal  domains  as  in  Fig.  3.10  (section  2.10.4)  were 
subjected  to  SDS-PAGE  (12  %)  and  stained  with  coomassie  blue. 
A=  Purified  recombinant  C-terminus  of  Bap-5 
B=  Purified  recombinant  C-terminus  of  PRN 
C=  Purified  recombinant  C-terminus  of  TCF 
D=  Purified  recombinant  C-terminus  of  BrkA 
Fig.  3.12:  Immunoblot  showing  the  reaction  between  the  monoclonal  anti-BrkA  (C- 
terminus)  antibody  and  different  purified  recombinant  C-terminal  domains 
of  B.  pertussis 
Equal  amounts  of  the  protein  (2.10.5)  were  subjected  to  SDS-PAGE  (12%)  as 
shown  in  Fig.  3.11  and  blotted  to  Hybond-C  membrane  and  probed  with  the  mouse 
monoclonal  P28  to  the  BrkA  C-tern-linal  domain  (Table  2.7). 
A=  Purified  recombinant  C-terminus  of  Bap-5 
B=  Purified  recombinant  C-terminus  of  PRN 
C=  Purified  recombinant  C-terminus  of  TCF 
D=  Purified  recombinant  C-terminus  of  BrkA N 
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reacted  strongly  with  the  purified  recombinant  C-terminal  domain  of  BrkA  (lane  D)  and  it 
also  appeared  to  cross-react  to  some  extent  with  recombinant  Bap-5  (lane  A),  PRN  (lane 
B)  and  TCF  (lane 
Fig.  3.13  shows  a  blot  of  all  the  recombinant  C-termini  screened  with  the 
monoclonal  antibodies  to  TCF  (C-terminal).  This  antibody  reacted  strongly  with  the 
purified  recombinant  C-terminal  domain  of  TCF  (lane  Q  but  also  appeared  to  cross-react 
to  some  extent  with  recombinant  Bap-5  (lane  A),  PRN  (lane  B)  and  BrkA  (lane  D).  Fig. 
3.14  shows  a  blot  of  all  the  recombinant  C-termini  screened  with  the  mouse  polyclonal 
anti-PRN  (C-terminal)  serum.  Although  this  antiserum  reacted  strongly  with  the  purified 
recombinant  C-terminal  domain  of  PRN  (lane  B)  it  also  appeared  to  show  some  cross- 
reaction  with  recombinant  Bap-5  (lane  A)  and  TCF  (lane  Q  and  to  a  lesser  extent  with 
BrkA  (lane  D).  The  overall  result  suggested  that  it  would  be  extremely  difficult  to 
distinguish  the  C-terminal  region  of  Bap-5  in  B.  pertussis  Tabennan  I,  or  its  absence,  in  the 
bap-5  mutant  (Taberman  II)  with  any  of  these  antiserum  as  they  seem  to  cross-react  with 
the  C-termini  of  other  C-terminal  autotransporter  domains.  These  would  be  present  in 
whole-cell  or  outer  membrane-enriched  fractions  of  B.  pertussis  and,  due  to  their  similar 
molecular  weights,  the  sera  would  not  allow  the  presence  or  absence  of  the  Bap-5  C- 
terminal  domain  to  be  convincingly  demonstrated. 
3.2.2  Purification  of  His-tagged  Bap-5 
From  the  results  presented  in  section  3.2.1,  it  appeared  that  a  more  specific  anti- 
Bap-5  serum  was  needed  for  this  study.  Therefore  a  rabbit  polyclonal  anti-Bap-5  serum 
was  prepared  against  the  purified  His-tagged  recombinant  full  length  Bap-5  expressed  in  E. 
coli  expression  strain  M15  from  the  construct  pQE60  (Blackburn,  2000).  The  full  length 
Bap-5  was  purified  during  this  study  according  to  the  method  given  in  section  2.10.4.  Fig. 
118 Fig.  3.13:  Immunoblot  showing  the  reaction  between  the  monoclonal  anti-TCF(C- 
terminus)  antibody  and  different  purified  recombinant  C-terminal  domains 
of  B.  pertussis 
Equal  amounts  of  the  protein  (2.10.5)  were  subjected  to  SDS-PAGE  (12%),  blotted 
to  Hybond-C  membrane  and  probed  with  the  mouse  monoclonal  (49.4)  to  the  TCF  C- 
terminal  domain  (Table  2.7). 
A=  Purified  recombinant  C-terminus  of  Bap-5 
B=  Purified  recombinant  C-terminus  of  PRN 
C=  Purified  recombinant  C-terminus  of  TCF 
D=  Purified  recombinant  C-terminus  of  BrkA 
Fig.  3.14:  Immunoblot  showing  the  reaction  between  the  mouse  polyclonal  anti- 
PRN  (C-terminus)  antibody  and  different  purified  recombinant  C-terminal 
domains  of  B.  pertussis 
Equal  amounts  of  the  protein  (2.10.5)  were  subjected  to  SDS-PAGE  (12%),  blotted 
to  Hybond-C  membrane  and  probed  with  a  mouse  monoclonal  to  the  PRN  C-terminal 
domain  (Table  2.7). 
A=  Purified  recombinant  C-terminus  of  Bap-5 
B=  Purified  recombinant  C-terminus  of  PRN 
C=  Purified  recombinant  C-terminus  of  TCF 
D=  Purified  recombinant  C-tenninus  of  BrkA Habib  Bokhari  Results 
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3.15  (lane  A)  shows  Bap-5,  which  runs  at  -90  kDa  on  SDS-PAGE,  in  the  urea-extract  of 
the  inclusion  bodies  obtained  from  the  E.  coli  expression  strain  M15.  Lane  B  represents 
the  first  eluant  obtained  from  the  Ni-NTA  agarose  column  using  buffer  A,  pH=6.0 
(Appendix  1),  lane  C  the  second  elution  using  buffer  B,  pH=5.2,  lane  D  the  third  elution 
collected  with  the  first  flushing  of  buffer  C,  pH=4.5  and  lane  E  the  fourth  elution  collected 
with  the  second  flushing  of  buffer  C,  pH=4.5.  The  last  elution  uncoupled  most  of  the  His- 
tagged  Bap-5  bound  to  the  Ni-NTA  agarose  affinity  column.  The  Bap-5  was  further 
purified  by  SDS-PAGE  and  transferred  by  blotting  onto  a  nitrocellulose  membrane.  The 
Bap-5  band  was  excised  from  the  membrane  and  an  extract  (section  2.12)  was  sent  to  Dr, 
D.  Xing,  NIBSC,  London  to  raise  a  rabbit  antiserum.  This  anti-serum  was  used  in 
subsequent  work  (section  3.3). 
3.2.3.  The  role  of  Bap-5  in  B.  pertussis 
The  Bap-5  protein  belongs  to  the  family  of  B.  pertussis  autotransporters  and  all  of 
the  previously  characterised  autotransporter  members  in  B.  pertussis  are  regulated  by  the 
Bvg  two-component  regulatory  system.  Two  points  had  to  be  borne  in  mind  when  using 
the  bap-5  mutant  strain.  As  the  mutagenesis  was  carried  out  by  inserting  the  kMR  cassette 
downstream  of  the  predicted  translational  start  site  (-510bp)  (Appendix  II),  there  was  the 
possibility  of  getting  transcription  of  truncated  bap-5  and  that  could  cause  difficulties  in 
clearly  defining  the  role  of  the  gene.  The  other  area  that  had  to  be  borne  in  mind  was  the 
possible  effect  of  the  mutagenesis  on  neighbouring  genes.  The  data  base  search  of  the 
flanking  regions  of  bap-5  using  the  B.  pertussis  genome  sequence  (BLAST  search 
performed  at  http:  //www.  sanger.  ac.  uk/projects/B-pertussis)  indicated  that  a  gene  located 
5'-upstream  of  bap-5  is  an  amino  acid  transport  gene  and  during  a  search  for  potential 
BvgA  binding  sites  in  the  5'-upstream  region  of  bap-5,  two  potential  BvgA-binding  sites 
120 Fig.  3.15:  Stages  in  the  purification  of  His-tagged  full-length  Bap-5. 
Bap-5  prepared  from  the  urea-solubilised  inclusion  bodies  was  allowed  to  interact 
with  Ni-NTA  agarose  and  then  eluted  with  buffers  of  different  pH  values  (2.10.4). 
A=  Urea  extract  of  Bap-5 
B=  Buffer  A  elutate 
(8M  urea,  O.  IM  sodium  phosphate,  0.01M  Tris,  pH  6.0) 
C=  Buffer  B  eluate 
(8M  urea,  O.  IM  sodium  phosphate,  0.01M  Tris,  pH  5.2) 
D=  Buffer  C  eluate  1 
(8M  urea,  O.  lM  sodium  phosphate,  0.01M  Us,  pH  4.0) 
E=  Buffer  C  eluate  2 
(8M  urea,  O.  lM  sodium  Phosphate,  0.01M  Tris,  PH  4.0) Habib  Bokhari 
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(Appendix  III,  shown  in  red)  at  844  bp  and  936  bp  from  the  predicted  translational  start 
site  i.  e.  first  methionine  (ATG  1)  were  located  from  the  B.  pertussis  genome  sequence 
(Contig  1069)  between  the  amino  acid  transport  gene  and  bap-5.  A  gene  located  3'- 
downstream  was  a  hypothetical  gene  of  unknown  function,  which  did  not  appear  to  form  a 
part  of  an  operon  with  bap-5. 
The  Bap-5  protein  has  certain  conserved  motifs  that  have  already  been  suggested  to 
play  some  role  in  defining  the  function  of  the  well  characterized  B.  pertussis 
autotransporter  proteins.  These  are  the  RGD  and  SGXG  motifs  (Fig.  1.3).  RGD  is  an 
integrin-binding  motif  and  is  thought  to  play  a  significant  role  in  the  adherence  properties 
of  PRN  and  TCF.  The  glycosaminoglycan-binding  site,  SGXG,  is  an  important  feature  of 
BrkA  and  there  is  a  possibility  that  the  SGXG  motif  may  be  involved  in  conferring  serum 
resistance  on  B.  pertussis  against  complement-mediated  killing  by  the  classical  pathway 
(Fernandez  and  Weiss,  1994;  Barnes  and  Weiss,  2001).  Hence  these  properties  were 
worthy  of  investigation  in  relation  to  the  role  of  bap-5  in  B.  pertussis.  It  also  seemed 
desirable  to  see  if  the  bap-5  mutagenesis  had  produced  any  effects  on  the  production  of  the 
already  well-characterised  autotransporter  virulence  factors  of  B.  pertussis  i.  e.  PRN  and 
BrkA  before  going  any  further.  Another  aim  was  to  study  Bap-5  localisation  in  B. 
pertussis. 
3.2.3.1:  Expression  of  bap-5  under  non-modulating  (Bvg')  and  modulating  (Bvg) 
conditions. 
The  expression  of  bap-5  in'the  wild-type  B.  pertussis  was  investigated  initially  by 
RT-PCR  as  described  in  section  3.1  and  in  Fig.  3.2.  As  all  the  B.  pertussis  autotransporters 
(section  1.9)  described  to  date  were  found  to  be  bvg-regulated,  and  taking  this  consensus  as 
a  precedent,  the  expression  of  bap-5  in  a  Bvg-  strain  BP347,  of  B.  pertussis  Toharna  was 
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examined.  Also,  any  expression  of  bap-5  in  the  bap-5-defective  B.  pertussis  Taberman  11 
and  Tohama  II  mutants  was  checked.  The  bap-5  forward  and  NTS  REV  primers  (Table 
2.6)  for  the  bap-5  gene  were  selected  for  RT-PCR.  These  were  expected  to  amplify  a  505 
bp  fragment  from  the  3'  region  of  bap-5,  as  shown  in  Fig.  3.16;  lane  B  i.  e.  starting  from 
286bp  to  791bp  (Appendix  11)  (section  3.1.2).  The  RT-PCR  result  (Fig.  3.16)  once  again 
indicated  that  bap-5  is  expressed  (505  bp  product)  in  wild-type  B.  pertussis  Taberman  I 
and  Tohama  I  (lanes  C  and  E)  and  also  indicated  that  bap-5  expression  is  being  effectively 
blocked  by  the  successful  introduction  of  the  kin'  cassette  into  the  corresponding  bap-5 
locus  of  B.  pertiessis  chromosome  (lane  D,  Taberman  11;  lane  F,  Tohama  11).  The  RT-PCR 
was  repeated  twice  and  one  representative  gel  is  presented  (Fig.  3.16).  Lanes  A  and  B 
represent  PCR  reactions  with  the  genomic  DNA  extracted  from  the  bap-5  mutant  (505 
bp+1300bp  kl?,  R  cassette)  and  its  wild-type  B.  pertussis  strain,  Taberman  1  (505  bp), 
respectively.  There  is  again  an  anomaly  in  these  results  which  was  described  before  in 
section  3.1.1  (Fig.  3.2),  in  that  a  band  of  -100  bp  was  present  in  both  bap-5  wild-type 
strains  (lanes  C,  E)  and  in  BP347  (lane  G).  This  band  was  not  present  in  the  bap-5  mutant 
RT-PCR  products.  Hence,  the  RT-PCR  result  could  not  rule  out  the  possibility  of  a 
truncated  bap-5  transcript  in  bap-5  mutants,  which  possibly  may  have  occurred  in  the 
portion  of  the  gene  prior  to  the  kin  R  cassette  insertion  site.  The  other  impo'rtant  finding  was 
the  absence  of  desired  product  of  correct  size  (505  bp)  in  Bvg-  BP347  strain  (lane  G). 
However,  the  absence  of  the  desired  product  from  BP347  strain  suggests  that  bap-5  is  bvg- 
regulated  but  the  appearance  of  the  smaller  product  is  harder  to  explain.  After  this  stage, 
as  already  stated  in  section  3.1.3  there  were  some  problems  regarding  the  abnormal 
phenotype  of  the  Tohama-derived  bap-5-defective  mutant  so  only  B.  pertussis  Taberman  I 
and  its  bap-5  mutant  Taberman  11  was  used  for  further  characterisation  study. 
123 Fig.  3.16:  RT-PCR  results  with  RNA  prepared  from  B.  pertussis  wild-type  strains, 
bap-5  mutants  and  B.  pertussis  strain  BP347  (Bvg). 
RT-PCR  was  performed  according  to  the  protocol  given  in  section  2.11.3  using  the 
RNA  isolated  as  in  section  2.11. 
1=I  Kb  ladder 
A=  PCR  control  using  genomic  DNA  from  B.  pertussis  Taberman  II,  bap-5  mutant 
B=  PCR  control  using  genomic  DNA  from  B.  pertussis,  Taberman  I 
C=  RT-PCR  with  the  RNA  from  the  B.  pertussis,  Taberman  I 
D=  RT-PCR  with  the  RNA  from  the  B.  pertussis,  Taberman  II,  bap-5  mutant 
E=  RT-PCR  with  the  RNA  from  the  B.  perlussis,  Tohama  I 
F=  RT-PCR  with  the  RNA  from  the  B.  pertussis,  Toharna  11,  bap-5  mutant 
G=  RT-PCR  with  the  RNA  from  the  B.  pertussis,  Tohama,  BP347  (Bvg-) Habib  Bokhari 
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Fig.  3.17A  shows  the  whole-cell  protein  profiles  of  B.  pertussis  Tabennan  I  (lane 
A),  its  derived  bap-5-defective  mutant  Taberman  II  (lane  B)  and  modulated  (growth  in  the 
presence  of  40mM  MgS04)  Taberman  I  (lane  Q  as  well  as  modulated  bap-5-defective 
mutant  Taberman  II  (lane  D).  The  SDS-PAGE  (Fig.  3.17A)  profile  of  whole  cells  of 
parent  and  mutant  strains  look  alike  apart  from  the  fact  that  modulated  strains  are  deficient 
in  number  of  protein  bands,  presumably  representing  virulence  factors  regulated  by  the  two 
component  Bvg-system.  Contrary  to  this,  the  immunoblot  (Fig.  3.17B)  of  the  above 
mentioned  SDS-PAGE  gel  screened  with  polyclonal  rabbit  anti-,  Bap-5  serum  (Table  2.8) 
shows  a  definite  difference  between  the  B.  pertussis  Taberinan  I  (lane  A)  and  its  derivafive 
bap-5-defective  mutant  Taberman  11  (lane  B)  at  -90kDa.  There  is  some  cross  reaction 
apparent  in  all  4  lanes  at  -75  kDa.  Thus  the  immunoblot  confirms  the  above  described 
RT-PCR  results  in  particular  regarding  the  bvg-regulation  of  bap-5  in  B.  pertussis. 
3.2.3.2  Localisation  of  Bap-5  in  B.  pertussis 
3.2.3.2.1:  Agglutination  test 
A  agglutination  procedure  (section  2.15.1)  was  carried  out  using  a  rabbit  polyclonal  anti- 
whole-cell  B.  pertussis  serum  (1:  10  of  stock),  rabbit  anti-PRN  antibody  (anti-P.  69)  and 
rabbit  polyclonal  anti-whole  Bap-5  specific  antibody  (section  2.12,  Table  2.7).  The 
agglutination  test  was  carried  out  in  96-well  u-shaped  microplates  using  bacterial  cells 
scraped  from  BG  plates  and  suspended  in  PBS  and  the  suspension  standardized  using  an 
opacity  rod.  A  dense  fluffy  type  of  agglutination  was  observed  in  cases  wherever  a 
positive  (  ...  )  reaction  occurred  with  the  anti-whole-cell  B.  pertussis  serum,  presumably 
due  to  the  cross-linking  of  surface  appendages  such  as  FHA  and  fimbriae.  However,  in  the 
case  of  rabbit  anti-PRN  and  rabbit  anti-whole  rBap-5  sera,  wherever  positive  (+)  reactions 
were  seen,  a  less  dense,  granular  type  of  agglutination  was  noticed,  presumably  due  to  a 
125 Fig.  3.17:  SDS-PAGE  showing  the  protein  profile  of  the  whole  cell  of  B.  pertussis  in 
non-modulating  and  modulating  conditions 
Solubilised  whole  cells  were  prepared  from  bacteria  grown  in  CL  medium  to 
OD600nm  -  1.0.  The  whole  cell  proteins  were  screened  with  rabbit  anti-whole  Bap-5  serum. 
3.17A  SDS-PAGE 
A=B.  pertussis,  Taberman  I 
B=B.  pertussis,  Taberman  II,  bap-5  mutant 
C=B.  pertussis  Taberman  I  modulated  by  adding  MgS04  to  the  growth  medium 
D=B.  pertussis  Taberman  II,  bap-5  mutant  modulated  by  adding  MgS04  to  the 
growth  medium 
3.17B  Immunoblot 
A=B.  pertussis,  Taberman  I 
B=B.  pertussis,  Taberman  II,  bap-5  mutant 
C=B.  pertussis  Taberman  I  modulated  by  adding  MgS04  to  the  growth  medium 
D=B.  pertussis  Taberman  II,  bap-5  mutant  modulated  by  adding  MgS04  to.  the 
growth  medium Habib  Bokhari 
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closer-association  of  bacteria  created  by  antibodies  to  the  outer-membrane  proteins.  The 
result  was  repeated  twice  and  similar  results  were  observed.  Table  3.1  shows  a  summary 
of  the  results  which  indicated  that  incubation  of  B.  pertussis  Taberman  I  strain  with  rabbit 
polyclonal  anti-whole-cell  B.  pertussis  serum  produced  a  fluffy  type  of  agglutination, 
whereas  the  anti-PRN  and  anti-,  Bap-5  sera  produced  a  granular  type  of  agglutination.  The 
B.  pertussis  bap-5  mutant  (Taberman  II)  behaved  like  its  parent  Taberman  I  strain  except 
after  incubation  with  rabbit  anti-whole,  Bap-5  antibodies,  where  the  bap-5  mutant  appeared 
to  form  a  clear  and  prominent  button  which  suggested  lack  of  agglutination  due  to  the 
absence  of  the  relevant  surface  antigen  i.  e.  Bap-5.  The  bap-5  mutant  did  however 
agglutinate  with  anti-PRN  serum.  B.  pertussis  Tohama  (BP338)  and  its  derived  brkA 
mutant  (BP2041)  strain  also  appeared  to  show  a  fluffy  type  of  agglutination  when 
incubated  with  anti-whole-cell  B.  pertussis  serum  whereas,  on  incubation  with  anti-PRN 
and  anti-,  Bap-5  antisera,  they  showed  the  granular  type  of  agglutination.  B.  pertussis 
BBC29  and  its  pm  mutant  BBC30  strain  produced  the  fluffy  type  of  agglutination  on 
reacting  with  anti-whole-cell  B.  pertussis  serum  and  a  granular  type  of  agglutination  was 
observed  with  rabbit  anti-,  Bap-5  antiserum.  However,  the  pm  mutant  after  incubation  with 
anti-PRN,  appeared  to  form  a  clear  and  prominent  button  which  suggested  a  lack  of 
agglutination  due  to  the  absence  of  relevant  surface  antigen  i.  e.  PRN,  unlike  its  parent 
strain  BBC29.  The  table  also  shows  the  results  with  B.  bronchiseptica  BBC17  and  its  Bvg- 
derivative  and  its  reaction  with  different  antisera.  As  most  of  the  outer-membrane  proteins 
are  regulated  by  the  two  component  Bvg  system  (section  1.5),  a  lack  of  those  proteins  on 
the  bacterial  surface  would  be  expected  to  produce  a  negative  result  on  incubation  with  the 
antisera  which  was  raised  predominantly  against  them.  The  expected  result  was  observed 
as  there  appeared  to  be  no  visible  agglutination  in  the  case  of  Bvg'BBC17  strain,  whereas 
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the  parent  BBC17  strain  appeared  to  show  the  fluffy  type  of  agglutination  on  incubation 
with  rabbit  anti-whole-cell  B.  pertussis  serum  and  the  granular  type  of  agglutination  when 
incubated  with  anti-PRN  and  anti-,  Bap-5  antisera.  This  result  showed  close  cross- 
reactivity  between  B.  perfussis  and  B.  bronchiseptica  bvg-regulated  OMPs.  The  Table  also 
shows  the  cross  reaction  between  E.  coli  M15  expressing  the  full  length  recombinant  Bap- 
5  with  anti-,  Bap5  serum  but  not  the  other  sera.  The  E.  coli  strain  expressing  Bap-5  seemed 
to  show  a  stronger  agglutination  with  the  anti-,  Bap-5  antiserum  than  the  B.  pertussis  strains 
and  B.  bronchiseptica  BBC17  strain.  This  result  strongly  suggested  that  Bap-5  is  surface 
exposed  in  this  E.  coli  strain,  M15.  The  last  result  shows  that  B.  pertussis  Tabennan  I 
strain,  when  modulated  by  growing  in  the  growth  medium  containing  40mM  MgS04,  gave 
some  granular  type  of  agglutination  on  incubation  with  rabbit  anti-whole-cell  B.  pertussis 
serum  only,  which  suggested  that  most  of  the  surface  agglutinogens  are  not  present  to  react 
with  their  respective  antiserum  components.  The  last  column  represents  the  different 
bacterial  cells  resuspended  in  PBS  alone  (negative  control). 
3.2.3.2.2:  Immunofluorescence 
To  prove  that  Bap-5  is  surface-located,  like  many  other  virulence  determinants  of  . 
B.  pertussis,  an  indirect  immunofluorescence  assay  was  carried  out  using  rabbit  anti-whole 
,  Bap-5  serum.  The  bacteria  were  stained  with  Hoechst  33272  stain  and  immobilised  on 
poly  L-lysine  (Sigma)  coated  slides  (Section  2.19.2)  and  were  then  exposed  to  different 
concentrations  of  rabbit  anti-,  Bap-5  serum.  An  initial  high  fluorescence  background 
problem  was  minimized  by  using  the  antiserum  at  a  dilution  of  1:  200  and  by  incorporating 
extensive  washing  between  each  step.  A  FITC-conjugated  goat  anti-rabbit  secondary 
antibody  was  used  to  detect  any  surface  bound  anti-,  Bap-5  antibody.  Figs.  3.18A  and 
3.18C  show  B.  pertussis  Taberman  I  and  Taberman  11,  its  bap-5  mutant  strain  visualised 
129 Fig.  3.18:  Immunofluorescence  detection  of  Bap-5  antigen  on  the  surface  of  B. 
pertussis  using  rabbit  anti-rBap-5  antibody. 
B.  pertussis  from  BG  agar  was  stained  with  Hoechst  stain  as  in  section  2.15.2.1  and 
subjected  to  immunofluorescence  as  in  section  2.15.2.2  and  viewed  under  a  Zeiss- 
Axioskop  epifluorescence  microscope. 
A=B.  pertussis  strain  Taberman  I  as  seen  by  phase  contrast  microscopy. 
B=  Image  of  the  same  field  (A)  viewed  by  the  fluorescence  microscopy. 
B.  pertussis  Taberman  II,  bap-5-defective  mutant,  as  seen  by  phase  contrast 
nucroscopy. 
D=  Image  of  the  same  field  (C)  viewed  by  the  fluorescence  microscopy. 
All  the  images  were  visualised  with  a  63  x  neofluor  Ph3  lens  (magnification 
63  x  20  =  1260). Habib  Bokhari  Results 
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by  phase-contrast  microscopy.  Figs  3.18B  and  3.18D  respectively  show  the  same  fields  as 
3.18A  and  3.18C  when  visualised  by  fluorescence  microscopy  (magnification  1260).  As 
shown  in  Fig.  3.18,  it  could  be  demonstrated  that  Bap-5  in  B.  pertussis  (Taberman  1)  is 
surface  exposed  (3.18B)  as  the  individual  bacterial  cells  were  clearly  fluorescent. 
However,  the  bap-5  mutant  (Taberman  II)  of  B.  pertussis  did  not  appear  to  react  with  anti- 
,  Bap-5  serum  (3.18D)  as  no  fluorescence  was  detected  from  individual  cells.  There 
appeared  to  be  some  non-specific  binding  of  the  antibody  to  clumped  bacteria. 
3.2.3.2.3:  Localisation  of  Bap-5  in  different  cellularfractions 
This  section  was  intended  to  give  detailed  information  on  the  localisation  of  Bap-5 
in  B.  pertussis.  After  showing  by  immunofluorescence  and  agglutination  that  Bap-5 
appears  to  be  surface-exposed,  the  next  attempt  was  to  identify  Bap-5  in  the  different 
cellular  compartments  of  B.  pertussis.  This  would  also  presumably  generate  information 
about  the  processing  of  Bap-5.  Figure  3.19  shows  an  immunoblot  of  the  different  fractions 
of  B.  pertussis  Taberman  I  and  its  derived  bap-5  mutant  Taberman  H.  These  fractions 
were  screened  with  rabbit  anti-whole  Bap-5  antibody.  A  prominent  difference  was 
observed  between  the  whole-cell  fractions  i.  e.  lane  A  (Taberman  I)  showing  a  band  at  -90 
kDa  (indicated  by  an  arrow),  whereas  this  was  not  seen  in  lane  B  (Taberman  II,  bap-5 
mutant),  a  result  similar  to  that  shown  in  Fig.  3.17  previously.  This  band  runs  at  a  higher 
molecular  weight  than  the  predicted  size  of  Bap-5  i.  e.  -79  kDa  and  it  may  be  that  the 
I  protein  runs  anomalously  on  SDS-PAGE.  This  behaviour  has  been  described  for  other 
autotransporters  such  as  mature  PRN,  which  has  molecular  weight  of  61  kDa  but  runs  at  69 
kDa  on  SDS-PAGE.  There  was  another  difference  noticed  in  the  outer  membrane- 
enriched  fractions.  In  B.  pertussis  Taberman  1,  the  outer  membrane  fraction  showed  a 
band  at  -65  kDa  (lane  C,  indicated  by  an  arrow),  which  was  absent  in  the  bap-5  mutant 
131 Fig.  3.19:  Immunoblot  showing  different  fractions  of  B.  pertussis  Taberman  I  and  its 
bap-5  mutant,  reacted  with  anti-whoIerBap-5  serum 
B.  pertussis  strains  grown  to  same  OD600,,,,,  -l  in  CL  medium  were  used  to  isolate 
different  cellular  fractions,  as  described  in  section  2.10.1. 
A=B.  pertussis  Taberman  1,  whole  cell  preparation 
B=B.  pertussis  Taberman  11,  bap-5  mutant  whole  cell  preparation 
C=B.  pertussis  Taberman  I,  outer  membrane  preparation 
D=B.  pertussis  Taberman  11,  bap-5  mutant  outer  membrane  preparation 
E=B.  pertussis  Taberman  I,  inner  membrane  preparation 
F=B.  pertussis  Taberman  II,  bap-5  mutant  inner  membrane  preparation Habib  Bokhari 
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(Taberman  II,  lane  D).  This  may  be  the  processed  form  of  Bap-5  running  at  an 
approximately  higher  than  expected  size  (predicted  to  be  49  kDa).  The  inner-membrane 
fractions  of  Taberman  I  and  its  derived  bap-5  mutant  Taberman  II  showed  similar  profiles. 
The  anti-whole  Bap-5  serum  cross-reacted  strongly  in  all  fractions  with  two  bands  at  -70- 
75  kDa,  which  may  have  represented  cross-reactions  with  other  autotransporter  proteins 
e.  g.  mature  BrkA  protein  (73  kDa). 
Fig.  3.20  shows  the  outer  membrane-enriched  fractions  of  B.  pertussis  Taberman  I 
and  its  derived  bap-5  mutant  Taberman  11,  prepared  on  a  separate  occasion  to  those  shown 
in  Fig.  3.19.  The  SDS-PAGE  (3.20A)  and  the  corresponding  immunoblot  (3.20B)  again 
show  a  difference  between  the  two  at  -90  kDa.  This  is  presumably  the  surface-exposed 
unprocessed  Bap-5.  There  are  other  minor  differences  at  65  kDa  and  49  kDa.  Also,  the 
antiserum  again  cross-reacted  strongly  with  bands  at  -70-75  kDa  (Fig.  3.2013).  However 
the  other  major  difference  between  Taberman  I  (Fig.  3.20A,  lane  A)  and  its  derived  bap-5 
mutant  (Fig.  3.20  lane  B)  is  at  -16  kDa  which  is  consistently  reproducible  in  SDS-PAGE 
gels  stained  with  coomassie  blue,  but  the  difference  is  also  present  as  a  weak  reaction  in 
the  immunoblot  (Fig.  3.2013,  lane  B).  This  could  possibly  be  the  N  -terminal  portion  of  the 
Bap-5  being  processed  by  some  unknown  outer  membrane  proteases  or  perhaps  may 
represent  the  processing  of  the  -30  kDa  C-terminal  portion  of  Bap-5  which  is  not 
immediately  obvious  in  SDS-PAGE  gels  or  immunoblots. 
Fig.  3.21  shows  SDS-PAGE  profiles  of  the  outer  membrane  fractions  of  Taberman 
I  and  its  derived  bap-5  mutant  Taberman  II  (lanes  A  and  B)  run  on  a  16%  polyacrylamide 
gel.  The  BrkA  parent  strain,  BP338  and  B&A-deficient  mutant  BP2041  (lanes  C  and  D) 
were  included  as  controls  for  the  outer  membrane  preparation  as  BrkA  is  known  to  be  a 
surface-exposed  protein.  The  -16  kDa  protein  noticed  in  previous  result  (Fig.  3.20A)  is 
133 Fig.  3.20:  SDS-PAGE  and  corresponding  Immunoblot  showing  the  outer  membrane- 
enriched  preparations  of  B.  pertussis  Taberman  and  its  bap-5  mutant 
reacting  with  anti  whole  Bap-5  serum 
B.  pertussis  strains  grown  in  CL  medium  were  used  to  isolate  different  cellular 
fractions  as  in  section  2.10.1 
3.20A  SDS-PAGE 
A=  Outer  membrane  preparation  from  B.  perlussis  Taberman  I 
B=  Outer  membrane  preparation  from  B.  pertussis  Taberman  11,  bap-5-mutant 
3.20B  Immunoblot 
I=  Protein  ladder 
A=  Outer  membrane  preparation  from  B.  pertussis  Taberman  I 
B=  Outer  membrane  preparation  from  B.  pertussis  Taberman  11,  bap-5-mutant Habib  Rokhari 
3.20A 
3.20B 
kDa  AB 
90  Aýl  IOWA, 
7  65 
50  49 
k,  1)21  1 
150  *o  0  lw, 
wo 
75 
AB 
90  kDa 
50  Aft 
37 
-16kDa 
134 
Results Fig.  3.21:  SDS-PAGE  showing  the  outer  membrane-enriched  fractions  of  different  B. 
pertussis  strains  and  the  effect  of  solubilisation  temperature  on  the  mobifity 
of  Bap-5 
1=  Pre  stained  protein  marker 
A=  Outer  membrane  preparation  from  B.  perfussis  Taberman  I 
B=  Outer  membrane  preparation  from  B.  pertussis  Taberman  11,  bap-5-mutant 
C=  Outer  membrane  preparation  from  B.  perlussis  BP338 
D=  Outer  membrane  preparation  from  B.  pertussis  brkA  mutant  (BP2041) 
E=  Outer  membrane  preparation  from  B.  periussis  Taberman  I  solubilised  without 
heat  treatment 
F=  Outer  membrane  preparation  from  B.  pertussis  Taberman  11,  bap-5-mutant 
solubilised  without  heat  treatment Habib  Bokhari 
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present  in  lane  A  (Taberman  1)  and  absent  in  its  bap-5  mutant  lane  B  but  there  is  no 
obvious  difference  at  -90  kDa  and  -65  kDa.  A  difference  at  -73  kDa  (indicated  by  an 
arrow)  can  be  noted  between  lane  C  (BP338)  and  lane  D  (brkA  mutant,  B2041),  which  may 
correspond  to  the  processed  BrkA  protein.  Also  a  difference  in  band-density  at  30  kDa  can 
be  seen  in  the  lanes  C (bold  band  present)  and  D  (fainter  band  present),  which  may  reflect 
the  absence  of  the  30  kDa  autotransporter  domain  of  BrkA  protein.  Lanes  E  and  F  show 
the  profiles  of  outer-membrane  preparations  of  B.  pertussis  Taberman  I  and  its  bap-5 
mutant  when  solubilised  for  SDS-PAGE  without  heating.  The  rationale  for  doing  this  was 
to  see  any  differences  in  outer  membrane  proteins  due  to  their  heat  modifiable  nature  and 
ability  to  run  differently  on  the  SDS-PAGE.  In  this  case,  there  is  no  obvious  difference 
between  the  two  strains,  and  the  prominent  -16  kDa  protein  is  absent. 
It  was  of  interest  to  determine  whether  Bap-5,  like  most  of  the  well-characterised  B. 
pertussis  autotransporter  members,  is  processed  and  released  into  the  culture  supemate.  B. 
pertussis  was  grown  in  CL  medium  for  -48-72  h  (OD600nm-1.2).  Supernate  samples  were 
concentrated  (-50  times)  with  centrifuge  columns  (centricons;  Greiner,  U.  K)  of  30,000 
M.  W.  cut  off  size  according  to  manufacturer's  instructions  (section  2.10.1).  The 
concentrated  supemate  fractions  of  different  Bordetella  species  grown  in  CL  medium  as 
specified  in  section  2.1.3  and  2.1.4  (Table  2.4),  were  run  on  SDS-PAGE  and  blots  were 
screened  with  the  rabbit  anti-whole  Bap-5  serum  (Fig.  3.22).  The  SDS-PAGE  profile 
(Fig.  3.22A)  showed  that  there  was  no  apparent  difference  between  the  culture  supernates 
of  Taberman  I  (lane  A)  and  its  bap-5  mutant  (lane  B),  whereas  there  was  a  difference 
between  Tohama  BP338  (BrkA  parent)  (lane  Q  and  its  brkA  mutant  strain  BP2041  at  the 
correct  place  i.  e.  -73  kDa.  Lanes  E  and  F  show  B.  pertussis  BBC29  and  its  pm  mutant 
BBC30.  The  latter  supernate  unfortunately  did  not  concentrate  well  enough  or  proteins 
were  degraded  by  proteolytic  activity  of  some  unknown  nature.  Similarly,  the  supernates 
136 Fig.  3.22:  SDS-PAGE  (A)  and  its  corresponding  immunoblot.  (B)  showing  the 
concentrated  culture  supernates  of  various  Bordelella  species  reacting 
with  anti-wholerBap-5  serum 
Bordetella  species  were  grown  in  CL  medium  to  OD6oom  -I  and  their  supernatant 
fractions  were  concentrated  as  in  section  2.10.1  and  separated  on  12%  SDS-PAGE  and 
also  transferred  onto  nitrocellulose-membrane  for  immunoblotting. 
1=  Protein  ladder 
A=B.  pertussis  Taberman  I 
B=B.  pertussis  Taberman  II,  bap-5  mutant 
C=B.  pertussis  BP338 
D=B.  pertussis  BP2041,  brkA  mutant 
E=B.  pertussis  BBC29 
F=B.  pertussis  BBC30,  pm  mutant 
G=B.  pertussis  Taberman  1,  modulated  by  growing  in  the  presence 
Of  MgS04. 
H=B.  parapertussis  (NCTC  5952) 
I=B.  avium  4480 
J=B.  bronchiseptica  BBC17 Habib  Bokhari 
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for  B.  paral)ertussis  (lane  H)  and  B.  avium  (lane  1)  showed  that  little  protein  was  present. 
Lane  G  contains  the  supcmate  from  Taberman  I  strain,  modulated  with  MgS04  which 
shows  that  few  proteins  are  present.  Lane  J  shows  B.  bronchiseptica  strain  (BBC17).  The 
corresponding  inununoblot  (Fig.  3.2213)  of  the  gel  shows  consistent  cross-reaction  at  the 
same  position  in  all  lanes  i.  e.  -65  kDa  with  the  exception  of  lane  G.  Thus,  overall  the 
results  suggest  that  a  Bap-5  does  not  appear  to  be  significantly  released  into  the  culture 
supernates,  but  that  some  component(s)  of  the  supernates,  possibly  other  Bvg-regulated 
au  to  transporters  common  to  B.  pertussis  and  the  other  Bordetella  species,  are  released  and 
cross-react  with  the  anti-,  Bap-5  serum. 
3.2.3.3:  Localisation  of  other  B.  perfussis  autotranspoHer  proteins 
Ile  production  of  other,  well-characterised  autotmnsporters  in  B.  pertussis  was 
also  investigated  by  using  their  specific  antiscra  in  immunoblots  of  the  various  cell 
fractions  of  the  different  parent  and  mutant  strains.  Fig.  3.23  shows  an  immunoblot  of 
concentrated  (50  times)  supernatant  fractions  (2.10.1)  of  different  B.  pertussis  strains 
grown  in  CL  medium  under  exactly  the  same  conditions  and  to  the  same  cell  density 
(OD6w.,  n  -  1.2).  B.  pertussis  rabbit  anti-PRN  (P.  69  kDa)  serum  (Table  2.7)  kindly 
provided  by  Prof.  M.  Roberts,  Dept.  of  Veterinary  Pathology,  University  of  Glasgow,  was 
used  to  identify  pertactin  (PRN).  A  prominent  band  at  -69  kDa  (white  arrow)  was 
observed  from  the  culture  supernatant  fractions  of  the  wild-type  strains  of  B.  pertussis 
Taberman  I  (lane  A),  B.  pertussis  BP338  (lane  Q,  and  B.  pertussis  BBC29  (lane  E) 
showing  that  PRN  is  released  from  the  cell  surface.  The  bap-5  mutant  Taberman  11  (lane 
B)  and  brkA  mutant,  BP2G41  (lane  D)  also  reacted  with  rabbit  anti-PRN  serum.  However, 
no  band  was  seen  with  the  concentrated  culture  supernatant  fraction  from  the  pm  mutant 
BBC30  (lane  F)  and  Taberman  I  modulated  with  MgS04  (lane  G).  Hence  the  result  clearly 
138 Fig.  3.23:  Immunoblot  of  concentrated  culture  supernates  of  various  B.  Pertussis 
strains  screened  with  anti-PRN  serum  to  identify  pertactin 
Bordetella  pertussis  strains  were  grown  in  CL  medium,  whereas  E.  coli  strains 
expressing  recombinant  proteins  were  grown  in  LB  medium,  and  their  supernatant 
fractions  were  concentrated  as  in  section  2.10.1  and  separated  on  12%  SDS-PAGE  and 
transferred  onto  the  nitrocellulose-membrane  for  immunoblotting  with  anti-P.  69  serum 
(Table  2.7). 
I=  Protein  ladder 
A=B.  pertussis  Taberman  I 
B=B.  pertussis  Taberman  II,  bap-5  mutant 
C=B.  pertussis  BP338 
D=B.  pertussis  BP2041,  brkA  mutant 
E=B.  pertussis  BBC29 
F=B.  pertussis  BBC30,  pm  mutant 
G=B.  pertussis  Taberman  I,  modulated  by  growing  in  the  presence  Of  MgS04. 
H=  Purified  recombinant  whole  Bap-5 
I=  Supernatant  fraction  of  E.  coli  KS272  expressing  full  length  pertactin  (p41869) 
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showed  that  the  mutagenesis  of  bap-5  did  not  affect  the  production  of  PRN  in  Taberman  11, 
the  bap-5  mutant  as  was  also  the  case  with  the  brkA  mutant,  BP2041.  The  result  also 
indicated  that  there  was  no  cross-reaction  between  antiserum  to  P.  69  and  purified 
recombinant  Bap-5  (lane:  H).  Lane  I  shows  the  culture  suPernate  obtained  when  full 
length  recombinant  PRN  (P.  93)  is  expressed  in  E.  coli  (KS  272).  It  appeared  (lane  1)  that 
rabbit  anti-PRN  serum  reacts  with  the  PRN  being  processed  at  a  slightly  lower  molecular 
weight  (-67  kDa;  indicated  by  black  arrow).  This  anomaly  may  be  due  to  the  different 
processing  of  PRN  in  a  non  native  system  (E.  coli),  but  a  cross-reacting  band  at  a  similar 
size  was  also  seen  in  B.  pertussis  supernates,  although  at  a  lower  concentration  to  the  -69 
kDa  protein.  Thus,  PRN  appeared  to  be  processed  and  released  into  the  culture  supernate 
when  expressed  in  E.  coli. 
Fig.  3.24  shows  an  immunoblot  of  outer  membrane-enriched  fractions  of  different 
B.  pertussis  strains,  grown  under  the  same  conditions  and  to  the  same  cell  density  (OD600n,  " 
-1.2)  as  before.  A  mouse  monoclonal  anti-BrkA  C-terminal  antibody  (P28)  (Table  2.7) 
was  used  to  screen  these  preparations.  A  prominent  band  at  31  kDa  was  observed  from  the 
culture  supernatant  fractions  of  the  wild-type  strains  of  B.  pertussis  Taberman  I  (lane  A), 
Tohama  BP338  (lane  D)  and  BBC29  (lane  F).  Moreover,  the  bap-5  mutant  Taberman  11 
(lane  B)  and  priz  mutant,  BBC30  (lane  G)  have  also  reacted  with  the  monoclonal  anti-BrkA 
(C-terminus)  serum.  However,  no  band  was  seen  with  the  outer  membrane  enriched 
fraction  of  the  BrkA-deficient  mutant  BP2041  (lane  E)  and  with  the  Taberman  I  modulated 
strain  (lane  Q,  although  there  seems  to  be  some  carry-over  in  lane  C  from  the  adjacent 
lane.  However,  the  result  shows  that  BrkA  production  is  normal  in  the  Taberman  11,  bap-5 
mutant  and  in  the  BBC30,  pm  mutant  strains  of  B.  pertussis. 
140 Fig.  3.24:  Immunoblot  showing  various  B.  perlussis  strains  screened  with  anti-BrkA  (C. 
terminal)  serum  to  identify  BrkA  in  their  outer  membrane  preparations 
Bordetella  penussis  strains  were  grown  in  CL  medium  to  OD6wn.  -  1.0,  and  their 
outer  membrane  -enriched  fractions  were  prepared  as  described  in  section  2.10.1  and 
separated  on  12%  SDS-PAGE  and  transferred  onto  nitrocellulose  membrane  for 
immunoblotting  with  anti-BrkA-C-terminal  serum  (Table  2.7). 
I=  Protein  ladder 
A=B.  pertussis  Taberman  I 
B=B.  pertussis  Taberman  11,  bap-5  mutant 
C=B.  pertussis  Taberman  1,  modulated  by  growing  in  the  presence  of  40  mM 
MgS04. 
D=B.  pertussis  BP338 
E=B.  pertussis  BP2041,  brkA  mutant 
F=B.  pertussis  BBC29 
G=B.  pertussis  BBC30,  prn  mutant Habib  Bokhari 
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3.2.4.  Serum  killing  assays 
Results 
The  serum  killing  assays  (2.15.3)  were  carried  out  to  determine  whether  Bap-5,  due 
to  its  putative  structural  homology  (Fig.  1.3)  with  the  autotransporter  protein  BrkA  (serum 
resistance  factor),  could  also  confer  a  serum  resistance  phenotype  on  B.  pertussis.  All  the 
assays  were  performed  using  pooled  normal  human  serum  (section  2.19.3.1)  obtained  from 
volunteers  with  no  recent  history  of  pertussis.  The  incubation  time  for  the  assay  was 
determined  initially  by  doing  a  time-course  study  for  killing  of  B.  pertussis  BP338  and  its 
brkA  mutant  (BP2041)  as  well  as  B.  pertussis  Taberman  I  and  its  bap-5  mutant  Taberman 
II,  by  the  human  serum.  The  survival  was  calculated  from  the  number  of  survivors  from 
the  normal  human  serum  as  a  percentage  of  the  number  of  survivors  from  heat-inactivated 
serum.  The  heat  treatment  (56'C  for  30  min)  removes  the  inherent  complement  activity  of 
the  serum.  A  preliminary  comparison  of  the  number  of  survivors  from  a  PBS  control  and 
the  heat-inactivated  serum  showed  a  slight  but  non-significant  difference  over  the  90  min 
incubation  time  (Result  not  shown).  This  observation  suggested  that  any  decrease  in 
bacterial  counts  due  to  agglutination  by  any  antibodies  present  in  the  human  serum,  rather 
than  killing,  was  negligible.  A  time-course  experiment  indicated  that,  after  exposure  to 
10%  normal  human  serum  for  10  min,  -65%  of  B.  pertussis  Taberman  I  strain  survived 
compared  to  only  -40%  of  its  bap-5  mutant  Taberman  II  (Fig.  3.25).  The  result  also 
showed  that,  after  exposure  to  normal  serum  for  90  min,  the  Taberman  I  parent  was  still  a 
better  survivor  (-30%)  compared  to  its  bap-5  mutant  (<10%).  Strain  BP338  and  its  brkA 
mutant  BP2041  were  controls  in  this  experiment.  Strain  BP338,  after  exposure  to  normal 
human  serum  for  10  min  appeared  to  survive  better  (>80%)  compared  to  its  brkA  mutant 
(-55%).  This  difference  increased  slightly  with  time.  After  90  min,  about  50%  of  B. 
pertussis  BP338  survived  compared  to  10%  for  the  brkA  mutant  BP2041.  Thus,  these 
results  show  that  B.  pertussis  Taberman  I  strain  appeared  to  be  more  resistant  to  serum- 
142 Fig.  3.25:  Time  course  of  killing  of  B.  pertussis  strains  by  normal  human  serum 
(10%  V/V) 
The  results  are  the  means  of  three  separate  experiments  and  bars  indicate  die 
standard  deviations. 
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killing  compared  to  its  bap-5  mutant  Taberman  11  and  that  B.  pertussis  Tohama  derivative 
BP338  seemed  to  be  inherently  more  resistant  compared  to  the  B.  pertussis  Taberman  I 
parent  strain.  From  the  time  course  result,  an  incubation  time  of  45  min  was  selected  for 
the  further  serum  killing  assays  as  there  was  little  change  thereafter  in  the  number  of  CFU 
of  B.  pertussis  recovered  from  the  normal  serum. 
The  time  course  assay  was  repeated  several  times  using  different  additional 
parameters  to  investigate  the  mechanisms  whereby  Bap-5  could  confer  the  serum 
resistance  phenotype  on  B.  pertussis.  Previous  work  suggested  that  the  classical  (antibody- 
dependent)  pathway  of  complement  activation  is  responsible  for  killing  of  B.  pertussis 
(Barnes  and  Weiss,  1998).  To  block  the  classical  pathway,  the  pooled  normal  human 
serum  was  treated  with  EGTA-MgC12  (final  concentration  lOmM  of  each)  to  render  this 
pathway  inactive  by  chelating  calcium  ions  (W),  an  essential  component  of  this  pathway. 
Fig.  3.26  shows  the  result  taken  from  the  average  of  4  separate  experiments.  The  shaded 
bars  represent  the  survivors  in  the  normal  human  serum  after  exposure  for  45  min.  The 
results  presented  in  the  form  of  solid  bars  show  the  number  of  survivors  in  normal  human 
serum  in  the  presence  of  EGTA-MgC12  after  exposure  for  45  min.  The  result  shows  that  B. 
pertussis  Taberman  I  (lane  A,  shaded)  survives  better  than  its  bap-5  mutant,  (lane  B, 
shaded)  (*P<0.001)  in  agreement  with  the  results  presented  in  Fig.  3.25.  Similarly  the 
percentage  survival  after  exposure  to  normal  serum  for  45  min  of  strain  BP338  (lane  Q 
was  significantly  more  than  that  of  its  brk-A  mutant,  BP2041  (lane  D)(*P<  0.05).  A  slight 
discrepancy  was  seen  regarding  the  difference  in  percentage  survival  compared  to  previous 
result  (Fig.  3.25).  The  brkA  mutant  survived  better  here  than  the  bap-5  mutant  although 
the  reverse  was  the  case  in  Fig.  3.25.  Lanes  E  and  F  show  B.  Pertussis  BBC29  and  its  prn 
mutant,  BBC30.  The  prn  mutant,  BBC30  has  been  reported  to  be  slightly  more  serum- 
sensitive  compared  to  its  parent  (BBC29)  although,  the  effect  was  not  found  to  be 
144 Fig.  3.26:  Classical  pathway-mediated  serum  killing  of  B.  pertussis 
The  results  are  the  mean  values  and  standard  deviations  of  the  combined  results  of 
4  separate  experiments.  Shaded  bars  represent  the  percentage  of  survivors  in  10  %  normal 
human  serum  after  exposure  for  45  min.  Solid  bars  represent  the  percentage  of  survivors 
in  the  presence  of  EGTA-MgC12  in  the  normal  serum  after  exposure  for  45  min.  Student's 
t-test  was  used  to  compare  the  strains.  *P<0.05,  **P<0.0001. 
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D=  B.  pertussis  BP2041,  brkA  mutant 
E--  B.  pertussis  BBC29 
F=  B.  pertussis  BBC30  prn  mutant 
G=  B.  pertussis  Taberman  I,  modulated  by  adding  MgS04  to  the  growth  medium 
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statistically  significant  (Fernandez  and  Weiss,  1994).  This  study  supported  the  previous 
work  as  lanes  E  shows  that  BBC29  does  not  seem  to  be  significantly  different,  in  terms  of 
percentage  of  survival  in  normal  serum,  compared  with  its  prn  mutant  BBC30  (lane  F) 
(P>0.05).  Both  BBC29  and  BBC30  (PRN")  showed  a  similar  degree  of  resistance  to  serum 
killing  as  the  B.  pertussis  Taberman  I  (lane  A)  and  BP338  (lane  Q  strains. 
Lanes  G  and  H  show  the  B.  pertussis  Taberman  I  parent  and  its  derived  Taberman 
II  bap-5  mutant  grown  under  modulating  conditions  i.  e.  in  the  presence  of  40mm  M9SO4, 
(Bvg-  mode).  Most  of  the  known  virulence  determinants  of  B.  pertussis  are  known  to  be 
regulated  by  the  Bvg  system,  i.  e.  their  production  is  switched  off  when  B.  pertussis  is 
exposed  to  modulators  such  as  40mM  MgS04  in  this  study.  The  percentage  of  survival  of 
B.  pertussis  Taberman  I  strain  (lane  G),  grown  under  modulating  conditions,  was 
significantly  reduced  when  exposed  to  normal  human  serum  for  45  min  compared  to  that 
of  its  counterpart  grown  under  non-modulating  conditions  (lane  A)  strain  (*P<  0.05).  This 
was  also  true  for  the  Taberman  11,  bap-5  mutant  grown  under  modulating  conditions, 
although  the  difference  between  modulated  (lane  H)  and  non-modulated  (B)  bap-5  mutant 
strains  was  not  significant  (P>0.05). 
The  results  also  suggested  (solid  bars)  that  the  presence  of  the  EGTA-MgCl2  almost 
completely  inhibited  killing  by  the  human  serum  (survival  95%  to  99%)  except  in  the  case 
of  the  Taberman  II  bap-5  mutant  strain  (lane  B;  solid  bar;  80%)  and  the  strains  grown 
under  modulating  conditions  (lanes  G  and  H;  solid  bars;  80%).  Overall,  these  results 
showed  that,  in  addition  to  BrkA,  Bap-5  also  seems  to  play  a  role  in  conferring  serum 
resistance  on  B.  pertussis  against  the  classical  pathway-mediated  killing  of  complement.  It 
can  be  concluded  that  the  presence  of  both  BrkA  and  Bap-5  protect  B.  pertussis  against  the 
bactericidal  activity  of  serum. 
146 Habib  Bokhad  Results 
The  complement  proteins,  the  key  players  in  killing  B.  pertussis,  are  very  labile  and 
their  activity  can  be  affected  during  the  procedural  steps  involved  in  preparation  of  serum 
and  storage.  Thus,  it  was  possible  that  the  pooled  normal  human  serum  used  in  this  work 
had  sub-optimal  levels  of  complement.  An  experiment  was  devised,  therefore,  to  assess 
the  killing  ability  of  the  pooled  normal  human  serum  (same  lot  as  used  in  previous 
experiments)  that  had  been  de-complemented  by  heating  to  56T  for  30  min  and 
supplemented  with  a  commercially-prepared  source  of  complement  (guinea  pig  serum, 
Sigma).  The  heat-inactivated  human  serum  would  act  as  a  source  of  cross-reacting 
antibodies,  whereas  the  guinea  pig  serum,  which  was  presumably  free  of  anti-B.  pertussis 
antibodies,  would  provide  the  complement  activity.  The  experiment  (Fig.  3.27)  was 
performed  by  adding  the  source  of  complement  (5%  v/v  guinea  pig  serum)  to  the  10%  v/v 
heat-inactivated  human  serum  (section  2.15.3).  It  is  worth  mentioning  here  that  B. 
pertussis  Taberman  11,  bap-5  mutant  was  found  to  be  somewhat  sensitive  to  complement 
alone  compared  to  its  Taberman  I  parent  strain,  which  will  be  discussed  in  section  3.3.5. 
However,  the  brkA  mutant  BP2041  was  similar  to  parent  BP338  strain  in  its  sensitivity  to 
complement  alone.  A  significant  reduction  was  noticed  in  the  percentage  survival  of  the 
Taberman  II  bap-5  mutant  (lane  B)  compared  to  its  parent  B.  pertussis  Taberman  I  strain 
(lane  A)  (*P<0.05).  As  expected,  B.  pertussis  BP338  (lane  Q  was  found  to  be  more 
resistant  compared  to  its  brkA  mutant  strain  BP2041  (lane  D)  (*  P<0.05).  The  percentage 
survival  of  B.  pertussis  BBC29  (lane  E)  was  not  found  to  be  significantly  different  from  its 
prn  mutant  BBC30  (lane  F;  P>0.05).  The  difference  in  survival  between  the  non- 
modulated  (lane  A)  compared  to  that  of  its  modulated  Taberman  I  strain  counterpart  (lane 
G)  was  statistically  significant  (*P<0.05).  The  modulated  Taberman  II,  the  bap-5  mutant 
147 Fig.  3.27:  Effect  of  de-complemented,  normal  human  serum  and  added  complement  on  the 
killing  of  different  B.  pertussis  strains 
The  human  serum  (10%  v/v)  was  de-complemented  as  described  in  section  2.15.3.2 
and  a  commercially-prepared  source  of  complement  (guinea  pig  serum  5%  v/v)  was  added 
to  it.  The  results  show  the  percentage  survival  after  exposure  for  45  min  and  are  the  means 
and  standard  deviations  of  3  separate  experiments.  Student's  mest  was  used  to  compare 
the  strains.  *  P<0.05 
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F=  B.  pertussis  BBC30  prn  mutant 
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(lane  H)  was  also  highly  sensitive  to  serum  killing  in  this  assay  but  when  compared  to  its 
non-modulated  counterpart  (lane  B)  which  is  also  sensitive  to  serum  killing,  no  significant 
difference  was  noticed  (P>0.05). 
Thus  the  result  obtained  using  the  external  source  of  complement  to  supplement  the 
de-complemented  human  serum,  supported  the  findings  of  the  previous  experiment  (Fig. 
3.26).  It  can  also  be  concluded  that  the  complement  proteins  were  perhaps  fully  preserved 
in  the  original  human  serum  preparation,  but  this  procedure  eliminates  one  possible 
variable  in  the  serum  killing  assays. 
3.2.5  Bactericidal  effect  of  anti-rBap-5  antibody 
The  bactericidal  effect  of  a  rabbit  antiserum  raised  against  purified  recombinant 
Bap-5  (anti-,  13ap-5  antibody)  (section  2.15.3.3)  was  determined.  The  assay  was  carried  out 
using  5%  v/v  (final  concentration)  guinea  pig  serum  as  a  source  of  complement  and  filter 
sterilized,  anti-,  Bap-5  diluted  to  2%  v/v  (final  concentration)  (section  2.15.3.3).  A 
preliminary  assay  was  conducted  with  a  rabbit  polyclonal  anti-P.  69  serum  (Table  2.7) 
kindly  provided  by  Prof.  M.  Roberts,  Department  of  Veterinary  Pathology,  University  of 
Glasgow,  which  had  been  reported  to  be  bactericidal  for  B.  pertussis. 
The  percentage  of  survival  was  detern-dried  from  the  number  of  survivors  in  the 
test  serum  (anti-P.  69  serum  +  guinea  pig  serum)  compared  to  bacteria  treated  with  PBS 
alone  after  exposure  for  45  min.  Survival  was  also  determined  after  treatment  with  anti- 
P.  69  serum  and  de-complemented  guinea  pig  serum.  A  1%  v/v  final  concentration  of  anti- 
P.  69  serum  was  used,  as  higher  concentrations  of  the  antiserum  alone  caused  agglutination. 
In  fact,  this  1%  v/v  concentration  itself  slightly  reduced  the  bacterial  counts  (by  2-6%), 
compared  to  the  PBS  control  (result  not  shown).  The  antiserum.  was  de-complemented  by 
heat  treatment  at  56*C  for  30  min  before  use.  The  results  (Fig  3.28)  indicated  that  the  - 
149 Fig.  3.28:  Bactericidal  effect  of  anti-P.  69  antibody  on  different  A  pertussis  strains 
with  or  without  added  complement. 
The  anti-P.  69  serum  was  de-complemented  as  described  in  section  2.15.3.3  and  the 
effect  of  added  guinea  pig  serum  (5%  v/v),  as  a  source  of  complement,  was  seen.  The 
percentage  of  B.  pertussis  survivors  was  determined  after  exposure  for  45  min.  The  solid 
bars  show  the  percentage  of  survivors  in  anti-P.  69  +  de-complementcd  guinea  pig  serum. 
The  shaded  bars  show  the  percentage  of  survivors  in  anti-P.  69  +  guinea  pig  serum.  The 
results  are  the  means  and  standard  deviations  of  3  separate  experiments.  Student's  I-test 
was  used  to  compare  the  strains.  *P<0.05,  **P  <0.0001 
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anti-P.  69  serum  and  complement  had  a  bactericidal  effect  on  the  wild-type  A  pertussis 
strain  BBC29  (shaded  bar;  lane  Q  and  when  the  percentage  of  survivors  was  compared  to 
that  in  the  absence  of  active  complement  (de-complements  guinea  pig  serum;  solid  bar, 
lane  C),  a  significant  difference  was  observed  (*P<0.05)  as  expected.  However,  the  prn 
mutant  strain  BBC30,  treated  with  anti-P.  69  serum  and  complement  (lane  D;  shaded  bars) 
did  not  appear  to  be  killed  and  when  its  percentage  of  survival  was  compared  to  that  in  the 
absence  of  active  complement  (lane  D;  solid  bar)  the  difference  was  not  significant 
(,  P>0.05).  The  percentage  of  survival  of  A  pertussis  strain  Taberman  I  treated  with  anti- 
P.  69  serum  and  complement  (lane  A;  shaded  bar)  was  when  compared  to  that  in  the 
absence  of  active  complement  (lane  A;  solid  bar)  a  significant  difference  was  noticed 
(*P<0.05).  The  percentage  of  survival  of  B.  pertussis  Taberman  II,  bap-5  mutant  treated 
with  anti-P.  69  serum  and  complement  (lane  B;  shaded  bar)  also  showed  a  significant  drop 
compared  to  that  seen  in  the  absence  of  active  complement  (lane  B;  solid  bar)  (*P<0.05). 
Hence,  except  for  the  prn  mutant  all  other  strains  were  killed  to  a  significant  extent  when 
exposed  to  anti-P.  69  antiserum  and  normal  guinea  pig  serum. 
Fig.  3.29  shows  the  effect  of  guinea  pig  serum  (5%  v/v)  alone  as  a  source  of 
complement  on  the  B.  pertussis  wild-type  strains  and  their  mutants  deficient  in  one  or other 
Bvg-regulated  gene  products.  The  percentage  of  survival  was  deteniiined  from  the  number 
of  survivors  in  the  unheated  guinea  pig  serum  (normal  complement)  (shaded  bars)  and 
compared  with  the  number  of  survivors  in  the  heat-inactivated  guinea  pig  serum  (56'C  for 
30  min,  de-complement  source  of  complement)  (solid  bars).  The  results  suggests  that  the 
bap-5  mutant  (Taberman  11;  lane  B)  appears  to  be  more  sensitive  (<60  %  survival)  to 
complement  alone  compared  to  its  parent  Taberman  I  strain  (>90%  survival)  (lane 
A;  *P<0.05).  However,  with  R  pertussis  Taberman  1,  there  was  some  killing  by 
complement  alone,  but  the  viability  of  its  bap-5  mutant  strain  was  reduced  significantly 
151 Fig.  3.29:  Effect  of  unheated  or  &-complemented  guinea  pig  serum  on  the  viability 
of  B.  pertussis 
The  guinea  pig  serum  used  was  either  unheated  or  de-complemented  by  heat- 
treatment  at  56'C  for  30  min.  The  percentage  of  B.  pertussis  survivors  was  determined 
after  exposure  for  45  min.  The  shaded  bars  show  the  percentage  of  survivors  in  nonnal 
guinea  pig  serum.  The  solid  bars  show  the  percentage  of  survivors  in  de-complemented 
guinea  pig  serum.  The  results  are  the  means  and  standard  deviations  of  3  separate 
experiments.  Student's  t-test  was  used  to  compare  the  strains.  *P<0.05,  **P<0.0001 
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compared  to  its  heat-inactivated  complement  control  (lane  B;  solid  bar)  (*P<0.05). 
However,  the  percentage  of  survivors  of  B.  perlussis  BP338  (lane  C;  solid  bar)  and  its  brk,  4 
mutant  BP2041  (lane  D;  solid  bar)  in  heat-inactivated  guinea  pig  serum  was  not  different 
(P>0.05)  compared  to  the  survivors  in  normal  guinea  pig  serum  i.  e.  lane  C;  shaded  bar  and 
lane  D;  shaded  bar,  respectively.  Also,  some  killing  was  noticed  in  the  case  of  brk,  4 
mutant  in  normal  guinea  pig  serum  compared  to  the  de-complemented  serum  (lane  D).  A 
perlussis  BBC29  (lane  E)  and  its  prn  mutant  BBC30,  behaved  more  or  less  similarly  in 
terms  of  their  percentage  of  survival  (P>0.05)  like  BP338  and  BP2041  as  above.  Lane  G 
(shaded  bar)  shows  the  percentage  of  survivors  of  B.  pertussis  Taberman  1,  grown  under 
modulating  conditions  (Bvg-  mode),  in  normal  guinea  pig  serum  and  when  its  percentage 
of  survival  was  compared  to  its  non-modulated  counterpart  (lane  A,  shaded)  a  highly 
significant  difference  was  noticed  (**P<0.0001).  Lane  H  (shaded  bar)  shows  the 
percentage  of  survivors  of  A  perlussis  Taberman  11  bap-5  mutant  grown  under  modulating 
conditions  in  normal  guinea  pig  serum  and,  again  compared  to  its  non-modulated 
counterpart  (lane  B,  shaded  bar)  a  significant  difference  was  noticed  (**P<0.0001).  B. 
perlussis  Taberman  I  grown  under  modulating  conditions  was  killed  to  a  significant  extent 
(**  P  <0.0001)  in  normal  guinea-pig  serum  (lane  G;  shaded)  when  compared  to  its  killing 
by  heat-inactivated  complement  (lane  G;  solid).  A  similar  effect  was  noticed  with  the 
modulated  strain  of  B.  perlussis  Taberman  11,  bap-5  mutant  (lane  H). 
To  determine  the  percentage  of  complement-mediated  killing  and  in  order  to  check  the 
possibility  of  any  cross-reacting  antibody  in  the  source  of  complement,  which  could 
enhance  killing  of  the  B.  perlussis  by  the  classical  pathway  (antibody-dependent)  of 
complement  activation,  EGTA.  MgC]2,  an  inhibitor  of  this  pathway  was  included  in  the 
assay. 
Fig.  3.30  show  the  effect  of  guinea  pig  serum  in  the  presence  (solid  bars)  and 
153 Fig.  3.30:  Effect  of  complement  in  the  presence  and  absence  of  EGTA,  MgC12  on  B. 
pertussis 
The  effect  of  complement  (guinea  pig  serum  5%  v/v)  alone  was  observed  in  the 
presence  and  absence  of  EGTA-MgC12,  an  inhibitor  of  the  classical  pathway-mediated 
killing  of  B.  pertussis  as  described  in  section  2.15.3.3.  The  percentage  of  B.  pertussis 
survivors  was  determined  after  exposure  for  45  min.  The  shaded  bars  show  the  percentage 
of  survivors  in  guinea  pig  serum  in  the  absence  of  EGTA.  MgCl,.  The  solid  bars  show  the 
percentage  of  survivors  in  guinea  pig  serum  in  the  presence  of  EGTA.  MgCl,.  The  results 
are  the  means  and  standard  deviations  of  3  separate  experiments.  Student's  t-test,  was  used 
to  compare  the  strains.  *P<0.05,  **P<0.0001 
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absence  (shaded  bars)  of  EGTA-MgC12  (lOmM  final  concentration  of  each).  The  addition 
of  EGTA-MgC12  to  guinea  pig  serum  did  not  make  any  significant  difference  to  the 
percentage  of  survival  of  the  B.  pertussis  strains  i.  e.  Taberman  I  (A),  BP338  (C),  BP2041 
(D),  BBC29  (E)  and  BBC30  (F)  compared  to  their  survival  in  the  absence  of  EGTA,  MgC]2 
(P>0.05)  (shaded  bars).  It  appeared  that  B.  pertussis  strain  Taberman  11,  bap-5  mutant 
(lane  B,  solid  bar)  attained  better  percentage  of  survival  in  the  presence  of  EGTA-MgC12 
compared  to  that  in  the  absence  of  EGTA,  MgC12  (lane  B,  shaded  bar)  (*P<0.05). 
However,  the  addition  of  EGTA,  MgC12  to  guinea  pig  serum  did  not  appear  to  improve  the 
percentage  of  survival  (67.5%)  of  Taberman  11,  bap-5  mutant  to  the  extent  seen  in  its  heat- 
inactivated  complement  (95%)  as  described  in  Fig.  3.29  (lane  B,  solid  bar)  (*P<0.05). 
Lanes  G  and  H  (solid  bars)  show  the  percentage  of  survival  of  B.  pertussis  Taberman  I 
strain  and  its  Taberman  Il  bap-5  mutant  grown  under  modulating  conditions  in  the  guinea 
pig  serum  in  the  presence  of  EGTA-MgC12  and  when  compared  to  their  counterparts  in  the 
absence  of  EGTA-MgC12  (lanes  G  and  H;  shaded  bars)  a  significant  difference  was  noticed 
in  terms  of  their  percentage  of  survival  (**P<0.0001).  Thus  it  can  be  concluded  that  B. 
pertussis  Taberman  II,  the  bap-5  mutant  strain  is  sensitive  to  complement-mediated  killing 
even  in  the  absence  of  an  antibody  source. 
The  next  part  of  the  experiment  was  carried  out  to  determine  if  antibody  to  Bap-5 
could  potentiate  bacterial  killing  in  the  presence  of  guinea  pig  serum  as  a  source  of 
complement  and  also  to  see  the  effect  of  added  EGTA-MgC12  on  the  killing  ability  of  the 
test  serum  (anti-,  Bap-5  antibody  +  guinea  pig  serum).  The  B.  pertussis  strains  were 
exposed  to  guinea  pig  serum  (5%  v/v)  and  rabbit  anti-,  Bap-5  serum  (2%  v/v)  (Table  2.7) 
for  45  min.  Western  blotting  results  indicated  in  section  3.2.3.2  that  the  rabbit  anti-,  Bap-5 
antiserum  could  cross-react  with  perhaps  other  autotransporters  such  as  BrkA  (-73  kDa) 
protein.  To  minimise  any  effect  due  to  the  cross-reaction,  the  anti-rBap-5  serum  was 
155 Habib  Bokhari  Results 
absorbed  with  a  suspension  of  the  B.  pertussis  Taberman  11,  bap-5  mutant  (section 
2.15.3.3).  The  percentage  of  survival  was  determined  by  calculating  the  number  of  B. 
pertussis  survivors  in  absorbed  anti-,  Bap-5  serum  +  normal  guinea  pig  serum  and  the 
number  of  survivors  in  absorbed  anti-rBap-5  serum  +  normal  guinea  pig  serum  +  EGTA. 
MgCl2- 
Fig.  3.31  shows  the  percentage  of  survivors  of  B.  pertussis  in  absorbed  anti-,  Bap-5 
serum  +  normal  guinea  pig  serum  (shaded  bars)  and  in  absorbed  anti-,  Bap-5  serum  + 
normal  guinea  pig  serum  +  EGTA.  MgC12  (solid  bars).  Lane  A  shows  the  percentage  of 
survivors  of  B.  pertussis  Taberman  I  strain  in  the  absence  of  EGTA,  MgC12  (shaded  bar) 
and  when  compared  to  that  of  in  the  presence  of  EGTA-MgC12  (solid  bar),  a  significant 
difference  was  observed  (*P<0.05).  Lane  B  indicates  the  percentage  of  survivors  of  B. 
pertussis  Taberman  11,  the  bap-5  mutant  strain  in  the  absence  of  EGTA.  MgC,  2  (shaded 
bar)  and  when  compared  to  that  of  in  the  presence  of  EGTA.  MgC12  (solid  bar),  a 
significant  difference  was  seen  (*P<0.05).  The  percentage  of  survivors  of  the  bap-5 
mutant  in  the  presence  of  EGTA.  MgC12  (77%)  was  not  improved  to  the  extent  as  it  did  in 
the  case  of  B.  pertussis  Taberman  1  (93%).  Surprisingly,  the  bap-5  mutant  was  more 
sensitive  to  killing  by  the  anti-,  Bap-5  serum  and  complement  than  the  wild-type  Taberman 
strain  and  this  is  presumably  due  to  the  sensitive  nature  of  bap-5  mutant  to  complement 
activity  alone  as  seen  by  the  results  of  Fig.  3.29  (lane  B,  shaded  bar).  However,  there  is 
one  anomaly  compared  to  the  result  seen  in  Fig.  3.30  in  terms  of  the  difference  of 
percentage  of  survivors  (solid  bars)  of  B.  pertussis  Taberman  II,  bap-5  mutant  that  can  be 
due  to  the  tube  to  tube  variation  of  the  activity  of  source  of  complement  (guinea  pig  serum) 
used  in  these  experiments.  Lane  C  shows  the  percentage  of  survivors  of  B.  pertussis 
BP338  in  the  absence  of  EGTA,  MgC12  (shaded  bar)  and  in  the  presence  of  EGTA-MgC12 
156 Fig.  3.31:  Bactericidal  effect  of  the  anti-,,  Bap-5  serum  +  complement  on  different  B. 
pertussis  strains  in  the  presence  or  absence  of  EGTA-MgC12 
The  rabbit  anti-,  Bap-5  serum  was  de-complemented  and  absorbed  with  the  B. 
pertussis  Taberman  II,  the  bap5  mutant,  to  minimise  any  cross  reaction  with  other  closely- 
related  surface  antigens  as  described  in  section  2.15.3.3  and  the  effect  of  added  guinea  pig 
serum  (5%  v/v),  as  a  source  of  complement,  was  seen.  The  percentage  of  B.  pertussis 
survivors  was  determined  after  exposure  for  45  min.  The  results  are  tile  means  and 
standard  deviations  of  3  separate  experiments.  The  shaded  bars  show  the  percentage  of 
survivors  in  anti-,  Bap-5  +  guinea  pig  serum.  The  solid  bars  show  the  percentage  of 
survivors  in  anti-,  Bap-5  +  guinea  pig  serum  +  EGTA-MgC12-  Student's  t-test  was  used  to 
compare  the  strains.  *  P<0.05,  **P<0.0001 
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(solid  bar)  and  a  significant  difference  was  seen  (*P<  0.05).  Lane  D  shows  the  percentage 
of  survivors  of  the  corresponding  brkA  mutant,  BP2041  in  the  absence  (shaded  bar)  and 
presence  of  EGTA-MgC12  (solid  bar),  and  again  a  significant  difference  was  observed  (*P< 
0.05).  Similar  differences  were  seen  with  B.  pertussis  BBC29  (lane  E)  (*P  <0.05)  and  B. 
pertussis  BBC30  (lane  F)  the  corresponding  prn  mutant  (*P<  0.05).  A  similar  situation 
was  observed  when  B.  pertussis  Taberman  I  and  its  bap-5  mutant  strain  Taberman  11, 
grown  in  modulating  conditions,  were  treated  in  the  absence  of  EGTA-MgC12  (lanes  G  and 
H,  shaded  bars)  and  in  the  presence  of  EGTA.  MgC12  (lanes  G  and  H,  solid  bars)  and 
compared  (**P<  0.0001). 
These  results  have  clearly  suggested  that  antibody  to  Bap-5  can  potentiate  the 
bactericidal  effects  in  the  presence  of  added  source  of  complement.  The  results  also 
suggested  that  EGTA-MgC12  can  to  some  extent,  prevent  the  killing  of  B.  pertussis  by 
blocking  the  classical  pathway  of  complement-activation.  However,  the  percentage  of 
survival  of  B.  pertussis  Taberman  11,  the  bap-5  mutant,  did  not  appear  to  improve  to  the 
extent  as  shown  by  the  other  B.  pertussis  strains  in  the  presence  of  EGTA-MgC12  in 
complement-mediated  bacterial  killing  assays. 
3.2.6  Adhesion  studies 
The  term  adhesion  describes  the  relatively  stable  and  irreversible  association  of 
bacteria  to  a  surface.  The  interaction  usually  occurs  between  the  surface  proteins  of  the 
bacterium  and  carbohydrate-containing  molecules  of  the  eukaryotic  cell  membrane  or 
glycocalyx  in  a  ligand-receptor  fashion.  Adhesion  to  the  host  tissues  enables  B.  pertussis 
to  avoid  host  defence  mechanisms  such  as  removal  by  fluid  flow,  mucociliary  clearance 
and  other  physical  processes.  During  the  colonisation  of  the  respiratory  tract,  B.  pertussis 
can  adhere  specifically  to  ciliated  epithelium;  however,  it  has  also  been  observed  that  B. 
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pertussis  can  adhere  to,  invade  and  persist  within  human  macrophage  and  other  cell  types 
(Ewanowich  et  al.,  1989;  Masure,  1992;  Boschwitz  et  al.,  1997).  Adhesion  is  therefore  an 
essential  prerequisite  for  successful  bacterial  colonisation  of  the  host  and  hence  can  be 
regarded  as  a  virulence  attribute.  Among  the  members  of  the  autotransporter  family,  PRN 
is  a  well-studied,  major  adhesin  of  B.  pertussis.  A  prn  mutant  of  B.  pertussis  was  shown  to 
adhere  much  less  well  than  the  wild-type  parent  strain  to  Chinese  hamster  ovary  (CHO) 
cells  and  a  human  epithelial  laryngeal  (HeLa)  cell  line  (Roberts  et  al.,  1991;  Leininger  et 
al.,  1992).  A  brkA  mutant  of  B.  pertussis  has  also  been  reported  to  invade  and  adhere  less 
well  to  certain  cell  types  (e.  g.  HeLa  cells  and  human  lung  fibroblast  cell  line  MRC-5)  than 
its  wild-type  parent  strain  (Fernandez  and  Weiss,  1994). 
Due  to  some  structural  features  (amino  acid  motifs)  shared  by  Bap-5  protein,  with 
other  B.  pertussis  adhesins  e.  g.  the  RGD  integrin-binding  motif,  the  SGXG 
glycosaminoglycan-binding  motif,  it  was  of  interest  to  explore  a  potential  adhesive 
function  due  to  such  features  in  Bap-5.  Different  tissue  culture  cell  lines  (Table  2.8)  were 
used  to  assess  the  role  of  Bap-5  as  an  adhesin  in  vitro.  The  enzyme-linked  immunosorbent 
assay  (ELISA)  (section  2.15.4)  provides  an  easy  way  to  manipulate  many  samples  at  the 
same  time.  A  rabbit  anti-whole-cell  B.  pertussis  antibody  was  used  to  detect  the  adherent 
bacterium.  The  antibody  concentration  was  adjusted  by  measuring  the  antibody  titre  in 
preliminary  ELISA  experiments  (not  shown)  and  a1  in  10,000  dilution  was  selected  for 
the  ELISA-based  adhesion  assays.  Each  well  of  a  tissue  culture  plate  (Costar)  was 
inoculated  with  105  mammalian  target  cells  and  left  for  24-48  h  to  form  confluent 
monolayers.  About  107  CFU  of  B.  pertussis  were  added  to  each  well  (mammalian  cell  : 
bacterial  cells,  1:  100).  Some  of  the  wells  contained  mammalian  target  cells  only.  After 
the  ELISA  reaction,  the  absorbance  at  492  nm  was  the  measure  of  adhered  bacterial  cells 
(section  2.15.4). 
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Fig.  3.32  compares  the  adhesion  of  different  B.  pertussis  wild-type  strains  and  their 
mutants  to  HeLa  229  cells.  Lanes  A  and  B  show  the  result  with  B.  pertussis  strain, 
Taberman  I  and  Taberman  11,  its  derived  bap-5  mutant,  respectively.  The  bap-5  mutant 
strain  of  B.  pertussis  was  less  able  to  bind  to  this  cell  line  compared  to  its  parent, 
Taberman  I  strain  (*P  <  0.05).  On  the  other  hand,  lanes  C  and  D  showed  that  the  adhesion 
of  B.  pertussis  BP338  and  its  brkA  mutant  BP2041  to  HeLa  cells  were  not  significantly 
different  from  each  other  (P  >0.05).  B.  pertussis  BBC29  (lane  E)  was  slightly  better  in 
adhering  to  HeLa  cells  compared  to  its  prn  mutant  strain  BBC30  (lane  F)  but  no  significant 
difference  was  noted  (P>0.05).  Another  interesting  observation  was  noted  when  the  B. 
pertussis  Taberman  I  (lane  G)  and  Taberman  11,  the  bap-5  mutant  (lane  H)  were  incubated 
with  the  pre-absorbed  rabbit  anti-,  Bap-5  serum  (pre-absorption  was  carried  out  with  the 
cell  suspension  of  B.  pertussis  Taberman  II,  the  bap-5  mutant  strain  to  minimise  any 
possibility  of  cross-reaction  with  other  closely-related  surface  antigen  as  described  in 
section  2.15.3.3.  )  at  37'C  for  one  hour  prior  to  the  assay.  The  bacterial  cells  incubated 
with  the  absorbed  anti-rBap-5  serum  were  then  spun  down  and  re-suspended  in  PBS  to 
standardise  their  concentration.  Thereafter,  an  equal  number  of  bacterial  cells  i.  e.  _107  was 
added  to  the  wells  containing  the  mammalian  cells  in  a  96-well  microtitre  plate.  A 
comparison  of  Lane  G  (antibody-treated,  Taberman  1)  with  lane  A  (untreated,  Taberman  1) 
shows  that  anti-,  Bap-5  antibody  seems  to  interfere  with  the  adherence  process  of  B. 
pertussis  Taberman  I  strain  to  HeLa  cells  (**P<0.0001).  With  Taberman  11,  the  bap-5 
mutant  strain,  the  antibody  had  no  effect  on  adherence  as  shown  by  a  comparison  of  lane  H 
(antibody-treated)  and  lane  B  (non-treated)  (P>0.05).  Lane  I  shows  the  background  level 
of  absorbance  in  the  absence  of  bacteria  which  indicates  that  the  anti-whole-cell  B. 
pertussis  antiserum  and  the  anti-rabbit  IgG  HRPO-conjugate  were  adhering  to  the  plastic 
surface  or  to  the  target  cells  to  some  extent.  Bacterial  cells  alone  showed  a  high  level  of 
160 Fig.  3.32:  Adhesion  study  using  human  epithelial  laryngeal  cell  line  (HeLa-229) 
with  different  B.  pertussis  strains 
An  ELISA-based  method  was  used  to  determine  the  adhesion  ability  of  different  B. 
pertussis  strains  for  HeLa  229  cells.  HeLa  229  (-1  x  105)  cells  were  infected  with  _107 
CFU  of  B.  pertussis  at  37'C  for  2h.  The  adherence  of  bacteria  was  estimated  by  measuring 
the  absorbance  (492nm)  of  each  strain  after  adding  rabbit  anti  -whol  e-cel  I  B.  pertussis 
serum  followed  by  the  addition  of  anti-rabbit  IgG  HRPO  conjugate.  Each  absorbance 
value  shown  is  the  average  of  8  independent  values  and  bars  represent  the  standard 
deviations  for  each  group.  *P<0.05,  **P<0.0001 
A=  B.  pertussis  Taberman  I 
B=  B.  pertussis  Taberman  11,  bap-5  mutant 
C=  B.  pertussis  BP338 
D=  B.  pertussis  BP2041,  brM  mutant 
E=  B.  pertussis  BBC29 
F=  B.  pertussis  BBC30,  pnz  mutant 
G=  B.  pertussis  Taberman  I  pre-incubated  with  anti-,  Bap-5  antibody 
H=  B.  pertussis  Taberman  II  pre-incubated  with  anti-,  Bap-5  antibody 
I=  Background  absorbance  (antibodies  adhering  to  the  plastic  surface  or  target  cells  in 
the  absence  of  bacteria) 
Fig.  3.33:  Adhesion  study  using  a  human  lung  epithelial  cell  line  (A549)  with 
different  B.  pertussis  strains 
The  detailed  information  of  the  procedure  are  same  as  in  legend  of  Fig.  3.32. 
A=  B.  pertussis  Taberman  I 
B=  B.  pertussis  Taberman  II,  bap-5  mutant 
C=  B.  perlussis  BP338 
D=  B.  pertussis  BP2041,  brkA  mutant 
E--  B.  pertussis  Taberman  I  pre-incubated  with  anti-,  Bap-5  antibody 
F=  B.  pertussis  Taberman  Il  pre-incubated  with  anti-,  Bap-5  antibody 
G=  Background  absorbance  (as  described  above) Habib  Bokhari 
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background  absorbance  by  adhering  to  the  plastic  surface  (result  not  shown),  however  the 
mammalian  target  cells  were  used  only  when  they  covered  the  wells  almost  completely 
(>90%  confluence)  by  making  a  monolayer.  Hence,  the  preliminary  result  indicated  that 
Bap-5  does  seem  to  have  a  role  in  adherence  of  B.  pertussis  Taberman  I  to  HeLa  cells  and 
loss  of  Bap-5  reduced  adherence  (Taberman  11),  whereas  loss  of  PRN  and  BrkA  did  not 
have  much  effect.  However,  although  similar  results  were  obtained  in  three  repeat 
experiments,  they  should  perhaps  be  investigated  further  for  consistency. 
The  next  adhesion  studies  (Fig.  3.33)  were  carried  out  using  the  human  Caucasian 
lung  carcinoma  (epithelial)  cell  line  A549  (ECACC  No  86012804).  The  adherence  of  the 
B.  pertussis  strains  to  this  particular  cell  line  seems  to  be  less  efficient  compared  to  HeLa 
cells  as  the  absorbance  values  (measure  of  adherence)  obtained  by  the  ELISA  method  were 
generally  lower.  Lane  A  shows  B.  pertussis  Taberman  I  and  when,  compared  with 
Taberman  11,  the  bap-5  mutant  (lane  B),  no  significance  difference  in  their  absorbance 
values  was  noted  (P>0.05).  Lane  C  shows  B.  pertussis  BP338  and  lane  D  shows  its  brkA 
mutant  (BP2041)  and  again,  when  their  absorbance  values  were  compared,  no  signific.  ant 
difference  was  observed  (P>0.05).  In  a  separate  experiment,  B.  pertussis  BBC29  and  its 
prn  mutant  BBC30  gave  similar  absorbance  values  and  the  results  were  not  significantly 
different  (not  shown).  Treatment,  with  anti-,  Bap-5  serum,  of  B.  pertussis  Taberman  I 
(lane  E)  prior  to  the  assay  did  not  seem  to  inhibit  its  adherence  when  compared  to  its  non- 
treated  counterpart  (lane  A)  (P>0.05).  Likewise  treatment  with  anti-,  Bap-5  of  Taberman 
II,  the  bap-5  mutant  strain,  did  not  appear  to  inhibit  its  adherence  to  A549  cells  compared 
to  its  non-treated  counterpart  (lane  B)  (P>0.05).  Lane  G  shows  the  background  level  of 
absorbance.  In  conclusion,  none  of  the  parent  strains  showed  significantly  greater 
adherence  to  human  lung  carcinoma  epithelial  cell  line  A549  compared  to  their 
corresponding  mutant  strains. 
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The  next  result  (Fig.  3.34)  shows  the  adhesion  of  different  wild-type  B.  pertussis 
strains  and  their  respective  mutant  strains  to  the  human  epithelial  cell  line  (Hep-2).  B. 
pertussis  filamentous  haemagglutinin  and  fimbriae  have  been  reported  to  mediate 
adherence  to  these  cells  (section  1.8.1).  However  PRN  did  not  seem  to  be  involved  in 
adhesion  of  B.  pertussis  to  this  epithelial  cell  line  (Mahon  et  al.,  1999),  although  E.  coli 
expressing  recombinant  PRN  has  been  shown  to  adhere  better  than  the  E.  coli  host  alone 
(Everest  et  al.,  1996).  The  results  showed  that  B.  pertussis  Taberman  I  (lane  A),  seems  to 
be  better  in  adhering  to  Hep-2  cells  compared  to  Taberman  II,  the  bap-5  mutant  (lane  B) 
(*P<  0.0001)  and  compared  to  all  other  B.  pertussis  strains  included  in  the  study.  B. 
pertussis  BP338  (lane  Q  did  not  show  any  significant  difference  in  absorbance  value  to  its 
brkA  mutant  (lane  D)  (P>  0.05),  nor  was  there  any  differences  between  B.  pertussis 
BBC29  (lane  E)  and  its  prn  mutant  BBC30  (lane  F)  (P  >0.05).  Lane  G  shows  B.  pertussis 
Taberman  I  strain  treated  with  the  absorbed  anti-,  Bap-5  serum  prior  to  the  assay  and  this 
treatment  seems  to  inhibit  its  adherence  when  compared  with  its  non-treated  counterpart 
(lane  A)  as  shown  by  their  absorbance  values  (**  P  <0.0001).  Lane  H  shows  Taberman  II, 
the  bap-5  mutant  strain  treated  with  anti-,  Bap-5  serum  prior  to  the  assay  and,  when  its 
absorbance  value  is  compared  to  that  of  its  non-treated  counterpart  (lane  B),  no 
significance  difference  was  noted  (P>0.05).  Lane  I  shows  background  level  of  absorbance 
in  the  absence  of  bacteria.  Thus  it  appeared  from  these  results  that  Bap-5  protein  does 
seem  to  play  a  role  in  adherence  of  B.  pertussis  to  Hep-2  cells,  although  no  role  for  BrkA 
or  PRN  was  evident. 
Fig.  3.35  shows  the  adhesion  of  the  different  wild-type  B.  pertussis  strains  and 
mutants  to  the  human  colon  carcinoma  cell  line  (Caco-2).  Lanes  A  and  B  show  the  B. 
pertussis,  Taberman  I,  and  its  bap-5  mutant  whose  absorbance  values  were  not 
significantly  different  (P>0.05).  Lanes  C  and  D  show  B.  pertussis  BP338  and  its  brkA- 
163 Fig.  3.34:  Adhesion  study  using  human  epithelial  cell  line  (Hep-2)  with  different 
B.  pertussis  strains 
An  ELISA-based  method  (section  2.15.4)  was  used  to  detennine  the  adhesion 
ability  of  different  B.  pertussis  strains  for  Hep-2  cells.  Hep-2  (-I  X  105)  cells  were 
infected  with  -Mý  CFU  of  B.  pertussis  at  37'C  for  2h.  The  adherence  of  bacteria  was 
estimated  by  measuring  the  absorbance  (492nm)  of  each  strain  after  adding  rabbit  anti- 
whole-cell  B.  pertussis  serum  followed  by  the  addition  of  anti-rabbit  IgG  HRPO  conjugate. 
Each  absorbance  value  shown  is  the  average  of  8  independent  values  and  bars  represent  the 
standard  deviations  for  each  group.  *P<0.05,  **P<0.0001 
A=  B.  pertussis  Taberman  I 
B=  B.  pertussis  Taberman  II,  bap-5  mutant 
C=  B.  pertussis  BP338 
D=  B.  pertussis  BP2041,  brkA  mutant 
E--  B.  pertussis  BBC29 
F=  B.  pertussis  BBC30,  pnz  mutant 
G=  B.  pertussis  Taberman  I  pre-incubated  with  anti-,  Bap-5  antibody 
H=  B.  pertussis  Taberman  II  pre-incubated  with  anti-,  Bap-5  antibody 
I=  Background  absorbance  (antibodies  adhering  to  the  plastic  surface  or  target  cells  in 
the  absence  of  bacteria) 
Fig.  3.35:  Adhesion  study  using  human  colon  carcinoma  cell  line  (Caco-2)  with 
different  B.  pertussis  strains 
The  detailed  information  of  the  procedure  is  same  as  in  legend  of  Fig.  3.34. 
A=  B.  pertussis  Taberman  I 
B=  B.  pertussis  Taberman  11,  bap-5  mutant 
C=  B.  pertussis  BP338 
D=  B.  pertussis  BP2041,  brkA  mutant 
E--  B.  pertussis  BBC29 
F=  B.  pertussis  BBC30,  prn  mutant 
G=  Background  absorbance  (as  above) Habib  Bokhari 
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mutant  and  again,  when  their  absorbance  values  were  compared,  no  significant  difference 
was  seen  (P>0.05).  Lanes  E  and  F  show  B.  pertussis  BBC29  and  its  pm  mutant  BBC30 
and  again  the  comparison  of  their  absorbance  values  showed  no  significant  difference 
(P>0.05).  Lane  G  shows  background  level  of  absorbance  in  the  absence  of  bacterial  cells. 
None  of  the  B.  pertussis  strain  showed  any  strong  affinity  for  this  particular  cell  line  as 
indicated  by  the  uniformly  low  absorbance  values.  These  values  were  not  significantly 
different  from  the  background  absorbance  control  (lane  G)  as  measured  by  ELISA  method. 
This  presumably  reflects  the  non-respiratory  nature  of  the  cell  line  used  (Caco-2)  for  the 
adhesion  study. 
Fig.  3.36  describes  the  adhesion  of  different  wild-type  B.  pertussis  strains  and  their 
mutants  to  the  murine  macrophage  cell  line  P338D-1  (Table  2.8).  The  results  show  that  B. 
pertussis  Taberman  I  (lane  A)  is  better  in  adhering  to  this  cell  line  compared  to  the 
Taberman  II,  the  bap-5  mutant  (lane  B)  as  evident  from  their  absorbance  values  (*P<0.05). 
On  the  other  hand,  a  comparison  of  B.  pertussis  Taberman  I  treated  with  anti-rBap-5  serum 
(lane  Q,  and  its  non-treated  counterpart  (lane  A),  did  not  show  any  significant  inhibition  of 
adhesion  (P>0.05).  This  anomaly  is  hard  to  explain  and  needs  to  be  repeated  before 
drawing  any  definitive  conclusion.  The  comparison  between  the  Taberman  II,  bap-5 
mutant  strain  (lane  B)  and  its  counterpart  treated  with  anti-,  Bap-5  serum  (lane  D)  showed 
no  significance  difference  in  adherence  to  P338D-1  cells  (P>0.05).  In  a  separate 
experiment  the  B.  pertussis  Taberman  I  strain  grown  under  modulating  conditions  (40MM 
MgS04)  seemed  to  be  defective  in  its  binding  capability  compared  to  its  non-modulated 
counter-part  (results  not  shown).  Lane  E  shows  the  background  level  of  absorbance  in  the 
absence  of  bacteria.  The  results  suggest  that  the  loss  of  Bap-5  can  reduce  the  adherence  of 
B.  pertussis  Taberman  II  to  murine  macrophages  P33813-1  compared  to  wild-type  parent 
strain,  although  the  reason  for  the  lack  of  inhibition  of  adherence  where  bacteria  were 
165 Fig.  3.36:  Adhesion  study  using  murine  macrophage  cell  line  11338D-1  with  different 
B.  pertussis  strains. 
An  ELISA-based  method  (2.15.4)  was  used  to  determine  the  adhesion  ability  of 
different  B.  pertussis  strains  for  P338D-Icells.  P338D-I  (-I  x  105)  cells  were  infected 
with  _107  CFU  of  B.  pertussis  at  37'C  for  2h.  The  other  details  are  the  same  as  described 
in  the  legend  of  the  previous  Fig 3.34.  *P<0.05 
A=  B.  pertussis  Taberman  I 
B=  B.  pertussis  Taberman  11,  bap-5  mutant 
C=  B.  pertussis  Tabennan  I  pre-incubated  with  anti-,  Bap-5  antibody 
D=  B.  pertussis  Taberman  II  pre-incubated  with  anti-fBap-5  antibody 
E=  Background  absorbance  (antibodies  adhering  to  the  plastic  surface  or  target  cells  in 
the  absence  of  bacteria) 
Fig.  3.37:  Adhesion  study  using  murine  macrophage  cell  line  (RAW  264.7)  with 
different  B.  pertussis  strains. 
The  detailed  information  of  the  procedure  is  same  as  in  legend  of  Fig.  3.34. 
*P<0.05 
A=  B.  pertussis  Taberman  I 
B=  B.  pertussis  Taberman  II,  bap-5  mutant 
C=  B.  pertussis  Taberman  I  pre-incubated  with  anti-,  Bap-5  antibody 
D=  B.  pertussis  Taberman  II  pre-incubated  with  anti-,  Bap-5  antibody 
E=  Background  absorbance  (antibodies  adhering  to  the  plastic  surface  or  target  cells  in 
the  absence  of  bacteria) Habib  Bokhari 
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pre-treated  with  anti-,  Bap-5  is  unclear. 
Results 
Fig.  3.37  shows  the  adhesion  of  different  wild-type  B.  pertussis  strains  and  their 
mutants  to  the  murine  macrophage  cell  line  RAW  264.7.  The  data  indicate  that  B. 
pertussis  Taberman  I  (lane  A)  does  not  seem  to  be  different  in  its  binding  affinity  for  RAW 
cells  compared  to  its  bap-5  mutant  (lane  B)  (P>0.05).  However,  this  time the  Taberman  I 
strain  treated  with  anti-,  Bap-5  serum  (lane  Q  did  show  a  small  but  significant  reduction 
(*P<0.05)  in  its  binding  affinity  compared  to  its  non-treated  counterpart  strain  (lane  A). 
When  B.  pertussis  Taberman  II,  the  bap-5  mutant,  treated  with  anti-rBap-5  serum  (lane  D) 
prior  to  assay,  was  compared  with  its  non-treated  counterpart  (lane  B),  no  significant 
difference  was  observed  in  their  adherence  to  RAW  264.7  cells  (P>0.05).  Lane  E  shows 
background  level  of  absorbance  in  the  absence  of  bacteria.  Thus,  as  with  P338D-1  cells, 
the  results  are  somewhat  contradictory.  In  this  case  the  adherence  of  B.  pertussis 
Taberman  I  (lane  A)  strain  was  not  effected  by  the  bap-5  mutation  but  it  was  inhibited  by 
the  anti-,  Bap-5  serum  treatment  (lane  Q.  Antibody  treatment  did  not  alter  the  adherence 
of  Taberman  II,  the  bap-5  mutant  (lane  D)  compared  to  its  non-treated  counterpart  (lane 
B).  It  can  be  concluded  that  lack  of  Bap-5  or  use  of  anti-,  Bap-5  serum  has  little  effect  on 
adherence  of  B.  pertussis  to  the  macrophage  cell  lines  investigated  in  this  study. 
During  the  adhesion  study  a  constant  bacterial  cell  density  was  used  against  various 
tissue  culture  cell  lines  and,  due  to  time  constraints  different  multiplicity  of  infections 
(MOI)  were  not  tried  to  see  if  the  results  were  reproducible. 
3.3  Mouse  virulence  test 
Several  members  of  the  B.  pertussis  autotransporter  family  are  known  to  play  an 
important  role  in  the  pathogenesis  of  pertussis.  In  brief,  the  interaction  of  B.  pertussis  with 
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ciliated  epithelial  cells  of  the  respiratory  tract  is  thought  to  be  mediated,  at  least  in  part  by 
the  autotransporter  adhesins  PRN,  BrkA  and  TCF.  The  newly-identified  B.  pertussis 
autotransporter  Bap-5  shares  some  common  features  with  these  well-characterised 
autotransporter  proteins.  Therefore,  one  of  the  aspects  examined  in  a  search  for  a  role  for 
Bap-5  was  to  determine  its  virulence  potential  in  a  mouse  model  of  B.  pertussis  infection 
(section  2.13.2). 
Randomised  groups  of  5  mice  were  inoculated  intransally  with  approximately 
IX105  (in  experiment  1)  and  IX106  (in  experiment  2)  colony  forming  units  /mouse.  The 
mice  were  sacrificed  on  day  7  and  their  tracheas  and  lungs  were  removed  aseptically  and 
nasal  washes  were  also  collected,  to  study  the  colonisation  of  B.  pertussis  at  different  sites 
in  the  mouse  respiratory  tract.  The  virulence  of  B.  pertussis  Taberman  I  strain  was 
compared  with  Taberman  II,  the  bap-5  mutant  strain.  The  standard  mouse  virulent  strain 
18-323  was  used  as  a  positive  control  (in  experiment  1).  In  the  experiment  2,  B.  pertussis 
BBC29  and  its  pni  mutant  BBC30  were  included.  The  raw  viable  count  data  are  given  in 
appendices  IV,  V  and  VI.  The  number  of  colony  forming  units  (CFU)  of  B.  pertussis 
strains  recovered  from  the  lungs  of  different  mouse  groups  in  these  two  separate 
experiments  is  presented  in  Figs.  3.38a  and  3.38b.  The  recovered  lung  count  for  the  B. 
pertussis  18-323  group  (mean  log  count=  6.893  CFU/Iung)  was  significantly  higher  than 
for  B.  pertussis  Taberman  I  strain  (mean  log  count=  5.741  CFU/Iung)  (**P<0.0001). 
However,  this  latter  strain  colonised  the  lungs  to  a  greater  extent  than  its  bap-5  mutant 
(mean  log  count=  4.979  CFU/Iung)  (*  P<0.05).  The  higher  colonisation  ability  of  18-323 
reflects  the  fact  that  18-323  is  a  standard  mouse-virulent  B.  pertussis  strain  used  for 
vaccine  tests  and  this  particular  batch  of  the  challenge  strain  had  previously  been  passaged 
through  the  mouse  (R.  Parton,  personal  communication). 
168 Fig.  3.38a:  Mouse  virulence  data  showing  numbers  of  B.  pertussis  wild  type  and 
mutant  strains  recovered  from  the  mouse  lungs  after  intranasal  challenge 
Mice  (CD1  strain,  female  -3  weeks  of  age)  in  groups  of  rive  were  challenged 
intranasally  either  with  B.  pertussis  18-323,  B.  pertussis  Taberman  I  or  its  bap-5  mutant 
Taberman  11  strain  (-1  x  105  CFU/  mouse),  under  mild  halothane  anaestliesia  (section 
2.13.2).  On  day  7  after  challenge,  mice  were  killed  with  an  overdose  Of  C02  and  the  lungs 
were  removed  aseptically  and  viable  count  data  were  obtained  by  plating  different  dilutions 
of  the  lung  homogenate  on  the  BG-agar  plates.  I'lie  data  presented  are  the  means  and 
standard  deviations  of  the  Loglo  CFU/lung.  Raw  data  of  lung  counts  from  individual  mice 
are  presented  in  appendix  IV.  Student's  r-test  was  applied  to  compare  the  groups. 
*P<0.05,  **P<0.0001 
Fig.  3.38b:  Mouse  virulence  data  showing  number  of  B.  perfussis  wild  type  and 
mutant  strains  recovered  from  the  mouse  lungs  after  intranasal  challenge 
Mice  (CDI  strain,  female  -3  weeks  of  age)  in  groups  of  five  were  challenged 
intranasally  either  with  B.  pertussis  BBC29,  BBC30  (prn  mutant),  B.  pertussis  Taberman 
or  Taberman  II  (bap-5  mutant)  strain  (-I  X  106  CFU1  mouse)  and  lung  count  data  were 
obtained  as  described  above. Ilabib  Bokhari 
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The  results  obtained  in  the  second  experiment  (experiment  2),  (Fig.  3.38b)  showed 
that  strain  BBC29  was  better  able  to  colonise  the  lungs  (mean  log  count=  6.414  CFU/Iung) 
compared  to  its  priz  mutant  BBC30  strain  (mean  log  count=  5.991  CFU/lung)  (*  P<  0.05). 
Also,  B.  pertussis  Taberman  I  strain,  as  in  the  previous  experiment,  was  able  to  colonise 
lungs  more  efficiently  (mean  log  count=  5.703  CFU/Iung)  compared  to  Taberman  II,  the 
bap-5  mutant  strain  (mean  log  count=  4.940  CFU/Iung)  (*P<  0.05).  These  finding  suggest 
that  Bap-5,  like  PRN  (Roberts  et  al.,  1991)  may  have  a  role  in  colonisation  of  the 
respiratory  tract  of  the  mouse  by  B.  pertussis. 
Figs  3.39a  and  3.39b  indicate  the  number  of  B.  pertussis  recovered  from  the 
tracheas  of  the  mice  on  day  7  after  being  inoculated  with  different  B.  pertussis  strains.  In 
Fig  3.39  (Expt.  1)  the  tracheal  counts  for  B.  pertussis  Taberman  11,  the  bap-5  mutant  and 
its  wild-type  parent  Taberman  I  are  shown.  The  data  indicated  that  the  Taberman  I  parent 
strain  was  far  better  in  colonising  the  mouse  trachea  (mean  log  count=  3.137  CFU/trachea) 
than  its  bap-5  mutant  Taberman  11  strain  (mean  log  count=1.449  CFU/trachea)  (*P=0.05). 
In  a  second  experiment,  as  shown  in  Fig.  3-39b,  B.  pertussis  BBC29  and  its  pm 
mutant,  BBC30,  strains  were  included.  BBC29  (mean  log  count  =4.918  CFU/trachea)  was 
found  to  be  better  able  to  colonise  the  mouse-trachea  compared  to  its  PRN  mutant  strain, 
BBC  30  (mean  log  count=  4.394  CFU/trachea)  (*P<0.05).  Again,  B.  pertussis  Taberman  I 
(mean  log  count=  3.404  CFU/trachea)  proved  to  be  better  able  to  colonise  mouse  trachea 
compared  to  its  bap-5  mutant  strain,  Taberman  11  (mean  log  count=  2.495  CFU/trachea) 
(*P<0.05).  These  results  suggest  that  Bap-5,  like  PRN,  seems  to  be  involved  in 
establishing  colonisation  of  the  mouse  trachea. 
170 Fig.  3.39a:  Mouse  virulence  data  showing  number  of  B.  pertussis  wild  type  and 
mutant  strains  recovered  from  the  mouse  tracheas  after  intranasal  challenge 
Mice  (CD1  strain,  female  -3  weeks  of  age)  in  groups  of  five  were  challenged 
intranasally  either  with  B.  perlussis  18-323,  B.  pertussis  Taberman  I  or  its  bap-5  mutant 
Taberman  II  strain  (-I  x  105  CFU/  mouse),  under  mild  halothane  anaesthesia  (section 
2-13.2).  On  day  7  after  challenge,  mice  were  killed  with  an  overdose  Of  C02  and  the 
tracheas  were  removed  aseptically  and  viable  count  data  were  obtained  by  plating  different 
dilutions  of  the  tracheal  homogenate  on  the  BG-agar  plates.  The  data  presented  are  the 
means  and  standard  deviations  of  the  Loglo  CFU/trachea.  Raw  data  of  tracheal  counts 
from  individual  mice  are  presented  in  appendix  V.  Student's  t-test  was  applied  to  compare 
the  groups.  *P<0.05,  **P=0.0001 
Fig.  3.39b:  Mouse  virulence  data  showing  number  of  B.  pertussis  wild  type  and 
mutant  strains  recovered  from  the  mouse  tracheas  after  intranasal  challenge 
Mice  (CDI  strain,  female  -3  weeks  of  age)  in  groups  of  five  were  challenged 
intranasally  either  with  B.  pertussis  BBC29,  BBC30  (pni  mutant),  B.  pertussis  Taberman  I 
or  Tabennan  11  (bap-5  mutant)  strain  (-I  x  106  CFU/  mouse)  and  tracheal  count  data  were 
obtained  as  described  above.  Other  details  are  same  as  above.  *P<0.05. Habib  Bokhari 
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Fig.  3.40  shows  the  number  of  organism  recovered  on  day  7  from  the  nasal  cavities 
of  the  mice  inoculated  intranasally  with  B.  pertussis  Taberman  I  and  its  bap-5  mutant 
strain.  The  result  suggested  that  Taberman  I  (mean  log  count=  1.920  CFU/nasal  wash)  and 
its  bap-5  mutant  strain,  Taberman  11  (mean  log  count=  1.926  CFU/nasal  wash)  were  not 
significantly  different  from  each  other  in  colonising  the  mouse  nasal  cavity  (P>0.05). 
172 Fig.  3.40:  Mouse  virulence  data  showing  number  of  A  pertussis  wild  type  and 
mutant  strains  recovered  from  the  mouse  nasal  washes  after  intranasal 
challenge 
Mice  (CDI  strain,  female  -3  weeks  of  age)  in  groups  of  five  were  challenged 
intranasally  either  with  B.  pertussis  18-323,  B.  pertussis  Taberman  I  or  its  bap-5  mutant 
Taberman  11  strain  (-I  x  105  CFU/  mouse),  under  mild  halothane  anaestliesia  (section 
2.13.2).  On  day  7  after  challenge,  mice  were  killed  with  an  overdose  of  C02and  the  nasal 
washes  were  collected  (in  I  ml  volume  of  casamino  acids)  aseptically  and  viable  count 
data  were  obtained  by  plating  neat  and  dilutions  of  the  nasal  washes  on  BG-agar  plates. 
The  data  presented  are  the  means  and  standard  deviations  of  the  Loglo  CFU/nasal  wash. 
Raw  data  of  nasal  wash  counts  from  individual  mice  are  presented  in  appendix  VL 
Student's  t-test  was  applied  to  compare  the  groups. Habib  Bokhari 
3 
2.5 
Z, 
C 
C, 
C 
0, 
￿3 
=1 
0 
-I 
0.5 
Strains 
Results 
173 
Tabormsn  I  Taborman  11,  bap-5  mutant Habib  Bokhari  Results 
3.4  Mouse  protection  test  using  re-natured  P.  30,  the  C-terminal  domain  of 
pertactin 
In  a  previous  mouse  protection  study  by  Blackburn  (2000),  mice  were  vaccinated 
twice  (subcutaneously,  at  a  three  week  interval)  with  10  pg  of  P.  30  /injection.  Two  weeks 
after  the  2  nd  injection  they  were  given  an  intranasal  challenge  with  a  sub-lethal  dose 
(-IxIO5  CFU/mouse)  of  B.  perlussis  18-323.  No  protection  against  respiratory  tract 
colonisation  by  B.  pertussis  was  seen  compared  to  the  control,  non-vaccinated  animals 
(Blackburn,  2000).  The  lack  of  protection  may  have  been  due  to  the  use  of  the  P.  30 
fragment  in  a  denatured  state.  As  a  preliminary  to  determine  any  protective  effect  using 
recombinant  Bap-5  or  its  component  N-terminal  or  C-terminal  domains  as  vaccine 
antigens,  an  experiment  was  done  to  investigate  the  protective  ability  of  a  re-natured 
preparation  of  the  C-terminal  30  kDa  moiety  of  PRN  (P.  30)  kindly  provided  by  the  group 
of  Prof.  Neil  Isaacs,  Dept  of  Chemistry,  University  of  Glasgow.  The  recombinant  P.  30 
cloned  in  pQE60,  (Blackburn,  2000),  was  expressed  in  E.  coli  strain  M  15).  A  urea-soluble 
fraction  from  the  resultant  inclusion  bodies  (section,  2.10.3),  was  obtained  which  was 
highly  enriched  with  P.  30.  The  re-natured  preparation  of  P.  30  were  prepared  by  diluting 
the  urea-solubilised  P.  30  with  refolding  buffer  (Personal  communication). 
A  preparation  of  native  purified  PRN  (P.  69)  (kindly  provided  by  Prof  M.  Roberts)  (section 
2.13.1)  being  a  known  protective  antigen  in  mice  against  respiratory  tract  colonisation, 
acted  as  a  positive  control.  Alhydrogel  alone  (diluent)  was  included  as  a  negative  control. 
The  same  route(s)  of  injection,  timing  and  challenge  dose  of  the  antigens  were  used  as  in 
the  experiment  by  Blackburn  (2000).  Mouse  lungs  and  tracheas  were  removed  and  nasal 
washes  collected  on  post  challenge  days  0,3,9  and  14.  Viable  counts  from  individual 
mice  were  obtained  and  the  raw  data  of  the  experiment  are  given  in  appendices  VII,  VIII 
and  IX  and  are  surnmarised  in  appendix  X. 
174 Habib  Bokhari  Results 
Fig.  3.41  shows  the  number  of  colony  forming  units  (CFU)  of  B.  pertussis 
recovered  from  the  nasal  cavities  of  n-ke  in  the  different  groups  at  intervals  after  challenge 
with  B.  pertussis  18-323.  At  day  0,  i.  e.  immediately  after  the  challenge,  approximately 
2.32  CFU/nasal  cavity  (mean  log.  count)  of  B.  pertussis  could  be  recovered.  However,  by 
day  3,  the  mouse  group  immunised  with  P.  69  showed  some  protection  (mean  log  count= 
1.345)  against  colonisation  compared  to  the  sham  group  (mean  log  count=  2.932) 
(*P<0.05).  The  group  vaccinated  with  P.  30  also  showed  a  lower  count  than  the  sham 
group  but  the  difference  was  not  significant  (P>0.5).  The  counts  for  all  groups  had 
increased  by  day  9  and  had  declined  by  day  14.  Although  the  counts  for  the  P.  30  group 
and  especially  the  P.  69  group  were  lower  than  those  of  the  sham  group  on  these  days,  no 
significant  difference  was  observed  (P>0.05).  The  results  also  indicated  that  the  mice 
treated  with  P.  30  appeared  to  show  no  significant  protection  against  nasal  colonisation 
compared  to  the  sham  group  (P>0.05)  throughout  the  experiment,  whereas  P.  69  gave  some 
protection  at  day  3. 
Fig.  3.42  shows  that  P.  69  appeared  to  provide  strong  protection  against  tracheal 
colonisation  in  mice  compared  to  the  sham  group  and  the  protection  was  evident 
throughout  the  duration  of  the  experiment  (*P<0.05).  There  was  little  difference  in  B. 
pertussis  colonisation  of  the  trachea  in  the  P.  30  and  sham  group  (P>0.05),  where  the 
infection  reached  a  peak  at  day  9  and  then  showed  some  clearance  by  day  14,  as  was  seen 
in  the  nasal  cavity  (Fig.  3.41). 
175 Fig.  3.41:  Mouse  protection  data  showing  the  CFU  recovered  from  the  nasal  cavities 
of  the  mice  after  intranasal  challenge  with  A  pertussis  18-323. 
Mice  vaccinated  twice  subcutaneously  with  P.  69,  re-natured  P.  30  or  with  the 
diluent  (a1hydrogel)  only  were  challenged  intranasally  with  a  sub-lethal  dose  of  the 
standard  mouse-virulent  A  pertussis  strain  18-323  (-ixiol  cr.  U/mouse)  and  then 
sacrificed  at  intervals.  One-way  analysis  of  variance  (ANOVA)  test  was  applied  to 
determine  the  statistical  difference  between  the  groups.  The  P  value  <0.0001  is  considered 
extremely  significant  whereas  the  P  value  <0.05,  is  significant.  Each  point  represents  the 
mean  of  the  Loglo  CFU  recovered  from  the  nasal  cavities  of  four  individual  mice  and  the 
error  bars  the  S.  E.  M.  Raw  data  of  nasal  wash  counts  from  individual  mice  are  given  in 
appendix  VIL 
Fig.  3.42:  Mouse  protection  data  showing  the  CFU  recovered  from  the  tracheas  of  the 
mice  after  intranasal  challenge  with  A  pertussis  18-323 
Each  point  represents  the  mean  of  the  Loglo  CFU  recovered  from  the  tracheas  of 
four  individual  mice  and  the  error  bars  the  S.  E.  M.  Other  details  are  same  as  described  in 
the  legend  to  Fig.  3.41.  Raw  data  of  tracheal  counts  from  individual  mice  are  given  in 
appendix  VIII. Habib  Rokhari  Results 
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Fig.  3.43  shows  the  lung  counts  obtained  from  the  different  groups  of  mice  during 
the  course  of  experiment.  It  is  apparent  that  immunisation  with  P.  69  provided  clear 
protection  against  colonisation  of  the  lungs,  as  of  the  trachea.  This  protection  is  evident 
from  the  results  obtained  on  day  3  and  continues  to  day  14.  In  contrast,  the  P.  30  group 
does  not  seem  to  show  any  protective  effect  against  the  natural  course  of  the  B.  pertussis 
infection  at  any  stage  during  the  experiment  and  the  lung  counts  closely  paralleled  those  in 
the  sham  group,  with  the  infection  again  reaching  a  peak  around  day  9  and  thereafter 
beginning  to  decline.  The  data  suggested  that  re-natured  P.  30  did  not  appear  to  provide 
protection  under  the  conditions  used. 
177 Fig.  3.43:  Mouse  protection  data  showing  the  CFU  recovered  from  the  lungs  of  the 
mice  after  intranasal  challenge  with  A  pertussis  18-323 
Each  point  represents  the  mean  of  the  Logio  CFU  recovered  from  the  lungs  of  four 
individual  mice  and  the  error  bars  the  S.  E.  M.  Other  details  are  same  as  described  in  the 
legend  to  Fig.  3.41.  Raw  data  of  nasal  wash  counts  from  individual  mice  are  given  in 
appendix  IX. "abib  Rokhari 
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3.5  Secretion  mechanism  of  a  Bordetellapertussis  autotransporter 
protein  in  protease-deficient  strains  of  E.  coli 
Many  of  the  virulence  determinants  of  B.  pertussis  are  proteinacious  in  nature  and 
are  usually  either  exported  to  the  bacterial  cell  surface  or  secreted  into  the  external 
environment.  Bap-5,  being  the  newest  member  of  the  autotransporter  family,  is  the  least 
understood  as  far  as  its  processing  is  concerned.  There  seems  to  be  no  typical  signal 
sequence  identified  in  the  amino  acid  sequence  of  Bap-5  protein.  The  bap-5  gene  cloned 
in  the  high  copy  number  expression  vector  (pQE60)  was  not  considered  as  a  suitable 
system  for  a  processing  study.  There  was  the  possibility  of  blocking  the  secretion 
apparatus  of  the  host  organism  due  to  the  over  expression  of  Bap-5  in  the  high  copy 
number  expression  plasmid,  which  could  cause  lethality  for  the  host  strain.  Due  to  time 
constraints,  creation  of  a  suitable  Bap-5  expression  system  to  study  its  processing  and 
secretion  mechanism  was  not  attempted.  However,  a  study  was  performed  on  another  B. 
pertussis  autotransporter  protein,  PRN  (section  1.8.1).  This  particular  protein  was  selected 
as  the  pni  gene  (2770  bp)  was  available  in  a  form,  ready  to  use,  cloned  into  a  broad  host 
range,  medium  copy  number  vector  (7.9  Kb  plasmid  pMMB66EH)  kindly  provided  by 
Prof.  M.  Roberts,  Department  of  Veterinary  Pathology,  University  of  Glasgow.  As  with 
Bap-5,  the  mechanism  of  processing  of  the  precursor  PRN  (P.  93)  to  mature  PRN  (P.  69),  is 
not  clear.  Tile  release  of  passenger  domain  from  the  pro-protein  may  occur  either  by  auto- 
proteolytic  cleavage  as  in  the  case  of  the  IgA  protease  of  Neisseria  gonorrhoeae,  or  by  the 
help  of  some  of  the  outer  membrane-localised  proteases  e.  g.  serine  protease  (OmpT) 
(Table  2.2). 
A  set  of  protease-deficient  E.  coli  strains  (Table  2.2)  was  kindly  provided  by  Prof. 
G.  Georgiou,  Department  of  Chemical  Engineering,  University  of  Austin,  U.  S.  A.  As  these 
strains  were  isogenic,  any  differences  in  the  protein  profiles  of  the  various  cell  fractions  of 
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the  E.  coli  expressing  pni  should  correlate  with  the  presence  or  absence  of  particular 
protease  and  hence  the  accumulation  of  the  different  forms  of  PRN  (processed  or 
unprocessed,  secreted  or  non  secreted).  Thus  by  comparing  the  protein  profiles  in  different 
compartments  of  the  cell  it  may  be  possible  to  determine  the  cell  envelope  proteases  that 
may  have  a  role  in  the  processing  of  the  precursor  protein  into  a  mature  protein  at  the 
different  stages  of  the  secretion  process. 
The  export  of  the  passenger  domain  (P.  69)  was  investigated  in  E.  coli  strains 
lacking  various  combinations  of  envelope-associated  proteases  i.  e.  DegP,  Esp,  Ptr  and 
OmpT  (Table  2.2;  section  2.1.2).  The  pertactin  gene  (prn)  (2.7  Kb)  cloned  into  the  broad 
host  range  vector  pMMB66EH  (7.9  Kb)  was  under  the  control  of  an  IPTG-inducible  tac 
promoter  to  give  p41869  (10.5  Kb)  (Fig.  3.44)  and  this  plasmid  was  transformed  by 
electroporation  into  the  E.  coli  protease  deficient  strains.  Fig.  3.45  shows  the  plasmid 
preparations  from  these  E.  coli  transformants.  All  the  E.  coli  strains  carrying  pMMB66EH 
(control)  or  p41869  (expressing  prn)  were  grown  in  modified  Luria  Broth  medium 
supplemented  with  glucose  0.2%  w/v.  The  expression  of  the  recombinant  PRN  was 
induced  by  adding  ImM  IPTG  to  the  culture  during  the  late  log  phase  (OD600,,  n,  -0.9)  with 
incubation  at  37'C  continued  for  -3  h. 
Figs.  3.46a  and  3.46b  show  the  protein  profiles,  obtained  by  SDS-PAGE,  of  the 
whole-cell  fractions  of  the  various  protease-deficient  strains  of  E.  coli,  and  the 
corresponding  immunoblot.  The  protein  profiles  of  the  parent  strain  carrying  only  the 
backbone  vector  pMMB66EH  (lane  A)  or  expressing  pm  (p41869)  (lane  B)  and  all  the 
protease-deficient  strains  expressing  prn  (p41869)  (lanes  C-I),  were  complex  and 
indistinguishable  by  SDS-PAGE.  However  there  were  some  differences  evident  in  the 
corresponding  immunoblot  (Fig.  3.46b).  All  the  lanes  with  the  exception  of  lane  A  (parent 
strain,  pMMB66EH)  showed  the  -93  kDa  band  which  is  the  expected  size  of  the  full 
180 Fig.  3.44:  A  restriction  map  showing  theprn  gene  cloned  into  a  broad  host  range 
vector  pMMB66EH  to  create  p41869. 
The  map  shows  the  important  features  of  the  plasmid  41869.  Ile  expression  of  the 
full  length  prn  gene  is  regulated  by  the  tac  promoter  which  is  controlled  by  the  IacP 
repressor.  It  also  contains  an  ampicillin  resistance  encoding  gene  (bla). Habib  Bokhad 
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I  E.  coli  HM130  degp,  ompT,  tsp,  eda,  ptr  p41869 
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IB Fig.  3.46:  Protein  profiles  and  corresponding  immunoblot  showing  the  whole-cell 
fractions  of  various  protease-deficient  strains  expressing  full  length 
pertactin 
The  figure  shows  the  whole-cell  protein  profiles  by  the  SDS-PAGE  (12%)  of 
various  E.  coli  strains  grown  in  LB  medium.  Fig.  3.46b  shows  an  immunoblot  of  Fig. 
3.46a,  obtained  with  rabbit  anti-P.  69  antiserum  (Table  2.7). 
1=  Protein  standard  with  molecular  weights  shown  in  the  left 
A=E.  coli  KS272  parent  containing  pMMB66EH 
B=E.  coli  KS272  H  H  p,  41869 
C=E.  coli  SFI  10  ompT,  degp  H  p41869 
D=E.  coli  SF120  ompT,  degp,  ptr  H  p41869 
E=E.  coli  HMIOI  Isp,  eda  H  p41869 
F=E.  coli  HM1  11  ompT,  tsp,  eda  p41869 
G=E.  coli  HM1  12  ptr,  tsp,  eda  H  p41869 
H=E.  coli  HMI  19  degp,  ompT,  tsp,  eda  H  p,  41869 
I=E.  coli  HM130  degp,  ompT,  tsp,  eda,  ptr  H  p41869 Habib  Bokhari 
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length  of  PRN.  They  also  showed  a  band  at  69  kDa  which  is  the  expected  size  of  the 
mature  form  of  PRN,  except  in  lane  I  (HM130,  strain  deficient  in  most  of  the  proteases) 
which  did  not  seem  to  produce  the  mature  PRN  (P.  69).  The  result  suggested  that  several 
protease-activities  had  to  be  absent  to  prevent  processing,  indicating  that  a  non-specific 
proteolytic  activity  may  be  involved. 
The  next  set  of  results  (Figs  3.47a  and  3.47b)  show  the  protein  profiles,  obtained  by  SDS- 
PAGE,  of  the  outer-membrane  fractions  of  the  wild-type  and  protease-deficient  strains 
expressing  prit  and  their  corresponding  immunoblot.  The  protein  profiles  show  some 
differences  between  the  wild-type  strain  containing  pMMB66EH,  not  expressing  prn  (lane 
A)  and  wild-type  and  the  protease-deficient  strains  containing  p4l.  869,  expressing  pm. 
There  seems  to  be  the  precursor  PRN  visible  in  all  lanes  at  the  correct  predicted  size  (93 
kDa)  with  the  exception  of  lane  A  (wild-type,  carrying  the  vector  pMMB66EH  only).  The 
mature  PRN  (P.  69)  seems  to  be  visible  at  the  predicted  size  (69  kDa)  in  the  outer- 
membrane  fractions  of  all  the  strains  expressing  pm,  with  the  exception  of  the  most 
deficient  strain  HM130  (lane  I).  Confirmation  of  the  SDS-PAGE  results  is  provided  by  the 
corresponding  immunoblot,  obtained  with  the  polyclonal  anti  P.  69  serum  (Fig.  3.47b).  The 
precursor  protein  P.  93  is  apparent  in  all  lanes  except  lane  A  and  the  mature  PRN  (P.  69)  is 
not  present  in  the  outer-membrane  fraction  of  the  most  protease-deficient  strain  (lane  1)  but 
is  present  in  the  outer-membrane  fractions  of  all  other  strains  except  lane  A  again 
containing  the  vector  only.  The  other  minor  bands  apparent  in  all  lanes  except  the  negative 
control  (lane  A)  in  the  immunoblot,  are  presumably  the  degradation  products  of  PRN  and 
possibly  some  non-specific  cross-reactions. 
To  determine  whether  PRN,  after  being  exported  to  the  outer-membrane,  is 
released  or  not,  concentrated  (50  times)  culture  supernate  fractions  from  the  wild-type  and 
protease-deficient  strains  were  collected  (section  2.10.1). 
184 Fig.  3.47:  Protein  profile  and  corresponding  immunoblot  showing  outer-membrane 
fractions  of  various  protease-deficient  strains  and  their  parent  expressing 
full  length  pertactin. 
The  figure  shows  the  outer-membrane  preparations  by  the  SDS-PAGE  (12%)  of 
various  E  coli  strains  grown  in  LB  medium.  profiles  (loaded  with  same  amount  of  protein 
in  each  well).  Fig.  3.47b  shows  an  immunoblot,  of  Fig.  3.47a,  obtained  with  rabbit  anti- 
P.  69  antiserum  (Table  2.7). 
I=  Protein  standard  with  molecular  weights  shown  in  the  left 
A=E.  coli  KS272  parent  containing  pMMB66EH 
B=E.  coli  KS272  H  H  p41869 
C=E.  coli  SM  10  ompT,  degp  H  p41869 
D=E.  coli  SF120  ompT,  degp,  ptr  H  p41869 
E=E.  coli  HM101  tsp,  eda  H  p41869 
F=E.  coli  HM1  11  ompT,  tsp,  eda  p41869 
G=E.  coli  HM1  12  ptr,  tsp,  eda  p41869 
H=E.  coli  HM1  19  degp,  ompT,  tsp,  eda  H  p41869 
I=  E.  coli  HM130  degp,  ompT,  tsp,  eda,  ptr  p41869 Habib  Bokhari 
3.47a 
kDa  IA  13  CDEFGH 
100 
75 
50 
37 
3.47b 
::  M  ,  "*e-,  -  .  *WANN 
ABC 
kDa 
I 
Results 
93  kDa 
69  kDa 
4dWP 
4dow 
400P 
A-  93  kDa 
69  kDa 
75 
'WNW  low*? 
50 
37 
,.  ro- 
185 Habib  Bokhafi  Results 
Figs.  3.48a  and  3.48b  shows  the  protein  profile  obtained  by  SDS-PAGE  of  these 
supernate  fractions  and  their  corresponding  immunoblot  screened  with  rabbit  anti-P.  69 
serum.  There  was  a  clear  difference  between  the  supernate  fraction  of  the  wild-type  strain 
not  expressing  pm  (lane  A)  and  wild-type  and  protease-deficient  strains  expressing  prn. 
The  strains  expressing  pm  seem  to  be  producing  a  range  of  degradation  products  in  their 
culture  supernate  fractions.  The  SDS-PAGE  profile  indicates  that  mature  PRN  may  be 
present  in  the  supernate  fractions  at  the  predicted  size  i.  e.  -69  kDa,  in  all  the  strains  with 
the  exception  of  wild-type  not  expressing  prn  (lane  A)  and  the  most  deficient  E.  coli  strain 
HM  130  expressing  pni  (lane  1)  although  this  is  difficult  to  assess  because  of  the  number  of 
polypeptides  visible.  The  immunoblot  (Fig.  3.48b)  confirms  the  presence  of  the  mature 
P.  69  form  in  supernatant  fractions  of  all  the  strains  except  the  strain  with  vector  alone  (lane 
and  the  most  deficient-protease  strain  (lane  I). 
The  overall  results  indicate  that  the  processing  of  the  precursor  PRN  protein  P.  93 
into  its  passenger  domain  P.  69  and  the  P.  30  domain  (P-barrel  forming  domain)  was  not 
dependent  on  any  specific  protease  investigated  in  this  study,  but  suggests  that  a  non- 
specific  proteolytic  activity  may  be  required,  which  is  absent  in  the  most  protease-deficient 
strain  HM130.  A  summary  of  the  results  is  presented  in  Table  3.2. 
186 Fig.  3.48:  Protein  profiles  and  corresponding  immunoblot  showing  supernatant 
fractions  of  various  protease-deficient  strains  and  their  parent 
expressing  full  length  pertactin. 
The  figure  shows  the  concentrated  supernate  fractions  by  the  SDS-PAGE  (12%)  of 
various  E.  coli  strain  grown  in  LB  medium  and  their  supemates  were  concentrated  to  same 
degree  (section  2.10.1).  Fig.  3.48b  shows  an  immunoblot  of  Fig.  3.48a,  obtained  with 
rabbit  anti-P.  69  antiserum  (Table  2.7). 
1=  Protein  standard  with  molecular  weights  shown  in  the  left 
A=E.  coli  KS272  parent  containing  pMMB66EH 
B=E.  coli  KS272  H  p41869 
C=E.  coli  SFI  10  ompT,  degp  H  p41869 
D=E.  coli  SF120  ompT,  degp,  ptr  H  p41869 
E=E.  coli  HMIOI  tsp,  eda  p41869 
F=E.  coli  HMI  II  ompT,  tsp,  eda  H  p.  41869 
G=E.  coli  HMI  12  ptr,  tsp,  cda  fl  p41869 
H=E.  coli  HM1  19  degp,  ompT,  Up,  eda  fl  p41869 
I=E.  coli  HM130  degp,  ompT,  tsp,  eda,  pir  H  p41869 flabib  Bokhari 
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Table  3.2  Presence  of  precursor  pertactin  (P.  93)  and  mature  pertactin  (P.  69)  in 
various  protease-deficient  strains  in  different  cellular  compartments. 
Strains  Whole  Cells 
kDa 
OM  Fractions 
kDa 
Supernatant  fractions 
kDa 
A=KS272(parent)  93/69  93"/69'  69' 
B=SFI  10  93'/691  1  93/69'  69' 
C=SF120  93"/691  93'/69'  69' 
D=HMIOI  93"/69  93'/69'  69' 
E--HM  I  11  93'/69  93"/69"  69' 
F=HM  112  93'/696  93'/69'  69" 
G=HM  119  93'/69"  93/69'  69' 
H=HM130  93/69-  93/69'  69- 
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3.5.1  Secretion  and  processing  of  C-terminal  and  linker  region  of  pertactin.  in  E.  coli 
strains 
The  G  terminal  domains  of  the  autotransporter  proteins  are  postulated  to  have  a 
barrel  structure  consisting  of  several  amphipathic  anti-parallel  P-strands.  The  next 
experiment  was  carried  out  to  see  whether  the  C-terminal  (30  kDa)  portion  and  the  linker 
region  (15  kDa;  involving  PQP  repeat  region;  Fig  1.4  )  of  the  PRN,  located  between  the 
beginning  of  the  C-terminus  and  the  end  region  of  the  N-terminus,  are  processed  like  the 
full  length  PRN  (p41869),  which  is  processed  into  P.  69  and  P.  30  domains  in  the  parent  E. 
coli  strain  KS272  and  others  but  appeared  not  to  get  processed  and  surface  exposed  in  the 
most  protease  deficient  strain  HM130  of  E.  coli.  A  Sacl  and  EcoRI  fragment  (1.1  Kb 
insert)  encoding  P.  30  and  linker  (15  kDa)  was  cloned  into  the  4.1  Kb  vector  pBAD/gIII 
(Invitrogen)  (Fig.  3.49)  which  is  provided  with  a  signal  sequence  (Blackburn,  2000).  This 
plasmid  was  transformed  by  electroporation  into  the  parent  strain  (KS272)  and  into  the 
most  protease-deficient  E.  coli  strain  (HM130).  Expression  of  the  P.  30  and  its  linker 
domains  is  tightly  regulated  by  an  arabinose  promoter  (arac).  E.  coli  was  grown  in 
modified  Luria  broth  medium  in  the  presence  of  ampicillin  (60/ig/ml)  and  expression  of 
the  recombinant  protein  was  induced  by  0.2%  L-arabinose  (Sigma)  when  an  OD600"",  -0.9 
was  obtained. 
Ideally,  the  recombinant  protein  should  be  expressed  in  a  host  which  lacks  the 
ability  to  metabolise  arabinose.  In  a  previous  study  (Blackburn,  2000),  P.  30  and  linker 
region  was  expressed  in  E.  coli  strain  LMG194  (ara-).  The  outer-membrane  profile  of  the 
E.  coli  LMG194  expressing  the  recombinant  protein  showed  two  prominent  bands  of  about 
14  and  16  kDa  size  and  it  was  the  bigger  band  which  reacted  with  the  monoclonal  anti- 
PRN  linker  antibody  (131305)  (Table  2.8)  These  two  polypeptides  may  be  due  to 
processing  of  the  precursor  (C-terminal  +  linker  region)  at  two  different  sites  and  the 
189 Habib  Bokhari  Results 
additional  2  kDa  protein  in  the  -16  kDa  represents  the  immunodominant  region  of  the 
molecule,  which  actually  reacted  with  the  monoclonal  antibody  (BB05)  (Blackburn, 
2000).  The  E.  coli  strains  used  in  this  study  i.  e.  KS272  parent  and  HM130,  the  most 
protease-deficient  strain,  showed  some  arabinose  utilising  activity  as  determined  by  the 
AP120E  kit,  but  the  arabinose  concentration  (0.2%)  used  gave  reasonable  expression  of  the 
recombinant  Proteins  in  these  strains. 
Results  in  Fig.  3.50a  show  the  protein  profiles  of  whole-cell  fractions  of  the  wild- 
type  and  most  protease-deficient  strains  expressing  linker  region  and  P.  30  domain  of  prn, 
obtained  by  SDS-PAGE.  Lane  A  represents  the  non-induced  wild-type  E.  coli  strain 
(KS272),  whereas  the  lanes  B  and  C  show  the  induced  parent  and  the  most  protease- 
deficient  E.  coli  strain  (HM130).  There  is  a  clear  difference  seen  between  the  lane  A  and 
lanes  B  and  C  at  30  kDa  which  is  the  predicted  size  of  the  PRN  C-terminal  domain.  There 
is  a  minor  difference  at  -45  kDa  which  is  presumably  the  un-processed  precursor  protein 
(linker  +  C-terminal).  The  corresponding  immunoblot  (Fig.  3.50b)  was  developed  with  a 
monoclonal  antibody  (BB05)  raised  to  the  PRN-linker  region  and  kindly  provided  by  Prof. 
M.  Roberts,  Department  of  Veterinary  Pathology,  University  of  Glasgow.  The 
immunoblot  shows  reactions  at  -45  kDa  and  -15  kDa.  As  the  antibody  can  detect  the 
linker  region  only,  it  has  reacted  with  the  intact  -45  kDa  PRN  molecule  in  both  the  lanes  B 
(parent)  and  C  (most  protease-deficient  strain).  There  is  another  reaction  seen  only  in 
lanes  B  and  C  at  -15  kDa  and  that  is  reproducible  and  is  clearer  in  the  outer-membrane 
preparation  of  these  strains  (Fig.  3.51).  There  appears  to  be  three  bands  reacting  with  the 
monoclonal  anti-PRN  linker  antibody  presumably  due  to  some  abnormal  processing  or 
protein  degradation.  These  results  indicated  that  cleavage  of  the  expressed  protein  (45 
kDa)  had  occurred  in  both  parent  and  most  protease-deficient  E.  coli  strains. 
190 Fig.  3.49:  Shows  the  restriction  map  of  the  plasmid  pBAD/gIII  (linker  region  of  prit 
and  its  C-terminal  insert  (1.1  Kb)  cloned  into  the  vector  (4-1  Kb) 
The  expression  of  the  pertactin  C-terminal  and  linker  region  is  under  the  tight  the 
tight  regulation  of  the  arabinose  promoter  (araQ.  It  possesses  a  ColEl  origin  of 
replication  and  ampicillin  resistance  marker.  The  vector  is  provided  with  a  signal  sequence 
(gIII)  which  is  capable  of  transporting  proteins  via  the  Sec-dependent  pathway  into  the 
periplasm.  The  insert  was  ligated  into  it  as  SacI  and  EcoRl  fragment. Ilabib  Bokhari 
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191 Fig.  3.50:  Protein  profile  and  its  corresponding  immunoblot  showing  the  whole  cell 
fractions  of  E.  coli  parent  and  most  protease-deficient  strains  expressing 
the  pertactin  C-terminal  and  linker  region 
The  figure  shows  the  whole-cell  profile  by  the  SDS-PAGE  (12%)  of  different  E. 
coli  strains  grown  in  LB  medium  with  and  without  arabinose  induction.  Fig.  3.50b  shows 
an  immunoblot  of  the  Fig  3.50a  obtained  with  monoclonal  anti-PRN-linker  antibody 
(BB05)  (Table  2.7). 
A=E  coli,  parent  strain  (KS272),  expressing  PRN  C-terminus  and  linker  region 
(non-induced) 
E.  coli,  parent  strain  (KS272),  expressing  PRN  C-terminus  and  linker  region 
(induced  with  L-arabinose) 
C=E.  coli,  most  protease-deficient  strain  (HM130),  expressing  PRN  C-terminus  and 
linker  region  (induced  with  L-arabinose) 
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To  further  elucidate  the  processing  of  the  PRN  C-terminus  and  its  linker  region  into 
-30  kDa  C-terminal  domain  and  the  -15  kDa  linker  polypeptide,  the  outer-membrane 
preparations  of  both  strains  were  prepared.  Fig.  3.51  shows  an  immunoblot  of  outer- 
membrane  fractions  prepared  from  the  parent  E.  coli  strain  (KS272)  and  the  most  protease- 
deficient  E.  coli  strain  (HM130)  expressing  the  linker  region  and  P.  30  domain  of  pm. 
There  appeared  to  be  a  cross-reaction  at  -37  kDa  in  both  induced  E.  coli  parent  (KS272) 
and  the  most  protease-deficient  E.  coli  (HM130)  strain.  This  was  not  quite  the  predicted 
size  (-45  kDa)  of  the  linker  and  C-terminal  domain  of  PRN.  However,  there  seemed  to  be 
another  product  at  -15  kDa  in  the  induced  outer-membrane  fractions  of  both  the  parent  and 
most  deficient  E.  coli  strains,  and  both  proteins  are  absent  from  the  non-induced  fractions 
of  both  the  strains.  This  result  was  reproducible  and  the  -15  kDa  band  was  presumably  the 
processed  linker  region  that,  after  being  cleaved  from  the  C-terminal  domain  seemed  to  be 
associated  with  the  outer-membrane  of  both  E.  coli  strains.  The  15  kDa  band  was 
associated  with  the  outer-membrane  surface  after  cleavage,  although  it  may  behave 
differently  in  this  respect  than  the  mature  -69  kDa  PRN  molecule  generated  by  cleavage  of 
the  93  kDa  precursor  PRN.  The  processed  recombinant  30  kDa  band  would  not  react  with 
the  anti-PRN  linker  antibody  (BB05)  after  cleavage  of  the  linker  region  and  would  not  be 
visible  in  the  immunoblot. 
These  particular  results  suggest  that  there  is  no  protease,  amongst  those  under 
investigation,  that  have  a  role  in  the  processing  of  this  particular  form  of  PRN.  However, 
there  is  the  provision  that  the  45  kDa  (linker  +  C-terminal)  domain  may  not  behave  in  the 
same  way  as  the  93  kDa  PRN  precursor.  The  overall  results  indicate  that  none  of  the 
proteases  lacking  in  the  most  protease-deficient  strain  HM130  were  involved  in  processing 
of  PRN  and  they  do  not  support  the  conclusions  of  the  work  presented  in  the  previous 
section. 
193 Fig.  3.51:  Immunoblot  of  the  OMP  fractions  of  the  E.  coli  parent  and  most  protease- 
deficient  strain  expressing  the  linker+C-terminal  region  (-43kDa)  of 
pertactin 
The  outer  membrane-enriched  fractions  were  prepared  from  the  parent  and  most 
protease-deficient  strain  grown  under  inducing  and  non-inducing  conditions,  separated  on 
10%  SDS-PAGE  and  screened  using  monoclonal  anti-PRN-linker  antibody  (131305,  Table 
2.7). 
A=  Pre-stained  Protein  ladder  with  molecular  weights  shown  on  the  left 
Outer  membrane  fraction  prepared  from  E.  coli  parent  strain  (KS272)  expressing 
PRN  C-terminus  and  linker  region  (induced  with  L-arabinose) 
C=  Outer  membrane  fraction  prepared  from  E  coli  parent  strain  (KS272)  expressing 
PRN  C-terminus  and  linker  region  (non-induced) 
D=  Outer  membrane  fraction  prepared  from  E.  coli  most  protease-deficient  strain 
(HM130)  expressing  PRN  C-tenminus  and  linker  region  (non-induced) 
E  Outer  membrane  fraction  prepared  from  E.  coli  most  protease-dericient  strain 
(HM130)  expressing  PRN  C-terminus  and  linker  region  (induced  with  L-arabinose) Habib  Bokhari 
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4.1:  Overview 
Discussion 
The  main  objective  of  any  research  on  B.  pertussis  in  recent  years  has  been  to 
identify  the  nature  of  its  interaction  with  its  host  during  infection.  This  can  be  achieved  by 
identifying  the  bacterial  surface  components  and  the  host  tropism  and  the  host  response 
towards  the  pathogen  during  the  disease  process.  The  candidate  genes  thought  to  be 
involved  in  pathogenesis,  once  identified,  can  then  be  mutated  to  generate  a  B.  pertussis 
strain  deficient  in  expression  of  the  putative  virulence-associated  factor.  The  mutated 
strain  can  then  be  tested  for  virulence  by  comparison  with  its  wild-type  B.  pertussis  strain. 
Bordetella  autotransporter-five  gene  (bap-5-,  Appendix  II)  was  identified  initially 
due  to  a  misprimed  PCR  reaction  designed  for  amplification  of  the  pm  gene  from  the  B. 
pertussis  genome  (section  1.8.1).  A  search  of  the  databases  has  shown  that  homologues  to 
the  bap-5  gene  also  exist  in  other  Bordetella  species  i.  e.  B.  bronchiseptica,  B. 
parapertussis  and  B.  avium  (Blackburn,  2000).  In  this  study,  the  bap-5  gene  has  been 
shown  by  RT-PCR  as  well  as  by  immunoblotting  with  a  rabbit  anti-rBap-5  serum,  to  be 
expressed  in  B.  pertussis.  RT-PCR  results  have  also  suggested  that  bap-5  expression  is 
regulated  by  the  two  component  regulatory  system  bvgAS.  B.  pertussis  bap-5  mutants  of 
Taberman  and  Tohama  wild-type  strains  (Table  1.4)  were  constructed  successfully  by 
insertion  of  a  kanamyci  n-resi  stance  cassette.  B.  pertussis  Taberman  I  and  its  derived 
Taberman  II  bap-5  defective  mutant  were  selected  for  further  characterisation  studies  of 
bap-5.  SDS-PAGE  profiles,  immunoblots  and  RT-PCR  results  confirmed  the  absence  of 
expression  of  bap-5  in  B.  pertussis  Taberman  11,  the  bap-5  mutant.  , 
-1  The  structural  similarities  between  Bap-5  (the  product  of  bap-5)  and  other  already 
well-characterised  B.  pertussis  autotransporter  proteins  i.  e.  PRN,  TCF  and  BrkA  (Fig  1.3) 
suggested  that  the  Bap-5  protein  could  perhaps  function  as  an  adhesin  or  a  serum  resistance 
factor.  The  results  suggested  that  Bap-5  behaves  like  BrkA  (serum  resistance  factor)  in  B. 
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pertussis  (Taberman  1)  i.  e.  it  confers  resistance  on  B.  pertussis  to  killing  by  human  serum 
mainly  by  the  classical  pathway.  The  mouse  virulence  tests  (section  3.3)  suggested  that 
Bap-5  aids  B.  pertussis  in  colonising  the  lower  respiratory  tract  of  the  animal.  The  results 
of  in  vitro  adhesion  studies  were  less  clear  but  there  was  some  suggestive  evidence  that 
Bap-5  contributes  to  B.  pertussis  adherence  to  certain  cell  types. 
A  mouse  protection  study  (section  3.4)  was  carried  out  with  the  re-natured  PRN 
autotransporter  domain  (P.  30),  as  a  previous  result  with  the  denatured  P.  30  showed  that  it 
had  no  protective  capacity  in  a  murine  model  (Blackburn,  2000).  The  re-natured  P.  30  used 
in  a  mouse  protection  study  did  not  prove  to  be  a  protective  antigen  against  respiratory 
tract  colonisation  of  B.  pertussis.  It  would  have  been  of  interest  to  test  the  processed  30 
kDa  C-terminal  and  mature  forms  of  Bap-5  as  a  protective  antigen  but  there  was 
insufficient  time  to  clone  the  required  gene  sequences  in  an  expression  vector  in  order  to 
obtain  enough  protein  for  immunisation  studies. 
There  is  little  information  in  the  literature  regarding  the  processing  of  the 
autotransporter  proteins  of  B.  pertussis.  A  study  was  carried  out  to  investigate  this  using 
the  well-characterised  B.  pertussis  autotransporter,  PRN.  The  PRN  precursor  (P.  93)  is 
processed  into  a  mature  passenger  domain  (P.  69)  and  a  C-tern-tinal  pore  forming  domain 
(P.  30).  There  appears  to  be  no  information  as  to  whether  PRN  has  an  inherent 
autoproteolytic  activity  to  produce  the  above  mentioned  two  final  processed  products  or 
whether  some  unknown  envelope-associated  protease  activity  is  required.  The  processing 
of  PRN  was  studied  in  a  set  of  E.  coli  strains  (section  3.5)  which  were  deficient  in  known 
envelope-associated  or  periplasmic  proteases. 
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4.2:  B.  pertussis  genome  sequence  and  bap-5 
Recently,  the  sequencing  of  the  B.  pertussis  Tohama  I  genome  has  been  completed, 
although  the  published  annotated  version  is  still  awaited,  whereas  genome  sequencing  of  B. 
bronchseptica  and  B.  parapertussis  is  close  to  completion.  A  comparative  study  between 
these  three  closely-related  species  of  the  genus  Bordetella  may  reveal  why  such  closely 
related  organisms  exhibit  different  host  ranges  and  produce  different  disease  symptoms. 
The  presence  of  bap-5  (1.8.5;  Appendix  II)  in  the  genomes  of  B.  pertussis  and  B. 
bronchiseptica  was  confirmed  from  the  genome  sequences.  B.  bronchiseptica  bap-5  gene 
shows  close  homology  to  that  of  its  B.  pertiessis  counterpart.  The  sequence  in  the  B. 
pertussis  Tohama  I  strain  sequenced  by  the  Sanger  centre  has  100%  nucleotide  identity  to 
the  bap-5  nucleotide  sequence  obtained  for  the  Taberman  strain  of  B.  pertussis  (Blackburn, 
2000)  using  the  BLAST  search  engine  at  http:  //www.  Sanger.  ac.  uk  (BLAST  search  results). 
The  sequence  analysis  of  the  bap-5  region  has  shown  that  it  does  not  possess  a  typical 
Shine-Delgarno  sequence  (Shine  and  Delgarno,  1975)  in  the  5'  region  of  its  proposed  open 
reading  frame,  like  other  known  autotransporter  genes.  However,  the  genome  sequence 
search  during  this  study  showed  the  existence  of  two  potential  BvgA  dimer  binding  sites 
TTTC(A/G)TA  (section  1.5)  upstream  from  the  predicted  translational  start  site  of  bap-5 
(ATG  1)  (Appendix  III),  which  are  similar  to  a  characteristic  heptameric  sequence 
MC(C/T)TA  (Marques  and  Carbonetti,  1997;  Kinnear  et  al.,  1999).  Similar  repeats  are 
located  upstream  of  the  Bvg-regulated  pm,  jha,  ptx,  cya  and  bvg  genes  of  B.  pertussis.  The 
BvgA  dimer  is  required  for  regulating  the  transcription  of  these  genes  through  its 
interaction  with  the  RNA  polymerase.  Three  classes  of  bvg-activated  promoters  have  been 
reported  in  B.  pertussis  which  are  categorised  on  the  basis  of  their  temporal  activation  after 
an  inducing  signal.  The  early  class  is  represented  by  flia  and  bvg  and  the  late  class  is 
represented  by  ptx  and  cya,  whereas  pnz  promoter  activation  is  thought  to  occur  at  the  time 
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between  fta  and  ptx  and  hence  it  constitutes  an  intermediate  class  of  bvg-activated 
promoter  (Kinnear  et  al.,  1999).  The  distance  of  the  putative  primary  BvgA  binding  site 
upstream  from  the  promoter  regions  perhaps  determines  the  affinity  of  BvgA  interaction 
with  RNA  polymerase  for  the  primary  binding  sites  and  hence  the  kinetics  of  these 
promoters  (Kinnear  et  al.,  1999).  The  promoter  region  of  bap-5  could  be  analysed  to 
determine  which  class  it  belongs  to  by  determining  at  what  stage  it  begins  to  be  transcribed 
compared  with  the  other  vag  genes.  This  could  be  done  by  an  RT-PCR  method  similar  to 
that  described  earlier  by  preparing  RNA  samples  at  intervals  after  switching  the  culture 
from  Bvg-  to  Bvg+  phase.  Alternatively,  RNA  preparations  could  be  separated  by 
electrophoresis  in  a  formaldehyde  agarose  gel  followed  by  transfer  of  the  RNA  to  a  nylon 
membrane  and  detecting  the  relevant  RNA  by  hybridisation  with  a  labelled  probe.  These 
probes  could  be  prepared  by  using  Dig-labelled  dNTPs  in  PCR  reaction  or  by  a  random 
Dig-labelling  method.  The  preliminary  work  of  designing  the  primer  sets  for  the 
housekeeping  gene  i.  e.  sodB  as  a  control  and  other  bvg-regulated  genes  likejha  (early  bvg- 
class)  and  cyaA  (late  bvg-class)  was  done  but,  due  to  insufficient  time,  this  work  could  not 
be  continued.  Alternatively,  fusion  of  the  promoter  region  of  bap-5  to  a  reporter  function 
such  as  GFP  or  Lux  would  allow  the  time  of  promoter-activation  to  be  determined. 
There  appears  to  be  a  rho-independent  terminator  sequence  downstream  of  the  bap- 
5  gene  (Appendix  IL  shown  in  green)  as  with  prn  (Charles  et  al.,  1989),  with  the  exception 
that  it  is  further  from  the  translational  stop  codon  and  smaller  than  that  of  prn.  The 
secondary  structure  formed  by  this  rho-independent  terminator  adopts  the  shape  of  a 
hairpin  or  loop  and  presumably  is  responsible  for  RNA  polymerase  pausing  and  thereafter 
preventing  mRNA  synthesis  beyond  the  point  of  palindrome  formation.  There  are  some 
common  features  shared  by  the  bap-5  gene  product  with  other  B.  pertussis  autotransporter 
members  (section  1.8)  such  as  an  integrin-binding  motif  (RGD),  a  glycosaminoglycan- 
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binding  site  (SGXG),  a  proteolytic  processing  site  (ALSKRLGEL)  and  an  outer  membrane 
localisation  signal  which  ends  at  a  cyclic  amino-acid  like  other  autotransporters  in  Grain- 
negative  bacteria  (FHLGYRYTW)  (Appendix  11,  shown  in  yellow). 
Some  other  novel  B.  pertussis  putative  autotransporters,  Bap-6  and  Bap-9 
(Blackburn,  2000)  and  Phg  (Antoine  et  al.,  2000),  have  been  identified  in  the  genome 
sequence  which  need  to  be  characterised.  For  example,  the  latter  is  deposited  in  Genbank 
as  a  cold  shock  protein  of  B.  pertussis.  There  are  also  some  recent  reports  about  other 
possible  autotransporters  in  B.  pertussis,  which  are  mentioned  in  section  1.8.5. 
4.3:  Expression  of  bap-5  and  construction  of  bap-5-defective  mutant 
The  expression  of  bap-5  was  confirmed  by  RT-PCR  results  which  produced  the 
products  of  predicted  size  (section  3.1).  The  results  also  suggested  the  existence  of  some 
other  smaller  transcript  in  the  Taberman  I  (wild-type)  which  could  be  the  product  of  non- 
specific  primer-binding  or  there  could  be  another  promoter  to  regulate  the  production  of 
this  smaller  transcript.  There  is  also  the  possibility  of  the  involvement  of  some  other  bap-5 
homologue  in  B.  pertussis.  The  RT-PCR  and  Western  blotting  results  suggested  that  the 
expression  of  Bap-5  is  under  bvg-regulation  like  other  B.  pertussis  autotransporter  proteins 
such  as  PRN  and  BrkA. 
The  bap-5-defective  mutant  of  B.  pertussis  was  created  using  the  suicide  vector 
pSS11229  (Stibitz,  1989)  for  gene  replacement.  This  vector  was  previously  used  for 
creating  JhaB-defective  and  bvgA-defective  mutants  in  B.  pertussis.  The  ligation  of  the 
mutated  (with  kanamycin-resistance  cassette)  bap-5  gene  into  the  pS  S  11229  vector  proved 
to  be  a  difficult  task  perhaps  due  to  the  high  GC-content  of  the  bap-5  gene.  The  Nal  and 
Sm  spontaneous  antibiotic  resistant  strain  of  B.  pertussis  proved  to  be  valuable  selection 
markers  for  selecting  the  mutant  strains  of  B.  pertussis  and  also  for  inhibiting  the  growth  of 
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the  undesired  DNA-inobilising  E.  coli  strain  SM  I  OAPIR-  PCR  and  Southern  blotting  results 
showed  the  successful  incorporation  of  the  mutated  bap-5  into  the  chromosome  of  B. 
pertussis  strains  of  Taberman  and  Tohama.  However,  only  Taberman  I  (wild-type)  strain 
and  its  bap-5-defective  mutant  were  selected  for  the  characterisation  studies  because  the 
bap-5  mutant  of  Toliama  seemed  to  have  lost  its  virulence  properties,  as  suggested  by  its 
non-haernolytic  nature  and  growth  kinetics.  However,  it  would  be  worth  trying  to  create 
bap-5  mutants  of  other  B.  Pertussis  strains  and  of  other  Bordetella  species. 
4.4  Characterisation  of  Bap-5 
Bap-5,  the  product  of  the  bap-5  gene  (Appendix  II),  is  predicted  to  be  a  protein  of 
-79.9  kDa.  However,  it  appears  to  run  anomalously  on  SDS-PAGE,  at  -90  kDa,  and  thus 
shows  some  similarity  to  PRN  (predicted  size  91  kDa,  apparent  size  93  kDa).  Like  BrkA, 
but  unlike  other  B.  pertussis  autotransporter  proteins  such  as  PRN,  Bap-5  does  not  possess 
a  typical  amino-terminal  signal  sequence  upstream  from  its  putative  translational  start  site. 
It  can  be  speculated  that  another  protein,  perhaps  BrkB  (section  1.8.3)  or  an  analogous 
protein,  may  be  involved  in  aiding  Bap-5  translocation  across  the  inner  membrane. 
However,  there  are  many  membrane  proteins  that  lack  discrete  signal  peptides  but  their 
first  transmembrane  segments  can  act  as  targeting  signals  (Friedlander  and  Blobel,  1985). 
The  processing  of  Bap-5  at  the  putative  cleavage  site  (ALSKRLGEL)  would  lead  to 
a  mature  product  of  49.9  kDa  and  a  30  kDa  C-terminal  domain  in  the  outer  membrane. 
Unfortunately,  although  a  rabbit  antiserum  was  raised  against  the  whole  precursor  Bap-5 
molecule  cloned  and  expressed  in  E.  coli,  it  did  not  seem  to  react  with  its  C-terminal 
moiety.  The  putative  -30  kDa,  0  barrel-fon-ning  domain  of  Bap-5  would  be  expected  to  be 
present  in  the  outer  membrane,  but  it  was  not  possible  to  detect  it  either  in  whole-cells  or  in 
outer  membrane-enriched  fractions  using  the  rabbit  anti-rBap-5  serum.  It  is  possible  that 
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this  domain  did  not  have  immunodominant  epitopes  and  hence  was  not  recognised  by  the 
anti-,  Bap-5  serum.  It  can  also  be  speculated  that  antiserum  was  raised  against  SDS- 
denatured  Bap-5  and  so  this  could  have  reduced  its  immunogenicity.  However,  the  anti- 
,  Bap-5  serum  reacted  with  the  precursor  Bap-5  whose  expected  size  is  79.9  kDa  from  the 
predicted  translational  site  but  ran  at  -90  kDa  in  whole  cell  fractions  and  in  outer 
membrane-enriched  fractions  of  B.  Pertussis  Taberman  1.  It  also  reacted  with  a  band  at 
-65  kDa  which  is  presumably  the  mature  Bap-5  that  again,  runs  at  a  higher  molecular 
weight  than  the  expected  size  (49.9  kDa).  This  anomaly  again  can  be  compared  with  the 
anomalous  mobility  on  SDS-PAGE  of  PRN,  whose  processed  passenger  domain  is  actually 
61  kDa,  but  runs  at  69  kDa  on  SDS-PAGE.  The  difference  between  the  predicted  and 
apparent  size  of  the  mature  Bap-5  i.  e.  -16  kDa,  appears  to  be  much  higher  than  in  the  case 
of  PRN  (-8  kDa).  A  possible  explanation  for  this  size  discrepancy  may  be  that  Bap-5  is 
translated  further  from  the  first  ATG  site  towards  the  3',  at  one  of  two  other  putative  start 
sites  to  produce  a  -65  kDa  precursor  protein  (Appendix  11),  as  the  true  translational  start 
site  of  bap-5  is  yet  to  be  confirmed. 
The  outer  membrane  preparations  (Fig.  3.20,3.21)  showed  a  very  clear  and 
significant  difference  between  B.  pertussis  Taberman  I  and  its  derived  Taberman  II  the 
bap-5  mutant  i.  e.  the  presence  of  a  -16  kDa  band  in  the  parent  Taberman  I  strain  of  B. 
pertussis,  in  addition  to  the  above  described  differences.  There  seems,  to  be  a  precedent  in 
the  literature  with  another  outer  membrane  associated  protein  Ail  encoded  by  the 
chromosomal  gene  ail  in  Yersinia  enterocolitica,  which  is  17  kDa  protein  (Miller  et  al., 
1990).  Ail  is  predicted  to  form  eight  membrane-spanning  amphipthic  P-strands  and  four 
extracellular  loops  (Miller  et  al.,  1990)  and,  coincidentally  it  is  known  to  play  a  role  in 
serum  resistance  (like  Bap-5)  and  invasion  (Miller  at  al.,  2001).  Recombinant  Ail  has 
been  shown  to  confer  a  high  level  of  serum  resistance  to  E.  coli  (Bilska  and  Falkow,  1992; 
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Pierson  and  Falkow,  1993).  Sequencing  of  the  -16  kDa  band  present  in  the  outer- 
membrane-enriched  fraction  of  B.  pertussis  Taberman  I  could  generate  further  information 
about  the  processing  of  Bap-5  (-79.9  kDa)  but  there  is  the  possibility  of  some  other, 
smaller  transcript  within  the  larger  bap-5  ORF,  which  encodes  the  -16  kDa  outer 
membrane  protein.  Alternatively  it  may  be  cleaved  further  away  from  the  putative 
predicted  cleavage  side  towards  the  C-terminal  to  produce  a  -16  kDa  C-terminal  domain 
and  a  mature  -65.5  kDa  passenger  domain. 
The  rabbit  anti-,  Bap-5  serum  also  cross-reacted  to  some  extent  with  the  BrkA 
protein  (-73  kDa)  in  the  outer  membrane-enriched  fractions  of  B.  pertussis.  This  may  be 
due  to  the  existence  of  common  immunodominant  epitopes.  The  work  also  indicated  that 
precursor  BrkA  (103  kDa)  seemed  to  be  processed  efficiently  from  its  C-terminal  domain 
(30  kDa)  into  a  mature  73  kDa  form  that  remained  surface  bound.  This  surface  localisation 
is  perhaps  due  to  sorne  non-covalent  interaction  with  its  C-terminal  domain  or  with  other 
surface  components  of  B.  pertussis,  as  seen  in  the  case  of  the  AIDA-I  autotransporter 
protein  of  E.  coli  (Benz  and  Schmidt,  1989). 
4.4.1  Bap-5  as  a  serum-resistance  factor 
B.  pertussis  appears  to  thrive  well  in  its  host  by  employing  a  range  of  surface 
associated  or  released  virulence  factors  to  overcome,  delay  or  evade  the  immune  effector 
mechanisms  deployed  against  it.  Although  B.  pertussis  is  a  mucosal  pathogen,  it  can  still 
be  exposed  to  levels  of  antibody  and  complement  which  in  the  respiratory  tract  are  about 
20%  of  what  is  present  in  the  normal  human  serum  due  to  plasma  exudation  from  the 
underlying  capillaries.  These  levels  may  be  further  increased  during  inflammation 
(Persson,  1991;  Barnes  and  Weiss,  2001).  Like  Vibrio  cholerae,  another  mucosal 
pathogen,  B.  pertussis  appears  to  have  mechanisms  in  place  to  resist  complement  (Weiss  et 
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al.,  1999).  It  was  seen  in  the  case  of  V.  cholerae  that  immunity  to  cholera  did  not  correlate 
with  the  immune  responses  to  cholera  toxin.  The  vibriocidal  assay,  which  reflects  the 
ability  of  the  serum  to  kill  the  V.  cholerae  by  antibody-mediated  complement  fixation,  has 
been  correlated  with  immunity  to  cholera  as  well  as  immunity  from  asymptomatic 
colonisation  (Glass  et  al.,  1985). 
The  complement  cascade  can  be  activated  by  either  carbohydrates  on  bacterial 
surfaces  (such  as  lipopolysaccharide,  LPS),  that  can  activate  the  alternate  pathway  (Taylor, 
1992;  Moffit  and  Frank,  1994)  or  by  the  deposition  of  antibody  on  the  bacterial  surface 
which  can  activate  the  classical  or  primarily  antibody-dependent  pathway  of  the 
complement  system  (section  1.9,  Fig  1.6).  Thus  Complement  is  part  of  the  innate  immune 
defences,  and  provides  a  defence  against  pathogens  that  have  not  previously  infected  the 
host  by  recognising  repeating  structures  such  as  lipopolysaccharide  (LPS)  and  other 
components  found  on  the  surface  of  bacteria.  It  is  also  a  part  of  the  inducible  defences 
activated  by  antibodies. 
This  study  has  suggested  a  role  for  Bap-5  in  B.  pertussis  Taberman  I  in  resisting 
complement-mediated  killing.  Bap-5  was  shown  to  confer  a  considerable  resistance  on  B. 
pertussis  Taberman  I  to  killing  by  normal  human  serum  compared  to  its  Bap-5-deficient 
mutant  (*P<0.05)  (section  3.2.4).  Moreover,  it  was  observed  that  Bap-5  protects  B. 
pertussis  mainly  from  the  classical  (antibody-dependent)  pathway  of  complement 
activation. 
However,  some  preliminary  data  also  suggested  that  Bap-5  may  have  a  role  in 
providing  some  resistance  to  B.  pertussis  Taberman  I  against  the  alternative  (antibody- 
independent)  pathway  of  complement  activation  (section  3.2.5,  Fig  3.29).  The  result 
presented  in  Fig  3.29  showed  that  the  bap-5  mutant  is  sensitive  to  killing  by  complement 
alone  (<60  %  survival)  compared  to  the  wild-type  Taberman  I  parent  strain  (91  % 
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survival).  However,  the  results  with  modulated  (Phase  IV)  strains  (lanes  G  and  H)  showed 
that  some  other  functions  may  also  contribute  to  resistance  to  complement-mediated  killing 
because  these  strains  were  hugely  sensitive  to  killing  (<10  %  survival)  by  guinea  pig  serum 
(source  of  complement).  The  brkA  mutant  BP2041  strain  (87%  survival)  was  not  sensitive 
to  complement  alone  like  its  wild-type  strain  BP338  (92%  survival).  There  was  some 
discrepancy  in  this  result  as  the  Fig.  30  showed  that  the  sensitivity  to  complement  alone 
can  be  inhibited  by  the  addition  of  EGTA-MgC]2  as  shown  in  lanes  B,  G  and  H.  This 
suggests  that  complement  killing  is  Ca'  dependent  and  therefore  due  to  the  classical 
pathway  or  MBL  pathway.  Even  with  the  addition  of  EGTA-MgC12  to  guinea  pig  serum 
with  bap-5  mutant  there  was  still  some  residual  killing  effect  (-70  %  survival).  The 
modulated  strains  were  slightly  better  survivors  (-77%),  which  was  reproducible  but 
unexpected  result.  However,  further  investigation  would  be  required  to  determine  which 
arm  of  the  complement  pathways  Bap-5  mediates  protection  against.  Further  investigation, 
perhaps  by  blocking  or  inhibiting  the  key  components  of  these  various  pathways  (section 
1.9)  might  give  a  clearer  picture  of  the  actual  mechanisms  involved. 
The  presence  of  BrkA  (serum  resistance  factor)  inhibits  deposition  of  C4,  C3  and 
C9  and  production  of  soluble  membrane  attack  complex  (section  1.9,  Fig  1.6).  In  contrast, 
BrkA  does  not  affect  the  deposition  of  Cl,  suggesting  that  BrkA  possibly  acts  before  C4 
(second  component  of  the  classical  pathway  to  be  activated)  deposition.  It  is  proposed  that 
BrkA  inhibits  the  activation  or  promotes  degradation  of  C4  after  its  deposition  on  the 
bacterial  surface  (Barnes  and  Weiss,  2001).  The  actual  molecular  mechanism  by  which 
BrkA  inhibits  complement  has  not  been  determined  but  in  theory  it  could  adopt  one  of  the 
following  routes  as  suggested  by  Bames  and  Weiss,  (2001):  BrkA  could  prevent 
complement  functions  by  acting  as  a  protease;  It  could  recruit  complement-inhibitory 
soluble  C4  binding  protein  or membrane-bound  cofactors  CD46  and  CRI;  It  could  recruit 
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host  protectin  (CD59),  another  complement  inhibitor,  which  is  usually  considered  to  be 
bound  by  the  host  membrane,  as  seen  in  the  case  of  E.  coli  (Rautemmaa  et  al.,  1998). 
The  mechanism  of  action  of  Bap-5  was  not  examined,  but  there  is  a  possibility  that 
Bap-5  may  affect/prevent  the  deposition  of  Cl  in  the  first  instance,  a  role  which  BrkA  has 
not  been  suggested  to  play  (Bames  and  Weiss,  2001).  In  this  way  it  could  possibly  prevent 
killing  of  B.  pertussis  by  the  classical-pathway  of  complement-mediated  killing  and  also 
by  the  alternative  pathway  of  complement-mediated  killing,  as  spontaneous  deposition  of 
Cl  on  the  bacterial  surface  can  initiate  the  formation  of  membrane-linked  terminal  lytic 
complex  C5b-9  on  the  bacterial  surface. 
As  this  study  has  suggested  that  Bap-5  played  a  role  in  protecting  B.  pertussis  from 
killing  by  the  complement  source  (guinea  pig  serum),  there  is  a  possibility  that  it  could 
recruit  some  host  protein,  such  as  vitronectin  or  S  protein  (section  1.9,  Fig  1.6),  which, 
after  linking  with  the  C5b-9  complex  forms  the  fluid  phase  SC5b-9  complex.  It  has  been 
proposed  that  vitronectin  combines  with  fluid-phase  terminal  lytic  complex  at  the  stage  of 
C5b-7  and  this  can  lead  to  the  formation  of  less  destructive  SC5b-9  with  regard  to  its 
membrane  insertion  into  bacteria  (Mills  et  al.,  1993). 
one  possible  line  of  investigation  would  be  to  restore  the  ability  of  the  Bap-5- 
deficient  mutant  to  resist  killing  by  serum  or  complement  by  allowing  the  spontaneous 
deposition  of  purified  recombinant  Bap-5  protein  on  its  surface  and  then  carrying  out 
serum  killing  assays  on  this  strain  along  with  parent  and  untreated  bap-5  mutant  strain.  A 
similar  experiment  was  done  using  a  purified  preparation  of  BrkA  with  a  brkA  mutant  and 
the  outcome  of  the  experiment  confirmed  the  role  of  BrkA  in  serum  resistance  (Oliver  and 
Fernandez,  2002). 
It  was  interesting  to  note  that  in  both  the  B&A-deficient  and  Bap-5-deficient 
mutants,  there  remained  a  considerable  amount  of  residual  serum  resistance  whereas 
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almost  greater  sensitivity  was  exhibited  by  the  Bvg-modulated  parent  strain  of  Bap-5 
Taberman  I  (section  3.2.4).  The  interpretation  of  this  result  could  be  that  both  BrkA  and 
Bap-5  contribute  to  serum  resistance  and,  when  neither  is  expressed,  under  modulating 
conditions,  the  bacterium  is  highly  serum  sensitive.  This  hypothesis  could  be  tested  by  the 
creation  of  a  BrkA  and  Bap-5  double  mutant  construct,  which  should  show  full  serum 
sensitivity.  PCR  results  with  chromosomal  DNA  prepared  from  BP338  and  its  brkA 
mutant  strain  BP2041  confirmed  the  presence  of  the  bap-5  gene  and  a  streptomycin 
spontaneous  resistant  mutant  was  created  (Sm  R)  for  BP2041.  An  attempt  was  made  to 
make  a  bap-5,  brkA  double  mutant  of  BP338  in  the  brkA  mutant  BP2041  background  but, 
unfortunately,  the  first  few  conjugations  between  E.  COU  SM101PIR  carrying  the  mutated 
bap-5  gene  cloned  in  the  suicide  vector  pBap5-Kana  and  B.  pertussis  BP2041  did  not  yield 
transconjugants.  Due  to  time  constraints,  this  line  of  investigation  was  not  continued. 
The  restoration  of  resistance  to  serum  killing  by  putting  back  the  wild-type  copy  of 
the  bap-5  gene  on  a  plasmid  into  the  bap-5  mutant  Taberman  11  strain  of  B.  pertussis 
would  also  be  a  step  forward  in  order  to  confirm  the  phenotype  conferred  by  bap-5. 
Another  investigation  would  be  to  study  serum  resistance  in  E.  coli  by  expressing 
recombinant  Bap-5.  The  agglutination  test  with  anti-,  Bap-5  serum  using  E.  coli  M15 
expressing  Bap-5  (pQE60)  suggested  that  it  is  surface  exposed  in  this  organism  and,  its 
serum-resistance  potential  of  this  E.  coli  should  be  compared  with  that  of  the  E.  coli 
containing  vector  alone. 
A  previous  study  has  suggested  that  BrkA  is  not  involved  in  conferring  resistance 
to  B.  bronchiseptica  against  serum  killing  (Rambow  et  al.,  1998),  so  it  would  be  interesting 
to  determine  the  role,  if  any,  of  Bap-5  in  B.  bronchiseptica  and  other  bordetellae  in  this 
regard.  The  presence  of  the  smooth  LPS  in  B.  bronchiseptica  has  been  correlated  with  the 
resistance  to  killing  in  vitro  by  antibody  and  complement  (Byrd  et  al.,  1991)  and  anti- 
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microbial  peptides  (Baneman  et  al.,  1998).  The  LPS  of  B.  pertussis  was  reported  to  have  a 
simple  structure  consisting  of  lipid  A,  core  polysaccharide  and  a  single  O-chain 
trisaccharide  (Lebbar  et  al.,  1994;  Allen  et  al.,  1998).  B.  pertussis  lacking  the 
oligosaccharide  side  chains  was  found  to  be  more  sensitive  to  these  agents  (Preston  and 
Maskell,  2002).  However  many  new  genes  and  some  unexpected  genes  (e.  g.  the  capsule 
biosynthesis  locus)  have  been  identified  with  the  completion  of  the  genome  sequence  of  B. 
pertussis,  which  may  lead  to  a  new  outlook  on  the  organism  and  the  manner  in  which  it 
interacts  with  the  innate  immune  system  (Preston  and  Maskell,  2002). 
Another  area  to  look  for  a  complement  resistance  mechanism  is  to  explore  the 
possible  involvement  of  the  antibody-independent  route  of  the  classical  pathway  i.  e.  the 
lectin  pathway,  in  B.  pertussis  killing.  There  is  evidence  that  a  deficiency  of  mannan- 
binding  lectin  (MBL)  is  associated  with  an  increased  susceptibility  to  bacterial  infection  in 
rnice  as  it  reduces  the  efficiency  of  the  lectin-pathway  of  complement-mediated  killing 
mechanism  (section  1.9;  Fig  1.6)  (Turner,  1996).  MBL  binds  to  carbohydrate  surface 
structures  (Ikeda  et  al.,  1987)  on  bacteria,  yeast,  parasitic  protozoa  and  viruses  (Turner, 
1996)  and  is  structurally  similar  to  Clq  and  is  able  to  activate  complement  via  associated 
serine  proteases  (MASP-1  and  MASP-2)  (Matsushita  and  Fujita,  1992).  Killing  is 
mediated  by  the  terminal  lytic  complement  pathway  or  possibly  by  increased  phagocytosis. 
Thus  complement  and  MBL  have  an  important  role  in  innate  immunity  through  both 
opsonisation  and  alternative  complement  pathway  activation  as  is  the  case  with  N. 
meningifidis.  Similar  mechanisms  may  be  operative  in  B.  pertussis  via  Bap-5  as  it  may  be 
involved  in  preventing  the  initial  deposition  of  MBL  protein  on  the  surface  of  B.  pertussis. 
In  the  light  of  the  outcome  of  this  study,  the  most  probable  strategies  employed  by 
B.  pertussis  to  evade  host  defences  can  be  updated,  with  the  inclusion  of  defence  strategies 
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against  the  classical  pathway  of  complement-mediated  killing  (BrkA  and  Bap-5)  and 
possibly  the  alternative  pathway  of  complement-mediated  killing  (Bap-5)  (Table  4.1). 
4.4.2  Anti-Bap-5  serum  and  its  bactericidal  effect  on  B.  pertussis 
Understanding  the  role  of  antibody-mediated  immunity  against  intracellular  and 
extracellular  pathogens  is  important  for  fundamental  immunology,  vaccine  design  and 
development  of  immunotherapy. 
Surface-located  components  of  bacteria  could  either  mediate  serum  resistance  by 
blocking  complement  killing  or  act  as  targets  for  bactericidal  antibodies.  Antibodies  to 
surface  antigens  play  a  role  in  protection  against  B.  pertussis.  Antibodies  may  act  either  by 
neutralising  bacterial  toxins,  inhibiting  the  extracellular  bacterial  binding  to  the  cells  in 
mucosal  tracts  or  by  facilitating  bacterial  uptake  and  destruction  by  macrophages  and 
neutrophils.  It  is  presumed  that  anti-LPS  antibodies  are  the  major  antibodies  responsible 
for  bactericidal  activity  against  B.  pertussis,  as  they  can  activate  the  classical  pathway  of 
complement  and  they  have  been  detected  in  humans  and  mice  (Weiss  et  al.,  1999).  B. 
pertussis  is  known  to  express  two  forms  of  LPS:  band  A,  consisting  of  lipid  A,  core  and  0- 
chain  (LOS)  and  band  B,  a  partial  structure  consisting  of  lipid  A  and  core  without  O-chain. 
In  other  words,  unlike  the  highly  polymerised  LPS  of  the  enteric  bacteria,  the  LPS  of  B. 
pertussis  does  not  seem  to  protect  it  from  complement-mediated  killing. 
B.  pertussis  infection  results  in  humoral  and  cell-mediated  immunity  that  is  largely 
influenced  by  the  polarised  Thl  response  (Ryan  et  al.,  1997;  Mills  et  al.,  1998).  Thi 
responses  (via  cytokines,  especially  IFN-y)  can  also  stimulate  the  production  of  opsonising 
antibody  and  complement-fixing  IgG  antibody  subtypes  e.  g.  IgG3.  Thl  responses 
generated  either  by  B.  pertussis  infection  or  by  vaccination  with  the  whole-cell  pertussis 
vaccine  have  been  shown  to  correlate  with  increased  clearance  of  B.  pertussis  (Mills  et  al., 
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Table  4.1:  Probable  evasion  strategies  employed  by  B.  pertussis 
Discussion 
Immune  effector  Probable  evasion  strategy  References 
mechanisms 
Muco-ciliary  clearance  Attachment  colonization  factors  Tuomanen  and  Weiss, 
(FHA,  PRN,  TCF,  Brk-A,  Bap-5),  1985. 
destruction  of  ciliated  cells  by  Luker  et  al.,  1993. 
tracheal  cytotoxin  This  study 
Complement  (classical,  BrkA,  BrkB  and  Bap-5  Fernandez  and  Weiss, 
possibly  alternative)  1994. 
Fernandez  and  Weiss,  1998. 
This  study 
Phagocyte  function  Avoidance  of  respiratory  burst,  Cundell  et  al.,  1994. 
neutrophil  intoxication  Pearson  et  al.,  1987. 
FHA,  PTX,  ACT.  Meade  et  al.,  1985. 
McGuirk  et  al.,  1998. 
B  cells,  antibody  Intracellular  niche,  PT  mediated-  Saukonen  et  al.,  1991. 
immunomodulation,  switching  from  Masure,  1992. 
more  severe  to  less  protective  arm  of 
the  immune  response 
Cell-mediated  immunity  Altered  co-stimulation,  migration 
ý  McGuirk  et  al.,  1998. 
and  antigen  presentation  FHA,  PTX  Spangrude  et  al.,  1985. 
Data  has  been  taken  from  Mahon  and  Mills  (1999)  and  modified 
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1998).  Bactericidal  activity  of  the  serum  from  adults  exposed  to  B.  pertussis  or  immunised 
with  Pa  (acellular  pertussis  vaccine)  correlated  with  the  presence  of  IgG3  antibodies  to 
LPS,  the  IgG  subclass  which  is  most  efficient  at  fixing  complement.  Natural  infection  or 
immunisation  with  Pw  (whole-cell  pertussis  vaccine)  induces  a  significant  protection  in 
rnice  via  Thl  cells  and  mostly  IgG2a  antibodies.  The  Pa,  which  is  not  as  protective  as  Pw, 
induces  Th2  cells  and  low  levels  of  IgG2a  antibodies  (Mahon  et  al.,  1996;  Mills  et  al., 
1998).  However,  Pa  induces  high  levels  of  IgG1  in  the  mouse  and  this  subclass  may  be 
important  in  neutralising  toxins  and  inhibiting  bacterial  adherence  to  the  ciliated  epithelial 
cells  in  the  respiratory  tract  (Mills  et  al.,  1998).  Among  the  antibody  classes,  IgM  is 
known  to  activate  complement  very  well,  whereas  IgA  is  not  effective.  In  humans,  IgG3 
activates  complement  better  than  IgG1,  which  in  turn  is  better  than  IgG2.  IgG4  does  not 
activate  complement. 
A  previous  study  showed  that  neither  the  antibodies  to  Pertussis  toxin  or  FHA  nor 
immunisation  with  vaccines  containing  these  antigens  were  correlated  with  bactericidal 
activity  (Cherry  et  al.,  1998;  Storsaeter  et  al.,  1998).  This  is  most  likely  due  to  the  secreted 
nature  of  pertussis  toxin  or  the  loosely  surface-bound  FHA  antigen,  which  make  them 
inappropriate  targets  for  bactericidal  antibodies.  Surface-association  is  a  property  that  is 
required  for  directing  the  membrane  attack  complex  to  the  bacterial  membrane.  It  was 
reported  that  the  monoclonal  antibodies  to  band  A  LPS  (LOS)  have  a  bactericidal  effect 
and  that  passive  immunisation  with  anti-LPS  antibodies  from  the  sera  of  individuals 
convalescing  from  natural  infection  (Shahin  et  al.,  1994;  Weiss  et  al.,  1999),  or  with 
monoclonal  antibodies  to  LOS,  resulted  in  increased  clearance  of  B.  pertussis  from  the 
mouse  lungs  following  an  aerosol  challenge  (Mountzouras  et  al.,  1992). 
The  immunisation  of  mice  with  PRN  (P.  69)  resulted  in  reduced  colonisation  of  the 
lungs  after  subsequent  challenge  and  the  antibodies  produced  in  response  to  P.  69  were 
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shown  to  be  bactericidal  (Gotto  et  al.,  1993).  More  recently  it  has  been  shown  that  anti- 
BrkA  serum  can  augment  the  killing  of  B.  pertussis  when  added  to  human  serum  (Oliver 
and  Fernandez,  2002). 
The  present  study  has  suggested  that  antiserum  raised  against  the  Bap-5  precursor 
can  not  only  recognise  the  surface-exposed  antigen  but  like  anti-BrkA  antibodies  (Oliver 
and  Fernandez,  2002)  can  potentiate  the  killing  of  B.  pertussis  in  the  presence  of 
complement  (section  3.3.5).  However,  the  killing  ability  of  the  antiserum  seems  to  vary 
for  each  B.  pertussis  strain  e.  g.  BP338  and  BBC29  strains  were  less  sensitive  to 
complement-mediated  killing  via  the  classical  pathway  than  B.  pertussis  Taberman.  This 
difference  can  presumably  be  attributed  to  the  level  of  production,  processing  and  surface 
exposure  of  Bap-5  or  possibly  other  cross-reacting  factors  in  different  strains  of  B. 
pertussis.  It  is  also  likely  that  antiserum  raised  against  a  preparation  of  the  Bap-5  protein 
in  native  form  would  be  more  effective  in  recognising  and  binding  to  the  surface-exposed 
epitope  of  Bap-5,  which  may  include  conformational  epitopes  not  present  in  denatured 
preparations  of  the  protein.  As  mentioned  before  (section  3.2.3.2.3),  the  rabbit  anti-,  Bap-5 
serum  cross-reacted  to  some  extent  with  another  outer  membrane  protein,  possibly  BrkA, 
hence  all  the  bactericidal  assays  were  carried  out  using  the  anti-Bap-5  serum  absorbed  with 
the  outer  membrane-enriched  fractions  extracted  from  the  B.  pertussis  bap-5  mutant  of  the 
Taberman  I  strain.  Due  to  time  constraints,  it  could  not  be  evaluated  whether  anti-,  Bap-5 
serum  has  a  potentiating  effect  on  the  killing  ability  of  the  human  serum.  This  study  also 
strongly  suggests  that  Bap-5,  like  BrkA,  appears  to  be  mainly  surface  located  rather  than 
secreted. 
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4.4.3  In  vitro  adhesion  studies 
Discussion 
B.  pertussis  colonises  the  respiratory  tract  and  is  thought  to  preferentially  adhere  to 
ciliated  epithelial  cells  (van  den  Berg  et  al.,  1999)  and  also  possibly  to  alveolar 
macrophages  (Relman  et  al.,  1990).  There  is  a  diverse  range  of  virulence  factors, 
including  FHA,  PRN,  FIM,  PTX  and  TCF  that  are  considered  to  play  a  role  in  adherence 
of  B.  pertussis  to  epithelial  cells  (Locht  et  al.,  1993;  Funnell  and  Robinson,  1993:  Everest 
et  al.,  1996;  Finn  and  Stevens,  1995).  B.  pertussis  FHA  has  been  suggested  to  mediate 
adherence  to  macrophages  and  possibly  other  leukocytes  in  vitro  (Ishibashi  et  al.,  1994),  a 
function  which  may  have  immunomodulatory  effects,  either  by  altering  the  host  cell  signal 
transduction  systems  or  by  facilitating  the  delivery  of  secreted  toxins,  such  as  ACT/HLY 
(Boschwitz  et  al.,  1997).  Moreover  FHA  has  also  been  shown  to  be  involved  in  adhesion 
to  laryngeal,  bronchial  and  human  lung  epithelial  cells,  whereas  fimbriae  are,  involved  in 
adhesion  to  laryngeal  epithelial  cells  (Mahon  et  al.,  1991;  Ishibashi  et  al.,  2001).  Tracheal 
colonisation  factor  (TCF)  is  thought  to  be  involved  in  B.  pertussis  colonisation  of  the 
trachea  of  mice  but  not  the  lungs  (Finn  and  Stevens,  1995). 
A  B.  pertussis  strain  deficient  in  PRN  autotransporter  protein,  another  well- 
characterised  adhesin  has  been  shown  to  have  reduced  adherence  to  human  epithelial  cell 
lines  of  non-respiratory  origin  such  as  HeLa  229,  Chinese  hamster  ovary  (CHO)  cells  and 
human  laryngeal  epithelial  (Hep-2)  cells  in  vitro  compared  to  the  PRN  parent  strain  of  B. 
pertussis  (Ewanowich  et  al.,  1989;  Everest  et  al.,  1996).  There  are  some  contradictory 
reports  regarding  the  role  of  PRN  in  adhesion  of  B.  pertussis  to  Hep-2  cells.  The  study 
from  Roberts  et  al.  (1991)  using  B.  pertussis  BP536,  a  Sm  R  derivative  of  Toharna  and  its 
derived  BB52  PRN  mutant  strain,  suggested  no  significant  difference  in  their  ability  to 
adhere  to  and  invade  Hep-2  cell  lines.  On  the  other  hand  Leininger  et  al.  (1991)  suggested 
that  PRN  seemed  to  play  a  role  in  B.  pertussis  adherence  to  Hep-2  cells.  However, 
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recombinant  PRN  expressed  on  the  surface  of  E.  coli  (HB  10  1)  was  shown  to  impart  better 
adhesive  properties  for  Hep-2  and  CHO  cells  (Everest  et  al.,  1996).  So  far,  no  receptor  for 
PRN-mediated  adhesion  has  been  identified.  An  understanding  of  the  precise  roles  of  the 
individual  bacterial  virulence  factors  (adhesins)  involved  in  adhesion  to  specific  primary 
cells  and  tissue  culture  cell  lines  will  be  difficult,  because  of  the  overlapping  functions  of 
different  factors  during  the  course  of  infection. 
An  ELISA-based  adhesion  study  like  that  used  by  Everest  et  al  (1996),  using 
different  B.  pertussis  strains  with  different  tissue  culture  cell  lines  was  performed  (section 
3.2.6).  The  Taberman  strain  of  B.  perfussis  was  selected  as  its  Bap-5-deficient  mutant  was 
available.  This  adhesion  study  suggested  that  Bap-5  may  play  a  role  in  adherence  of  B. 
pertussis  to  non-respiratory,  HeLa  229  cells,  human  respiratory  epithelial  laryngeal  (Hep- 
2)  cells  and  to  murine  macrophages  P338D-I  as  demonstrated  by  the  better  adherence  of 
the  wild  type  Taberman  I  strain  compared  to  its  Bap-5-deficient  mutant  Taberman  II  strain. 
However  there  were  some  inconsistencies  in  the  results  such  as  the  adhesion  study  with 
Hep-2  cells  which  showed  that  it  was  only  the  B.  pertussis  Taberman  I  wild-type  strain 
which  was  more  adherent  compared  to  other  wild  type  B.  pertussis  strains.  The  adhesion 
study  also  showed  that  Bap-5  wild-type  strain  of  B.  pertussis  was  better  able  to  adhere  to 
HeLa-229  cells,  Hep-2  cells  as  well  as  P338D-1  macrophages  compared  to  its  Taberman  11 
bap-5  mutant.  The  other  wild-type  B.  pertussis  strains  were  generally  only  slightly  better 
than  their  mutants  i.  e.  pm  mutant  (BBC30)  and  brkA  mutant  (BP2041)  in  adhering  to 
different  cell  lines  used  in  this  study  and  no  significant  differences  were  observed. 
However,  It  would  be  worth  trying  to  use  different  B.  pertussis  strains  other  than  those 
used  in  this  study  and  the  pm  and  brkA  mutants  derived  from  them  as  well  as  different 
concentrations  of  the  bacterial  cells  in  the  adhesion  study  to  confirm  the  results. 
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In  many  adhesins  that  have  been  studied  it  is  the  RGD  peptide  which  is  implicated 
as  the  key  player  in  catalysing  the  adhesion  of  their  carrier  organism  to  the  host  cells.  The 
cell  lines  like  human  enterocyte  like  cell  line  (Caco-2)  are  known  to  have  receptors  for 
binding  proteins  carrying  the  RGD  peptide  and  there  are  certain  cells,  like  CHO  cells, 
which  lack  such  receptors.  These  can  be  useful  tools  for  assessing  the  adhesion  activity  of 
RGD-containing  proteins.  However,  none  of  the  B.  pertussis  strains  showed  strong  affinity 
towards  Caco-2  cells  in  this  study.  In  addition,  Everest  et  al  (1996)  presented  evidence 
that  the  RGD  sequence  on  PRN  was  not  involved  in  adhesion. 
There  is  also  evidence  that  most  of  the  adhesins  if  not  all,  in  B.  pertussis  are 
regulated  by  the  two  component  Bvg  system.  In  the  present  study  this  was  shown  by  the 
reduction  of  adherence  of  B.  pertussis  Taberman  to  Hep-2  cells  when  the  organism  was 
modulated  with  MgS04.  However,  it  would  be  worth  mentioning,  that  due  to  repeated 
sub-culturing,  there  is  a  strong  possibility  that  these  cell  lines,  particularly  human 
respiratory  epithelial  cells,  undergo  morphological  variation  and  hence  have  altered  surface 
characteristics.  This  could  have  affected  the  adhesion  study.  It  would  be  an  important 
consideration  that  any  such  study  should  be  done  with  the  primary  cell  lines  as  they 
produce  a  homogenous  cell  population  or  perhaps  with  engineered  cell  lines  which  show 
little  variation  in  their  surface  properties  (Dowling  and  Wilson,  1998).  Moreover  it  will  be 
extremely  difficult  to  manipulate  adhesion  studies  in  vitro  by  replicating  the  exact 
environment  of  respiratory  mucosa  where  the  cells  are  bathed  with  the  mucus  and  ciliary 
beating  is  operative.  However,  these  studies  can  give  some  lines  of  direction  to  investigate 
the  role  of  any  functionally  unknown  gene. 
The  ability  of  antibodies  to  the  surface  antigens  of  B.  pertussis  to  inhibit  adherence 
to  cells  in  culture  should  in  theory  provide  a  useful  functional  assay  for  assessing  their 
ability  to  prevent  infection  in  the  respiratory  tract.  It  was  shown  that  antisera  from  children 
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immunised  with  Pw  (pertussis  whole-cell  vaccine)  or  convalescing  from  pertussis  inhibit 
adherence  of  B.  pertussis  to  the  human  respiratory  cells  in  vitro  (Tuomanen  et  al.,  1984). 
Antibodies  to  FIM  have  been  shown  to  block  the  adherence  of  B.  pertussis  to  Vero  cells 
(Ashworth  et  al.,  1988)  and  HeLa  cells.  Also,  the  antibodies  to  FHA,  PRN,  PTX,  LPS  and 
a  40  kDa  outer  membrane  protein  were  also  shown  to  inhibit  adherence  to  human  bronchial 
epithelial  cells  (Tuomanen  et  al.,  1984;  Van  Den  et  al.,  1999).  Another  study  has  suggested 
that  monoclonal  antibodies  raised  against  either  B.  pertussis  FHA,  fimbriae,  PRN  or  PTX 
inhibited  adherence  of  B.  pertussis  but  not  B.  parapertussis  to  human  bronchial  epithelial 
cells  (Mahon  et  al.,  1999). 
An  anti-,  Bap-5  serum  was  also  used  in  this  study  to  demonstrate  a  role  for  Bap-5  in 
adhesion  of  B.  peaussis  to  different  mammalian  cell  lines.  The  anti-rBap-5  serum  was 
absorbed  with  outer  membrane-enriched  fractions  from  the  Bap-5-deficient  mutant  prior  to 
use  in  the  study  to  reduce  any  cross-reaction  against  other  surface  components  such  as 
BrkA.  There  were  also  some  anomalies  in  these  adhesion  studies,  for  example  the  anti- 
Bap-5  serum  appeared  to  reduce  adherence  of  B.  pertussis  Taberman  to  some  cells  i.  e. 
HeLa  229,  Hep-2  and  murine  macrophages  RAW  264.7  cells  but  did  not  have  an  effect 
with  other  cells  i.  e.  A549  (human  lung  epithelial  cells),  Caco-2  (human  carcinoma 
intestinal  cell  line)  and  to  P338D-I  macrophages  even  though,  in  some  cases,  the  bacteria 
adhered  equally  well. 
These  findings  suggest  that  interaction  between  the  bacteria  and  mammalian  cells  is 
complex  and  possibly  depends  on  many  different  adhesins  and  receptors.  In  those  cases 
where  the  bap-5  mutant  adhered  less  well  than  the  wild-type  strain  or  the  anti-,  Bap-5 
serum  has  significant  effect  in  reducing  adherence,  the  interaction  of  Bap-5  and  its 
unspecified  receptors  may  have  a  significant  role  to  play  in  adhesion  process. 
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4.5  Mouse  virulence  tests 
Discussion 
B.  pertussis  infection  begins  by  attachment  to  the  respiratory  tract  of  its  human  host 
with  the  help  of  a  variety  of  surface-exposed  virulence-related  proteins.  The  successful 
establishment  of  colonisation  depends  on  the  ability  of  the  organism  to  avoid  clearance  by 
the  mucociliary  escalator,  either  by  developing  strong  attachments  to  the  ciliated  epithelial 
cells  or  by  paralysing  the  cilia,  and  resisting  the  host  immune  defences  that  are  operative  in 
this  site.  However,  bacterial  colonisation  and  infection  of  the  airways  may  also  result  from 
pre-existing  damage  to  local  defence  mechanisms,  rather  than  to  bacterial  virulence  factors 
(Dowling  and  Wilson,  1998).  There  is  a  range  of  B.  pertussis  virulence  factors 
, 
including 
toxins  and  adhesins  such  as  FHA,  PRN,  TCF,  BrkA  and  fimbriae,  that  are  co-ordinately 
regulated  by  the  bvg  locus.  Strains  with  mutations  in  the  bvg  locus  are  unable  to  produce 
these  factors  and  are  avirulent  in  animal  models  (Weiss  and  Goodwin,  1989).  It  is  likely 
that  the  expression  of  the  members  of  the  bvg  regulon  is  altered  or  tuned,  dependent  on  the 
different  sites  or  environmental  niches  encountered  in  the  respiratory  tract.  Most  of  the 
autotransporter  proteins  studied  to  date  have  been  found  in  pathogenic  bacteria  and  are 
often  associated  with  virulence  e.  g.  PRN  acts  as  an  adhesin,  BrkA  acts  as  a  serum 
resistance  factor. 
The  present  study  (section  3.3)  has  suggested  that  a  bap-5  mutant  of  the  Taberman 
strain  of  B.  pertussis  was  less  able  to  persist  and  colonise  the  trachea  and  the  lungs  of 
mice  compared  to  its  isogenic  parent  strain,  Taberman  I.  However,  no  significant 
difference  was  observed  in  their  colonisation  of  the  nasal  cavities  of  mice  as  was  the  case 
with  a  pm  mutant  of  B.  bronchiseptica  which  colonised  the  nasal  cavity  as  well  as  the 
parent  strain  (Prof.  M.  Roberts,  unpublished).  There  may  be  some  other  unknown  factors 
involved  in  colonising  this  particular  site.  The  results  with  other  strains  also  produced 
some  useful  information.  B.  pertussis  BBC30,  a  pm  mutant,  was  also  found  to  be  less  able 
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to  persist  and  colonise  the  trachea  and  the  lungs  of  mice  compared  to  its  isogenic  parent 
strain,  BBC29.  These  results  suggested  that  Bap-5,  like  PRN,  appears  to  participate  in 
establishing  B.  pertussis  infection  in  the  trachea  and  lungs  of  mouse.  However,  such 
findings  should  be  treated  with  caution  as  they  may  not  be  representative  of  the  natural  B. 
pertussis  infection  in  man  and  because  relatively  large  challenge  doses  are  required  to 
initiate  the  infectious  process. 
A  previous  study  suggested  that  a  B.  pertussis  PRN  mutant  was  cleared  more 
quickly  from  the  lungs  of  intranasally-infected  mice  than  its  wild-type  strain  (Khelef  et  al., 
1994).  A  B.  bronchiseptica  PRN  mutant  was  reduced  in  its  ability  to  colonise  the  lower 
respiratory  tract  but  not  the  nasal  cavity  of  mice  (Prof.  M.  Roberts,  unpublished).  A  B. 
pertussis  TCF  mutant  was  found  to  have  reduced  ability  to  colonise  the  tracheas  of  mice 
and  intranasal  immunisation  of  mice  with  an  attenuated  Vibrio  cholerae  strain  expressing 
TCF  reduced  the  ability  of  B.  pertussis  to  subsequently  colonise  the  trachea  (Chen  et  al., 
1998).  A  B.  pertussis  brkA  mutant  was  found  to  be  10-fold  less  virulent  in  colonising  the 
respiratory  tract  (lungs)  in  intranasally  challenged  infant  mice  than  the  parent  strain 
(Fernandez  and  Weiss,  1994).  However,  a  B.  pertussis  vag-8  mutant  colonised  the  trachea 
and  lungs  of  mice  as  efficiently  as  the  isogenic  parent  (Finn  and  Amsbaugh,  1998). 
These  animal  studies  illustrate  the  important  role  that  most  of  the  B.  pertussis 
autotransporter  proteins  play  in  the  infection  process. 
4.6  Mouse  protection  test 
Previous  mouse  protection  studies  using  the  purified  C-terminal  domains  of  B. 
pertussis  autotransporter  proteins  of  BrkA,  TCF,  PRN  and  Bap-5  suggested  that  they  were 
not  immunodominant,  protective  regions  of  the  autotransporter  proteins  (Blackburn,  2000). 
These  C-terminal  domains  however,  were  presented  to  the  mice  in  denatured  form  after 
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expression  in  E.  coli  and  solubilisation  of  inclusion  bodies  in  urea,  which  could  be  the 
reason  for  the  lack  of  provision  of  protection  by  the  protective  epitopes  against  B. 
pertussis.  In  the  present  study,  to  circumvent  the  doubt  regarding  the  denatured  form  of 
P.  30,  a  re-natured  preparation  of  the  recombinant  C-terminal  domain  was  used.  In  parallel, 
a  purified  preparation  of  P.  69,  which  is  a  known  immunogen,  was  used  in  its  native  form. 
This  study  (section  3.4)  suggested  that  no  protection  was  afforded  by  the  re-natured 
P.  30  against  B.  pertussis  colonisation  of  the  respiratory  tract  of  the  mice,  whereas  P.  69  (at 
the  same  dose)  afforded  a  clear  protection  against  tracheal  and  lung  colonisation  and  to 
some  extent  colonisation  of  the  nasal  cavity.  There  is  a  possibility  that  P.  30  may  not  have 
an  immunodominant  epitope  which  can  generate  an  effective  immune  response  and  hence 
provide  protection  against  B.  pertussis  or,  even  if  it  does,  there  is  a  possibility  that  anti- 
P.  30  antibodies  may  not  have  access  to  this  antigen  because  of  its  presumed  embedded 
nature  in  the  outer  membrane  (Charles  et  al.,  1994).  Unfortunately,  blood  serum  samples 
were  not  collected  from  the  pre-immunised  and  post-immunised  mice,  which  would  have 
given  useful  information  regarding  the  presence  of  P.  30-specific  antibodies'in  the  mouse 
model.  Similar  protection  studies  could  be  devised  for  the  Bap-5  protein  to  see  if  its  re- 
natured  mature  and  C-terminal  domains  have  any  role  in  providing  protection  against  B. 
pertussis.  It  has  been  reported  that  a  good  immune  response  occurs  when  some  B. 
pertussis  antigens  are  presented  in  their  correct  form,  for  example  as  outer  membrane 
complexes  (Hanistra  et  al.,  1995;  Shahin  et  al.,  1995).  It  has  been  reported  that  the  TCF  C- 
terminus  (-33  kDa),  protein  when  used  in  the  form  of  outer  membrane  complexes  was 
protective  in  the  intracerebral  mouse  protection  test  (Hamstra  et  al.,  1995).  However,  the 
vaccine  preparations,  challenge  doses  and  routes  of  administration  of  the  vaccines  and 
adjuvant  effects  of  different  formulations  are  all  potential  areas  to  be  explored  in  the  field 
of  pertussis  vaccinology.  Moreover,  the  complete  genome  sequence  data  is  available  and  it 
218 will  give  information  on  all  the  surface  exposed  and  secreted  proteins  of  an  organism.  This 
can  lead  to  tile  identification  of  potential  novel  antigens  from  the  genome  sequence  for 
possible  inclusion  in  the  next  generation  of  acellular  vaccines,  a  strategy  known  as  reverse 
vaccinology  (Preston  and  Maskell,  2002). 
Previous  studies  using  the  mouse  model  of  infection  have  suggested  that 
immunisation  with  purified  B.  pertussis  FHA,  PTX,  Fim.  or  PRN  protects  against  an 
intranasal  or  aerosol  challenge  with  B.  pertussis  (Mills  et  al.,  1993,1998;  Mahon  et  al., 
1999;  Guiso  et  al.,  1999).  This  is  consistent  with  the  presence  of  antibodies  against  B. 
pertussis  FHA  and  fimbriae  in  humans  which  protect  against  B.  pertussis  by  interfering 
with  its  adherence  (Mahon  et  al.,  1999).  The  antibodies  against  the  other  surface  structures 
i.  e.  LPS  (Shahin  et  al.,  1994)  and  other  outer-membrane  associated  proteins  can  also 
reduce  the  adherence  of  B.  perlussis,  B.  parapertussis  and  B.  bronchiseptica  as  evident  by 
the  protection  provided  by  these  immunogens  (Fernandez  and  Weiss,  1998). 
The  protection  against  B.  pertiessis  provided  by  the  members  of  its  autotransporter 
family  is  another  area  to  be  exploited  by  researchers,  to  enhance  the  efficacy  of  the 
acellular  vaccines.  Natural  and  recombinant  preparations  of  purified  pertactin/P.  69  have 
been  shown  to  induce  a  protective  immune  response  against  an  intranasl  or  aerosol 
challenge  of  B.  pertussis  in  experimental  models  (Shahin  et  al.,  1990;  Roberts  et  al.,  1992). 
The  protective  capacities  of  purified  TCF,  BrkA  and  Vag-8  have  not  been  reported  so  far. 
Vag-8  (92  kDa  protein)  had  been  reported  to  be  protective  only  in  the  presence  of  non- 
protective  levels  of  pertussis  toxin  (Hamstra  et  al.,  1995).  The  autotransporter  PRN  is 
known  to  be  an  important  protective  component  of  many  current  acellular  vaccines. 
However,  there  is  increasing  evidence  of  sequence  variations  of  at  least  two  important 
constituents  of  current  acellular  vaccines  e.  g.  PRN  and  PTX  in  B.  pertussis  strains 
circulating  in  the  population  (Gerlach  et  al.,  2001).  This  has  been  suggested  to  be  due  to 
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the  selective  pressure  imposed  by  current  vaccines  (Mooi  et  al.,  1998)  and  this  situation 
has  prompted  the  search  for  additional  protective  antigens  that  will  be  useful  in  enhancing 
the  protective  efficacy  of  the  new  generation  of  acellular  pertussis  vaccines. 
4.7  Secretion  niechanisni  of  a  B.  pertussis  autotransporter  protein  in  protease- 
deficient  strains  of  E.  coli 
B.  pertussis  autotransporters,  i.  e.  PRN,  TCF,  BrkA,  Vag-8  and  Bap-5  are  associated 
with  bacteria]  virulence.  There  are  many  examples  of  such  virulence  associated 
autotransporter  proteins  in  other  Gram  negative  bacteria,  e.  g.  IgA  protease  (N. 
gonorrhoeae),  adliesins  like  AIDA-I  (E.  coli)  (Benz  and  Schmidt,  1989)  and  invasins  such 
as  Hap  (H.  influenzae)  (St  Geme  et  al.,  1994),  proteases  such  as  Esp  (E.  coli)  Mecsas  and 
Strauss,  1996)  and  SepA  (S.  flexneri)  (Benjelbun-Touimi  et  al.,  1995)  and  toxins  such  as 
VacA  (H.  I)ylori)  (Cover  and  Blaser,  1992)  and  Pet  (Henderson  et  al.,  1999)  (Table  1.1). 
Some  of  these  proteins  e.  g.  IgAl  and  Hap  proteases  are  members  of  the  serine  protease 
family  whose  outer  membrane  translocation  is  dependent  on  the  activity  of  the  trypsin-like 
active  site  (GDGSP,  where  S  is  the  catalytic  residue).  Most  of  the  members  of  this  family, 
after  being  exposed  on  the  cell  surface,  are  processed  and  released  into  the  medium.  There 
is  another  class  within  the  autotransporter  family  of  Gram-negative  bacteria  which  are 
known  as  non-protease  autotransporters  e.  g.  Ag43  and  AIDA-1.  They  are  grouped  on  the 
basis  of  amino  acid  homology  and  the  presence  of  repetitive  amino  acid  motifs  (Henderson 
et  al.,  1999).  In  this  way,  they  appear  to  resemble  PRN  of  Bordetella  spp  which  also 
contains  repetitive  sequences  e.  g.  (GGXXP)5  and  (PQP)5.  The  members  of  the  non- 
protease  autotransporter  family,  upon  cleavage,  appear  to  remain  bound  to  the  outer 
membrane  of  the  bacteria  due  to  noncovalent  interactions  with  their  respective  C-termini 
which  form  P-domains  in  the  outer  membrane  (Benz  and  Schmidt,  1992).  There  appears  to 
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be  no  information  regarding  the  exact  mechanism  of  their  processing  into  the  surface- 
exposed  passenger  domains  and  C-  terminal,  P-domains.  It  is  possible  either  that  they  are 
processed  by  membrane-associated  proteases  or  they  may  have  an  inherent  autoproteolytic 
ability  which  brings  about  their  cleavage  into  the  passenger  domain  and  C-terminal 
domain.  The  autoproteolytic  ability  of  IgA-1  protease  is  well  known  as  it  can  bring  about 
its  own  processing  in  the  absence  of  the  outer  membrane  serine  protease  (omp7)  in 
recombinant  E.  coli  (Klauser  et  al.,  1992).  B.  pertussis  PRN  (P.  93)  is  known  to  produce 
two  fragments,  a  N-terminal  passenger  domain  P.  69  and  a  C-terminal  domain  P.  30,  after 
processing  (Roberts  et  al.,  1991).  The  possibility  of  any  involvement  of  any  protease(s)  in 
the  processing  of  the  autotransporters  was  investigated  in  a  range  of  protease-deficient  E. 
coli  strains  (section  3.6). 
The  study  suggested  that  lack  of  any  of  the  proteases  alone  or certain  combinations 
appeared  to  have  no  effect  in  preventing  the  processing  of  P.  93  in  E.  coli  strains  as  P.  69 
was  found  to  be  outer-membrane  associated  in  these  strains  as  well  as  released  into  the 
supernate.  Unfortunately,  the  anti-P.  30  serum  available  was  unable  to  detect  P.  30  in  the 
outer  membrane  fractions  of  protease-deficient  strains  expressing  full  length  PRN  (P.  93) 
containing  plasmid  p41869.  However,  by  comparing  the  SDS-PAGE  profiles  of  the  outer 
membrane  proteins  of  the  protease-deficient  strains  of  E.  coli  expressing  P.  93  (p4l.  869) 
with  the  E.  coli  parent  strain  containing  the  vector  only  (pMMBE66H),  a  30  kDa  C- 
terminal  region  of  pertactin,  P.  30,  and  theý  mature  passenger  domain,  P.  69  could  be 
visualised  in  the  former  case.  However,  the  most  deficient  E.  coli  strain  (HM130)  did  not 
appear  to  process  the  surface  exposed  P.  93  into  P.  69  and  P.  30.  This  observation  can 
perhaps  be  explained  by  the  fact  that  due  to  many  protease-deficiencies  in  HM130  strain,  it 
was  not  active  in  processing  the  P.  93  at  the  outer  membrane.  Alternatively,  these 
deficiencies  could  have  caused  blockage  of  the  secretion  channels  due  to  the  accumulation 
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of  undegraded  proteins  in  the  periplasm.  P.  93  which  reached  the  outer  membrane  may  not 
have  been  comparable  to  that  found  in  the  other  less  protease-deficient  strains  in  terms  of 
its  quantity.  Moreover,  there  is  the  possibility  that  P.  93  would  not  be  able  to  gain  a  correct 
conformation  in  the  most  protease-deficient  strain  which  may  have  hindered  its  processing 
and  release.  This  possibility  can  be  supported  by  the  successful  processing  of  the  linker 
region  from  its  C-terminal  domain  (section  7.2)  as  seen  in  the  outer  membrane  fraction  of 
the  most  protease-deficient  strain  of  E.  coli  expressing  linker  region  and  C-terminal  of 
pertactin  (pBADpct/linker).  The  linker  region  (15  kDa)  appeared  to  be  detached  from  the 
P.  30  domain  and  found  equally  in  the  outer-membrane  fractions  of  parent  E.  coli  strain  and 
its  most  protease-deficient  strain  HM130.  It  would  be  worth  checking  the  culture 
supernate  fraction  of  the  latter  strain  for  the  presence  or  absence  of  linker  region. 
However,  it  would  be  more  appropriate  if  various  domains  of  interest  of  PRN  and  other 
autotransporters  could  be  investigated  in  the  B.  pertussis  native  system.  Moreover,  with 
the  recent  availability  of  the  complete  B.  pertussis  genome  information,  the  hunt  for  any 
envelope-associated  proteases  of  interest  will  become  easier  and  simplify  the  investigation 
of  their  role  in  the  processing  of  B.  pertussis  autotransporter  proteins.  In  this  regard,  a 
series  of  protease-deficient  strains  of  B.  pertussis  could  be  created  (similar  to  those  of  E. 
coli)  and  their  ability  to  export  and  release  the  various  B.  pertussis  autotransporter  proteins 
in  the  native  system  could  be  examined. 
The  host-pathogen  interaction  can  also  play  a  crucial  role  in  determining  the  fate  of 
the  surface-located  protein.  For  example  the  autotransporter  proteins  Hap  (adhesin)  and 
IgA  protease  of  Haeniophilus  influenzae  has  been  reported  to  be  cleaved  by  lactoferrin 
(milk  protein)  without  interrupting  bacterial  cell  growth  (Plaut  et  al.,  2002).  This  opens  up 
new  possibilities  for  the  processing  and  release  of  the  auotransporter  proteins  of  B. 
pertussis  by  host  proteins  with  proteolytic  activity.  The  benefit  of  this  sophisticated  action 
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for  the  host  may  be  to  make  initial  colonisation  by  the  bacteria  of  the  respiratory  tract  less 
effective  and  for  the  bacteria  it  may  result  in  the  conversion  of  the  more  severe  host 
immune  response  into  a  comparatively  less  severe  response. 
In  conclusion,  the  study  showed  that  Bap-5  is  expressed  and  regulated  by  the  Bvg 
system  in  B.  pertussis.  It  also  showed  that  Bap-5  plays  a  role  in  conferring  resistance  to  B. 
pertussis  against  complement-mediated  (classical  and  possibly  alternative)  killing  and  it 
possibly  aids  B.  pertussis  in  adhering  better  to  certain  tissue  culture  cell  types  in  vitro. 
Antibody  to  Bap-5  can  potentiate  killing  of  B.  pertussis  in  the  presence  of  a  source  of 
complement  and  it  also  can  inhibit  B.  pertussis  adhesion  to  certain  tissue  culture  cell  lines 
in  vitro.  Moreover,  the  mouse  virulence  tests  have  shown  that  Bap-5  aids  B.  pertussis  in 
colonising  the  lower  respiratory  tract  of  mice.  Characterisation  of  the  other  autotransporter 
protein  PRN  showed  that  its  C-terminal  protein  does  not  possess  the  ability  to  provide 
protection  in  a  mouse  model.  The  study  also  suggested  that  PRN  (P.  93)  appeared  to  be 
processed  into  mature  P.  69  as  well  as  the  15  kDa  linker  plus  the  C-terminal  domain  (30 
kDa)  of  PRN  into  its  components  without  requiring  any  specific  accessory  protein  in 
various  protease-deficient  E.  coli  strains. 
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Appendix  I 
Media  composition 
Luria  Bertani  broth  (LB) 
I  litre 
Tryptone  log 
Yeast  extract  5g 
Sodium  chloride  log 
Add  1.2%  agar  for  solid  media 
Cyclodextrin  Liquid  (CL)  media 
I  litre 
Sodium-L-glutamate  10.7g 
L-proline  0.24g 
Sodium  chloride  2.5g 
Sodium  di-hydrogen  orthophosphate  0.5g 
Magnesium  chloride  (6H20)  O.  Ig 
Calcium  chloride  0.02g 
Tris  6.  Ig 
Casamino  acids  log 
Methyl-B-cyclodextrin  0.25g 
Potassium  chloride  0.2g 
pH  to  7.6  and  add  vitamin  solution  to  0.5% 
Vitamin  Solution/CL-supplements 
75  ml 
L-cysteine  0.04g 
Iron  sulphate  (7H20)  O.  Olg 
Nicotinic  acid  0.004g 
Glutathione  0.15g 
Ascorbic  acid  0.4g 
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Stainer-Scholte  medium 
L-Glutamic  acid  (mono-sodium  salt)  63.4mM 
Proline  2.  ImM 
NaCl  43.  OmM 
KH2pO4  3.7mM 
KCI  2.7mM 
Tris.  HCl  20.  ImM 
Tris  48.5mM 
M9Cl 
2.6H 
20  0.5mM 
CaC12  *2H 
20  0.135mM 
Phosphate-buffered  saIine  (PBS) 
NaCl  128mM 
KCI  2.7mM 
KH2po4  1.5mM 
K,  HP04  5.  OmM 
Casamino  acid  (CAA)  solution 
I  Litre 
Casein  hydrolysate  log 
Magnesium  chloride  (6H20)  O.  Ig 
Calcium  chloride  0.016g 
Sodium  chloride  5g 
pH  -to  7.1;  supplement  with  20%  glycerol  for  storage  of  B.  pertussis  at  -80'C 
SOC  Medium 
I  Litre 
Tryptone  20g 
Yeast  extract  5g 
Salts  1  (250  mM  KCI,  IM  NaCl)  10m]. 
Appendices 
After  autoclaving,  add  10m]  of  sterile  2M  glucose  and  10ml  of  Salts  III  (IM  MgC12.6H20, 
1M  MgS04.7H20) 
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Molecular  biology  solutions 
Stop  Solution 
SDS 
Tris 
EDTA 
0.5%  w/v 
50mM  (pH=  7.5) 
OAM 
Add  I  mg/mI  proteinase  K  immediately  before  use. 
Tris-Borate-EDTA  (TBE)  buffer.  5x  stock  solution 
Tris  54g 
Boric  acid  27.5g 
EDTA  (0.5M  stock)  20ml 
DNA  loading  buffer.  6x  stock  solution 
Tris  60mM 
EDTA  6mM 
Sucrose  40% 
Bromophenol  blue  0.25% 
Southern  blot  solutions 
Denaturing  solution 
Sodium  hydroxide  0.5M 
Sodium  chloride  1.5M 
Neutralising  solution 
Sodium  chloride  3M 
Tris.  HCI  0.5M,  pH=  8.0 
SSC.  20x  stock  solution 
Sodium  chloride  3M 
Sodium  citrate  0.3M,  pH=  7.0 
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Maleic  acid  buffer 
Maleic  acid  0.1m 
NaCl  0.15M 
pH  adjusted  to  7.5 
Blockina  reaaent 
Blocking  stock  solution  (Boehringer  Mannheim)  (10%  w/v)20ml 
Maleic  acid  buffer  180ml 
Dissolved  with  heating  and  shaking 
Prehybridisation  solution 
In  a5x  SSC  (prepared  from  20  x  SSC  stock)  was  added 
10  ml  N-laurylsarcosine  (from  10%  w/v  stock  solution) 
2ml  SDS  (from  10%  w/v  stock  solution) 
100  ml  blocking  reagent  (from  10%  stock  solution) 
Added  888ml  of  dH20  to  make  I  litre  prehybridisation  slution. 
Washing  solution  I 
2x  SSC 
0.1%  SDS 
Washing  solution  2 
O.  IX  SSC 
0.1%  SDS 
Detection 
Equilibrating  solution 
Maleic  acid  loomm 
Appendices 
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NaCl  150mM 
pH  adjusted  to  7.5  and  added 
Tween-20  0.3% 
Antibody  blocking  solution/  Blocking  buffer 
Maleic  acid  loomm 
NaCl  150mm 
pH  adjusted  to  7.5  and  added 
Blocking  reagent  1.0% 
Detection  buffer 
Tris.  HCL  loomm 
NaCl  loomm 
pH  adjusted  to  9.5. 
Protein  analysis  solutions 
Protein  sample  buffer 
Glycerol  5ml 
20%  SDS  2.5ml 
2-mercaptoethanol  0.5ml 
Tris  (0.5ml,  pH  6.8)  2.5n-d 
Bromophenol  blue  0.25% 
Stacking  gel  (6%) 
Acrylamide/Bis  solution  4ml 
dH20  10.69ml 
Tris-HCI  (0.5M,  pH  6.8)  5ml 
20%  SDS  100111 
TEMED  10111 
10%  Ammonium  persulfate  (APS)  2001d 
Envelope  buffer 
NaH,  PO4  20mM 
Na,  HP04  20mM 
Appendices 
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28  ml  of  first  is  mixed  with  72  ml.  of  second  and  then  added  100  ml  of  dH 
20  to  produce  a 
IOx  envelope  buffer 
Separating  gel  (12%,  adjust  volume  of  Acrylamide/Bis  solution  and  dH20  to  change 
percentage) 
Acrylamide/Bis  solution  4ml 
dH20  12.6ml 
Tris  (1.5M,  pH  8.8)  10MI 
10%  SDS  0.4ml 
TEMED  301tl 
10%  APS  0.3ml 
PAGE  running  buffer  (IOx)/Electrode  buffer 
I  Litre 
Tris  30g: 
Glycine  144g 
SDS  log 
pH  8.3 
Coomassie  gel  stain 
Coomassie  blue  0.5g 
Methanol  500ml 
Acetic  acid  100ml 
dH20  400ml 
For  destain  preparation,  coomassie  blue  was  omitted  from  the  Coomassie  gel  stain  recipe. 
Blocking  buffer 
In  PBS 
3%  Blotto  powder  (dried  milk) 
0.2%  Tween  20 
RNA  analvsis 
lOx  DNase  buffer 
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Tris.  HCI  (pH=8.5)  500mM 
MgC12  50mM 
DTT  lomm 
RNA  running  buffer/MOPS  (5  X) 
0.1  M  MOPS  (pH  7.0) 
40  mM  Sodium  acetate 
5  mM  EDTA  (pH  8.0) 
Appendices 
Dissolve  20.6g  of  3-(N-morpholino)  propane-sulfonic  acid  (MOPS)  in  800  ml  0.1%  DEPC- 
treated  (overnight)  50  mM  sodium  acetate.  Adjust  pH  to  7.0  with  2N  NaOH  and  then  add 
10  ml  DEPC-treated  0.5  M  EDTA  (pH  8.0)  and  adjusted  final  volume  to  I  litre  with  DEPC- 
treated  water  and  covered  the  solution  with  tin  foil  to  protect  from  light. 
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Appendix  II 
Appendices 
10  20  30  40  50  60  70 
1111111 
TCCCGATTATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAATTCCACGGTTCACCATAACTATGC 
PIITVPRLSTPVRIISRIPRFTITMR 
80  90  100  110  120  130  140  150 
11111111 
GGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAACCTCGCTCGGGGATAAGGCCATACTCAACGTTACCGACAG 
PSRSKTR*ESG,  PRSGIRPYSTLPTA 
160  170  180  190  200  210  220  230 
11111111 
('(-,  A(;  ('  TAT  ((-,  CTCAT(-(7,  CTT(7,  (,  CGGGGGGGGCGAAGCGACATTTACCGATTCGGTC(ITGCGTG 
pyPVRGARSSVGGGGEATFTDSVLRG 
bap-5  forw2rd 
240  250  260  270  280  0  300  310 
1111111 
GTTCGGCCTTCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCTTCGATTCGCGTCC 
SAFGLYAEMCDTCRDDDGTSPSIRVQ 
320  330  340  350  360  370  380 
NTS-Forward 
op. 
390 
AAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAATAACGTCGCTGTGGTGGCAACAGGGTCTGGAAAGGTCGCGATCG 
GGVVQGGMGANNVAVVATGSGKVAIE 
400  410  420  430  440  450  460 
1111111 
AGAATGCGC,  AACTGCTCGGAGCCAGCGGCATGTACGCCACGTTCGGCGCGCAGGTCGATATGAAAGGCGGGCGCATTC 
NýA  ELLGASGMYATFGA  QV  DMKGGRIL 
470  480  490  500  510  520  530  540 
11111111 
TGGCGCACAACACCAATATCCTGGGAAGCCAGGGTTACGCCGATGGTCCCTATGGCGGCGTGGTCGTGACAGAGGACG 
AHNTNTLGS0GYADGPYGGVVVTEDG 
550  560  570  580  590  600  610  620 
11111111 
GTCAAGTCAACCTGGAGGGCGCCAAGGTCAGTGCAACTGGCCTGGGGGCCGCCGGCTTGTGGTTGCTGGGCGACAAGG 
QVNLEGAKVSATGLGAAGLWLLGDK 
_D 
630  640  650  660  670  680  690  700 
11111111 
ACACCAC,  CCCGCC,  AGCCAGCCTGCGCAACACCGACGTCCACGGAGAGGTCGCCGCCATTGCGCTGGGGTTCAATGGCG 
TS  PR  ASLRNTDVHGEVAAIALGFNGE 
710  720  730  740  750  760  770 
780 
AGGCC,  AACATCTCGGGCGGCAGCTTGAGCGTAGAGGATGGGGCCGTGCTCACCACCCTGACGCCCGATGCAGTCGAGT 
__A-. 
N-I_-SGGSLSVEDGAVLTTLTPDAVEY 
790  800  810  820  830  840  850 
NTS-Reverse  NcoI 
I 
ATTACTACGACTACGCCTTGTCCATGGAGCATCTGCCAGCTGATGCGCCGTTGACGCCGGTCCGCGTCACGCTGTCCG 
YYDYALSMEHLPADAPLTPVRVTLSD 
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860  8-10  880  890  900  910  920  930 
11111111 
ATGGCGCGCGCGC-CAGCGC,  AC,  a-AACGTTCYATCGCGCATGGCGGGTTGTTGCCCATGACGCTGCGCTTGAGCAGCGGGG 
GARASGETLIAHGGLLPMTLRLSSGV 
940  950  960  970  980  990  1000  1010 
IIIIIIII 
TCGA(7GCCCC,  CGGCGACATCGTCACGCTGCCGCCTTCCGCGCCGCCCGATTCCGCGGAGCAACCGGATGCCGAGCCGG 
DT 
--L 
P---R  SAEP2S 
-A 
E 
-2 
P 
--I! 
A 
--jq 
P-E 
1020  1030  1040  1050  1060  1070  1080  1090 
11111111 
AACCGGATGCCGAGCTGGAACCGGACGCCGCGGCGCAGTCGGACGCCAAGGCGAATGCGCGGGTCATGGCGCAGGTAG 
PDAELEPDAAAQSDAKANARVMAQVD 
1100  1110  1120  1130  1140  1150  1160  1170 
11111111 
ATGGCGGGGAACCTGTTGCCGTGCCGATCCCGGCCCCTTCGCATCCCGATGCCCCGATCGACGTGTTCATCGACAGCG 
GGEPVAVPIPAPSHPDAPIDVFIDSG 
1180  1190  1200  1210  1220  1230  1240 
1111111 
GTC,  CCCAATGGCGGGGCATGACCAAGACCGTCAATGCGTTGCGCATCGAGGACGGCACCTGGACCGTCACCGGGTCGT 
AQWRGMTKTVNALRIEDGTWTVTGSS 
1250  1260  1270  1280  1290  1300  1310  1320 
11111111 
CCACGGTGAACAGCCTGCACCTGCAGGCAGGCAAGGTGGCGTACGCAACGCCTGCCGAAAGCGACGGAGAATTCAAAC 
TVNSLHLQAGKVAYATPAESDGEFKH 
1330  1340  1350  1360  1370  1380  1390  1400 
11111111 
ACCTGCGGGTCAAGACCCTCTCGGGAAGCGGCCTGTTCGAGATGAACGCCAGCGCCGACCTGAGCGATGGCGACCTGC 
LRVKTLLFEMNASADLSDGDLL 
1410  1420  1430  1440  1450  1460  1470  1480 
11111111 
TGGTCGTGTCCGACGAGGCCAGCGGGCAGCACAAGGTGCTGGTGCGAGGAGCCGGCACGGAACCCACCGGTGTGGAAA 
VVSDEASGQHKVLVRGAGTEPTGVES 
1490  1500  1510  1520  1530  1540  1550  1560 
11111111 
GCCTGACGCTGGTCGAGCTGCCCGAGGGCAGCCAGACGAAGTTCACGCTTGCCAACCGGGGCGGGGTGGTCGACGCCG 
LTLVELPEGSQTKFTLANRGGVVDAG 
1570  1580  1590  1600  1610  1620  1630 
1111111 
GCGCGTTCCGCTATCGCCTGACGCCGGACAACGGTGTCTGGGGCCTGGAACGGACCAGCCAGCTTTCGGCCGTCGCCA 
AFRYRLTPDNGVWGLERTSQLSAVAN 
1640  1650  1660  16670  1680  1690  1700  1710 
11111111 
ACGCGGCCTTGAATACCGGGGGCGTGGGCGCGGCCAGCAGCATCTGGTATGCGGAAGGCAATGCGCTCTCCAAGCGCC 
AALNTGGVGAASSIWYAEGN  ýL  LSKR 
11 
1720  1730  1740  1750  1760  1770  1780  1790 
11111111 
TGGGCGAGTTGCGGCTCGATCCCGGCGCGGGCGGCTTCTGGGGGCGCACGTTCGCCCAGAAGCAGCAGCTCGACAACA 
f---G-E---IýRLDPGAGGFWGRTFAQKQQLDNK 
F---- 
1800  1810  1820  1830  1840  1850  1860  1870 
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IIIIIIII 
AGGCTGGCCGACGCTTCGACCAGAAGGTGTACGGTTTCGAGCTGGGGGCCGACCATGCCATCGCAGGACAGCAAGGGC 
AGRRFDQKVYGFELGADHAIAGQQGR 
1880  1890  1900  1910  1920  1930  1940  1950 
11111111 
GCTGGCACGTGGGCGGCCTGCTGGGCTATACCCGCGCAAGGCGCAGCTTCATCGATGACGGCGCCGGGCATACCGACA 
WHVGGLLGYTRARRSFIDDGAGHTDS 
1960  1970  1980  1990  2000  2010  2020 
1111111 
GCGCGCATATCGGGGCCTACGCGGCGTACGTGGCGGACAACGGCTTCTATTTCGATTCGACCCTGCGCGCCAGCCGCT 
AHIGAYAAYVADNGFYFDSTLRASRF 
2030  2040  2050  2060  2070  2080  2090  2100 
11111111 
TCGAGAACGACTTCACGGTAACGGCCACCGACGCCGTTTCCGTACGGGGCAAGTACCGGGCCAATGGGGTAGGCGCCA 
ENDFTVTATDAVSVRGKYRANGVGAT 
2110  2120  2130  2140  2150  2160  2170  2180 
11111111 
CCTTGGAGGCCGGCAAACGTTTCACGTTGCACGACGGCTGGTTCGTCGAACCTCAGTCCGAGGTGTCGCTGTTCCATG 
LEAGKRFTLHDGWFVEPQSEVSLFHA 
2190  2200  2210  2220  2230  2240  2250  2260 
11111111 
CCAGCGGCGGAACCTACCGTGCCGCGAACAACCTGTCGGTCAAGGACGAAGGCGGCACCTCCGCCGTGCTGCGCCTGG 
SGGTYRAANNLSVKDEGGTSAVLRLG 
2270  2280  2290  2300  2310  2320  2330  2340 
11111111 
GCTTGGCGGCCGGGCGACGCATCGACCTGGGCAAGGACCGCGTGATCCAGCCCTATGCCACCCTGAGCTGGCTGCAGG 
LAAGRRIDLGKDRVIQPYATLSWL0E 
2350  2360  2370  2380  2390  2400  2410 
1111111 
AATTCAAAGGCGTCACGACCGTTCGCACCAACGGGTACGGGCTGCGCACCGACCTGAGCGGTGGCCGGGCTGAATTGG 
FKGVTTVRTNGYGLRTDLSGGRAELA 
2420  2430  2440  2450  2460  2470  2480  2490 
11111111 
CGCTGGGCCTGGCCGCCGCGTTGGGGCGCGGCCACCAGCTCTACACTTCGTACGAGTACGCCAAGGGCAACAAGCTGA 
LGLAAALGRGHQLYTSYEYAKGNKL 
bap-5  Reverse 
2.500  2510  2530  2540  2550  2560  2570 
11,  IIIIII 
TGGGCTATCGCTACACCTGGTAGCGGCGCATC  CCTTGCCTTGGACGTTC, 
tAýCC. 
LPWTHLGYRYTRRIATTGSSRPR 
2580  2590  2600  2610  2620  2630  2640  2650 
ATTCCCGGACCGCGCTGCGGTCAGACCAGCCCGGGCCGTCGACCACGCGTGCCCTATAGTAAGGGCGAAT 
CCIPGPRCGQTSPGRRPRVPYSKGEF 
2660  2670  2680  2690  2700  2710  2720 
1111111 
TCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCATGCATCTAGAGGGCCCAATTCGCCCTATAGTGATAG 
CRYPSHWRPLEHASRGPNSPYSD 
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CCGTCGCCTGATCGATATGGCGCGCCGCATGGGCGCGCGCGAGCCCGAAGTGCTCGGCGAC 
GGCTTGATGCTGCTCATCGAGGGCGCTTTCATTTCGGGCCAGCTATTTCACGGCGACGGGC 
CGGCGCGTCACGTCGCGCGATTGGCCGACAGATTGATCGAAGCCAGTCTGTAGCGATTCCG 
TTTCATATTCGTTCGATTTTCAAGCCGCCCCTCGGGGCGGTTTTTTTTGGTGGGGGAGGGC 
GATGTGCCGCGTGTAAGTCCGCCATTTTCGTACGTGTTCAGGTGCCGATTGCCGGTATCGG 
GATATATGGGCTTATTTGAAACTAGAACAGCTTTTTCACCGGGTGCCAGGCACCTGTTCGC 
AGCAGTTTTTTCACGACTGTTTATTGGCCTCCTTTACCGATTTGAATATGAATGACAGAAA 
ATCCAATAGCATGTCGCCAGCGGCGAGATACTTGCGTTTCGGCGTTGTCGCGGTAGCGGGT 
GTGGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCCGCGCCGGCCGCCGCCG 
AGGTAGCCAAGATCGAGGCTCTGTCGGATGCGGACATTTACAGCGACTACGAGCACGAGCA 
TGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGTTACAGGTCCGCCGAGAGC 
GGTCGTCCGAAGCCCCCCCCCCCCCCTTTCAAACTTCAAACCATTGGGTAATGACGTCGTA 
GCGGAGCGGATACGGGTAGAAGTGCACGGTGACGAAACCCTCGGCGTGTATGTCGACTCGG 
AGCACCGTTCGCTCACCGTGCGTGACAGCACGATAGATGCATACGGCAAGCCGCCTTCCGT 
CGACTCTCCCGATTATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAAT 
TCCACGGTTCACCATAACTATGCGGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAA 
CCTCGCTCGGGGATAAGGCCATACTCAACGTTACCGACAGCGAGGTATCGGGTGCGAGGGG 
CGCGGTCATCGGTTGGGGGGGGGGGCGAAGCGACATTTACCGATTCGGTCCTGCGTGGTTC 
GGCCTTCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCT 
TCGATTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAATAACGTCGCTGTGG 
TGGCAACAGGGTCTGGAAAGGTCGCGATCGAGAATGCGGAACTGCTCGGAGCCAGCGGCAT 
GTACGCCACGTTCGGCGCGCAGGTCGATAT 
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Mouse  lung  counts  obtained  at  day  7,  after  intranasal  challenge  with  B.  penussis  strains. 
Experiment  B.  pertussis  challenge  strains  Total  lung  counts  from 
individual  mice  (CFU) 
Tabennanl  2.8xlO5,1.19XI06,9.  IX,  05, 
4.1  x  105,4.  IX105 
Taberman  II,  bap-5  mutant  1.7xlO5,1.  OX104  7xlO5, 
l.  lxlO5,6.  Oxlo4 
18-323  I.  OX107 
, 
8.7x  106  4.  Oxl  06, 
I.  OX107 
,  7.4xl  06 
Control  (diluent  only)  <102,  <102,  <102,  <102, 
<102 
Taberinan  I  9.7xlO*5,7.3x  105,1 
.  3x  103, 
1.  OX106 
,  3.5xlO5 
Taberman  11,  bap-5  mutant  2.7x  105  3  . 
9XI05  3  OX104, 
4.  Oxl  04  4.  Oxlo4 
BBC29  1.82x,  ()6 
,  2.94x106 
,  2.22x  1()6, 
3.12x  106 
, 
3.2x106 
BBC30,  prn  mutant  1.19XIO 
6  4.  OxlO5,8.9xlO5, 
1.53x  106,1.4xl  06 
*Limit  of  detection  is  =10'  CFU/Iung 
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Mouse  tracheal  counts  obtained  at  day  7,  after  intranasal  challenge  with  B.  pertussis  strains. 
Experiment  B.  pertussis  challenge  strains  Total  tracheal  counts  from 
individual  mice  (CFU) 
I 
11 
Taberman  I 
Taberman  11,  bap-5  mutant 
18-323 
Control  (diluent  only) 
Taberman  I 
Taberman  II,  bap-5  mutant  500,500,1.2x  103,100,100 
BBC29 
BBC30,  pm  mutant 
600,1.5x  103 
,  6.  Ox  103 
500,1.8x  103 
,.:  ý102",:  ý102  800,200,  ,:  ý102, 
1.0xiol 
.:  ý  1029  :ý  102,  :ý  102,  . cC  102,  ,:  C  102, 
1.6xl  03  4.6x  103 
,  2.9x  103, 
1.64xlo4  300 
9.6x  104,1.17x  105,1.09XI05, 
3.6x  104 
,  8.9x  1  04 
3  gX,  04  3.1XI04  4.3x  104, 
1.5XI04,1.2xI04 
*Limit  of  detection  is  =102  CFU/trachea 
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Appendix  VI  (mouse-virulence  tests) 
Mouse  nasal  counts  obtained  at  day  7,  after  intranasal  challenge  with  B.  pertussis  strains. 
Experiment  B.  pertussis  challenge  strains  Total  nasal  counts  from 
Appendices 
individual  mice  (CFU) 
I  Taberman  I  80,100,200,250,10 
Taberman  11,  bap-5  mutant 
Control  (  diluent  only) 
*Limit  of  detection  is  =  10  CFU/nasal  cavity 
60,180,60,200,330 
<10,  <10,  <10,  <10,  <10 
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Mouse  nasal  counts  obtained  at  different  days  after  intranasal  challenge  with  B.  pertussis 
strain  18-323,  the  standard  mouse-virulent  challenge  strain. 
0 
3 
3 
3 
9 
9 
9 
14 
14 
14 
Vaccine  Group  Total  counts  from  nasal  washes  of  individual  mice 
Sham  20,270,360,1000 
Sham  120,1040,1800,2380 
P.  30  (Renatured)  9,60,200,1150 
P.  69  9,9,9,9 
Sham  1.6xlO',  2.4xlO',  1.12x 
103,1.15xlO' 
P.  30  (Renatured)  4.4xlO',  6.4xlO',  8.48x 
103,1.42xl  04 
P.  69  780,1000,1120,1600 
Sham  60,100,320,410 
P.  30  (Renatured)  40,240,1030,2710 
P.  69  9,9,30,240 
The  limit  of  detection  is  10  and  for  statistical  purposes,  these  were  assigned  a 
nominal  values  of  9  CFU. 
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Appendix  VIII  (mouse-protection  tests) 
Mouse  lung  counts  obtained  at  different  days  after  intranasal  challenge  with  B.  pertussis 
strain  18-323,  the  standard  mouse-virulent  challenge  strain. 
Dayl  Vaccine  Group 
0 
3 
3 
3 
9 
9 
9 
14  1 
14 
14 
Total  counts  from  lungs  of  individual  mice 
Sham  <100,  I.  OxIO',  2.9xlO',  3.6xl 
04 
Sham  4.  OxIW,  8.64xlO',  9.6xlO',  1.06x 
106 
P.  30  (Renatured)  4.  OxIO4,4.6x 
104,1.96xlO',  I.  OX106 
P.  69  <100,  <100,2.6x 
104 
,  3.7x 
104 
Sham  4.7xlO',  9.6xlO',  1.04x 
106,  I.  lX  1  06 
P.  30  (Renatured)  5.  OxIO5,1.05x 
106,  IjX106,1.2x  106 
P.  69  <100,3.  OxIO',  8.  OxIO',  1.4xlO4 
Sham  1.2xlO',  7.8xlO4,9.7xlO4,1.65xlO' 
P.  30  (Renatured)  4.  OxIO',  7.4x 
104 
,  7.8x 
104,1.08XI05 
P.  69  <100,  <100,  <100,1.7xlO' 
The  limit  of  detection  is  >10'CFU/Iung 
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Appendix  IX  (mouse-protection  tests) 
Mouse  tracheal  counts  obtained  at  different  days  after  intranasal  challenge  with  B.  pertussis 
strain  18-323,  the  standard  mouse-virulent  challenge  strain. 
Dayl  Group  Total  counts  from  trachea  of  individual  mice 
0  Sham  <100,400,700,1500 
3  Sham  100,200,500,1.09X 
1  04 
3  P.  30  (Renatured)  100,400,7.1  x  10',  4.07x  10' 
3  P.  69  <100,  <100,  <100,  <100 
9  Sham  1.5xlO',  3.37xlO',  4.88xlO4,7.2xlo4 
9  P.  30  (Renatured)  1.12x 
104 
, 
2.03x 
104 
, 
2.47x 
104  6.  OxIO4 
9  P.  69  <100,  <100,  <100,  <100 
14  Sham  700,3.3x  10,7.  Ox  10',  9.7x  10' 
14  P.  30  (Renatured)  100,600,700,1.29x  1W 
14  P.  69  <100,  <100,  <100,4.  OxIO' 
The  limit  of  detection 
iS  ý:.  102  CFU/trachea 
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Appendix  X  (mouse-protection  tests) 
Appendices 
Statistical  analysis  of  respiratory  tract  colonisation.  (nasal  cavities)  of  the  different 
mouse  vaccine  groups  after  intranasal  challenge  with  B.  pertussis  strain  18-323. 
The  P  value  is  <0.0001  is  extremely  significant  (ANOVA)  and  if  the  value  of  q  is  greater 
than  4.764  (Tukey-Kramer  multiple  comparison  test)  then  the  P  value  is  less  than  0.05 
(significant) 
Group  comparison 
on  day  number 
Mean  difference  q  P 
Sham-3  vs.  P  69-3 
- 
1.587  5.696  <0.05 
Sham-9  vs.  P  69-9  0.6425  2.306  >0.05 
Sham-14  vs.  P  69-14  0.7597  2.727  >0.05 
Sham-3  vs.  P  30-3  0.9080  3.261  >0.05 
Sham-9  vs.  P  30-9  -0.2037  0.7312  >0.05 
Sham-14  vs.  P  30-14  -0.3830  1.375  >0.05 
P  30-3  vs.  P  69-3  0.6785  2.11  11  r%  435  >0.05 
P  30-9  vs.  P  69-9  0.8462  3.037  >0.05 
P  30-14  vs.  P  69-14  1.143  4.101  >0.05 
Statistical  analysis  of  respiratory  tract  colonisation.  (tracheas)  of  the  different  mouse 
vaccine  groups  after  intranasal  challenge  with  B.  pertussis  strain  18-323. 
Group  comparison 
on  day  number 
Mean  difference  q  P 
Sham-3  vs.  P  69-3  1.805  5.361  <0.05 
Sham-9  vs.  P  69-9  3.608  10.716  <0.001 
Sham-14  vs.  P  69-14  2.183  6.483  <0.01 
Sham-3  vs.  P  30-3  -0.5064  1.504  >0.05 
Sham-9  vs.  P  30-9  0.1805  0.5360  >0.05 
Sham-14  vs.  P  30-14  0.6154  1.828  >0.05 
P  30-3  vs.  P  69-3  2.311  6.865  <0.01 
P  30-9  vs.  P  69-9  3.428  10-18  <0.001 
P  30-14  vs.  P  69-14  1.567  4.655  >0.05 
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Statistical  analysis  of  respiratory  tract  colonisation  (lungs)  of  the  different  mouse 
vaccine  groups  after  intranasal  challenge  with  B.  pertussis  strain  18-323. 
Group  comparison 
on  day  number 
Mean  difference  q  P 
Sham-3  vs.  P  69-3  2.914  5.350  <0.05 
Sham-9  vs.  P  69-9  2.808  5.156  <0.05 
Sham-14  vs.  P  69-14  3.021  5.547  <0.05 
Sham-3  vs.  P  30-3  0.4973  0.9131  >0.05 
Sham-9  vs.  P  30-9  -0.0319  0.0587  >0.05 
Sham-14  vs.  P  30-14  0.1947  0.3575  >0.05 
P  30-3  vs.  P  69-3  2.416  4.437  >0.05 
1P  30-9  vs.  P  69-9  2.84  5.215  <0.05 
1P  30-14  vs.  P  69-14  2.826  5.189  <0.05 
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